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Abstract
The Transcriptomic Landscape of HIV-TB
Armin Deffur
August 2013
The thesis consists of four main parts. In Part 1 of this thesis I provide a broad overview of HIV-
TB with an emphasis on systems approaches followed by an overview of a systems-level study
aiming at addressing hypotheses relating to transcriptional differences in active tuberculosis and
HIV-1 infection, measured in blood and the site of disease in tuberculous pericarditis. The final
chapter in this part describes the methods used to generate and analyse the systems-level data, with
emphasis on microarray data generation and analysis.
Part 2 first presents analysis of transcriptional data generated by RT-PCR at the site of dis-
ease compared to blood in study subjects with tuberculous pericarditis, with results showing clear
evidence of transcriptional differences between compartments. A Technical Results chapter then
provides an overview of the microarray data, and an analytic paradigm based on sample embedding
in high-dimensional phenotype space is developed. I then assess the overall quality of the dataset
and exclude large-scale systematic bias, while comparison of the IMPI-MA data to exiting TB
transcriptomic data shows a close match. Part 2 concludes with a description of a comprehensive
analytic framework developed for the IMPI-MA data.
Part 3 presents the results of the analytic pipeline as applied to the transcriptional response in
blood to active tuberculosis in an HIV-1 uninfected population. A signature of active tubercu-
losis is described, and deconvolution analysis finds significant NK cell activation in active tuber-
culosis. Cell-type specific differential expression identifies CD4 T cells, NK cells and neutrophils
as the most likely contributors to the overall “signature” of active tuberculosis. Weighted gene
co-expression network analysis reveals multiple modules, whose expression is shown to be differ-
entially regulated based on disease category.
Part 4 summarises the results of analysing contrasts in three main contexts: tuberculosis, HIV-
1 infection and compartment. Two novel results are presented: Firstly, NK cells are shown to
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be functionally downregulated at the site of disease, suggesting a possible defence mechanism by
M. tuberculosis, and secondly, large-scale metabolic pathway dysregulation at the site of disease,
possibly favouring M. tuberculosis, is demonstrated.
Part 5 concludes the thesis with a summary and outlines future work.
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1 HIV/TB and studies at the site of
disease
Chapter summary
In this chapter I describe in detail the clinical, cellular and molecular characteristics of co-infection
with M. tuberculosis and HIV-1 (HIV-TB). I go on to describe systems approaches in general and
applied to tuberculosis, and finally argue for system-level studies in HIV-TB.
The text of this Chapter is taken verbatim from a review paper submitted to Pathogens and
Disease on 17 April 2013 and accepted for publication on 20 June 2013 [1]. Authors of this paper
are Armin Deffur (first author), Nicola Mulder and Robert J Wilkinson (senior author); the co-
authors provided input in line with their roles as supervisors. The rationale for including this
publication in the thesis is that it provides a comprehensive literature review of the problem of
HIV-1 and Mycobacterium tuberculosis co-infection. Please note that British English spelling rules
have been applied to the text where relevant.
1.1 Introduction/outline
Co-infection by HIV-1 and Mycobacterium tuberculosis is of great concern worldwide. In this
review I present a concise overview of clinical and immunological features of HIV-TB, review
experimental systems in which the biology of this co-infection is studied and finally discuss how a
systems approach may be employed in advancing understanding of these conditions.
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1 HIV/TB and studies at the site of disease
1.2 Clinical features and importance of HIV-TB
About a third of the human population are estimated to be infected with M. tuberculosis. In the
majority of cases the infection is clinically inapparent, with only approximately 10% of individuals
at risk of developing overt clinical tuberculosis in their lifetime.
This indicates a fine balance between effective host defences (resulting in bacterial containment
or clearance) and substantive infection that results in significant pathology, potentially killing the
host early in the course of infection. Either scenario is clearly not beneficial for the reproductive
success of M. tuberculosis, and a delicate balance has evolved that maintains the host-pathogen
relationship over long time periods. Even in the case of a shift towards active infection with con-
current pulmonary pathology, the resulting disease (pulmonary tuberculosis) can follow a chronic
course with 37% 5 year survival if left untreated [2]. The recent arrival of HIV-1 as a human patho-
gen has shifted the balance towards a dramatic increase in clinical disease and increased mortality
associated with tuberculosis in settings where HIV-1 is highly prevalent. This has resulted in a
deadly syndemic [3], where the consequences of co-infection manifest variability in clinical and
pathologic features and a shift towards worse outcome. The pathobiology of this clinically import-
ant co-infection is incompletely understood. While multiple risk factors have substantial impact on
the worldwide tuberculosis epidemic, HIV-1 infection is an important driver of tuberculosis. 13%
of worldwide incident cases of tuberculosis are HIV-1 co-infected, and HIV-1 remains the most
important risk factor in many high-burden settings [3]. HIV-TB accounts for a disproportionate
share of tuberculosis-related mortality. It is therefore instructive to review in outline what is known
about the interaction of HIV-1, M. tuberculosis and the human immune system at the individual
level. Population-level interactions will not be reviewed here.
1.2.1 Effect of HIV-1 on tuberculosis
HIV-1 co-infection increases risk for TB susceptibility to primary or re-infection. While in general
HIV-TB patients are less frequently sputum positive, their greater numbers in high-burden settings
for both tuberculosis and HIV-1 infection, suggests they may contribute substantially to transmis-
sion. A study in Harare found that HIV-1 infected individuals had high levels of incident TB, while
HIV-1 uninfected individuals had higher levels of prevalent smear-positive tuberculosis, suggesting
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that this subpopulation still drives transmission of M. tuberculosis, while HIV-1-infected individu-
als account for the majority of incident cases [4]. Of all opportunistic infections with associated
with HIV-1, the risk for developing clinical tuberculosis is increased shortly after HIV-1 infection
has taken place, well before the total CD4 count drops to levels below 500 cells per µl [5]. This
raises the question whether HIV-1 causes an early tuberculosis-specific defect in host immunity.
HIV-1 also increases the risk of progressing from one stage of tuberculosis to the next [6], in-
cluding increased risk of primary disease following exposure [7], reactivation of latent (clinically
quiescent) lesions [8, 2]and reinfection with M. tuberculosis following exposure [9, 10, 3].
Tuberculosis disease phenotypes are also altered by HIV-1 co-infection. While cavitatory pul-
monary tuberculosis is the most common clinical manifestation in HIV-1-uninfected individuals,
atypical presentations of pulmonary disease are much more prevalent in HIV-1 infected individu-
als [11, 12, 3]. This tendency to atypical pulmonary disease is linked to CD4 count, inasmuch
as individuals with preserved CD4 counts present with upper lobe cavitation much like their HIV-
1 uninfected counterparts, whereas low CD4 counts are linked to atypical infiltrates (middle and
lower lobe infiltrates, interstitial nodules), mediastinal lymph node involvement and even normal
chest radiographs [13]. While chest radiographs are unhelpful in detecting active tuberculosis in
HIV-1 infected individuals in many instances, so is the addition of Interferon-gamma release as-
says to screening strategies aimed at identifying smear-negative tuberculosis [14]. In addition to
pulmonary disease, which remains the most important presentation in HIV-1 co-infected individu-
als, extrapulmonary forms of tuberculosis are more common in this group compared to HIV-1
uninfected individuals [15, 5]. While extrapulmonary tuberculosis usually presents with a single
site in the absence of HIV-1 infection, HIV-1-co-infected individuals often present with concurrent
pulmonary and extrapulmonary disease.
In a prospective study of extrapulmonary tuberculosis, which consisted of HIV-1 infected and
uninfected individuals, the most common extrapulmonary sites were lymph nodes (43%), pleura
(23%), central nervous system (8%), musculo-skeletal system (7%), genitourinary tract (5%), and
gastrointestinal tract (2%) [6, 16] with other sites making up the remainder (Data was not strati-
fied by HIV-status in original study). Finally, HIV-1-co-infection increases tuberculosis-associated
mortality[7, 17].
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1.3 Clinical phenotypes and diagnosis: HIV-TB is a
heterogeneous syndrome
Tuberculosis infection in humans is classically divided into two distinct phenotypes[18]. In this
paradigm, latent tuberculosis infection results from primary infection of the lung that is contained
but not eradicated by a host adaptive immune response. This response is characterised by granu-
loma formation, intracellular (mainly within macrophages) location of mycobacteria, which do not
replicate and may be metabolically adapted to persistence, and the absence of any symptoms sug-
gestive of tuberculosis. The other phenotype is active pulmonary tuberculosis, (usually ascribed
to reactivation of a previously dormant lesion). This century-old description is being increasingly
questioned, and current thinking favours the concept of a spectrum of disease phenotypes [19],
ranging from cleared infection without or with immune sensitisation, inactive lesions containing
mycobacteria, active lesions with bacterial replication but without symptoms to full-blown active
disease (See Figure 1.1).
HIV-1 co-infection complicates this picture by skewing clinical and pathological phenotypes
towards more advanced disease, significantly contributing to the heterogeneity of clinical present-
ations of tuberculosis in the context of HIV-1 co-infection. In order to dissect this complexity,
more detailed phenotypes of human disease may be generated by using novel functional imaging
techniques [20, 21, 19].
Primary disease following recent tuberculosis exposure is also more common in HIV-1 co-
infection, as is an increased risk for reactivation of previously quiescent lesions as well as re-
infection of persons already infected with Mycobacterium tuberculosis. The question of whether
prior or current tuberculosis elicits an immune response that can protect from infection is controver-
sial. While a 2005 review [22] found that evidence for protective immunity (against re-infection)
induced by latent tuberculosis was not convincing, a recent systematic review [23] showed that in-
dividuals with latent tuberculosis had a 79% lower risk of progressive tuberculosis after re-infection
than unsensitised individuals.
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Figure 1.1: Clinical interactions of tuberculosis and HIV-1. HIV-1 and tuberculosis interact
with each other. The x-axis represents stages of tuberculosis, from infection through to
active disease, while the y-axis represents stages of HIV-1 infection. M. tuberculosis
bacterial burden and CD4 count are shown in blue along the respective axes. The spec-
trum of “latent” TB is represented as follows: (1) Infection eliminated without priming
antigen-specific T-cells. (2) Infection eliminated in association with T-cell priming. (3)
Infection contained with some bacteria persisting in a non-replicating form. (4) Bac-
terial replication maintained at subclinical level by the immune system. Clinical disease
(pulmonary and extrapulmonary tuberculosis) occurs in a subset of individuals who are
latently infected or who develop primary tuberculosis directly following infection or re-
infection. The annual risk is represented as follows: (A) HIV-1 uninfected: approxim-
ately 10% lifetime risk, or about 1% per annum (p.a.). (B) Shortly after HIV-1 infection,
and prior to substantial CD4 T-cell depletion, the risk for active tuberculosis increases.
(C) During the early stages of HIV-1 infection, this risk rises to approximately 10% p.a.
(D) In late-stage HIV-1 infection, the risk for active tuberculosis increases to 30% per
annum. The effects of HIV-1 on tuberculosis, and of tuberculosis on HIV-1 disease are
shown by the red arrows.
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1.4 Immune reconstitution after ART
Following initiation of highly active antiretroviral therapy (ART) in patients with HIV-1 infection,
tuberculosis incidence is reduced as protection from tuberculosis is restored with recovery of CD4
count. This reduction in incidence is only partial, however, as tuberculosis incidence still remains
higher after ART and CD4 restoration compared to HIV-1 uninfected individuals [24]. As reconsti-
tution of a protective immune response against many antigens occurs, individuals may also develop
worsening symptoms and signs of opportunistic infections due to a vigorous response against anti-
gens present in the host resulting from immune activation that may be modulated by corticosteroids
[25]. This is termed tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS). TB-
IRIS appears to be driven by increased recognition of M. tuberculosis antigens present shortly after
ART initiation; this may be associated with conversion of a negative TST to a strongly positive one.
Pathogenic mechanisms that have been considered in TB-IRIS include purified protein derivat-
ive (PPD)-specific expansion of Th1 responses [26] and defective restoration of regulatory T cell
function. However, Th1-specific expansions may also occur in individuals who do not develop
symptoms and signs of TB-IRIS [27, 25], and numbers of CD4+ Foxp3+ T cells in TB-IRIS cases
are similar in controls[28]. More recent work has focused on the interaction of innate and adaptive
responses, with evidence of myeloid activation [29, 30], cytolytic action of NK cells [31] as well
as killer immunoglobulin receptor (KIR)-negative γδ -T cells [32] all contributing to TB-IRIS.
In contrast to the pathologic responses associated with TB-IRIS, functional, non-pathologic im-
mune restoration is responsible for the enhanced protection from active tuberculosis seen following
start of ART. This response is associated with an increase in absolute CD4 T cell count, decline
in HIV-1 viral load, an absolute increase in effector function but a proportional decrease in the
ratio of effector to central memory CD4 T cells due to an even greater expansion of the central
memory pool, which provides the strongest correlate of ART-mediated immune restoration [33].
Another study found that the extent of immune restoration following ART initiation depended on
the baseline (nadir) CD4 T cell count. Only at nadir CD4 counts greater than 350 cells/ µl did the
immune restoration result in CD4 T cell populations similar to those in HIV-1 uninfected individu-
als, suggesting an immunological benefit of starting ART at that threshold [34].
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1.5 Disease mechanisms in co-infection
1.5.1 Immune mechanisms in tuberculosis
Immune control of M. tuberculosis, an intracellular pathogen relies on both innate and adaptive
cell-mediated immunity [35]. Although a vigorous humoral response to multiple mycobacterial
antigens is produced, the antibodies appear to be largely ineffective in controlling the disease due
to the mainly intracellular localisation of the bacterium; there is some debate whether opsonising
antibody may be helpful early in infection. The response therefore requires CD4 and CD8 T cells
that respond to M. tuberculosis antigens presented by either MHC class I, MHC class II or CD1
molecules on the surface of antigen presenting cells (macrophages and dendritic cells), a Th1 cy-
tokine milieu (IFN-gamma, IL-12, TNF) and appropriate regulatory responses that limit the extent
of the inflammatory response. Even in active tuberculosis, there is a delicate balance between pro-
and anti-inflammatory responses, that aim to contain the infection while limiting collateral dam-
age. This results in the often very protracted course of pulmonary tuberculosis, recognised as the
syndrome of “consumption” prior to the era of antimycobacterial chemotherapy. Co-infection with
HIV-1 has a dramatic impact on this balance.
1.5.2 Effect of HIV-1 on tuberculosis immunity
The most obvious effect on tuberculosis immunity by HIV-1 is the severe depletion of the CD4
T cell population, both in blood and in peripheral lymphoid tissues [36, 37]. In addition, HIV-1
induces CD4 T cell dysfunction as evidenced by reduced IL-2 or IFN-gamma production[38, 39,
40]. Early selective depletion of M. tuberculosis antigen-restricted CD4 cells was demonstrated in
2008, and likely explains the early increase in risk of tuberculosis following HIV-1 infection [41,
42]. It is hypothesised that HIV-1 may indirectly cause loss of M. tuberculosis-specific CD8 T-cells
through loss of M. tuberculosis-specific CD4 T cells, though this has not yet been experimentally
demonstrated in humans. CD8 T cells probably play an important role in containing tuberculosis
infection. This is view is based on data from in vitro work [43], mouse models [44], non-human
primate models [45], and cells isolated from individuals with tuberculosis following anti-TNF ther-
apy [46].
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1.5.3 Effect of tuberculosis on HIV-1: viral replication
Infection with Mycobacterium tuberculosis, and more directly the immune response directed against
it, result in enhanced intracellular HIV-1 replication in blood [47] and at sites of tuberculosis dis-
ease, including the lung [48] and pericardial space in the case of tuberculous pericarditis [49].
Multiple mechanisms have been implicated, including cytokine- and chemokine-mediated mech-
anisms[50, 51], loss of an inhibitory transcription factor C/EBP beta[52], activation of (NF)-κB
and signalling involving positive transcription elongation factor (P-TEFβ ) [53]. These mechan-
isms cause activation of transcription of HIV-1, resulting in enhanced viral replication, spread to
uninfected cells and their subsequent depletion.
1.5.4 Effect of tuberculosis on HIV-1: clinical disease progression
Active tuberculosis is associated with more rapid progression to severe CD4 T cell depletion and
higher risk for opportunistic infections resulting in late stage HIV-1 infection and the development
of AIDS [54, 55].
1.5.5 The role of host genetic variation
There is moderate evidence of human genetic susceptibility to tuberculosis [56]. For example,
using a genome-wide screening approach in M. tuberculosis-infected vs. non-infected dendritic
cells, Barreiro et al found a number of expression quantitative trait loci (eQTL) that associate with
tuberculosis in this system [57], and imputation of 1000 Genomes Project data [58] into a Ghanaian
genome-wide dataset (tuberculosis cases and healthy controls) revealed a resistance locus at 11p13
downstream of WT1 (Wilms tumor 1) [59]. Thus, host genetics introduces an additional factor to
consider when discussing the interaction between HIV-1 and tuberculosis. Recently, susceptibility
to tuberculosis in HIV-1 infected individuals was associated with a CARD8 genetic variant [60],
and a genotype resulting in high IL-10 production also appeared to predispose HIV-1 infected
individuals to TB infection [61]. It should be noted however, that studies that infer genetic risk
for tuberculosis are often inconsistent in their results, and study design is probably responsible for
this [62]. The definition of tuberculosis phenotype often varies across such studies, making them
hard to compare directly and to generalise their results. This caveat applies equally to studies of
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tuberculosis susceptibility in HIV-1 infected individuals.
1.6 Experimental systems
1.6.1 Isolated model systems
Experimental systems consisting of single cell types (e.g macrophages) manipulated in vitro are
useful for delineating actions of individual mediators (cytokines, chemokines), intracellular pro-
cesses (signalling cascades, autophagy) and processes that are ultimately reductionist. While yield-
ing invaluable data on the “parts list” of the immune response to tuberculosis, such systems by
definition lose higher-order information about the overall orchestration and coordination of the
immune response.
1.6.2 Animal models
Animal models of tuberculosis can be very useful in understanding higher-level immune phenom-
ena that are lost in simple systems, but care must be taken when extrapolating these phenomena to
human immunobiology without experimental evidence.
Early major contributions of the mouse model to understanding human tuberculosis are in-
sights into the key importance of IFN-γ , TNF-α and CD4 T-cells in containing tuberculosis. The
mouse model is utilised to study the effect of M. tuberculosis genomic variation (including induced
mutants), immune response, the effect of drugs and vaccines [63].
An argument against the use of mouse models is that they cannot effectively recapitulate HIV-1
co-infection in tuberculosis. Considerable effort has gone to develop mouse models of HIV-1 in-
fection [64, 65]. Basic models aim to mimic HIV-1 infection by CD4 T-cell depletion. While CD4
depletion is clearly important in HIV-1 pathogenesis, HIV-1 has additional effects on the immune
system that are not captured in this model (apoptosis, disruption of lymph node architecture, de-
pletion of M. tuberculosis-specific T cells and effects on macrophage function). Therefore, more
realistic models have been developed, including Nef-transgenic mice [66, 67, 68] and humanised
bone marrow-liver-thymus (BLT) mice [69, 70, 71] that support the entire life cycle of HIV-1 and
thus may become valuable tools in understanding aspects of tuberculosis and HIV-1 co-infection.
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In contrast to their indisputable utility in discovering disease mechanisms in tuberculosis [72],
use of mouse models at the system level (by the use of unbiased genomic screens) may also lead to
incorrect conclusions if great care is not taken when mapping mouse data onto human orthologs.
In a recent study, transcriptomic responses to three broad inflammatory stimuli were studied in hu-
mans and mice using a whole-blood transcriptomic approach [73]. In humans, the transcriptomic
responses were correlated with each other, but the corresponding mouse models of the inflammatory
conditions (burns, trauma, endotoxinaemia) were both uncorrelated with their human counterparts,
and with each other. This strongly suggests that overall control in the mouse immune system may
be wired differently than in humans, and that large-scale organisational features are not conserved
across this particular species barrier. This finding argues strongly to restrict systems-level investig-
ations into tuberculosis and HIV-1 co-infection to models other than mice, such as human (clinical)
and non-human primate models.
In contrast to mouse models, other animal models reca itulate more features of human tubercu-
losis, e.g. guinea pigs and rabbits both produce caseous granulomas, a hallmark of human disease,
but are limited by the availability of immunological reagents required to interrogate the models.
The non-human primate model is the closest approximation of human tuberculosis [74, 75]. Lon-
gitudinal samples including blood, broncho-alveolar lavage fluid and lymph node biopsy tissue
are available during the infection stage of the model, and all tissues are available at necropsy. As
non-human primates can be infected with simian retroviruses that cause an immunodeficiency syn-
drome in these animals, use of this model may extend to study the non-human primate equivalent
of HIV-TB [65]. Given these features, this model system is able to generate data that is essentially
impossible to generate from other animal models or human clinical disease models.
Despite their utility, all animal models are limited when performing system-level studies that
aim to understand precise mechanisms of tuberculosis and HIV-1 co-infection in humans. Given
these limitations it is imperative that an integrated, systems-level model of tuberculosis and HIV-1
co-infection be developed for humans in an unbiased way using systems approaches.
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1.6.3 Difficulty of in vivo work in humans
In vivo studies of human tuberculosis are difficult, as sampling of disease sites cannot be carried
out in the same way as in animal models. Post-mortem studies of human tuberculosis are available,
but relatively limited, and the ability to perform experimental challenges are very limited.
The bulk of our existing knowledge comes from technologies that may suffer from low spatial
resolution (e.g. chest radiographs may be normal in subclinical pulmonary disease) that may fail to
resolve phenotypes along the latency spectrum, and obscure the inherent heterogeneity of human
tuberculosis.
Our understanding of this low-resolution data has led to classical descriptions of tuberculosis
pathogenesis involving distinct, polarised phenotypes: Infection with Mycobacterium tuberculosis
leading to either latent tuberculosis or primary progressive disease, and reactivation (usually in the
lung apices) of latent infection which leads to full-blown clinical tuberculosis.
Compounding the problem is the fact that the early stages of tuberculosis are hard to study. It is
likely that very early events following exposure to aerosols containing M. tuberculosis are key in
determining the outcome of the exposure. Hypothetical outcomes are threefold:
1. Clearance of inhaled M. tuberculosis by innate immune responses (possibly mediated by
neutrophils alone or in combination with other innate cells) without presentation of cognate
antigen to adaptive immune cells, therefore not resulting in any acquired response.
2. Failure of the innate immune system to clear the infection, resulting in cells of the adapt-
ive immune system becoming actively involved, with antigen presentation on dendritic cells
and macrophages to T-lymphocytes and subsequent downstream events. At this stage the
infection may be cleared or contained within granulomas. IGRA and/ or TST responses are
used as indicators of this immune sensitisation to M. tuberculosis, but cannot differentiate
between cleared infection with a lasting memory response, a contained infection that may
yet reactivate, and subclinical disease.
3. The infection may overwhelm innate and adaptive responses and result in primary progress-
ive disease.
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1.6.4 Limitations of reductionist approaches
Current reductionist approaches have defined a multitude of genes, proteins, cellular mechanisms
and cell populations that are important in containing mycobacterial infection, account for immune
deficits caused by HIV-1 infection and describe the response to vaccines. However, these mo-
lecular and cellular-level mechanisms interact to produce high-level phenomena, such as protective
immune responses. At this stage, it is unknown what truly constitutes an immune response that
protects from infection with M. tuberculosis or from progressive disease following infection. The
simple single cell models and even animal models do not recapitulate human HIV-TB co-infection
completely. Simple models interrogate only a few dimensions of a very high-dimensional para-
meter space that describes the complex system fully. As a result, a large portion of this parameter
space remains unexplored. HIV-1 co-infection adds to this complexity by introducing one or more
orthogonal dimensions to the parameter space. An alternative is a systems approach to HIV-TB
co-infection that yields models that are able to predict emergent phenomena.
1.6.5 Evolutionary perspective
The association of Mycobacterium tuberculosis with human hosts is not a recent phenomenon, but
rather a long-standing one, with co-evolution of host and pathogen [76]. M. tuberculosis is found
wherever human populations are found, and at least seven distinct lineages have been identified
[77]. In addition, humans have evolved while exposed to multiple retroviruses, which remain as
genomic remnants in the form of HERVs (human endogenous retroviruses) [78]. Also, HIV-1 in-
fection disables key components of the adaptive immune response to tuberculosis (some specific for
M. tuberculosis responses) while leaving innate mechanisms more intact. HIV-1 and M. tubercu-
losis may affect each other’s evolution. An increase in HIV-1 heterogeneity may be associated with
a TB-mediated increase in HIV-1 replication discussed above, suggesting the possibility that HIV-1
and M. tuberculosis co-infection may alter the evolutionary dynamics of HIV-1[79]. Conversely,
an increase in multidrug-resistance conferring mutations in M. tuberculosis has sometimes been
noted in HIV-1 co-infected individuals, suggesting that HIV-1 may directly or indirectly influence
M. tuberculosis diversity [79].
Worldwide distribution of different lineages of M. tuberculosis mirrors that of geographically
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defined human population groups, which suggest that the specific strains are adapted to their (geo-
graphically) local population. This sympatric relationship is disrupted following HIV-1 infection,
in which a much higher likelihood of infection with allopatric strains was seen compared to HIV-1
uninfected individuals [80].
1.7 Systems approaches
1.7.1 Introduction to systems
A “system” can be loosely defined as a collection of entities that collectively exhibit particular
behaviour. A hallmark of complex systems is that this behaviour is hard to predict when given
information about the constituent parts. Systems are organised in levels of rganisational complex-
ity. A defining feature of systems is the concept of interaction: any particular level of organisation
may be viewed as a set that has members consisting of specific biological entities that interact with
each other. Usually, the set of interactions between the various members can be described using
network terminology. An intuitive example is the collection of signalling pathways within a spe-
cific cell type that consists of interactions between ligands, receptors, downstream linker molecules
and ultimately effector molecules (e.g. transcription factors) that alter gene expression. The set of
interactions between entities of one level of organisation then give rise to the next level of organisa-
tion, a set that has more complex members (e.g. protein complexes, double-layer lipid membranes),
which again interact with each other to form a higher-order system. This process is repeated from
the subatomic scale to the population level. Figure 1.2 shows the different levels of organisation,
components of those levels and examples of emergent properties resulting from members within
that level.
Systems biology is an emerging discipline that aims to describe complex systems by studying the
interactions within that system, and by modelling these interactions of known system constituents
discovering emergent properties of the system that could not be predicted a priori. Using this
approach of data-driven modelling, predictions about higher-order system behaviour can be made,
and importantly these predictions may be tested in the system of interest.
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Atom
Molecule
Macromolecule
Organelle
Cell
Tissue
Organ
Organ system
Multicellular
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Cytokines, chemokines, metabolites
DNA, proteins (receptors, signal transduction)
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Cell membranes, phagosomes, lysosomes
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lymphoid tissue, recruited cells
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Signalling cascades
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Macroscopic pathology: caseating necrosis,
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Disease state: Latent tuberculosis, active 
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Individual atoms Chemistry, biochemistry
Transmission dynamics of M. tbHuman populations
Figure 1.2: Levels of organisation in biological systems. At each level, entities of the same class
interact in complex interaction networks, and emergent properties of these entities and
their interactions define the next level up. The first column lists the hierarchical levels of
organisation of biological systems. Components that are studied at each particular level
are shown in the second column (these components do not form an exhaustive list).
In the third column, examples of emergent phenomena that result from interactions
between components are listed.
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1.7.2 Systems approaches
Systems approaches should be hypothesis driven, global/ unbiased and multi-scale. They should it-
erate over cycles of data collection, hypothesis formulation, model construction and model testing
[81] (Figure 1.3). Data collection requires unbiased sampling of the system and parallel meas-
urement of high numbers of parameters at multiple levels of organisation. This is facilitated by
the advent of various high-throughput biology technologies that measure whole genome gene ex-
pression (DNA sequencing, cDNA/cRNA microarrays, RNAseq), protein levels or presence (mass
spectrometry), small molecule metabolites and other large-scale phenomena. Such datasets may
then be incorporated into models of gene expression, metabolic pathways and other models. Im-
portant in this context is the concept of perturbation, where the experimental system is subjected
to specific changes, and the broad-based measurements mentioned above repeated. This data may
then be used to test hypotheses about emergent properties of the system formulated using the model.
1.7.3 Systems approaches to tuberculosis
An important contribution of the systems-level understanding of tuberculosis was made in 2010[82].
In this study, the authors collected whole blood for RNA extraction from a cohort of individu-
als with either active pulmonary tuberculosis or not active pulmonary tuberculosis (comprising
latent tuberculosis and individuals without evidence of immune sensitisation to M. tuberculosis
antigens). Extracted and processed samples were hybridised to Illumina Human HT12v3 gene ex-
pression microarrays. The resulting data was first subjected to unsupervised analysis followed by
statistical testing for significant differential transcript abundance. This approach [83, 84] yielded
an interferon-inducible, neutrophil driven blood transcriptional signature consisting of 393 tran-
scripts, shedding light on the potential role of neutrophils in active tuberculosis. Type-1 interferon-
inducible genes were shown to be highly expressed in neutrophils. In subsequent work [85, 86]
core features of this signature were independently replicated. This has led to new thinking regard-
ing the role of the innate immune system in the response to tuberculosis, and its interaction with the
adaptive response. This signature is being evaluated for diagnostic potential of early identification
of active tuberculosis, and has also been shown to revert towards the inactive signature following
antimycobacterial therapy [87]. An additional contribution of this paper was the finding that some
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Figure 1.3: A systems approach is an iterative process. For each system under study, exper-
imental data collection, data interpretation, modelling, prediction and further experi-
mentation follow each other. The key goal is correct prediction of system states follow-
ing perturbation of such systems using computational models.
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individuals who had the clinical phenotype of latent tuberculosis assigned based on the absence of
symptoms and evidence of prior immune sensitisation to M. tuberculosis clustered together with
cases of active tuberculosis, suggesting that their correct phenotype was subclinical active tuber-
culosis [82], supporting the idea that tuberculosis should be viewed as a spectrum. As this inter-
pretation lacks experimental support, alternative interpretations of the data should be considered.
For instance, the misclassified individuals may have another subclinical condition that produces a
transcriptional response that is similar to that associated with active tuberculosis. In this context,
it is worth noting that the 86-transcript signature described by Berry et al also distinguishes indi-
viduals with melioidosis from healthy controls [88], suggesting that this signature may not in fact
be specific for active tuberculosis. The paper concludes that type 1 and type 2 interferon-mediated
responses dominate the host response to both infections, and that transcriptional signatures based
on interferon signalling cannot distinguish between acute melioidosis and tuberculosis.
In developing systems approaches to tuberculosis, novel mathematical methods need to be de-
veloped and implemented such as scoring methods for protein interactions [89], investigation of
gene co-expression patterns in M. tuberculosis using microarray data [90] and modelling latent
tuberculosis using time-course microarray data [91]. Another approach to investigating tubercu-
losis has been developed by Kirschner et al. Here a systems biology approach [92, 93] is used to
integrate experimental data (e.g. flow cytometry, enzyme-linked immunosorbent spot (ELISPOT),
Luminex, immunohistochemistry, in situ hybridisation (ISH), in vivo and in vitro cytotoxicity as-
says, gene knockout (deletion) and cell and cytokine depletions, cytotoxicity assays, 2-photon mi-
croscopy) and computational models to study emergent properties of a system consisting of lung
and draining lymph nodes [94] down to the cellular level, and find that many aspects of granuloma
formation are recapitulated in this model [95]. A view of intracellular host factors important for
survival of M. tuberculosis has been developed based on genome-wide siRNA screens, which yiel-
ded a dense interaction network of 275 molecules [96]. A subset of 74 host proteins was shown to
be invariably required for survival of M. tuberculosis; over half of these act through regulation of
autophagy which implies that modulation of autophagy forms a basis for intracellular survival.
An EU-funded consortium (SystemTB) aims to combine experimentally-driven model develop-
ment and model-driven experimentation to improve the understanding of the biology of M. tuber-
culosis and its interactions with host cells and mediators by elucidating its interaction networks by
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various high-throughput screens performed under multiple conditions involving biologically relev-
ant perturbations (chemical and physical stresses, knock-out or knock-down mutants [97]. In the
USA, one of four NIH-funded Systems Biology of Infection centres based at the Broad institute has
established a collaborative network that will perform systematic profiling using high-throughput
screens during both in vitro and in vivo growth, integrating these data into predictive computational
models of the M. tuberculosis regulatory and metabolic networks [97].
1.7.4 Systems epidemiology
Systems epidemiology [98] aims to answer questions about the effect strain diversity on disease
phenotypes. In tuberculosis, relatively little is known about strain-specific effects. Questions of
this nature will be addressed by parallel high-throughput screens: individual strain sequencing
combined with high-resolution host phenotyping using transcriptomics, proteomics, metabolomics
and other approaches. One challenge of this approach will be to combine and integrate large-scale
genomic data from the pathogen with phenotypic data from the host. One approach may utilise
host transcriptomics to define the host response at high resolution, and to correlate the host states
with pathogen genomics.
1.7.5 Interface of M. tuberculosis and host, and how this is modified
Tuberculosis is defined by the presence of M. tuberculosis in the host, and the subsequent immune
response. In order for a response to occur, information about the pathogen has to reach the host via
an afferent information collection system. This information is processed, and a response generated
using effector components of the immune system. This flow of information from pathogen to host
is crucial, and occurs via the interface between the host and pathogen. Defining the exact nature
of this interface is required to understand host-pathogen information exchange. In addition to the
siRNA approach outlined above [96] which identified host autophagy machinery as a crucial part of
this interface, another method to understand this information exchange is the use of simultaneous
host and pathogen transcriptomics, reviewed in [99]. This approach is challenging, as the patho-
gen RNA occurs in quantities orders of magnitude lower than host RNA. Array-based methods
cannot routinely discriminate between different RNA isoforms, uncover unannotated non-coding
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RNA sequences, define transcript borders, and suffer from a low signal-to-noise ratio due to non-
specific and background hybridisation. In addition, RNA sample preparation is complex. RNAseq
overcomes many of these problems. The method requires RNA to be extracted from samples con-
taining both host cells and mycobacteria. This RNA is subjected to RNAseq, and resultant reads
are mapped to both genomes, allowing inferences to be made about correlations of transcriptomic
responses. As this technique relies on a stochastic sample of RNA from both host and organism, the
absolute amount of RNA recovered from the organism is still much lower than that of the host; this
has to be taken into account in the analysis of the dual RNAseq data. In order to partially alleviate
this, one might employ techniques to specifically enrich for RNA of the under-represented organ-
ism; this is not usually recommended. Another strategy consists of depletion of ribosomal RNA
(rRNA); this increases the relative information content of the prokaryotic RNA fraction. Again,
this approach is not recommended if the sequencing depth can be increased sufficiently in order to
identify transcripts of extremely low copy number. This, however, significantly increases costs.
1.7.6 Compartmentalisation and site of disease studies
Systems approaches may also be applied at the level of site of disease. For example, host tran-
scriptomics may be performed in whole blood and site of disease simultaneously (Deffur et al,
manuscript in preparation). For concurrent transcriptomics approaches to two compartments, care
must be taken to account for profound differences in cell populations in the compartments (e.g.
the site of disease is expected to be enriched for cell types germane to dealing with the infection
whereas the whole blood compartment serves as the conduit for the efferent arm of the immune
response [84]. One method of dealing with this is deconvolution of total compartment signatures
into cell-specific signals [100] and performing cell-specific differential expression analyses [101].
1.7.7 Challenges
Some challenges faced by systems approaches are data integration and model integration. Data sets
are generated on high-throughput platforms with unique readouts, and the difficulty becomes in-
tegrating the datasets at the level of the biological signal, and not the raw data, which contains both
signal and noise. Additional integration challenges are file format conventions, different methods
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of data storage (flat files, relation databases), the absence of metadata standards and the lack of
precise, structured vocabularies that describe the system components exactly. Some existing mod-
els perform an adequate function in recreating emergent properties observed in either the host or
the bacterium, making some simplifying assumptions about the other player in the two-component
system. What is required is the integration of a complete model of mycobacterial metabolism and
responses to stress and other perturbations within a multi-scale model of human immunology. In
order for this to be accomplished, a complete description of the interface of host and pathogen, with
associated transcriptional response networks is required.
1.7.8 Research priorities for systems approaches in co-infection with
Mycobacterium tuberculosis and HIV
Define and delineate (new) phenotypes. Given the added complexity of phenotypes of co-infection
with M. tuberculosis and HIV, the full range of phenotypes needs to be elucidated. This requires
high throughput screens of healthy, immunosensitised and symptomatic individuals, combined with
sensitive imaging techniques (e.g. PET/CT). High-resolution phenotyping is required in order to
perform meaningful comparisons between groups of samples that measure thousands of parameters
concurrently.
Controlled vocabularies. Terminology employed in clinical, animal model and molecular stud-
ies needs to be standardised, especially where higher order emergent phenomena are concerned. For
example, there is lack of consensus in the literature for the appropriate use of terms like “dormant”,
“latent” and “inactive” tuberculous lesions. On some occasions, different terms may mean the same
thing, and on others, one term may refer to multiple phenomena. What is required is a strict one-to-
one mapping of terms to biologic concepts. This is best accomplished by developing a controlled
vocabulary (ontology), which can be used in annotating specific aspects of biological and compu-
tational models. Development of a TB ontology is underway under the auspices of a collaborative
NHLBI-sponsored effort (TB Systems Biology).
What is the interface, and how does HIV change it? One of the main difficulties in integ-
rating models of human immunology and mycobacterial biology is definition of the interface that
allows bidirectional information flow between the two systems. In a way, this interface allows the
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one system to “read” the internal state of the other system. Many features of this interface are
known (ligands and receptors, signalling pathways), but others require elucidation (e.g. role of
mycobacterial secreted factors).
Model integration. Controlled vocabularies and knowledge of the host-pathogen interface are
both key to integrating computational models (e.g. metabolic models of M. tuberculosis and models
of granuloma formation). Many current models consider one side of the host-pathogen relationship
in considerable detail, while at the same time simplifying the biology of the other side. What
is required is convincing interaction between host and pathogen that incorporates sufficient detail
about both. Predictions of such models are again amenable to testing using either clinical samples
or realistic animal models.
Create integrated models of HIV co-infection. Models of HIV-TB co-infection will require
a significant increase in complexity, due to the increased phenotypic variability introduced by the
variable immune dysfunction associated with HIV, and will ideally model all three organisms. They
should exhibit known emergent properties of co-infection (e.g. effects of TB on HIV, effects of HIV
on TB, immune reconstitution inflammatory syndrome).
1.8 Conclusion
Systems approaches to TB-HIV will complement on-going reductionist approaches by synthesis of
models capable of predicting emergent phenomena related to this disease. In so doing, we will gain
a deeper and more complete understanding of the drivers of pathogenetic processes, and will hope-
fully identify novel ways in which to interfere with this system in order to produce more favourable
clinical outcomes. Systems approaches are challenging, and require a new ways of thinking about
TB-HIV co-infection specifically, and infectious diseases research more generally[101], with the
goal of ultimately redefining the host-pathogen research paradigm.
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2 IMPI-MA: a two-compartment survey of
the transcriptional landscape in HIV-TB
Chapter summary
In this chapter I describe IMPI-MA, the study that forms the basis for this thesis. First, the problem
of tuberculous pericarditis in the context of a major HIV-TB epidemic is presented, as this disease
presentation will serve as a two-compartment model of HIV-TB. Next, hypotheses and study ques-
tions are developed, followed by specific aims and objectives. Finally, I present the study design
and outline my approach for dealing with a very heterogenous dataset.
2.1 Tuberculous pericarditis
2.1.1 Tuberculosis worldwide and in South Africa
Currently, approximately one third of the world’s population is infected with Mycobacterium tuber-
culosis, and one in ten of those will develop clinically overt disease in their lifetime. In the most
recent report on the global TB epidemic [102], the WHO provided the following statistics: In 2011,
there were an estimated 8.7 million new cases of TB (13% co-infected with HIV) and 1.4 million
people died from TB, including almost one million deaths among HIV-negative individuals and
430,000 among people who were HIV-positive. Worldwide incidence rates continue to fall very
slowly. 5% of all cases of tuberculosis have multidrug resistant TB (MDR-TB).
In South Africa, the incidence of tuberculosis is amongst the highest in the world, at 993 cases
per 100,000 population per year [102]. A high proportion of this disease burden is borne by HIV-
infected individuals: approximately 70% of incident TB cases are HIV infected. Manifestations of
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tuberculosis in HIV-infected individuals are highly variable, but an increased proportion of cases
present with extrapulmonary tuberculosis.
2.1.2 Tuberculous pericarditis: phenotypes and complications
One of the less common but clinically very important presentations of tuberculosis is tuberculous
pericarditis (TB-PC). Approximately 1% of cases have cardiac involvement. In the acute setting,
tuberculous pericarditis presents with constitutional symptoms, chest pain and a pericardial effu-
sion. Patients may present with cardiac tamponade requiring emergency drainage of the effusion.
Despite adequate antimycobacterial chemotherapy, up to 25% of patients with tuberculous peri-
carditis develop constrictive pericarditis, which has a high level of morbidity and 25% mortality at
6 months. The mortality rate rises to 40% at 6 months in patients with HIV infection who have clin-
ical features of immunosuppression, and are not on antiretroviral therapy [103, 104]. This makes
TB-PC the second-most lethal form of tuberculosis after tuberculous meningitis (TBM).
Strategies are needed to reduce the high complication rate in patients with TB-PC. The use of
corticosteroids in tuberculous pericarditis is still controversial [105, 106], but is currently actively
being studied in a randomised, controlled clinical trial.
TB-PC exhibits one of several distinct haemodynamic phenotypes. The phenotypes are identified
using haemodynamic measurements obtained at the time of pericardiocentesis, and consist of the
following:
1. Dry (acute) pericarditis
2. Purely effusive, with normalisation of right atrial pressure when the pericardium is drained
to dryness
3. Effusive-constrictive, with evidence of visceral pericardial involvement and failure of right
atrial pressure to normalise when the pericardium is drained to dryness [103]
4. Constrictive pericarditis (late-stage complication)
Understanding the sequence of events that leads to constrictive pericarditis might aid in developing
tools to predict which patients with tuberculous pericarditis are at risk of developing constriction,
and to find novel ways of preventing constriction by targeted disruption of constriction-inducing
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pathways. The study, detailed below, in essence will try to elucidate biological processes that play
a role in the pathogenesis of constrictive pericarditis.
It is clear that pericardial involvement in patients with tuberculosis presents a significant problem
in South African healthcare setting. Better understanding of this disease is required in order to
develop improved diagnostic and therapeutic modalities. In summary, TB-PC is second only to TB
meningitis in terms of lethal potential, and it is an excellent model of extrapulmonary TB, with the
ability to sample material directly from the disease site.
2.2 IMPI and related substudies
The Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry [106] was
established by the Cardiac Clinic, Department of Medicine at the University of Cape Town in
order to study clinical, pathophysiological and outcome characteristics of a cohort of patients with
tuberculous pericarditis.
Over the years since the original IMPI-Africa Registry was established, a number of studies have
continued to collect data on patients with TB-PC. The broader registry can therefore be divided into
several “phases” with different research focus.
1. Original IMPI registry
2. Registry 2
3. Clinical trial of adjunctive immunotherapy in TB-PC
In addition to the three sequential studies above, a number of substudies have sampled from the
three populations above:
1. Haemodynamic phenotypes in TB-PC (Ntsekhe et al, manuscript in final review with PLOS
ONE)
2. Immunology of tuberculous pericarditis
3. Diagnosis of tuberculous pericarditis
4. Microarray substudy (IMPI-MA) - the subject of this thesis
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The complex relationship of study populations between studies and substudies is shown in Figure
2.1
Screening logs
Registry 1
Registry 2
Trial
Haemodynamic
Immunology
Microarray
All pericardiocentesis
Outcomes
Diagnostic
CONSENT
Pericardial Disease - Seen at or referred to GSH
Pericardiocentesis done
Figure 2.1: Relationship between various IMPI cohorts. The figure shows that three large co-
horts (ovals) of patients were drawn from a the set of patients with TB-PC seen at Groote
Schuur Hospital. A subset of patients presenting with TB-PC underwent pericardiocen-
tesis (red circle). Four substudies were performed on overlapping patient populations
(rectangles)
2.2.1 Immunology substudy
A collaboration between the Cardiology group leading the IMPI projects and the laboratory of
Professor Robert J Wilkinson at the IIDMM, University of Cape Town, has been active since 2006.
In work for her Masters and PhD degrees, Kerryn Matthews, together with her supervisor Katalin
A Wilkinson, has performed extensive immunological characterisation of samples obtained from
individuals with TB-PC
The following assays were performed:
1. Restimulation assay of whole blood and pericardial fluid using ESAT-6 and CFP-10 with
measurement of IFN-γ in the supernatant
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2. ELISPOT analysis of peripheral blood mononuclear cells (PBMC) and pericardial fluid cells
(PFC) for IFN-γ using multiple mycobacterial antigens
3. Surface phenotyping of T-cells from PBMC and PFC using fluorescence-activated cell sort-
ing (FACS)
4. Quantitative RT-PCR (TaqMan) for forty-two genes involved in inflammation and regulation
of inflammation
5. Measurement of twenty-four cytokines and other mediators involved in inflammation, fibrosis
and tissue destruction in serum and cell-free pericardial fluid using ELISA and luminex
Key findings reported in her PhD thesis [107]
1. Increased recognition of Mycobacterium tuberculosis-specific antigens by T cells in the peri-
cardial fluid with a phenomenon of “Pericardial” and “Peripheral dominance” in the recog-
nition of M. tuberculosis-specific antigens
2. There are more differentiated antigen experienced CD4+ and CD8+ T cells in HIV-1 unin-
fected TB-PC patients, while HIV skews the phenotype of memory T cells in the pericardium
towards less differentiated CD4+ and CD8+ T cells
3. HIV skews the cell-specific cytokine response towards a more polyfunctional T cell profile,
probably contributing to pathology of TB pericarditis, rather than protection
4. The pericardial space has been shown to be largely pro-inflammatory, but it is also pro-
fibrotic, with compartmentalisation of pro-collagen genes and lack of fibrotic regulators,
irrespective of the HIV status of the patients (see Chapter 5 for additional analysis of this
data)
5. There is dysregulation between MMP and TIMP molecule production and binding, which
may overstimulate the synthesis of inflammatory and profibrotic cytokines
2.2.2 Haemodynamic phenotypes
In a study submitted to PLOS ONE, Mpiko Ntsekhe, et al report a high prevalence (53%) of the
effusive-constrictive phenotype of TB-PC in the study population, and this phenotype is accom-
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panied by high interleukin 10 (IL-10) levels in blood and pericardial fluid. This suggests that the
inflammatory and anti-inflammatory milieu may be differentially regulated in effusive and effusive-
constrictive TB-PC.
2.2.3 Synthesis
The findings from the above work suggest the following:
1. Cellular profiles in blood and pericardial fluid in TB-PC may differ significantly between
HIV-1-infected and -uninfected individuals. This may be detectable as differential gene ex-
pression at whole sample and cell-specific level
2. Several components of the immune response to tuberculosis may be compartmentalised as
evidenced by differential mRNA transcript, protein levels and cell population proportions
between blood and pericardial fluid
3. In tuberculous pericarditis, the immune response may be differentially regulated based on
the haemodynamic phenotype of the pericardial effusion (in blood, pericardial fluid, or both)
2.3 Development of a systems approach
The finding of an interferon-inducible neutrophil-driven blood transcriptional signature in human
tuberculosis [82] in HIV-1 uninfected study subjects argues strongly for replicating this approach
in an HIV-1 infected cohort. In addition, site of disease data as produced by Matthews et al and Nt-
sekhe et al argue strongly that gene-expression patterns underlying cellular and cytokine responses
at the site of disease are amenable to discovery and may shed significant light on site-of-disease
pathogenetic mechanisms in HIV-TB. I therefore embarked on developing a theoretical framework
within which questions relating gene expression in tuberculosis, HIV and body compartment could
be answered, and the results compared.
In this context, it is worth briefly discussing what tissue-level transcriptomes actually repres-
ent. The transcriptome is the set of all RNA molecules, including mRNA, rRNA, tRNA, and other
non-coding RNA produced in one or a population of cells (http://en.wikipedia.org/wiki/
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2.4 Hypotheses and study questions
Transcriptome). It can be measured using array-based and sequencing-based techniques. Import-
antly, the transcriptome varies dynamically over time, and is strongly influenced by environmental
factors. The unit of measure for the transcriptome is “transcript abundance”, which is influenced by
factors such as constitutive expression, regulation of the activity of individual genes due to signal
processing within cells and stochastic processes. Individual types of cells exhibit a predilection to
express particular genes which, taken together, define and establish the specific properties of the
cell type.
2.4 Hypotheses and study questions
Three main hypotheses underlie this thesis.
1. Active tuberculosis is distinguishable from not active tuberculosis on the basis of differential
gene expression in both HIV-1 uninfected and HIV-1 infected individuals
2. HIV-1 infection is distinguishable from absence of HIV-1 inf ction on the basis of differential
gene expression in multiple health and disease contexts, including active tuberculosis
3. Differential gene expression between matched samples of blood and pericardial fluid is due
to both altered cell proportions between the compartments as well as cell-specific differential
gene expression
2.5 Aims and objectives
2.5.1 Aims
The broad aim of this work is to provide a survey of the transcriptional landscape of HIV-TB in a
two-compartment model at the level of individual genes, gene modules and individual cell types.
2.5.2 Objectives
1. Retrospective selection and prospective collection of matched blood and pericardial fluid
samples from individuals with suspected or confirmed TB-PC, and of blood samples of three
classes of controls (healthy, LTBI and pulmonary tuberculosis (PTB))
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2. Retrospective curation, prospective collection and synthesis of clinical and phenotype data
relating to the above samples
3. Measurement of host transcript abundance in pericardial fluid (PCF) and blood using cDNA
microarrays
4. Development of an analytic framework in the R programming language that allows for ad-
dressing the stated hypotheses and additional research questions. Importantly, results must
be output at gene, gene module and cellular levels
5. Placement of differentially expressed genes and modules in biological context by examining
gene modules in co-expression networks as well as biological pathways
2.6 Overall study design
This study, though complex in analytic design, is an observational study of a heterogenous cohort
of individuals, each of whom had contributed either a blood or matched blood and PCF samples,
depending on disease status. Throughout this manuscript, this study will be referred to as IMPI-MA
(IMPI-Africa registry MicroArray substudy).
2.6.1 Contrasts and comparisons
Two concepts are important to differentiate at this point:
1. Contrast: a contrast is defined as a phenotypic variable that defines exactly two states between
which differential gene expression is assessed. The full set of contrasts will be described and
justified in Chapter 8, where the full dataset and the associated phenotypes will be described.
The three contrasts defined a priori (as implied by the hypotheses) are:
a) TB-status, consisting of active tuberculosis (either PTB or TB-PC) or not active tuber-
culosis (either healthy individuals or asymptomatic individuals with evidence of prior
sensitisation to Mycobacterium tuberculosis)
b) HIV-status, consisting of HIV-1 infected and HIV-1 uninfected individuals, respect-
ively
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c) Compartment, consisting of whole venous blood or whole pericardial fluid samples
2. Comparison: a comparison is defined as an assessment of similarity or difference in two or
more groups following assessment of one particular contrast, based on another phenotypic
variable, termed the context variable. For example, differential expression analysis may
be performed for the contrast TB-status in two sample subsets (HIV-1 infected and HIV-1
uninfected), and the results compared. Conversely, HIV-status may be used as the contrast,
and active tuberculosis and not active tuberculosis status used as basis for the comparison.
Figure 2.2 shows this graphically.
active TB
HIV neg
not active TB
HIV neg
active TB
HIV pos
not active TB
HIV pos
contrast
contrast
comparison
active TB
HIV neg
not active TB
HIV neg
active TB
HIV pos
not active TB
HIV pos
contrast contrastcomparison
A B
Figure 2.2: The difference between the concepts Contrast and Comparison. In panel A, the
contrast TB-status is used to discover a list of differentially expressed genes in two
populations. The two gene lists can then be compared on the basis of HIV-status. In
panel B, the converse experiment is shown, with HIV-status being the contrast and TB-
status the comparator.
2.6.2 Phenotype space as hypercube
Given the three contrasts defined above, we can visualise each sample represented mapped to a
corner of a three-dimensional cube. Examination of the edges of the cube, shown in Figure 2.3
reveals all possible contrasts and comparisons involving these three parameters. This concept will
be expanded upon in Chapter 8, where we will generalise the parameter space for the full analysis
to a subgraph of a six-dimensional hypercube. The cubic graphical parameter space is analogous to
a three-dimensional space showing principal components of a dataset defined by three parameters.
In an ideal situation, the point clouds for each of the eight groups would be arranged in a cube-like
fashion, with the eight centroids forming the vertices of a cube.
The three-dimensional cube immediately suggests a design for an analytic algorithm that will
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BN+ BA+
BA-BN-
FN+ FA+
FA-FN-
+
-
N A
B
F
all
A B
Figure 2.3: 3D parameter space. Panel A. Three-dimensional cube representing the main para-
meter space required to address the three stated hypotheses is shown. Abbreviations: B
blood; F pericardial fluid; A active tuberculosis; N not active tuberculosis; + HIV-1 in-
fected; - HIV-1 uninfected. There are 23=8 combinations of the three variables, yielding
the eight corners of the cube as shown. Given the eight corners, there are a total of 12
potential contrasts and 6 potential comparisons (See Figure 2.2). Each face of the cube
corresponds to one of 2×3=6 views of the dataset. Panel B shows the three orthogonal
contrasts used to address the main hypotheses of this thesis.
potentially demonstrate a complete survey of the transcriptional landscape of HIV-TB in a two-
compartment model.
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Chapter summary
In this chapter I describe generation and analysis of preliminary data based on an RT-PCR ap-
proach, IMPI-MA study subjects, the clinical phenotype database, RNA sample processing, further
processing of RNA samples for microarray, microarray data generation, microarray data manage-
ment and a general approach to microarray data analysis as developed in R.
3.1 Preliminary data: RT-PCR data generation and analysis
One subset of the TB-PC immunology data will be discussed here, as I will present an analysis of
this data in Chapter 4. In work done prior to the project that is the subject of this thesis, Kerryn
Matthews studied matched blood and pericardial fluid samples from individuals with TB-PC by
quantitative real-time polymerase chain reaction (qRT-PCR). The generation of this data was per-
formed in 2006-2010, and the analysis reported in her PhD thesis [107]. For the purposes of devel-
oping an analytic framework for the microarray study, I re-analysed this dataset using a workflow
designed for micorarray data. Here I briefly review the laboratory work done by Kerryn Matthews,
and describe the analytic pipeline.
3.1.1 RNA collection and processing
Three mL of matched blood and pericardial fluid samples were collected in PAXgene Blood RNA
tubes (PreAnalytiX GmbH, CH, catalog number 762165) at the time of pericardiocentesis, and
frozen at −20 ◦C pending RNA extraction.
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3.1.2 Data generation1
All of the following work was performed by Kerryn Matthews and is hereby fully acknowledged.
Forty-two genes were chosen to evaluate the host transcriptional response in two compartments
based on known biological significance in tuberculosis or HIV pathogenesis. These genes are listed
in Table 3.1. RNA was extracted using the PAXgene Blood RNA Kit (PreAnalytiX, catalog number
762174) according to the manufacturer’s instructions, and stored at −80 ◦C. Quantity and quality
of the total RNA was determined using a NanoDrop (ND1000, Thermo Scientific, USA). RNA was
reverse transcribed to cDNA using the Quantitect Reverse Transcription kit (Qiagen, USA, catalog
number 205313) and a total of 1µg/ml of cDNA was used in each RT-PCR reaction. Primers and
probes for RT-PCR were purchased from Applied Biosystems as predesigned inventoried assay
reagents. The TaqMan Gene Expression Assays (Applied Biosystems, USA) used to determine the
gene expression of forty-two genes are listed in Table 3.1, and the experiments were performed in a
25µl final reaction volume under universal cycling conditions on the ABI 7000 platform (Applied
Biosystems, USA) as described [30]. Human beta-actin was used as the single internal endogenous
control for each sample assayed. All data values output are ∆CT values, calculated by subtracting
the cycle threshold of beta-actin from the cycle threshold of the gene of interest. See Figure 3.1
for illustration of this method. On occasions where the gene of interest failed to amplify after forty
cycles, the ∆CT value was recorded as “invalid” by the instrument.
delta CT
beta-actin
gene of interest
threshold
cycle threshold
10 20 30 40
Cycle
number
0.2
0.4
0.6
0.8
1.0
Delta
reaction
Figure 3.1: RT-PCR: calculation of ∆CT
1This subsection is based on original input by Kerryn Matthews
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3.1 Preliminary data: RT-PCR data generation and analysis
Table 3.1: 42 genes selected for RT-PCR analysis
HGNC Symbol HGNC Approved Name HGNC ID Entrez Gene ID Protein name
IL1B interleukin 1, beta 5992 3553 Interleukin-1 beta
IL2 interleukin 2 6001 3558 Interleukin-2
IL6 interleukin 6 6018 3569 Interleukin-6
IL18 interleukin 18 5986 3606 Interleukin-18
IL24 interleukin 24 11346 11009 Interleukin-24
TNF tumor necrosis factor 11892 7124 Tumor necrosis factor
IFNG interferon, gamma 5438 3458 Interferon gamma
CXCL10 chemokine (C-X-C motif) ligand 10 10637 3627 C-X-C motif chemokine 10
IL4 interleukin 4 6014 3565 Interleukin-4
IL13 interleukin 13 5973 3596 Interleukin-13
IL17A interleukin 17A 5981 3605 Interleukin-17A
IL22 interleukin 22 14900 50616 Interleukin-22
IL23A interleukin 23, alpha subunit p19 15488 51561 Interleukin-23 subunit alpha
TGFB1 transforming growth factor, beta 1 11766 7040 Transforming growth factor beta-1
IL10 interleukin 10 5962 3586 Interleukin-10
FOXP3 forkhead box P3 6106 50943 Forkhead box protein 3
IL8 Interleukin 8 6025 3576 Interleukin-8
LCN2 lipocalin 2 6526 3934 Neutrophil gelatinase-associated lipocalin
CAMP cathelicidin antimicrobial peptide 1472 820 Cathelicidin antimicrobial peptide
DEFB4A defensin, beta 4A 2767 1673 Beta-defensin 4A
ELANE elastase, neutrophil expressed 3309 1991 Neutrophil elastase
EGF epidermal growth factor 3229 1950 Pro-epidermal growth factor
CTGF connective tissue growth factor 2500 1490 Connective tissue growth factor
CSF2
colony stimulating factor 2
(granulocyte-macrophage)
2434 1437
Granulocyte-macrophage colony-stimulating
factor
IL9 interleukin 9 6029 3578 Interleukin-9
COL1A1 collagen, type I, alpha 1 2197 1277 Collagen alpha-1(I) chain
COL1A2 collagen, type I, alpha 2 2198 1278 Collagen alpha-2(I) chain
COL4A1 collagen, type IV, alpha 1 2202 1282 Collagen alpha-1(IV) chain
COL4A2 collagen, type IV, alpha 2 2203 2203 Collagen alpha-2(IV) chain
ARG1 arginase, liver 663 383 Arginase-1
SPARC
secreted protein, acidic, cysteine-rich
(osteonectin)
11219 6678 SPARC
MMP1
matrix metallopeptidase 1 (interstitial
collagenase)
7155 4312 Interstitial collagenase
MMP2
matrix metallopeptidase 2 (gelatinase A,
72kDa gelatinase, 72kDa type IV
collagenase)
7166 4313 72 kDa type IV collagenase
MMP3
matrix metallopeptidase 3 (stromelysin 1,
progelatinase)
7173 4314 Stromelysin-1
MMP7
matrix metallopeptidase 7 (matrilysin,
uterine)
7174 4316 Matrilysin
MMP8
matrix metallopeptidase 8 (neutrophil
collagenase)
7175 4317 Neutrophil collagenase
MMP9
matrix metallopeptidase 9 (gelatinase B,
92kDa gelatinase, 92kDa type IV
collagenase)
7176 4318 Matrix metalloproteinase-9
MMP10
matrix metallopeptidase 10 (stromelysin
2)
7156 4319 Stromelysin-2
MMP11
matrix metallopeptidase 11 (stromelysin
3)
7157 4320 Stromelysin-3
TIMP1 TIMP metallopeptidase inhibitor 1 11820 7076 Metalloproteinase inhibitor 1
TIMP2 TIMP metallopeptidase inhibitor 2 11821 7077 Metalloproteinase inhibitor 2
TIMP3 TIMP metallopeptidase inhibitor 3 11822 7078 Metalloproteinase inhibitor 3
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3.1.3 Analysis pipeline
In order to support development of an analysis pipeline for the microarray data, I developed a
simplified version of this pipeline to deal with the RT-PCR data as this data was analogous to
microarray data, but far less complex (by almost four orders of magnitude).
Raw RT-PCR data was expressed as delta cycle threshold (∆CT ) in both blood and pericardial
fluid samples. In order to emulate data generated in microarray experiments, the ∆CT values were
transformed by log10× 2∆CT , which yielded expression levels relative to beta-actin on a continuous
log scale, with smaller values indicating lower expression levels. No further normalisation was
performed, as each value was already normalised to beta-actin, and assumptions that apply to large
data sets of thousands of genes, as found in typical microarray experiments can not be assumed
to hold true for forty-two individually selected genes. Several genes failed to reach the detection
threshold by 40 cycles, and a ∆CT value of 40 was assigned in those cases, representing extremely
low levels of gene expression.
All downstream data analysis was performed in R [108], using packages from the biocon-
ductor suite (http://www.bioconductor.org), and additional packages from CRAN (http://cran.r-
project.org). The matrix of expression values was clustered by hierarchical clustering with Euc-
lidean distance and complete linkage. Correlation of gene expression in both blood and pericardial
fluid was assessed by computing the matrix of pairwise Pearson correlation coefficients. Genes that
had very low expression levels (∆CT value > 38 in more than 5% of samples) were removed from
the analysis by a non-specific filtering step.
Differential gene expression between blood and pericardial fluid was determined using a lin-
ear model approach implemented in R using the package limma [109]. In short, log-ratios were
estimated between two or more target RNA samples simultaneously by performing least-squares
regression modelling for each gene. The standard errors of each model are moderated using an em-
pirical Bayes model. The output of limma was a moderated t-statistic and a log-odds of differential
expression for each gene. The resulting log-fold changes (differential expression) and the corres-
ponding statistical significance were visualised using a volcano plot. Visualisation of various gene
subsets by principal component analysis was performed using the ClassDiscovery package from
[110]. Heatmaps were calibrated by including one column each of minimum and maximum values
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of the raw data. This preserves the colour hue and intensity of each datapoint across all heatmaps.
All values were clustered using hierarchical clustering with average linkage.
3.2 IMPI-MA study subjects
In order to address the three hypotheses above, I required RNA samples from “active tuberculosis”
cases and “not active tuberculosis controls”, stratified by HIV status and c mpartment (blood and
pericardial fluid). Instead of attempting to prospectively recruit adequate numbers of study sub-
jects, I had the opportunity to utilise samples collected prior to the start of the IMPI-MA project,
referred to below as “retrospective cases” and “retrospective controls”. The study subjects and their
respective phenotype data and RNA samples are described in detail. Even with a large retrospective
sample collection, it became apparent that prospective study subjects and samples were required
to reach adequate numbers of samples. Therefore, an additional cohort of prospectively collected
samples was generated.
3.2.1 Definitions of cases and controls
Specific definitions apply for certain terms used in this thesis, including case definitions of disease
states. These are summarised in Table 3.2.
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Table 3.2: Definitions of terms. Abbreviations: ADA: Adenosine deaminase, CXR: Chest X-Ray.
Tygerberg score refers to a numeric score based on clinical (fever, weight loss and night
sweats) and laboratory (serum globulin and leukocyte count) [111]
Term Criterion Value
TB Status Not active tuberculosis or Active tuberculosis
TB Status: Not
active
tuberculosis
Healthy or Latent TB infection
Healthy Symptoms, TST and IGRA
Asymptomatic, and no evidence of prior immune
sensitisation to Mycobacterium tuberculosis
(TST negative and IGRA negative)
Latent TB
infection Symptoms, TST and IGRA
Asymptomatic, and evidence of prior immune
sensitisation to Mycobacterium tuberculosis
(TST positive or IGRA positive)
TB Status:
Active
tuberculosis
PTB (definite) or TBPC (definite)
PTB (definite) Demonstration of Mycobacteriumtuberculosis in sputum
Sputum smear positive for acid-fast bacilli
OR Positive culture or PCR for Mycobacterium
tuberculosis in pericardial fluid
PTB (probable) Symptoms, CXR Symptoms and signs of PTB; compatible CXRchanges; response to therapy
TB-PC (definite) Demonstration of Mycobacteriumtuberculosis in pericardial fluid
Positive culture or PCR for Mycobacterium
tuberculosis in pericardial fluid
TB-PC
(probable)
Pericardial effusion AND Demonstration of significant pericardial effusionon echocardiogram
No evidence of pericardial infection
with other bacteria AND Negative bacterial culture of PCF
Elevated adenosine deaminase level in
pericardial fluid OR ADA > 40 U/L in PCF
Elevated IFNγ level in pericardial fluid
OR IFNγ > 50 pg/ml in PCF
Good clinical response to anti-TB
chemotherapy OR Clinical assessment of response to therapy
Demonstration of Mycobacterium
tuberculosis in a site other than PCF
OR
Positive smear, culture or PCR for
Mycobacterium tuberculosis at a site other than
PCF
Tygerberg score A Tygerberg score of 6 or greater
Effusive-
constrictive
TBPC
Pre-pericardiocentesis right atrial
pressure elevated AND > 8 mmHg
low transmural pressure gradient
AND ≤ 4 mmHg
Failure of Post-pericardiocentesis
RAP to fall to normal levels >11 mmHg
Effusive TBPC
Post-pericardiocentesis RAP falls to
normal levels and the
post-pericardiocentesis intrapericardial
pressure falls to to zero
HIV Status HIV-1 infected or HIV-1 uninfected
HIV-1 infected ELISA for HIV-1 ELISA for HIV-1 reactive
HIV-1 uninfected ELISA for HIV-1 ELISA for HIV-1 non-reactive
Compartment Blood or Pericardial Fluid
Blood Venous blood
Pericardial fluid Pericardial fluid collected at pericardiocentesis
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3.2 IMPI-MA study subjects
3.2.2 Retrospective TB-PC cases
Starting in 2006, Kerryn Matthews in the laboratory of Robert J Wilkinson at CIDRI, IIDMM,
UCT started collecting matched blood and pericardial fluid samples form patients being enrolled
in Registry 2 of the IMPI-Africa Registry by Mpiko Ntsekhe and colleagues. This specific sample
collection period ended in 2010 when the Biosafety Level 3 (BSL-3) facility at the IIDMM was
upgraded and all work requiring BSL-3 laboratory conditions ceased.
The majority of subjects during this time were also enrolled in a “Haemodynamic Phenotype”
substudy of the IMPI-Africa Registry. The clinical workflow is described in Figure 3.2. Patients
were included in the Registry if they were 18 years or older, gave written informed consent, had
an effusion of at least 500mm3 (at least 10 mm free fluid at the cardiac apex on echocardiogram)
and had tuberculosis suspected or confirmed as aetiology for their effusion. In addition patients
were included in the haemodynamic phenotype substudy if right atrial pressures pre- and post
pericardiocentesis were available.
1. Screening: Echocardiogram confirms pericardial effusion
2. Patient consented and enrolled in the IMPI-Africa Registry
3. Pericardiocentesis under fluoroscopic guidance in the Heart Catheterisation Labor-
atory at Groote Schuur Hospital
a) Effusion tapped to dryness
b) Blood and pericardial fluid samples collected
c) In a subset of cases, simultaneous right-heart catheterisation was performed
in order to obtain the measurements required for categorisation of haemody-
namic phenotype
4. Phenotyping
a) History and clinical examination
b) Appropriate microbiological tests to detect Mycobacterium tuberculosis
c) Additional biochemical and other tests on blood
Figure 3.2: Clinical workflow for retrospective TB-PC cases
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3.2.3 Retrospective controls
The ILULU partnership, an EU-funded consortium aiming to develop a novel diagnostic marker for
tuberculosis, enrolled children and adults in study sites in South Africa and Malawi in six clinical
phenotypes:
1. TB+ HIV-
2. TB+ HIV+
3. LTBI (Latent TB) + HIV+
4. LTBI+ HIV-
5. HIV+ with opportunistic infections other than TB
6. HIV- with acute and chronic infections other than TB
Following completion of the first phase of this study, hereafter referred to as the “EU study” (dur-
ing which cDNA microarrays were used to generate transcriptomic data), duplicate RNA samples
remaining at the study sites were available for subsequent use at the discretion of the site principal
investigator. I obtained permission from Professor Robert J Wilkinson, principal investigator for
the adult study in Cape Town, to utilise selected samples based on needs for positive and negative
controls for the IMPI-MA study.
The study subjects for the adult Cape Town arm of the study were enrolled at Ubuntu Clinic,
Site B, Khayelitsha, Cape Town. The workflow of enrolment is described in Figure 3.3. Mul-
tiple asymptomatic subjects were screened for inclusion into the LTBI arms of the study; a number
of these subjects turned out to have negative TST and IGRA responses, and while they were not
included in the ILULU consortium study, their samples remained available for study. These consti-
tuted the “healthy” controls (see Table 3.2). LTBI+ HIV+ and LTBI+HIV- constituted the “LTBI”
controls. Lastly, TB+ HIV+ and TB+ HIV- constituted the “PTB” controls.
3.2.4 Prospective TB-PC cases
Following completion of refurbishment work at the BSL-3 facility at the IIDMM, prospective
sample collection could be restarted. From March 2011 to February 2012 I collected blood and
pericardial fluid samples from patients enrolled in the diagnostic substudy of the ongoing IMPI
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3.2 IMPI-MA study subjects
1. Screening: History and clinical examination
2. HIV counselling and testing
a) If HIV-1 infected: CD4 count
b) If HIV-1 uninfected: no CD4 count
3. TST and IGRA performed on asymptomatic patients
4. Investigation of symptomatic patients
a) CXR
b) Sputum for AFB and TB culture
c) Other tests as indicated (specifically to detect other infections or malignan-
cies)
5. Phenotyping based on results of 1-4
Figure 3.3: Clinical workflow for retrospective controls
Registry and/or the IMPI trial, a prospective clinical trial of immunotherapy in tuberculous peri-
carditis.
1. Screening: Echocardiogram confirms pericardial effusion
2. Patient consented and enrolled in the IMPI-Africa Registry: Diagnostic substudy
and/ or IMPI-trial
3. Pericardiocentesis under fluoroscopic guidance in the Heart Catheterisation Labor-
atory at Groote Schuur Hospital
a) Effusion tapped to dryness
b) Blood and pericardial fluid samples collected
4. Phenotyping
a) History and clinical examination
b) Appropriate microbiological tests to detect Mycobacterium tuberculosis
c) Additional biochemical and other tests on blood
Figure 3.4: Clinical workflow for prospective TB-PC cases
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3.2.5 Ethics clearance for the various cohorts
All subjects provided written informed consent. This included sample storage for subsequent ana-
lysis. All subjects with TB-PC who were recruited into one of the IMPI cohorts are covered by
UCT HREC REF: 102/2003, 402/2005 & 289/2007, while all subjects recruited by the EU study
are covered by UCT HREC REF: 012/2007.
3.3 RNA and other Samples
3.3.1 Retrospective TB-PC cases
For each subject, 3 mL blood and pericardial fluid were collected in PAXgene containers. Following
manufacturer’s guidelines, the PAXgene tubes were frozen at −20 ◦C. Subsequently, RNA was
extracted using the PAXgene Blood RNA Kit (PreAnalytiX, catalog number 762174) according to
the manufacturer’s instructions, and stored at −80 ◦C. RNA of 28 matched blood and pericardial
fluid samples was used in the RT-PCR assay described in Section 3.1, and the remainder of extracted
RNA was kept frozen at −80 ◦C. RNA yield and quality was assessed using NanoDrop 1000 and
RIN as determined by AB Bioanalyzer 2100 (Agilent Technologies, USA).
Other blood and pericardial fluid samples were collected, processed and analysed as previously
described [107, 112, 49].
3.3.2 Retrospective controls
For each subject, 3 mL blood was collected in PAXgene containers, respectively. Following manu-
facturer’s guidelines, the PAXgene tubes were frozen at−20 ◦C. Subsequently, RNA was extracted
using PAXgene Blood RNA Kit and the extracted RNA was kept frozen at −80 ◦C. RNA yield and
quality was assessed using NanoDrop.
3.3.3 Prospective TB-PC cases
All work below was performed by myself in the BSL-3 facility at the IIDMM.
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RNA samples For each subject, 3 mL blood and pericardial fluid were collected in PAXgene
containers, respectively. Following manufacturer’s guidelines, the PAXgene tubes were frozen at
−20 ◦C after being allowed to stand undisturbed for at least two hours. Subsequently, RNA was
extracted using PAXgene Blood RNA Kit. The remainder of extracted RNA was kept frozen at
−80 ◦C. RNA yield and quality was assessed using NanoDrop (NanoDrop 2000c, Thermo Sci-
entific, USA).
Serum For each subject, venous blood was collected in 2× 5.0mL SST (BD, USA, Catalog
number 367955) tubes. Serum was separated using centrifugation of the SST tube at 3000 rpm for
10 minutes with the brake on; serum the above gel layer was removed by pipette and and transferred
to a Nunc CryoTube Vial (Thermo Scientific, catalog number 375418) (max. volume per vial = 1.8
mL) using a filter tip. Labeled cryotubes were frozen at −80 ◦C and recorded in the freezer log.
Separation of PBMC For each subject, venous blood was collected in 2×9.0mL VACUETTE
Plasma Sodium Heparin tubes (greiner bio-one, USA, catalog number 455051). Peripheral blood
mononuclear cells (PBMC) were separated from plasma using the Ficoll method. Blood was mixed
with an equal volume of Dulbecco’s Phosphate-buffered saline (PBS) (Sigma-Aldrich Life Science,
USA, catalog number D8537) and carefully layered onto Ficoll-Paque (GE Healthcare, USA, cata-
log number 17-1440-03) in a 50 mL conical tube (BD Falcon, USA, catalog number 352070).
The blood/PBS/Ficoll-Paque layered mixture was then centrifuged at 700g for 20 minutes with
the brakes off. Following this, the buffy coat containing PBMC (see Figure 3.5) was removed by
Pasteur pipette and transferred into 15mL RPMI-1640 (Sigma-Aldrich Life Science, USA, catalog
number R8758) medium, which was then made up to 40 mL for the first wash step by centrifuga-
tion at 600 x g for 10 minutes (brakes on). After this, the supernatant was discarded, and the pellet
resuspended with 10 mL RPMI containing 10% heat-inactivated foetal calf serum made up from
FBS Superior stock solution (RPMI+10%FCS) (Biochrom, Germany, catalog number S 0615). The
cells were counted twice using standard counting chambers using Trypan Blue (Sigma-Aldrich Life
Science, USA, catalog number T8154) and Crystal Violet (Sigma-Aldrich Life Science, USA, cata-
log number C3886-25G), respectively, and the results averaged. The former allows to distinguish
live from dead cells, and the latter lyses erythrocytes which may still be present). The cells were
71
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
3 Materials and methods
finally centrifuged at 600 x g for 10 minutes with brakes on, and frozen as described below.
Plasma, PBS, platelets
White cells: lymphocytes, monocytes, +/- platelets 
Ficoll
Red blood cells, granulocytes (mainly neutrophils)
Figure 3.5: Layering of components after Ficoll separation
PFC and Cell-free pericardial fluid The method used for separating pericardial fluid cells
(PFC) from pericardial fluid depended on blood content of the pericardial fluid. In some cases
there was gross blood admixture, and the fluid resembled blood macroscopically, and in other cases
the fluid was clear, serous fluid.
In case of no or minimal visible blood contamination, the contents of all three sodium heparin
tubes containing pericardial fluid were transferred to a sterile 50 mL conical tube and centrifuged
at 600 x g for 10 minutes with the brakes off. The supernatant, cell-free fluid (CFF), was removed
by pipette and transferred to a cryovial (max. volume per vial = 1.8 mL); in most cases I aimed to
freeze 3 x 1.8 mL. The remainder of the supernatant was discarded. The pellet containing PFCs
was resuspended in 40 mL RPMI and centrifuged in the first wash step at 600 x g for 10 minutes
with the brakes on. Supernatant was discarded and 10 mL of RPMI+10% HI-FCS added to the
cells, which were then counted as described above. The final wash step consisted of centrifuging at
600 x g for 10 minutes with the brakes on, and the cells were frozen as described below.
In case of gross blood contamination (i.e. blood visible to the naked eye), the Ficoll method was
used as above in order to cope with the large number of red cells, with the following modification:
two of the three tubes were transferred to a 50 mL conical tube without addition of PBS, and
the remainder of the steps were identical to the ones above in the Ficoll procedure for separating
PBMC from blood. The remaining sample tube was processed by the standard PCF method in
order to recover cell free fluid; the cells obtained in this process were discarded.
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Freezing procedure for PBMC and PFCs After the second wash step in RPMI+10%HI-FCS,
the supernatant was discarded. 1− 10× 106 cells (PBMC or PFC) were resuspended in 1 mL of
freezing solution by carefully adding 0.4 mL of RPMI+10% HI-FCS to the pellet with a pipette,
mixing carefully, and adding 0.5 mL of freezing medium (20% dimethylsulfoxide in 10% HI-
FCS) drop-wise, while gently agitating the mixture. The cell/ cell-freeze mix was transferred to a
labelled cryovial which was in turn transferred to a Mr Frosty and frozen at−80 ◦C overnight. After
overnight storage, the cells were transferred to the vapour phase of liquid nitrogen for long-term
storage, and the storage log completed.
3.3.4 Summary: RNA samples and banked specimens
RNA samples from blood, and in cases with TB-PC also pericardial fluid, were collected in a
uniform way as per manufacturer guidelines, stored in identical fashion prior to extraction and
extracted using identical kits. This addresses one potential source of technical bias in microarray
studies: use of different RNA collection, storage and extraction methods. Banked serum, cell free
fluid, PBMC and PFCs are available for future validation work.
3.4 Clinical phenotype database
Clinical phenotype data for the the RNA samples used in the IMPI-MA study was obtained by
multiple investigators over a five year period. All retrospective data was obtained in electronic
format from the investigators who had collected it, and I captured and collated all prospectively
collected clinical data (SET-2).
3.4.1 Data sets
Data sets are listed in Table 3.3. The data sets are heterogenous, as each was originally developed
for a specific purpose other than provision of clinical phenotype data for IMPI-MA. These datasets
required many hours of work to produce, and have been used in supporting numerous publications,
and will continue to support others. For the purposes of IMPI-MA, I required one dataset which
used identical variables for parameters of interest. This was to be achieved by integrating the data,
ensuring the ability to consistently phenotype all samples used in the microarray analysis.
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3.4.2 Integration strategy
The strategy for production of a single clinical phenotype database is outlined in Figure 3.6. This
was a complex process requiring multiple rounds of data cleaning and development of computer
code in Mathematica [113] that automated the process of TB class assignment based on the complex
case definitions in Table 3.2.
1. Merge datasets 1-4; clean data and fully eliminate redundancy. Folder review of study and hospital folders
to resolve any conflicts. Output = SET-1_clinical
2. Merge datasets 5-27; clean data and fully eliminate redundancy. Ensure correct matching of identifiers to
individuals in clinical dataset. Output = SET-1_immunology
3. Merge SET-1_clinical and SET-1_immunology. Each row in flat-file database contains all data on on
study subject. Output=SET-1_full
4. Identify potential microarray candidates using the following criteria: Blood RIN and PCF RIN of matched
blood and PCF samples > 6.0
5. Export clinical subset of this data as SET-1 (immunology data removed as not available in SET-2 or
controls)
6. Process SET-2: Ensure identical variable naming as SET-1 for integration purposes.
7. Entire SET-2 exported as microarray candidates as RIN data not available (RIN to be performed in UK)
8. In Mathematica, calculate tuberculosis class and export as SET-1 and SET-2
9. Merge SET-1 and SET-2 into full TB-PC clinical phenotype dataset
10. Search EU data for potential array candidates based on RNA availability and clinical phenotype (Healthy,
LTBI and PTB)
11. Verify RNA availability for potential samples
12. Match the three groups to identify 20 each of Healthy, LTBI and PTB using age, sex, HIV-status, CD4
count as matching criteria
13. Extract additional relevant clinical phenotype data from EU database and export data as Controls, with
identical column headers in the flat file datasheet
14. Manually merge TB-PC and Control datasets into single file
15. Duplicate phenotype entries as required, so that each sample type (blood and pericardial fluid) has a full
phenotype record
16. Examine final dataset for missing data, and perform final folder review of various study and hospital folders
to close gaps where possible
17. Export to production CSV file, to be used in all microarray analyses.
Figure 3.6: Workflow for data integration
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Figure 3.6: Workflow for data integration
3.5 RNA processing for microarray
3.5.1 Extraction and collation
RNA was extracted as described above, using the PAXgene Blood RNA Kit (PreAnalytiX, catalog
number 762174) according to the manufacturer’s instructions. RNA was extracted by different
individuals and different times, depending on the original study for which the RNA was intended.
1. Retrospective TB-PC cases: Kerryn Matthews and myself
2. Retrospective controls (EU study): Nzwaki Bangani
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3. Prospective TB-PC cases: Nzwaki Bangani and myself
As described previously, RNA samples were selected by different criteria depending on the original
study. As all samples in the retrospective TB-PC case series had RIN data available, only high-
quality samples were selected. The EU study controls had no RIN data available, so simply sample
availability was used as criterion to select sixty microarray candidates. Lastly, the prospective
TB-PC case series had no RIN data available, so all available matched blood and pericardial fluid
samples were selected as array candidates.
3.5.2 Shipping and storage
The selected samples were shipped on dry ice to the National Institute for Medical Research in
London (NIMR), UK, for further processing and microarray analysis, under an agreement with our
collaborator there, Dr Anne O’Garra, head of Immunoregulation at the NIMR and senior author of
the Nature paper [82] on which our laboratory had previously collaborated.
3.6 Microarray workflow
3.6.1 RNA preparation for microarray
All RNA processing for microarrays, as described in this subsection was performed by Christine
Graham in the laboratory of Anne O’Garra, and her contribution to this project is hereby acknow-
ledged. An outline of the process is shown in Figure 3.7.
The RNA preparation process followed the method outlined in [114]. The first step in prepar-
ing the extracted RNA samples for microarray was to verify RNA quality and yield, using an AB
Bioanalyzer 2100 instrument at the NIMR. This step was used to select samples for further pro-
cessing, as samples with degraded RNA (i.e. RIN values < 6) or low yield (i.e. yield <1250 ng)
would not be expected to produce useful results. Selected samples were then subjected to a globin
reduction step, in order to reduce interference from globin mRNA message with the transcripts
of interest [115, 116]. Quality control was then performed on all globin-reduced samples, and
all samples passing QC criteria taken forward the following step: cRNA generation. In short, the
mRNA in the sample was converted to cDNA, which in turn was converted to cRNA. A final QC
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All RNA
Preliminary QC
Globin reduction and QC
cRNA generation and QC
Chip layout
Exclude QC Fail
Exclude QC Fail
Exclude QC Fail
Figure 3.7: RNA preparation schema
step was performed to confirm high-quality cRNA for further use in microarray data generation.
All samples were processed independent of original sample type (blood and pericardial fluid) and
clinical phenotype. The samples passing all QC checkpoints were then randomly assigned to pos-
itions individual array chips. This array randomisation is vital to reduce the batch effects that are
due to the specific chip used [117]. The workflow for the RNA preparation step is summarised in
Figure 3.7.
3.7 Microarray data
3.7.1 Array technology
The BeadArray technology was first described in 2004 [118], as was a method used to decode such
arrays [119]. All microarray data was generated on the Illumina BeachChip platform, using the
current version of the assay and Illumina Human HT12-v4.0 BeadChips. Each BeadChip contains
twelve arrays; generating multiple arrays on a single chip further reduces batch effects. Each array
contains approximately 1-1.5 million beads, representing in excess of 47,000 probe sequences,
randomly distributed across the array, with approximately 30 replicates of each probe type on each
array. Given the random bead distribution, each array is unique, and requires decoding [119] prior
to use. The decoded array is then used for RNA hybridisation.
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1. Starting material: mRNA extracted from human sample
2. Globin reduction using GLOBINclear kit (Ambion, USA, catalog number AM1980) (a method utilising
capture of unwanted RNA by magnetic beads)
3. cRNA generation and purification (Illumina TotalPrep -96 RNA Amplification Kit,) (Illumina, USA, catalog
number AMIL1791)
a) Reverse transcription to synthesise first-strand cDNA
b) Second strand synthesis to generate double-stranded cDNA
c) cDNA purification to remove RNA and other components that could potentially inhibit or interfere
with downstream reactions
d) in vitro transcription to generate multiple copies biotinylated cRNA from double-stranded cDNA
templates
e) cRNA purification to remove unincorporated NTPs, salts and other residuals which could interfere
with the direct hybridisation assay
Figure 3.8: Workflow for RNA preparation
3.7.2 RNA hybridisation and addition of fluorophore
All microarray work, starting with biotinylated cRNA prepared by Christine Graham, was per-
formed by Harsha Jani at the Microarray Core Facility at the NIMR. The workflow for the microar-
ray work is listed in Figure 3.9.
1. Normalised quantities of cRNA are dispensed onto the BeadChip
2. The loaded BeadChips incubated overnight (10-14 hours) at 58◦C
3. Wash BeadChips using high-temperature wash buffer and follow with room-temperature washes
4. Apply streptavidin-Cy3 to BeadChips; this will allow for signal detection using a fluorescent light source
as the streptavidin-Cy3 fluorophore will bind to biotinylated cRNA present on the chip
5. Final wash steps and drying
Figure 3.9: Workflow for array hybridisation
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3.7.3 Imaging
After hybridisation, the BeadChips were scanned at the Microarray core facility using an Illumina
iScan microarray scanner. This step converted relative transcript abundance into a proportional
light signal. This light signal was captured during the imaging step by a powerful CCD camera,
which resulted in a high-resolution TIFF image. Each array was imaged in two passes, and the two
resulting images were then combined into a single image by the iScan software. At this stage, the
chip decoding data, unique to each BeadChip was loaded onto the controlling computer, in order to
assign bead identifiers to each bead on the chip.
3.7.4 Image processing and data summarisation for further analysis
The decoded high-resolution images generated by the iScan scanner were processed further us-
ing GenomeStudio, resulting in summarised probe-level data. Each step in the summary process
reduced the number of observations per array. This is illustrated for a single array in Table 3.4.
Table 3.4: Levels of data complexity
Level Data type Interpretation Number of observations
Raw image Pixel intensities One observation per pixel per
array
approx. 125×106
Bead-level Bead intensities One observation per bead per
array
approx. 1.0−1.5×106
Probe level Bead intensities summarised
by bead type
One observation per probe type
per array
47,231
The summarised bead intensity value consists of an average intensity value for a particular bead
type, together with the number of replicates and the standard deviation for the observation. This is
useful for the data transformation step.
The final microarray data was provided by the NIMR Microarray Core Facility as a tab-delimited
text file containing summarised probe-level data.
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3.8 Data analysis overview
3.8.1 Computing environment
All data analysis was performed on a mid 2010 MacBook Pro with dual-core Intel Core i7 pro-
cessors and 8GB non-ECC RAM running OS X 10.8.4. R software was used for the entire analysis
workflow.
3.8.2 Analysis framework
All data analysis was done in R version 2.15.2 using a set of scripts, and utilising several R and
bioconductor packages.
General data analysis revolves around analysis of RT-PCR data (see above), presentation of an
unbiased view of all microarray data, and demonstration of the relation of the IMPI-MA data to
previous studies of tuberculosis using blood transcriptomics approaches.
The core of the analysis revolves around seven questions (see Table 8.1) pertaining to the three
main hypotheses. Multiple analyses of different, overlapping subsets of the data in fact constitutes
a meta-analysis, as the goal is not only to evaluate a single contrast and reach a conclusion, but to
evaluate multiple contrasts, compare the results and then reach a more generalised conclusion about
the pathogenesis of HIV-TB in a two-compartment model. Each of the seven questions is addressed
using complementary analytic methods: detection of differential gene expression for the contrast
of interest, deconvolution of the data in order to estimate proportions of specific cell types in the
sample as well as cell-type-specific differential gene expression, and modular analysis by detection
of modules on the basis of co-expression networks in the microarray data. The scientific basis and
methodology underlying these analyses will be described in the remainder of this section. The
remaining sections of this chapter, together with Chapter 8, outline the R scripts that underlie vari-
ous aspects of the analysis, and shows how these scripts together constitute an end-to-end solution
for reproducible and well-documented (meta-) analysis of heterogenous microarray datasets that
consist of data based on samples from different tissue types and individuals with different disease
phenotype classes. All source code is reproduced with syntax highlighting in the Appendix (A),
and has been annotated to facilitate readability. The scripts produce output in three main classes:
RData files for further processing, images and delimited text files that can be imported in other
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applications (e.g. Microsoft Excel, Cytoscape).
3.8.3 Microarray analysis in general
The approach to studies involving microarray data should include pre-defined research questions.
Overall hypotheses must be stated prior to the analysis of the data, and the results presented in
the context of the hypotheses. Pre-stating clear hypotheses facilitates the process of selecting a
data analysis goal and therefore tools to achieve this goal. In general supervised and unsupervised
methods may be applied to microarray data, and their use depends on the research question (see
below).
Analysis of microarray data usually has one or more of three goals [120]: Class Comparison,
Class Prediction and Class Discovery. The aim of class comparison is to find genes that are dif-
ferentially expressed between groups of samples that belong to known and defined classes. The
analysis is supervised, as the classes are known and this knowledge is used to find differentially ex-
pressed genes. Class prediction uses unsupervised methods to separate classes in the data without
prior knowledge. These predicted classes can then be compared to the real classes, and sensitivity
and specificity calculated. Usually, the classifier is built using a training set, and then tested on a
separate test set. Class discovery again uses unsupervised methods to discover previously unknown
classes of samples. This may be used where sample phenotyping is unable to further differentiate
phenotypes within a set of samples that is suspected to be heterogenous at the molecular level. This
approach has been used in oncology to classify morphologically identical tumours into subclasses
that can be linked to survival or other clinico-pathological outcomes [121, 122].
3.8.4 Reduction in technical bias: array transformation and normalisation
As stated previously, there are many factors (which are not due to the controlled factors in an exper-
iment) that may influence the intensity of a particular probe type on a BeadArray chip, for instance
quantity of mRNA. In order to reduce the impact of this source of bias, array data should be nor-
malised. Multiple methods as applied to Illumina HumanHT12 v3 BeadArray were compared in a
recent paper[123], and on the basis of that paper, as well as recommendations in the documentation
of Illumina-specific analysis packages in R [124], variance stabilising transformation followed by
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quantile normalisation was performed.
3.8.5 Differential expression analysis
The most fundamental analytic technique applied to microarray datasets is the detection of differ-
ential expression of probes or genes between two or more classes of samples. While simple in
principle, in practice this problem is quite complex. The individual measured intensity values are
affected by multiple sources of fluctuation and noise. This problem is in part addressed by includ-
ing technical replicates on the microarray chip; the Illumina HumanHT12v4 chip used in this study
contains an average of 30 replicates for each probe type on the chip.
Multiple methods for detection of differentially expressed genes have been described. Many
rely on some form of statistical hypothesis testing, where the null hypothesis H0 is that there is no
difference in transcript abundance for probe (or gene) x. A simple method of testing this hypothesis
is to perform a simple t-test; all genes that are significant at a pre-specified p-value are labelled
as differentially expressed. This approach is likely to yield many false-positives, given the typical
number of tests performed (20,000-48,000 for Illumina data). A more rigorous approach would be
to subject the results to some form of multiple testing correction. A non-exhaustive list of potential
methods for selecting differentially expressed genes is shown in Table 3.5 (Table based on [125]).
In the analysis of the IMPI-MA data, we employ an approach first described by Smyth [109],
namely the use of a moderated t-statistic in selecting differentially expressed genes. This method
is widely used in the literature, and yields robust results.
This approach aims to fit a linear model to expression data that fully models the systematic part
of the data. The model is specified by a design matrix, where each row represents one array, and
each column represents one coefficient that describes the RNA source (i.e. a phenotype variable).
The purpose of this approach is to describe and account for the variability of the data. For single
channel arrays, linear modelling is similar to ordinary ANOVA or multiple regression, except that a
model is fitted to every gene (or probe type). Once the model is derived, an empirical Bayes method
is used to moderate the standard errors of the estimated log-fold changes. This results in estimators
that have robust behaviour, even for small numbers of arrays. The posterior odds statistic is thus
reformulated in terms of the moderated t-statistic where the posterior residual standard deviations
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Table 3.5: Methods for selecting differentially expressed genes
Name Method Advantages Disadvantages
Fold Change Select threshold Simple and intuitive arbitrary
Unusual Ratio Ratio of experiment to
control > 2 standard
deviations from mean
experiment/control
ratio
Simple
always selects 5% of
all genes
Hypothesis
testing
t-test followed by
multiple testing
correction
Powerful
Very conservative,
assumes genes are
independent
ANOVA Explicit model of all
sources of variance
Each source of
variance is accounted
for
Requires specific
experimental design
Noise sampling Estimate noise and
calculate confidence
levels for gene
regulation
Better sensitivity than
unusual ratio and better
specificity than fold
change methods
Provides estimates only
for log-ratios of genes
Model-based
maximum
likelihood
estimation
Generate mixture
model for distribution
of observed log ratios
for expressed and
non-expressed genes
General, powerful,
flexible
Require solution of
complex non-linear
equations; unreliable
for smaller samples
SAM Permutation-based to
discover genes
differentially regulated
for a given false
discovery rate
Useful for small
sample sizes
Moderated
t-statistic
Fit linear model to each
gene and determine
whether coefficient
differs significantly
from zero
Useful for small
sample sizes; powerful
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are used in place of ordinary standard deviations, resulting in more stable inference.
In the model, the array intensity values are represented by a continuous variable termed the
response variable. The contrast(s) of interest are represented by one or more categorical vari-
ables (explanatory variables or predictors). The goal of the procedure is to test the the association
between predictors and response. Equation 3.1 shows the model:
yi =
p
∑
j=1
β jxi j +β0 + εi (3.1)
Here, yi is the response for the ith sample, β j the coefficient for the jth predictor, xi j the value of
the predictor x j of the ith sample, β0 the intercept of the model, and εi the error term (or residual),
representing noise and the effect of all predictors not considered in the model.
A microarray experiment consists of a large number of probes or genes that have to be modelled,
therefore the equation above can be represented in matrix form as
y = X·β + ε (3.2)
where y is the response vector, X the design matrix, β the vector of coefficients and ε the vector
of residuals. Building a linear model then reduces to finding the values of the β s (coefficients) that
would minimise the error, i.e. solving y = X ·β . The R package limma implements an ordinary least
squares solution, as X is usually not a singular square matrix, and makes the following assumptions:
1. The residuals εi are normally distributed
2. The mean (expected value) of the residuals is zero and is independent of the values of the
predictors
3. The variance of the residuals does not depend on the values of the predictors (homoscedasti-
city)
4. The value of the residual for one sample is unrelated to the amount of residual for another
sample
A basic limitation of parametric modelling is that this approach only finds the best values for the
parameters available in the model.
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Once the fitted model with the moderated t-statistic is produced, multiple testing correction is
applied in order to reduce the number of false-positive calls. Throughout all analyses, a multiple
testing correction method described by Benjamini and Hochberg [126, 127], based on a specified
false discovery rate has been applied.
Issues with this study:
This study aims to compare the results of multiple differential expression analyses, each based
on a subset of data with an variable number of samples in each contrast category. As each differ-
ential expression analysis attempts to identify an effect size that may differ widely between sample
subsets, from small (difference between healthy and LTBI in blood in HIV uninfected) vs. large
(e.g. differences between gene expression in matched blood and pericardial fluid samples), the
statistical power of each DE analysis is different. Some sample subsets consist of large numbers
in each group, and the likely effect size is large, while others consist of small numbers and aim to
detect a small effect size, therefore the type II error rate for each DE analysis is different.
This is dealt with by limiting the number of called DE probes to a maximum of 2000, and by
including as a minimum the top 300 DE probes, regardless of whether the adjusted p-value is
significant or not. In the latter case, such an analysis will be regarded as exploratory, but may still
offer some biological insight and aid in the development of testable hypotheses.
3.8.6 Deconvolution and cell-specific differential expression
A common criticism of microarray approaches in general is that the expression profiles for a given
sample strongly depend on the cellular composition of the samples in question. Now, if the cellular
composition between samples varies widely, differences in gene expression profiles are in the first
instance ascribable to the differences in cellular composition, and not necessarily to differential use
of transcriptional pathways. In addition, the power to detect differentially expressed genes between
samples is strongly affected by sample variation in cell-type frequencies [128, 129, 130]. Therefore,
comparisons of gene expression between samples of different tissues (like blood and pericardial
fluid) are likely to yield many differentially expressed genes, most of which are uninformative
regarding true biological differences, and subtle differences in cell-type specific gene expression in
closely related conditions may be masked by the noise of the cell-type frequency component in the
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expression signal. To solve this dilemma, two approaches can be taken.
First, the samples may be separated into constituent cell populations. For example, a whole
blood sample may be separated into pre-defined cell subsets (neutrophils, CD4 T cells, CD8 T
cells, and others). Then, RNA is extracted separately and microarrays performed. This approach
has a number of disadvantages: it is time-consuming and expensive, must be done prospectively,
and the physical separation of the cells may have unexpected effects on gene expression in the
separated cells [131, 132]. This approach was not followed in this study.
The second option is to determine the proportions of cell types in the samples, and then per-
form a cell-type specific differential expression analysis on the expression matrix based on these
proportions. Determination of cell-type proportions in each sample may be performed by phys-
ical means (e.g. flow cytometry) or computationally, using a method called matrix deconvolution
and first described by Lu et al [133]. The analysis of the IMPI-MA dataset implements the matrix
deconvolution approach utilising a least-squares fit algorithm described by Abbas et al [100] and
implemented in the CellMix package [134].
Estimation of cell-type specific differential gene expression may also be performed computa-
tionally. This relies on known (or estimated) proportions of cells for each sample, and subsequent
application of differential expression analysis. A method utilising the permutation-based method
called significance analysis of microarrays (SAM) has been described [135] and will be used in this
analysis. This method is also implemented in the CellMix R package. Estimates of cell-type spe-
cific differential expression may uncover true biological differences between samples with variable
cellular composition.
A number of methods for gene expression deconvolution have been described (e.g. [100, 136,
137, 138]) and a full review can be found in the comprehensive documentation of the CellMix
package. Here I briefly describe the method used by Abbas et al [100], as this method was most
suitable to the data to be analysed. The objective of the deconvolution method is to find the solution
for a convolution equation
AX = B (3.3)
Here, B is the matrix of gene expression data, X is the matrix of proportions of cell types in all
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samples and A is the matrix of known expression levels of genes in all cellular components of B,
which is convolved with X. This equation is solved for X by standard least squares fitting using the
method pioneered by Lu [133], where one solves for X with the constraint that the resulting matrix
is contains only non-negative entries.
This approach requires knowledge of A, and in the Abbas paper [100], the authors describe their
method of generating this matrix of cell-type specific signatures, its validation and subsequent ap-
plication to a whole-blood microarray study of systemic lupus erythomatosus. The CellMix pack-
age implements multiple deconvolution methods. One method (gedBlood) replicates the Abbas
method exactly, and utilises the above cell-type signature matrix; this was used in the analysis of
the IMPI-MA data.
Once cellular proportions for all samples represented in the expression matrix are known, differ-
ential gene expression for each cell type represented in significant numbers should become possible.
A method to achieve this was published in 2010 [135].
The following two assumptions are made in the analysis as reported:
1. Blood and pericardial fluid are assumed to have the same cellular composition, differing only
in proportion
2. These cell-types consist of the cell-types isolated and studied by Abbas
In a study published in 2006 [139], Reuter et al performed flow cytometry on whole blood and
pericardial fluid in patients with tuberculous pericarditis (including HIV-1 infected and -uninfected
groups). Their findings show that the three most commonly cell-types were neutrophils, lymph-
ocytes and monocytes, while NK cells also occurred. The data also show that proportions of
cell types in blood and pericardial fluid, in both HIV-1 infected and -uninfected individuals, are
markedly different, with neutrophils being the most abundant cell-type in blood, but much less
frequent in pericardial fluid.
Despite the promise of using microarray data in order to infer cell proportions, some limita-
tions of this approach need to be recognised. Firstly, this approach only yields indirect evidence of
different cell proportions and cell-specific differential expression, and the results require verifica-
tion prior to accepting the results at face value. An experiment that does this is described below.
Secondly, the ability to detect differences in whole blood may be limited due to the dilution of the
89
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
3 Materials and methods
signal in mixed cell populations. In published papers[100, 135] however, the authors are able to re-
liably detect cell proportions and cell-specific differential expression. Indeed, sample heterogeneity
may mask true differential gene expression when performing differential gene expression analysis
on whole blood transcriptomes, while cell-specific differential expression correctly identifies the
cell type and transcript list of differentially expressed genes[135].
Validation of the deconvolution approach Given the limitations discussed above, validation
of the deconvolution method is warranted. This would be best achieved by collecting flow cyto-
metry data on whole blood on the same samples on which array data is available. In the absence of
such data (no whole blood flow cytometry data was generated for IMPI-MA), I used existing data
generated in the Berry et al study [82] (London Test Set) to partially validate this method.
Flow cytometry data was generated on whole blood samples on 27 patients, approximately
equally sampled from healthy controls, LTBI and PTB cases. 17 of these patients also had Illu-
mina HT12v3 microarray data available. All flow cytometry data was provided by Fin McNab in
the Anne O’Garra laboratory, NIMR, London, UK.
The flow cytometry data was received as three Microsoft Excel files; one each for healthy con-
trols, LTBI controls and PTB cases. For each workbook, one worksheet was dedicated to one class
of cells. I copied the original data into a new Excel workbook with one worksheet for each class of
cell, converting all cells containing formulas to static values; each worksheet contained data for all
patients. Next, I removed all rows (samples) from this for which no microarray data was available,
and all columns which did not contain relevant data for the intended comparison.
The following cell subsets were enumerated: Total T cells, CD4 T cells (and multiple subsets),
CD8 T cells (and multiple subsets), other T cells (i.e. double negative for CD4 and CD8), dendritic
cells (plasmacytoid and myeloid subtypes), inflammatory and non-inflammatory monocytes, NK
cells, and neutrophils. Full methods describing the flow cytometry approach are available in the
supplementary data for the Berry et al paper [82]. Based on proportions seen at flow cytometry
and total number of white blood cells as based on complete blood counts, numbers of each subtype
were calculated. The sum of numbers for all cell types was computed, and compared to the total
white blood cell count; this yielded the number (and proportion) of cells unaccounted for by flow
cytometry for the particular sample. Finally, the subset of the data representing the cell propor-
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tions matrix similar to the proportions matrix yielded by deconvolution was exported as a comma
delimited text file and used for further analysis. Only samples where the sum of all proportions
represented at least 80% of all cells were included. This aims to exclude noise introduced by addi-
tional cell types not measured by flow cytometry but which may influence the expression profiles
derived from whole blood.
Deconvolution using the method described above was applied to the full BERRY test set. Cell
types identified by deconvolution included CD4 T cells (resting and activated). CD8 T cells (resting
and activated), B cells (5 subtypes), plasma cells, monocytes (resting and activated), NK cells
(resting and activated), dendritic cells (resting and activated) and neutrophils.
In the analysis step, the two proportions matrices obtained from flow cytometry and deconvolu-
tion, using the same samples and containing cell subsets with identical labels, were used. Figure
3.10 shows how the cell subsets from the two approaches were related to each other to study a
unified subset of common cell types.
The function profplot, implemented in the CellMix package, was used to plot the combined
proportions matrices. For each cell type, the regression coefficient (α), Spearman rho (ρ) and
Pearson R2 with 95% confidence interval were calculated. The results of the analysis are presented
in Chapter 5.
3.8.7 Weighted gene co-expression network analysis (WGCNA)
The techniques described above for differential expression focus on finding individual genes that
may be important in a particular biological context. However, as described in Chapter 1, the focus
of systems approaches is to find explanations for behaviour and properties of complex systems, i.e.
identification of functional units instead of individual parts. Modules of co-expressed genes may be
related to emergent and other high-order phenomena of such complex systems, leading to improved
understanding of the underlying biology [140]. This leads to a reduction in high-dimensional data,
and allows for integration of multi-scale data.
An implementation of such an approach was first described in 2005 [140] and has been imple-
mented as the package WGCNA in R [141].
The fundamental concept underlying the functionality of the WGCNA package is that genes are
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Figure 3.10: Approach for unification of cell type subsets For the deconvolution cell subsets,
those subsets actually detected by the deconvolution algorithm in the array data are
marked in yellow.
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expressed in groups called modules, and that such modules are identifiable in microarray expres-
sion data. The processes involved in detecting such modules and interpreting their function and
importance relative to phenotypic or other information is described below.
The network is constructed by making use of interaction patterns in the raw expression data.
Pearson correlation is used as the measure of describing such interaction, as it is intuitive, avoids
overfitting, is computationally fast and is reproducible.
The first step in the analysis is therefore construction of the correlation matrix, containing the
Pearson correlation coefficient for each pairwise interaction for all genes studied. For large gene
lists this is a computationally intensive step, and the package provides some utilities to run the ana-
lysis on systems with relatively small amounts of RAM. For instance, a list of 8000 probes or genes
generates a square matrix with sixteen million entries. The next step of the analysis transforms the
correlation matrix into an adjacency matrix, where each entry represents the weighted connectivity
between all pairwise gene interactions, by using the power function
f (x) = xβ (3.4)
The parameter β is chosen in such a way that the resulting adjacency matrix exhibits scale-free
topology, as many biological networks that have been studied experimentally exhibit scale-free
topology [142, 143, 144, 145, 146, 147]. This is based on a previously described model fitting
index R2 [140]. For a perfectly scale-free network, this index is defined to equal one. Here, the
parameter β is chosen as the smallest exponent of the above power function such that the model
fitting index R2 ≥ 0.8. This is termed the soft-thresholding procedure. It preserves the continuous
information of the co-expression network and yields robust results with regard to different threshold
choices [148]. The result of this step is an adjacency matrix, where each entry corresponds to the
strength of the interaction between the two genes. This adjacency matrix is then transformed into a
topological overlap matrix (TOM) which enables rapid detection of modules. This matrix provides
a similarity measure for each pairwise interaction reflecting their relative interconnectedness.
Detection of modules (i.e. groups of genes whose expression profiles are highly correlated across
samples) is performed as the next step. First, the TOM-based dissimilarity matrix (i.e. 1-TOM) is
clustered using average linkage hierarchical clustering. Modules are then detected based on the
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clustering result, and this therefore depends on the choice of branch cut height, i.e. how distant
two clusters have to be to belong to separate modules. The WGCNA package [141] implements
a dynamic branch-cutting algorithm that allows for variation in branch cut height for different
modules.
In order to interpret the modules, they are next related to external information. For the purposes
of this study I have limited this to the contrast of interest, in order to identify modules import-
ant in that contrast. This allows for the discovery of “interesting” modules that may be analysed
further. Module eigengene expression can be linked to clinical data. This is implemented by correl-
ating eigengene expression values with clinical trait data. As clinical traits can be measured using
continuous or categorical variables, this presents us with a problem. To address this, categorical
clinical traits were first converted to ordinal data by encoding the individual categories using nu-
merical values either arbitrarily (e.g. sex), or where appropriate on scale of increasing severity (e.g.
healthy, latent TB, active TB). This allows for associating module eigengene expression with both
continuous variables as well as categorical variables.
Finally, module preservation across different datasets can be studied, and the key drivers (hub
genes) in the modules identified.
3.8.8 Pathway analysis
Exploratory pathway analysis was performed on several datasets, as proof of concept and for future
integration in the analytic framework. Pathway analysis was performed using the R package gage
[149], and pathways were visualised using the R package pathview [150]. Since these packages
require R version 3.0.1 or higher, the code was not integrated with the other scripts, as the current
analytic framework still runs in R version 2.15.2; code integration will require updating the R
installation to R version 3.0.1 and all Bioconductor packages to version 12.
Gage implements pathway analysis using publicly available data from KEGG (Kyoto Encyc-
lopedia of Genes and Genomes) [151, 152]. The method extends techniques used for gene set
enrichment analysis and provides a more robust environment for finding differentially regulated
pathways. It allows for unpaired samples, and case and control groups of different sizes. Gage
outputs over-represented pathways ranked by q-values.
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All pathways significant after multiple testing correction were visualised in using pathview, with
log-fold change values mapped to individual pathway components, indicating whether this com-
ponent was over- or underexpressed in the differential expression analysis.
Pathway analysis has several limitations. These have been reviewed recently in [153] and are
summarised here. These limitations can be divided into two main groups: Annotation challenges
and methodological challenges.
Annotation challenges Genomic annotation databases at present lack the resolution of new-
generation technologies used to generate state-of-the-art genomic data. Alternative splicing may,
for example, be detected using RNA-seq, but annotation databases may contain only information
for a single transcript. Multiple transcripts of the same gene may have different, even opposing,
biological functions, but this is not reflected in current databases. So, a query to KEGG will only
indicate that a given gene shows altered transcript abundance, but does not identify the biological
function of the specific splice variant. In addition, annotations contained in biological knowledge-
bases may be incomplete or inaccurate. Many genes are annotated as “hypothetical” genes with
no known function. Despite this, transcripts that map to these non-annotated genes appear to be
important in biological contexts. Finally, information on specific pathways is usually based on a
defined experimental system, but information regarding the experimental context is often missing
from pathway resources.
Methodological challenges Benchmark data for comparing different pathway analysis meth-
ods is not available. Methods are usually compared using simulated data, which yields reproducible
results but no indication of which method correctly identifies real biological phenomena. Also,
pathways are not independent of each other, yet analytical methods usually make that very assump-
tion. This results in a lack of a model that accounts for dependence among pathways at different
time points. This limits our ability to observe changes at a pathway level in a biological system.
This may in part be addressed by topology-based approaches.
Conclusion Pathway analysis, as implemented for this thesis has several limitations. Care must
be taken when interpreting results.
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3.8.9 Other methods
Multiple additional methods to analyse microarray data exist. I chose the above to provide a broad
view of the transcriptomic landscape in HIV-TB across many different contrasts. An additional
method that might have been implemented is transcription factor binding site analysis. This would
yield information regarding possible regulatory factors which might explain the observed variation,
and would definitely improve the biological insight gained from the various gene lists. Future work
may add this and other methods to the pipeline described above.
3.9 Code descriptions
In this section, the R code used for the analyses is described in outline. Full code listings with syntax
highlighting are provided in the Appendix. Additional information on customised R functions used
in the setup and analysis scripts can also be found in the appendix, together with the code for the
functions.
Some of the principles that are used in the code, specifically the idea of setting up the workspace
environment, as well as the general workflow for the the code in subsection A.9 are based on a
tutorial for performing the analysis of the Berry et al data, reported in 2010 [82] in R instead of
GeneSpring. I adapted the code as required; the utility functions mentioned on the website have
been incorporated in the system setup script.
IMPI-MA refers to data generated for this PhD project; BERRY refers to expression data pub-
lished in 2010 [82].
3.9.1 IMPI-MA: System setup
The code for this analysis is reproduced in full in Appendix Section A.6. This script is sourced by
all other analysis scripts, and standardises the analysis and output environment for each analysis.
The script performs the following actions:
1. Initialise the session by clearing the workspace and resetting the graphics devices
2. Configure local folders (project root, R-scripts folder, data folder)
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3. Load utility functions
4. Set global parameters (e.g. image export formats, graphics parameters)
5. Load all libraries required by the analysis scripts
3.9.2 IMPI-MA: Data manager
The code for this analysis is reproduced in full in Appendix Section A.7. This script performs the
following actions:
1. Source system setup script
2. Specify local data and output folders
3. Import expression (IMPI-MA and BERRY) and phenotype data using lumi
4. Make subsets of the datasets using CSC (compartment, subset, contrast) scheme
5. Export datasets to RData files; any subsequent use of the data is greatly sped up using RData
6. Import 393 and 86 transcript lists, and export for later use as RData files
3.9.3 RT-PCR data analysis as a prototype for more complex analyses
The code for this analysis is reproduced in full in Appendix Section A.8. The script performs the
following actions:
1. Setup
2. Source setup script
a) Make specific data and versioned output folders
b) Define additional functions redgreen and interleave
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3. Read in RT-PCR and phenotype data and make single data structure
4. Calculate statistics for summary table of participant clinical characteristics
5. Select phenotype categories used for colour in plots
6. Make data matrix used in DE analysis and matrix of relevant phenotype information
7. Plot raw data: box-and-whisker plots, heatmap and correlation matrix plots
8. Filter data based on low expression values
9. Plot filtered data
10. Differential expression analysis for contrast: compartment
11. Plot and export results
12. Principal component analysis of all, filtered data and selected genes
13. Protein analysis
a) Select protein data
b) Boxplots and statistics for differential protein abundance
14. Additional analysis for HIV status and lowCD4 contrasts in blood and pericardial fluid
3.9.4 Relation of IMPI-MA data to previously published work
The code for this analysis is reproduced in full in Appendix Section A.5. The code for the differen-
tial expression analysis (Baylor Method) is based on concepts described in an online tutorial (found
here: http://www.bigre.ulb.ac.be/courses/statistics_bioinformatics/practicals/microarrays_berry_2010/)
and adapted for use in this framework, but the remainder is original work.
The script performs the following actions:
1. System setup
2. Source setup script
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a) Create local data folders and versioned output folders
3. Load data and place in a list which is iterated over for each step of the analysis
4. Average normalisation (replicating a procedure originally carried out in BeadStudio)
5. Calculations for two-way table of clinical characteristics, comparing variables between datasets, and between
different disease classes within datasets
6. Show raw data using box-and-whisker charts, multidimensional scaling and principal component analysis
7. Data preprocessing: threshold low expression values to minimum of 10 and perform median scaling; visualise
data
8. Data filtering: detection filter and fold-change filter followed by selection of probes passing both filtering criteria;
visualise data
9. Calculate differential expression statistics
10. Generate lists of differentially expressed probes
11. Plot results and export lists of probes for further analysis
The code for the main analysis will be discussed in the Chapter 8, as development of this code
depended on specific technical results; the overall code structure was conceived only after the
microarray data had become available, together with information regarding the numbers of samples
in various classes with successful arrays.
3.9.5 An unbiased view of all IMPI-MA and BERRY data
The code for this analysis is reproduced in full in Appendix Section A.10. This simple linear script
performs the following actions:
1. Source setup script
2. Create local data and versioned output folders
3. Load data (IMPI-MA and BERRY)
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4. Generate quality control plots, including density plots, boxplots and MA plots
5. Multidimensional scaling analysis of IMPI-MA data (all samples, blood and fluid)
3.10 Comparisons
Comparisons of gene lists were made by calculating the intersection of two or more gene lists, and
visualising these using Venn diagrams in R; Code examples are shown in Appendix Section A.9.
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4 RT-PCR on matched blood and fluid
Chapter summary
This chapter describes the results of an analysis of RT-PCR data from patients with tuberculous
pericarditis, with particular focus on contrasting gene expression between the blood and pericardial
fluid compartments. We show that significant differential expression of genes is detectable between
compartments, and that this difference may be biologically informative.
Disclosure: The text is largely based on a manuscript in the early stages of preparation. All text
was written by myself, but incorporates significant input from the senior author of the manuscript,
Prof. Katalin A Wilkinson. For this reason, this chapter is written in the first person plural form. As
described in Section3.1, all data was generated by Kerryn Matthews and the IMPI Registry team.
4.1 General comments regarding the presentation of results
Throughout this thesis results of increased or decreased transcript abundance are reported, be it gen-
erated by RT-PCR or microarray. The terms “upregulation” and “downregulation” are frequently
employed to refer to increased and decreased transcript abundance as a form of convenient short-
hand. In reality, the observed changes are usually due to factors over and above changes in the
regulation of expression, and the use of the terms up- or downregulation should be read in their
(intended) wider sense.
Many images depicting clustered versions or PCA plots of pre-selected features are shown in
the results. These heatmaps and plots essentially show only that the selected features classify the
input data correctly. Future work will include experiments where the signatures obtained from the
IMPI-MA data will be validated against unrelated datasets.
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Interpretation of PCA plots can be rather subjective. As it stands, the current work does not
provide more objective metrics of similarity of datasets based on visual inspection of the scat-
terplots. Future work will incorporate calculation of Euclidean distances between centroids and
drawing ellipses. R packages that have these features exist.
4.2 Study subjects
27 patients with TB pericarditis (15 definite and 12 probable cases) were included in this analysis
(Table 4.1). Ten were HIV-1 uninfected and 17 were HIV-1 infected, with a median CD4 count
of 167.0 (98.0-343.0) cells/µl. There was no difference in proportions of definite or probable TB
diagnosis, gender or age between HIV status groups, but the CD4 count was significantly lower in
the HIV-1 infected patients (p=0.025). One HIV-1-infected participant was on antiretroviral therapy
at the time of sampling; duration of antiretroviral therapy was not recorded.
Table 4.1: Clinical characteristics of study participants. Proportions were compared using chi-
squared test, and medians of continuous variables (age, CD4 count, pericardial fluid
ADA and IFN)γ were compared using Wilcoxon rank sum test (Mann-Whitney U test)
Comparison*of*clinical*characteristics*of*patients*with*tuberculous*pericarditis,*stratified*by*HIV:status*
! All#participants#(N=27)# HIV51#uninfected#(N=10)# HIV51#infected#(N=17)# P5value#
Age!
Median!(IQR)!
#31.6#(28.7541.3)# #47.4#(28.9568.2)# #31.4#(28.9535.8)# #0.155#
Gender!
Female:!Male!
#10:17# #3:7# #7:10# #0.866#
TB!status!
Probable:!Definite!
#12:15# #6:4# #6:11# #0.397#
CD4!count!(cells/μl)! 167.0#(98.05343.0)# 306.5#(1905418.5)# 118#(895266)# 0.025#
Concurrent!steroids!
Yes:no!
#18:8# #5:4# #13:4# #0.230#
Fluid!ADA!(U/L)! 77.0#(54.5591.5)# 81.0#(65.05137.0)# 75.0#(52.0586.0)# 0.374#
Fluid!IFNHϒ!(pg/ml)! 1531.0#(205.554212.0)# 2084.25#(0.053993.0)# 1308.0#(498.054512.0)# 0.907#
Number!on!ART!
(yes:no)!
NA# NA# 1:16# NA##
4.3 Gene expression analysis
Overall expression values in the two compartments were similar (Figure 4.1).
As a first step in our analysis, we grouped the 42 genes studied into eight functional categories:
Th1, Th2, TH17, genes associated with immunoregulation, neutrophil associated, growth factors,
fibrosis associated and matrix metalloproteinase associated genes. This categorised gene expres-
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Figure 4.1: Overall expression values. Box-and-whisker plot showing the median, upper and
lower quartile of raw ∆CT values for blood (red) and pericardial fluid samples (yel-
low)
sion in blood and pericardial fluid is summarised in Figure 4.2. Gene-by-gene comparison (with
Benjamini-Hochberg multiple testing correction) yielded 21 genes that are differentially expressed
in blood compared to pericardial fluid following application of Benjamini-Hochberg multiple test-
ing correction (Table 4.2).
Overall, differences between compartments for the expression of Th1, Th2 and Th17- associated
genes were not evident, whereas genes associated with immunoregulation did show a difference. In
addition, overall differences in expression levels of fibrosis-associated genes were evident, as well
as some neutrophil-associated genes, growth factors and MMP genes, as well as their regulators.
As a second step, we employed cluster analysis in order to explore the data further. By com-
bining the expression values of all samples and all genes (as described in methods) we generated
a heatmap shown in Figure 4.3. While there was no differentiation between blood and fluid, we
found that strikingly, most blood and pericardial fluid samples from individual patients clustered
together. This appeared to be driven by highly correlated gene expression patterns between the two
compartments, specific for each individual, thus obscuring differences of gene expression between
the two compartments. Four clusters of genes can be seen based on very low, low, intermediate and
high expression regardless of compartment. Many genes appear to be expressed in groups. This
phenomenon of co-expression was further explored in these samples and is shown in the correla-
tion matrices of blood and pericardial fluid samples in Figure 4.4. Gene co-expression patterns in
blood were different from pericardial fluid, where pronounced co-expression of fibrosis-associated
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Table 4.2: Gene-by-gene comparison of expression between compartments. All comparisons
statistically significant (P≤0.05) are highlighted in yellow.
Gene Pval Bonf BH
IL1B 0.00 0.02 0.00
IL2 0.18 1.00 0.30
IL6 0.00 0.00 0.00
IL18 0.98 1.00 1.00
IL24 0.65 1.00 0.81
TNF 0.17 1.00 0.29
IFNG 0.02 0.63 0.03
CXCL10 0.30 1.00 0.45
IL4 0.05 1.00 0.09
IL13 1.00 1.00 1.00
IL17A 0.94 1.00 1.00
IL22 0.97 1.00 1.00
IL23A 0.59 1.00 0.76
TGFB1 0.00 0.01 0.00
FOXP3 0.00 0.00 0.00
IL10 0.00 0.08 0.00
IL8 0.00 0.10 0.01
LCN2 0.00 0.05 0.00
CAMP 0.00 0.00 0.00
DEFB4A 0.48 1.00 0.65
ELANE 0.07 1.00 0.12
EGF 0.00 0.01 0.00
CTGF 0.00 0.00 0.00
CSF2 0.54 1.00 0.71
IL9 0.76 1.00 0.89
COL1A1 0.00 0.00 0.00
COL1A2 0.00 0.00 0.00
COL4A1 0.00 0.00 0.00
COL4A2 0.04 1.00 0.07
ARG1 0.00 0.00 0.00
SPARC 0.00 0.00 0.00
MMP1 0.22 1.00 0.35
MMP2 0.00 0.00 0.00
MMP3 0.34 1.00 0.49
MMP7 0.73 1.00 0.87
MMP8 0.00 0.00 0.00
MMP9 0.00 0.00 0.00
MMP10 0.85 1.00 0.96
MMP11 0.95 1.00 1.00
TIMP1 0.00 0.09 0.00
TIMP2 0.00 0.07 0.00
TIMP3 0.48 1.00 0.65
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Figure 4.2: Expression values by compartment. Blood and pericardial fluid expression values for
all 42 genes are shown, grouped into eight categories. Expression values are log 2-fold
change relative to β −actin, and as such all values are negative. More negative values
correspond to lower expression.
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and neutrophil-associated genes could be seen, as well as co-expression of some pro- and anti-
inflammatory genes. The expression of several genes in fluid also exhibited negative correlation
(e.g. IL-9 is negatively correlated with IL-2, IL-4, ELANE and MMP1)
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Figure 4.3: Calibrated heatmap of all gene expression values. This heatmap shows all expression
values. Samples and genes are clustered by hierarchical clustering with average linkage.
Strikingly, most blood and pericardial fluid samples from the same individual cluster
together.
Given the very low expression levels of some genes, we next applied a non-specific filter to the
data, which removed genes with delta-CT values greater than 38 in 5% or more of the samples (see
Section 3.1.3). This step left 22 genes that separate blood and pericardial fluid to a large extent,
with three samples misclassified (Figure 4.5). This result indicates that overall gene expression in
the two compartments is very different and confirmed our previous suggestion that genes with low
levels of expression drive the patient-specific clustering, shown earlier.
Following computation of differential gene expression with multiple testing correction using a
linear models approach (see Section 3.1.3), 17 genes were found to be differentially expressed
between the blood and pericardial fluid compartments. These genes are summarised in Table 4.3
and illustrated on a volcano plot in Figure 9.2. The calibrated heatmap shown in Figure 4.7 illus-
trates that the selected genes collectively cluster the samples into two separate compartments of
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(a) Correlation matrix for 42 genes (blood).
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(b) Correlation matrix for 42 genes (pericardial fluid).
Figure 4.4: Correlation matrices for 42 genes. Colours indicate the value of R2 for each pairwise
correlation of gene expression (raw ∆CT values) in the range -0.5 to 1; red = positive
correlation, blue = negative correlation.
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Figure 4.5: Calibrated heatmap of all filtered expression values. This heatmap shows expression
values of filtered genes. Samples and genes are clustered by hierarchical clustering with
average linkage. At this stage, blood and pericardial fluid form two separate clusters.
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blood and pericardial fluid.
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Figure 4.6: Volcano plot of differentially expressed genes.
Table 4.3: Differentially expressed genes. The logFC value represents increased or decreased
transcript abundance in pericardial fluid relative to blood. A positive value indicates
higher in fluid, and a negative value indicates higher in blood.
Differentially+expressed+genes+
ID# logFC# P.Value# adj.P.Val#
COL1A1# 2.86# 6.51E:23# 1.43E:21#
COL1A2# 1.80# 3.41E:14# 3.75E:13#
MMP2# 1.37# 1.29E:12# 9.46E:12#
COL4A1# 1.26# 4.71E:09# 1.15E:08#
CTGF# 1.19# 3.40E:11# 1.25E:10#
IL6# 1.15# 1.89E:11# 9.30E:11#
IL8# 0.85# 1.49E:03# 2.53E:03#
FOXP3# 0.77# 8.07E:05# 1.61E:04#
IL10# 0.53# 6.67E:03# 8.63E:03#
TIMP1# 0.29# 1.87E:03# 2.94E:03#
TIMP2# :0.23# 5.50E:03# 7.56E:03#
TGFB1# :0.25# 4.08E:04# 7.48E:04#
IL1B# :0.52# 4.44E:03# 6.51E:03#
SPARC# :0.95# 5.32E:09# 1.17E:08#
MMP9# :1.36# 4.38E:11# 1.32E:10#
CAMP# :1.57# 4.80E:11# 1.32E:10#
ARG1# :1.66# 2.11E:11# 9.30E:11#!
Finally, we performed principal components analysis of the data using the three gene sets (all
42 genes, subset of 22 ‘filtered genes’ obtained after non-specific filtering, and the subset of 17
‘selected genes’ obtained after differential gene expression analysis). The results are represented in
Figure 4.8 (panels A, B, and C). While there was no separation of blood and fluid on the first two
principal components using ‘all genes’ (panel A), the 22 ‘filtered genes’ (panel B) did indicate a
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Figure 4.7: Calibrated heatmap of differentially expressed genes. This heatmap shows expres-
sion values of genes that are differentially expressed. Samples and genes are clustered
by hierarchical clustering with average linkage. As expected, blood and pericardial
fluid form two separate clusters.
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separation of the two compartments. Finally, the first principal component of the 17 differentially
expressed ‘selected genes’ (panel C) explained 60% of the observed variance.
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Figure 4.8: Principal component analysis. The first panel shows the results of principal compon-
ent analysis of the whole dataset. There is no principal component that clearly allows
for separation of blood and pericardial fluid samples. The second panel shows the same
analysis applied to the filtered genes. Now, blood and fluid do separate, but not in
a single dimension. Finally, PCA applied to only the differentially expressed genes
shows clear separation of blood and pericardial fluid. Colours: red = blood; blue =
pericardial fluid
4.4 Discussion
In this Chapter I demonstrate that significant differential abundance of gene transcripts can be
detected in tuberculous pericarditis when contrasting blood and pericardial fluid. Transcripts as-
sociated with a Th1 response and fibrosis are more abundant in the pericardial fluid compartment,
suggesting that larger-scale transcriptomic studies contrasting the blood transcriptome with that of
the site of disease may be informative regarding pathogenetic mechanisms of tuberculosis.
Specifically, transcripts associated with fibrosis (COL1A1, COL1A2 and COL4A1) are more
abundant, providing evidence at mRNA level of a profibrotic environment even without pericardial
constriction present and suggesting that collagen synthesis takes place much in advance of clinical
features of constrictive pericarditis. Increase of procollagen transcripts is accompanied by increase
of transcripts of the growth factor CTGF. CTGF protein is secreted by vascular endothelial cells
and promotes proliferation of chondrocytes, mediates cell adhesion in many cell types and enhances
fibroblast growth factor-induced DNA synthesis.
ARG1 and SPARC, two negative regulators of fibrosis are less abundant at transcript level, again
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underscoring the overall pro-fibrotic environment in pericardial fluid.
In addition to the pro-fibrotic environment in pericardial fluid there is some support for a Th1-
mediated inflammatory response in the pericardial compartment, with increase of IL-6 transcripts
in pericardial fluid. Other Th1-related markers are not increased, though, so this increase should be
interpreted with caution. The increase of IL-10 and FOXP3 transcripts may indicate a concurrent
anti-inflammatory response. Interpretation of pro-and anti-inflammatory responses in tuberculosis
is not without difficulty, as it is unclear whether Th1 responses are protective, injurious, or both, and
whether anti-inflammatory responses are protective or detrimental in the context of inflammation.
Neutrophil-associated genes IL-8 and CAMP are up-and downregulated in pericardial fluid, re-
spectively; this does not provide a clear indication of the role of neutrophil-specific activity in
tuberculous pericarditis.
Finally, matrix metallproteinases and their negative regulators appear to be dysregulated, with
upregulation of MMP2 and TIMP1 in pericardial fluid, and concurrent downregulation of MMP9
and TIMP1.
This proof-of-concept analysis demonstrates that informative and biologically plausible results
may be generated from analysis of matched blood and site-of-disease gene expression data.
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Chapter summary
In this chapter I provide an overview of all patients included in IMPI-MA, and develop the idea of
ordering the study subjects along the vertices of multi-dimensional hypercubes in order to define
contrasts and contexts for comparisons. This serves as the underpinning for a framework of ana-
lysing heterogeneous microarray data.
5.1 Included patients and samples
Figure 5.1 outlines the recruitment of study subjects into the IMPI-MA study, and the availabil-
ity of RNA samples for these subjects. As stated previously, recruitment into the study consisted
of three components: retrospective controls (EU Study), retrospective cases (recruited by Kerryn
Matthews for her PhD work) and prospective cases (recruited by myself for this study). A total of
140 study subjects were recruited to contribute RNA samples for microarray analysis, and these
individuals contributed a total of 220 blood and/ or pericardial fluid samples for quality assessment
and microarrays. These samples were shipped to the NIMR in London. At the NIMR, the RNA
was further processed and microarrays performed as described in Sections 3.6 and 3.7 . Follow-
ing assessment of RNA yield and microarray quality metrics at the NIMR in London (see Figure
5.2), 39 samples were excluded, leaving 181 samples for analysis. Table 5.1 lists the reasons for
exclusion of the 39 samples.
In order to plan the analysis, the 181 available microarrays were linked to phenotype information
and stratified by three main criteria, based on the main hypotheses of the study: compartment (blood
and pericardial fluid), HIV status (HIV+ and HIV-) and TB status (Healthy, LTBI, PTB and TB-PC).
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All subjects
TB pericarditis *TST or IGRA pos.20
TST and IGRA neg.
20
Sputum pos. M.tb
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Screened
50 (X2)
Screened
120 (X2)
Selected
40 (X2)
Selected
40 (X2)
Healthy
20
LTBI
20
PTB
20
TB-PC
80 (X2)
Potential arrays
220
Successful arrays
181
Excluded samples
39
Definite TB-PC
 – Histology
 – Demonstration of organism in pericardial fluid: Microscopy, 
culture or PCR
Probable TB-PC
 – Pericardial fluid ADA > 40 U/L or IFNg > 50 pg/l
 – Tygerberg index 6 or more (clinical parameters)
 – Pericardial effusion and good clinical response to TB therapy
*
Asymptomatic Asymptomatic Symptomatic Symptomatic
Figure 5.1: Study subject recruitment. The first three branches of the flowchart consist of the the
subjects from the EU Study whose whole-blood derived RNA samples were included
as controls (N=20× 3. The TB-PC arm of the study consists of retrospective (N=40
matched blood and pericardial fluid) as well as prospective (N=40 matched blood and
pericardial fluid) samples. The retrospective controls were selected on the basis of
sample and data availability, the retrospective cases on the basis of sample and data
availability as well as RNA quality (hence the large drop in numbers following screen-
ing), and the prospective samples on the basis of availability of matched blood and peri-
cardial fluid samples. Tygerberg index refers to a score based on clinical (fever, weight
loss, night sweats) and laboratory (serum globulin, blood leukocyte count) parameters
[111].
Table 5.1: Reasons for exclusion of RNA samples
Low yield (< 1250ng) Low RIN (< 6) Array QC fail Total
TB-PC blood 7 3 0 8
TB-PC fluid 21 12 1 24
PTB 3 0 0 3
LTBI 2 0 0 2
“Healthy” 1 0 0 1
Total 34 15 1 39
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Figure 5.2: RNA quality metrics. The top panel shows the RNA yield (ng, in log10 scale) for each
of the 220 samples, and the bottom panel the corresponding RNA quality (RIN, linear
scale). Green bars correspond to EU study samples; red (blood) and yellow (pericardial
fluid) bars correspond to retrospective (first pair) and prospective (second pair) TB-PC
samples. Blue lines indicate pre-specified cutoff values used for including samples in
further analysis.
The stratification of the 181 samples based on these criteria is shown in Figure 5.3.
5.2 Sample distribution along the vertices of a
multi-dimensional hypercube
As is evident from Figure 5.3, the choice of possible contrasts and comparisons for analysis of
this heterogenous and complex dataset is not immediately clear. The main problem lies with the
fact that any hierarchical ordering of the sample subsets, as shown in the figure is completely
arbitrary. Unsupervised analysis using principal component analysis may suggest an ordering,
but even then the biological relevance of such a hierarchy is unclear. There is another option
for representing the data, first discussed in Subsection 2.6.2, which allows for the fact that each
phenotypic variable is independent of all others, and thus lies orthogonally oriented to them in
phenotype space. Representing this graphically for three dimensions is trivial, as shown in Figure
2.3 for the three phenotype variables linked to the three main study hypotheses. Figure 5.4 (left
panel) now shows this same 3-cube, while the right panel shows each of the cube’s six faces,
together with their respective sample numbers. The edges joining the four vertices of each face
can now be interpreted as contrasts or comparisons (see Figure 2.2), where each contrast has a
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Figure 5.3: Sample classes. This figure illustrates the breakdown of sample numbers when strat-
ified by three criteria (Compartment, HIV status and TB status). It further shows that
subclasses may be recombined in different ways to yield additional groupings of poten-
tial interest for analysis.
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5.2 Sample distribution along the vertices of a multi-dimensional hypercube
Hamming distance [154] of 1, i.e. the phenotypes between the two vertices for each contrast differ
by exactly one character, with all others equal.
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Figure 5.4: Three-dimensional sample phenotype space. The left panel shows the three-
dimensional phenotype space relevant to the main study hypotheses (A) and the three
orthogonal contrasts (B). The right panel (C) shows each face of the cube, with each
vertex labeled by sample phenotype and number of available samples for that class. The
edges represent potential contrasts or comparisons. Solid lines represent contrasts in-
cluded in this study, and dotted lines represent contrasts excluded from the analysis due
to insufficient numbers. Abbreviations: B blood; F pericardial fluid; A active tuber-
culosis; N not active tuberculosis; + HIV-1 infected; - HIV-1 uninfected; m matched
samples exist
This idea can of course be extended into higher dimensions, where one additional dimension is
required for each additional phenotype variable to be used as a contrast. As there are a number of
interesting subgroups of phenotypes in the dataset that may shed additional light on HIV-TB, three
additional dimensions were explored: effect of TB site (pulmonary vs pericardial TB), early TB
(latent tuberculosis vs healthy) and haemodynamic phenotype in TB-PC (effusive non-constrictive
vs effusive-constrictive). Figure 5.5 illustrates the resulting higher-dimensional 3-cubes, and Fig-
ure 5.6 illustrates how the additional dimensions may be mapped to a three-dimensional repres-
entation of a six-dimensional hypercube (hexeract). This structure contains 160 cubic cells, the
four which are of interest are shown. To understand this more easily, ons should consider the ori-
ginal three-dimensional phenotype space, cube A in Figure 5.5. The left face of cube A consists
of all samples mapping to the “not active TB” phenotype. This phenotype may be divided into
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two groups (“Healthy” and “LTBI”) based on TST and IGRA results. This division “extends” the
two-dimensional left face of cube A into a three-dimensional cube of its own (cube B, Figure 5.5).
The six faces and associated sample numbers are shown in Figure 5.7. In contrast, the right face of
cube A consists of all samples mapping to the “active TB” phenotype, which may be divided into
two groups based on clinical presentation (“Pulmonary TB” and “Tuberculous pericarditis”), again
“extending” the two-dimensional right face of cube A into cube C (Figure 5.5 and Figure 5.8).
Finally, the right face of cube C (“Tuberculous pericarditis”) may yet again be “extended” into
cube D based on haemodynamic phenotype (“effusive non-constrictive pericarditis” and “effusive-
constrictive pericarditis”), shown in Figure 5.5 and Figure 5.9.
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Figure 5.5: Extension of three-dimensional cube to six dimensions. Cube A is the cube originally
discussed, and will serve as the reference point.
This concept of adding dimensions to a phenotype hypercube for each measured variable may be
further generalised to very high dimensions. The full description of the “system state” of a complex
system such as a human being requires a very large number of dimensions. This has important
implications for sampling. When drawing a sample from the study population, one ideally requires
a sample where samples for each contrast are present in equal numbers in each of the other contrasts,
in order to avoid bias and confounding.
Such a sampling strategy would then result in a balanced dataset with (1) similar numbers of
samples on all vertices of the n-dimensional hypercube, and (2) similar distributions for values of
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Figure 5.6: Six dimensional hypercube. The four cubes shown in Figure 5.5 may be mapped
to vertices in six-dimensional phenotype space, shown here as a three-dimensional
“shadow” of the six-dimensional space.
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Figure 5.7: Three-dimensional phenotype space for LTBI.
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Figure 5.8: Three-dimensional phenotype space f r TB-site.
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Figure 5.9: Three-dimensional phenotype space for HD phenotype.
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5.3 Validation of deconvolution approach: proof of concept data
all non-contrast variables (e.g. age, sex, ethnicity) for all vertices. By inspection we can verify from
Figures 5.4, 5.7, 5.8 and 5.9 that the first criterion is not satisfied in three or higher dimensions, as
the sample numbers for each vertex vary widely, and is often zero. Criterion (2), i.e. matching of
non-contrast-variable distributions will be assessed for each contrast that was analysed by inspect-
ing the table of clinical characteristics of each sample subset in the relevant results chapters of this
thesis.
In summary, the visualisation of the data mapped to vertices of a multi-dimensional hypercube
subgraph allows for data-driven selection of contrasts to examine. This concept will be re-visited
in Chapter 8, where the analytic framework for the main study analysis will be presented.
5.3 Validation of deconvolution approach: proof of concept
data
As pointed out in section 3.8.6, an attempt at validating the deconvolution method using flow cyto-
metry data was made. Figures 5.10 and 5.11 show the results.
The barplots indicate an important feature of the data. All proportions obtained by deconvolution
sum to one (by design) whereas the proportions obtained by flow cytometry do not.
Overall, the two methods correlate reasonably well (R2=0.77). Some cell types (CD8 T cells,
B cells, monocytes) correlate well, a second group (NK cells) less convincingly, and a third group
(CD4 T cells, neutrophils and dendritic cells) correlates poorly. With the data available, the reasons
for this are not clear. Dendritic cells and NK cells are observed at much higher proportions in the
deconvolution data, whereas CD4 T cells and neutrophils are observed at higher proportions in the
flow cytometry data.
The above results suggest systematic effects for these phenomena. A few potential reasons will
be discussed below, but I should emphasise that this analysis should not be considered definitive.
Firstly, neither of the proportion matrices contain “pure” proportions of single cell types but rather
“composite” cell types obtained by adding proportions of different cell types together, as shown
in Figure 3.10. Therefore the proportion signals do not necessarily represent the exact same cell
populations. Secondly, in the deconvolution method used, the basis matrix based on the Abbas
paper was generated on the Affymetrix platform, and mapping of transcript IDs (via Entrez IDs) to
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(a) Proportions obtained by deconvolution
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Figure 5.10: Barplots of proportions in 11 samples While the proportions in the top panel all sum
to one (by design), the proportions in the bottom plot do not. Each sample therefore
has an additional category of unassigned cells, which belong to one of the measured
categories, or to a different category (e.g. basophils, eosinophils)
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Figure 5.11: Correlations of cell proportions The CellMix function profplot was used to gener-
ate this plot. Prior to calculation of the correlations, the flow cytometry proportions
matrix was rescaled to one, which mirrors the deconvolution matrix. Different cell
populations are indicated by different colours. Clear systematic effects are visible for
NK cells, dendritic cells, neutrophils and CD4 T cells. The values for the overall plot
and the individual cell types represent the regression coefficient (α), Spearman rho (ρ)
and Pearson R2 with 95% confidence interval.
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the Illumina data recovered only a part of the original basis matrix (324 features of a total of 515,
i.e. 62.9%). This incomplete mapping may also influence the determination of cell proportions
using deconvolution. Finally, log2-transforming and quantile normalising the expression data may
also skew the reported proportions; indeed it has been reported that using non-transformed, non-
normalised data achieves more accurate results (R. Gaujoux, personal communication).
In conclusion, the deconvolution method is promising, but requires further validation, ideally
by generating a bespoke basis matrix based on locally generated flow cytometry data and single
cell type expression profiles using Illumina HT12v4 arrays, followed by prospectively collecting
samples from a diverse range of volunteers and subjecting these samples to whole-blood flow cyto-
metry and Illumina microarray with deconvolution.
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6 An unbiased view of all array data
Chapter summary
In this chapter I provide an overview of all IMPI-MA array data, for the purpose of defining overt
patterns in the data and to identify potential batch effects caused by technical factors. I compare
some aspects of this dataset to three datasets published previously[82], in order to argue that the
IMPI-MA dataset is similar to this previously published data.
6.1 Data
6.1.1 IMPI-MA
All data was generated as described in Section 3.7. The data consists of summarised, background-
corrected, non-normalised probe-level data for all 181 arrays. The term “IMPI-MA” will be used
to refer to this data.
6.1.2 BERRY
The data consist of the original summarised probe-level data used for the analysis of the Berry et
al paper [82], specifically the training, test and validation sets. In personal correspondence with
the first author of that paper I was able to obtain the raw, non-normalised probe-level data; this
was necessary as the publicly available version of the data includes some preprocessing steps in
the form of average normalisation (see Section 3.9.4). The term “BERRY” will be used to refer
to this data. Two BERRY subsets were included: the “training set” consisted of individuals with
active tuberculosis, LTBI and individuals without evidence of prior immune sensitisation; the same
groups were available in the IMPI-MA data. The BERRY validation set only included individuals
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with active tuberculosis or LTBI, but the study participants were recruited in South Africa and
therefore possibly more closely matched to the IMPI-MA data.
6.2 Quality control plots
Figure 6.1 shows plots of the probability density function for six groups of arrays. This is a quick
way to visually assess the similarity of expression profiles between arrays. As is clear from the
plots, the overall shape of the probability density function (PDF) is the same for all arrays in each
group but differs to some extent between groups of arrays. These differences are likely due to
technical factors rather than biology, and indicate the need for a normalisation step. These plots
highlight differences in array intensities for low to middle ranges of expression. In none of the plots
are individual arrays visible that vary dramatically from the rest.
Figure 6.2 shows plots of the cumulative density function for six groups of arrays. Similarly
to the PDF plots, these plots allow rapid assessment of all arrays for outliers in terms of overall
array intensities. In contrast to the PDF plots, the CDF plots allow for better visualisation of
intensity differences between arrays at the high and middle ranges of expression. Again, the need
for normalisation becomes evident by inspection of the plots.
After reviewing the PDF and CDF plots we concluded that no samples needed to be excluded
from analysis as no individual array differed dramatically from the rest. As the IMPI-MA and
BERRY arrays looked significantly different, we concluded that direct comparison of these two
studies might be problematic. Further comparison of the IMPI-MA and BERRY data is discussed
in Chapter 7.
We now review some more aspects of the IMPI-MA data. In Figure 6.3 we show an example of
pairwise correlation plots for five arrays from this dataset. These plots show that expression levels
for individual probes for different arrays are highly correlated, an expected finding. A plot for all
arrays was not done as the output would be illegible. As the data are not normalised, a high number
of probes for each correlation pair differs by a factor of 2. Again, this expected.
MA plots are used to visualise intensity-dependent ratios of raw microarray data; microarrays
typically show a bias here, with higher A resulting in higher M, i.e. the brighter the spot the more
likely an observed difference between sample and control. The MA plot uses M as the y-axis and
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(a) IMPI-MA: all arrays (b) IMPI-MA: blood arrays
(c) IMPI-MA: fluid (d) BERRY: training set
(e) BERRY: test set (f) BERRY: validation set
Figure 6.1: PDF plots of all IMPI-MA arrays. The first three plots show the superimposed prob-
ability density function (PDF) plots of all IMPI-MA data, and the blood and pericardial
fluid subsets, separately. The fluid arrays in general appear to have similar expression
distributions as blood, and important finding when considering batch effects. The last
three plots show the PDFs for the BERRY training, test and validation sets, respectively.
The x-axis shows the log2-intensity values, and the y-axis the corresponding probability
for that intensity.
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(a) IMPI-MA: all arrays (b) IMPI-MA: blood arrays
(c) IMPI-MA: fluid arrays (d) BERRY: training set
(e) BERRY: test set (f) BERRY: validation set
Figure 6.2: CDF plots of all IMPI-MA arrays. The first three plots show the superimposed cumu-
lative density function (CDF) plots of all IMPI-MA data, and the blood and pericardial
fluid subsets, separately. The last three plots show the CDF plots for the BERRY train-
ing, test and validation sets, respectively.
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6.2 Quality control plots
Figure 6.3: Pairwise sample correlation. Pairwise correlation of all probes on the first five arrays
in the IMPI-MA dataset are shown.
A as the x-axis and gives another quick overview of the distribution of the data. Figure 6.4 shows
M versus A (MA) plots for the first five arrays as an example. The M and A values are defined as
follows:
Mk = log2(
xki
xk j
) (6.1)
Ak =
1
2
log2(xki · xk j) (6.2)
The A values thus correspond to the mean of the two log values of two arrays i and j for all
probes k on each array, while the M values correspond to the difference of the two log values. A
Loess normalisation curve (shown in red) is fitted to the plot. In an ideal situation, this line should
be straight. As it is not, it highlights the need for between-array normalisation.
Lastly, a box-and-whisker plot can highlight individual samples that differ significantly from
all others. Such a plot is shown in Figure 6.5. The two ends of the box (“hinges”) are versions
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Figure 6.4: MA plots for five arrays. M versus A plots for the first five arrays in the IMPI-MA
dataset are shown.
of the first and third quartile1, and the “whiskers” extend to the most extreme data points. The
plot shows that overall, the blood and pericardial fluid arrays have a (order of magnitude) similar
median value, and that the median varies slightly between arrays, again indicating the need for
array normalisation.
6.3 Sample relations
The previous subsection focused on various methods to assess overall intensity distributions in or-
der to identify arrays that differed significantly from all others. This subsection now focuses on
the discovery of systematic effects within the array data which may indicate that further down-
stream data analysis will be problematic. Relationships between the individual samples were as-
sessed using a technique called metric multidimensional scaling (MDS). This methodology be-
longs to the class of methods called ordination, which aim to visualise information contained in
1The hinges equal the quartiles for odd n (where n <- length(x)) and differ for even n. Whereas the quartiles only equal
observations for n mod 4 == 1 (n = 1 mod 4), the hinges do so additionally for n mod 4 == 2 (n = 2 mod 4), and are
in the middle of two observations otherwise.
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Figure 6.5: Box-and-whisker plot of all IMPI-MA arrays. Blood arrays are coloured grey, and
pericardial fluid arrays are coloured yellow. Each box shows the upper “hinge”, median
and lower “hinge” for the log2-transformed expression data.
high-dimensional data matrices. Another well-known ordination technique is principal component
analysis (PCA). MDS aims to place high-dimensi nal objects in n-dimensional space, such that the
individual inter-object distances are preserved as accurately as possible. In this analysis we use two
dimensions for the target space.
Microarray data are of very high dimension (approx. 47,000 in the case of summarised probe-
level Illumina data), therefore dimension reduction techniques like MDS are useful for showing
how close or distant two samples are to each other. While the algorithm for performing MDS will
not be discussed here, some general principles are worth mentioning. The data object consist of
the matrix of expression values for all probes and all samples. A distance matrix for all entries
is computed (usually using a Euclidean metric), and this distance matrix is used to compute the
two-dimensional representation of the data by the use of singular value decomposition. The result
is a list of coordinates for each sample, on principal component axes. These coordinates preserve
the distance information of the original data matrix, and can be plotted in a scatterplot. In this
analysis, MDS is performed on all genes that are somewhat variable between samples (defined as
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standard deviation/mean > 0.1).
PCA in contrast computes a covariance matrix of the input data and performs eigenvalue decom-
position of that matrix, resulting in a list of principal components. The first principal component
is defined as the one that accounts for as much variability in the data as possible (i.e. the norm-
alised eigenvector with the largest associated eigenvalue of the sample covariance matrix). Each
successive component is constrained by the requirement that it is orthogonal to the preceding one,
and given this constraint explains as much of the remaining variance as possible. These two tech-
niques are similar in several respects. While we only use MDS here to visualise data relationships,
PCA will be used in later chapters of this thesis as well. In summary, MDS visualises dissimilarity
between samples, and PCA identifies linearly uncorrelated components that explain most of the
variance.
It is important to note that all of the analysis to follow was performed on non-normalised data.
This was done to highlight potential technical bias. True biological differences between samples
will be evaluated in later chapters, where that data has been normalised in order to deal with this
technical bias.
Figure 6.6 shows the results of MDS analysis of all 181 microarrays. It is immediately clear
that pericardial fluid arrays as a group behave very differently from blood arrays, and that the
blood arrays do not show distinct subgroups based on TB status; indeed, there is complete overlap
between the four categories (Healthy, LTBI, PTB and TB-PC).
MDS of blood samples is shown in Figure 6.7. Here, the samples are identified according to TB
status and HIV Status. Again we see significant overlap of all groups, and no significant pattern
suggesting another factor (e.g. technical) important in producing the observed differences.
Potential factors potentially biasing gene expression are sex [155] and the use of corticosteroids.
Sex and corticosteroids may result in multiple gene expression changes that may bias differential
expression analyses if the two groups contain unequal ratios of men to women. Figure 6.8 shows
that no sex-specific or corticosteroid-specific signal appears to dominate the data.
In pericardial fluid, HIV status, and TB culture status (separating definite from probable TB-
PC cases) may influence the overall pattern of gene expression. Figure 6.9 shows that neither TB
culture status or HIV status dominate the overall expression data; differences that may exist will
need to be sought by differential expression analysis.
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Figure 6.6: MDS: All IMPI-MA data. Each point consists of a sample. The sample classes are
shown in the figure legend. There is striking dissimilarity between blood and pericardial
fluid arrays.
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Figure 6.8: MDS: IMPI-MA blood samples (Sex/steroids). No clear separation appears between
men (blue) and women (red), and between individuals who were taking corticosteroids
(filled triangles) at the time of blood collection versus those who were not (hollow
triangles). Squares represent samples where the steroid status was unclear.
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Figure 6.9: MDS: IMPI-MA pericardial fluid samples (HIV-TB) No clear separation appears
between HIV positive (filled squares) and HIV negative (hollow squares) fluid samples,
or between samples that were culture positive for Mycobacterium tuberculosis (red)
versus those who were not (purple).
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6.4 Discussion
The unbiased view of all IMPI-MA array data shows the data to be of high quality, and the need
for normalisation between samples has been made evident. Multi-dimensional scaling views of
the data clearly demonstrate that fluid samples as a whole behave differently from blood samples.
Within the blood samples, I failed to detect gross technical bias. The individual sample classes
do not separate on the two axes shown, despite the fact that the TB-PC and non-TB-PC samples
were collected and processed at different times by different individuals. In addition, none of the
parameters used to label the data showed any evidence of grouping by any of the studied parameters.
This allowed me to proceed with confidence to subsequent analyses.
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Chapter summary
In this chapter I demonstrate the results of an analysis pipeline in R that replicates the exact method
used by Berry et al in the 2010 paper [82]. This is followed by application of the same method to a
subset of the IMPI-MA data, and the results are compared.
7.1 Data
This analysis considers similarities in differential expression analyses of conceptually similar data-
sets. Therefore, the data included in this Section consists of the BERRY training and validation
sets, and the subset of IMPI-MA data generated from blood samples in HIV-1 uninfected individu-
als who either had no clinical or microbiological evidence for active tuberculosis (Healthy, LTBI),
or who had culture-confirmed tuberculosis (either PTB or TB-PC). The BERRY validation set is
of interest, as the samples were collected in South Africa from a population demographically very
similar to the IMPI-MA cohort. After due consideration, the BERRY training sets was selected in
addition to the BERRY validation set as it was used to derive the 393 probe signature for active
tuberculosis, and was closer to the IMPI-MA data in terms of the specified phenotype classes. The
BERRY training set consisted of three sample classes (healthy, LTBI and PTB), the BERRY valida-
tion set only two (LTBI and PTB) and the IMPI-MA subset four (healthy, LTBI, PTB and TB-PC).
Despite this, it is reasonable to expect that differential expression profiles contrasting active and
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not-active tuberculosis should be comparable.
7.2 Study subjects
Table 7.1 shows comparisons between and within the three datasets across four clinical variables:
age, sex, TST size and ethnicity. The comparison between datasets for all classes shows significant
differences for age and ethnicity, but the datasets are matched for proportions of active to not active
TB and sex. For each of the subsets (healthy, LTBI and active TB) we find the following: The
healthy subset is mismatched w.r.t. ethnicity, the LTBI subset w.r.t. age, TST size and ethnicity,
and the active TB subset w.r.t. ethnicity and TB type.
Comparisons within datasets find that the following datasets are not matched with respect to
the following variables are not matched: BERRY training set: ethnicity; BERRY validation set:
age. These differences between and within datasets are likely to influence differential expression
analysis to some extent, but this is unavoidable.
7.3 Analysis
The raw data, following average normalisation looks similar across all three datasets (Figure 7.1).
When viewed using multidimensional scaling, none of the raw datasets show complete separation
along the contrast of interest. Both the BERRY datasets show some extent of separation along at
least one axis in the plot, suggesting a significant influence of the contrast variable.
Following the raw data visualisation, the data was processed as originally described in the sup-
plementary methods section of [82]; see Section 3.9.4 for details of implementation and links to
the relevant code. Table 7.2 shows the effects of applying the two non-specific filters to the three
median-scaled data sets. Strikingly, 2.9 times the number of probes are selected from the IMPI-MA
dataset (which used HT12 v4 arrays) when compared to the BERRY training set.
As the basis for the two filters may be dependent on technology, this may not be a fair com-
parison. For instance, newer technology may result in expression for more probes becoming de-
tectable, and improved dynamic range of new array imaging technology may result in improved
fold-change estimates. It is interesting that the BERRY validation set has results that are inter-
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Table 7.1: Table of clinical characteristics across datasets and contrasts Abbreviations:
n=number, p=proportion, med=median, iqr=interquartile range. P-values are given for
comparisons between datasets (second-last column) as well as within datasets (last three
rows), with the statistical test used for each comparison listed.
Subsets variables p-value test
N
age med iqr 30.5 25.0/35.0 24.0 21.0/27.0 33.9 26.55/51.48 1.341E/04 kruskal.test
n=(f) p=(f) 23 0.55 25 0.49 7 0.32
n=(m) p=(m) 19 0.45 26 0.51 15 0.68
n=(black) p=(black) 11 0.26 51 1.00 21 0.95
n=(white) p=(white) 17 0.40 0 0.00 0 0.00
n=(asian=other) p=(asian=other) 7 0.17 0 0.00 0 0.00
n=(south=asian) p=(south=asian) 6 0.14 0 0.00 0 0.00
n=(coloured) p=(coloured) 0 0.00 0 0.00 0 0.00
n=(indian) p=(indian) 0 0.00 0 0.00 1 0.05
n=(other) p=(other) 1 0.02 0 0.00 0 0.00
n=(active=TB) p=(active=TB) 13 0.31 20 0.39 12 0.55
n=(not=active=TB)p=(not=active=TB) 29 0.69 31 0.61 10 0.45
n=(healthy) p=(healthy) 12 0.29 0 0.00 5 0.23
n=(LTBI) p=(LTBI) 17 0.40 31 0.61 5 0.23
n=(PTB) p=(PTB) 13 0.31 20 0.39 4 0.18
n=(TBPC) p=(TBPC) 0 0.00 0 0.00 8 0.36
N
age med iqr 31.0 27.75/34.25 NA NA 30.7 23.8/32.7 7.503E/01 kruskal.test
TST=size med iqr 0.0 0.000/2.038 NA NA 0.0 0/0 2.346E/01 kruskal.test
n=(f) p=(f) 8 0.67 NA NA 1 0.20
n=(m) p=(m) 4 0.33 NA NA 4 0.80
n=(black) p=(black) 0 0.00 NA NA 5 1.00
n=(white) p=(white) 12 1.00 NA NA 0 0.00
n=(asian=other) p=(asian=other) 0 0.00 NA NA 0 0.00
n=(south=asian) p=(south=asian) 0 0.00 NA NA 0 0.00
n=(coloured) p=(coloured) 0 0.00 NA NA 0 0.00
n=(indian) p=(indian) 0 0.00 NA NA 0 0.00
n=(other) p=(other) 0 0.00 NA NA 0 0.00
N 17 31 5
age med iqr 32.0 25.0/39.0 21.0 19.5/24.0 29.1 22.7/34.7 7.253E/05 kruskal.test
TST=size med iqr 20.0 18.0/27.0 14.0 6.0/15.0 12.0 8.0/15.0 7.933E/05 kruskal.test
n=(f) p=(f) 9 0.53 20 0.65 1 0.20
n=(m) p=(m) 8 0.47 11 0.35 4 0.80
n=(black) p=(black) 7 0.41 31 1.00 5 1.00
n=(white) p=(white) 2 0.12 0 0.00 0 0.00
n=(asian=other) p=(asian=other) 5 0.29 0 0.00 0 0.00
n=(south=asian) p=(south=asian) 3 0.18 0 0.00 0 0.00
n=(coloured) p=(coloured) 0 0.00 0 0.00 0 0.00
n=(indian) p=(indian) 0 0.00 0 0.00 0 0.00
n=(other) p=(other) 0 0.00 0 0.00 0 0.00
N
age med iqr 29 23.0/33.0 31.5 25.0/42.0 40.67 33.69/52.86 8.391E/02 kruskal.test
n=(f) p=(f) 6 0.46 5 0.25 5 0.42
n=(m) p=(m) 7 0.54 15 0.75 7 0.58
n=(black) p=(black) 4 0.31 20 1.00 11 0.92
n=(white) p=(white) 3 0.23 0 0.00 0 0.00
n=(asian=other) p=(asian=other) 2 0.15 0 0.00 0 0.00
n=(south=asian) p=(south=asian) 3 0.23 0 0.00 0 0.00
n=(coloured) p=(coloured) 0 0.00 0 0.00 0 0.00
n=(indian) p=(indian) 0 0.00 0 0.00 1 0.08
n=(other) p=(other) 1 0.08 0 0.00 0 0.00
n=(PTB) p=(PTB) 13 1.00 20 1.00 4 0.33
n=(TB/PC) p=(TB/PC) 0 0.00 0 0.00 8 0.67
N
n=(Tempus) p=(Tempus) 42 1.00 51 1.00 0 0.00
n=(paxGene) p=(paxGene) 0 0.00 0 0.00 22 1.00
n=(HT12v3) p=(HT12v3) 42 1.00 51 1.00 0 0.00
n=(HT12v4) p=(HT12v4) 0 0.00 0 0.00 22 1.00
age_within p=value test 0.6616 kruskal.test 1.35E/06 kruskal.test 0.2276 kruskal.test
sex_within p=value test 0.5775 prop.test 0.01354 prop.test 0.5542 prop.test
ethnicity_within p=value test 0.0004998 fisher.test NA prop.test 1 fisher.test
LTBI
TB
Technical
BERRY-trainingvariable-descriptors
42
ethnicity
TB=type
ethnicity
sex
42
All
Healthy
12
BERRY-validation IMPI:MA
2.124E/01
4.998E/05
1.850E/01
51 22
4.998E/04
2.212E/01
4.998E/04
1.645E/01
sex
sex
ethnicity
classes
20 12
0 5
fisher.test
prop.test
prop.test
fisher.test
prop.test
fisher.test
prop.test
ethnicity
RNA=type
Array=type
13
51
sex
4.998E/04 fisher.test
4.055E/01 prop.test
9.995E/04 fisher.test
1.548E/06 prop.test
2.200E/16 prop.test
2.200E/16 prop.test
22
Table 7.2: Effect of non-specific filtering. Striking differences in the numbers of probes passing
the filters can be observed.
Dataset Original number Pass detection filter Pass Fold change filter Pass both filters
IMPI-MA 47,231 19,027 5,316 5,316
BERRY validation 48,802 15,418 3,388 2,824
BERRY training 48,802 15,391 1,836 1,835
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Figure 7.1: Box-and-whisker plots of the raw expression data for the three datasets. Colours in-
dicate sample classes: green=healthy, blue=LTBI, orange=PTB and red=TB-PC. Over-
all expression patterns look similar between the three datasets, and no extreme outliers
are obvious. Boxes indicate lower quartile, median and upper quartile, and whiskers the
extremes of data.
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Figure 7.2: Multidimensional scaling analysis. The three datasets are shown following multidi-
mensional scaling of the raw data.
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mediate to the other two datasets, and that overall the number of selected probes are closer to the
BERRY training set value. The two datasets based on samples collected in South Africa appear to
be more variable than the original BERRY training set; the reason for this is unclear.
Figure 7.3 shows heatmaps of the selected probes. The BERRY validation set is already well
separated into active TB and LTBI clusters, whereas the other datasets still show high levels of
misclassification. The heatmaps in question demonstrate that by only using non-specific filtering
to remove non-informative probes, much variability remains in the data obscuring potential dif-
ferences that may exist between probes belonging to different phenotypic classes. Essentially this
shows that in an unsupervised analysis, the various phenotypic groups do not cluster together in
the IMPI-MA dataset. This could be due to smaller sample size, or additional variability between
samples not explained by disease phenotype. This could include for instance concurrent viral in-
fections in otherwise healthy individuals.
Multidimensional scaling applied to the selected probes (i.e. the probes passing both filters)
show separation into clusters that does not relate well to the clinical phenotype.
Differential expression analysis was performed using the Kruskal Wallis test (IMPI-MA, BERRY
validation) for the contrast active TB vs. not active TB, and Kruskal Wallis ANOVA for BERRY
training set, as in the original paper. All results were corrected for multiple testing using the Ben-
jamini Hochberg procedure. Table 7.3 list the results. This comparison is problematic at multiple
levels. First, the number of conditions used for the comparisons is not identical for the three ana-
lyses. The original BERRY training set used Kruskal Wallis ANOVA to distinguish between three
conditions (healthy, LTBI and PTB). This yields 404 DE probes at an FDR of 0.01, a result that is
very similar to the original paper. Two conditions were used for the two other sets, as the validation
set did not include healthy controls, and the IMPI-MA subset was too small to yield significant
results for three conditions. Also of note is the fact that very different levels of FDR were used for
the three analyses. This was done to obtain a roughly similar number of DE probes, even though
the proportion of false positives in each results set was likely to be different due to this.
Given these results, and the caveats that accompany them, we now focus on the probes. The
differentially expressed probes are shown in heatmaps in Figure 7.5 and multidimensional scaling
plots in Figure 7.6. Of interest is whether the selected probes classify their input data correctly. As
can be seen in Figure 7.5, the respective lists of differentially expressed probes classify the input
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(a) IMPI-MA
(b) BERRY validation
(c) BERRY training
Figure 7.3: Heatmaps of selected probes. Each heatmap shows the expression values of the selec-
ted probes. Values are row-scaled, and range from low (blue) to intermediate (yellow)
to high (red). Samples are clustered using Spearman rank correlation, and probes are
clustered using Pearson correlation. Colours: green: healthy, blue: LTBI, orange: PTB,
red: TB-PC. Plot titles reflect the number of included probes.
145
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
7 Relation of IMPI-MA data to previous studies of blood transcriptomics in tuberculosis
−40 −20 0 20
−
60
−
40
−
20
0
20
Sample relations based on 5316 genes with sd/mean > 0.1
Principal Component 1 (20.7%)
Pr
in
ci
pa
l C
om
po
ne
nt
 2
 (1
3.7
%)
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Healthy
Latent
PTB
TB−PC
(a) IMPI-MA
−30 −20 −10 0 10 20
−
30
−
20
−
10
0
10
20
Sample relations based on 2824 genes with sd/mean > 0.1
Principal Component 1 (16.1%)
Pr
in
ci
pa
l C
om
po
ne
nt
 2
 (1
2.2
%)
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l l
l
l l
l
l
Latent
PTB
(b) BERRY validation
−20 −10 0 10 20
−
30
−
20
−
10
0
10
20
Sample relations based on 1835 genes with sd/mean > 0.1
Principal Component 1 (28.9%)
Pr
in
ci
pa
l C
om
po
ne
nt
 2
 (1
5.4
%)
l
l
l
l
l
l
l
l
l
l
l ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
Healthy
Latent
PTB
(c) BERRY training
Figure 7.4: Multidimensional scaling analysis of selected probes.
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Table 7.3: Results of differential expression analysis
Dataset N conditions FDR N DE probes
IMPI-MA 2 0.08 394
BERRY validation 2 0.0001 484
BERRY training 3 0.01 404
data reasonably well. In Figure 7.5a we find that one sample (“healthy” phenotype) is misclassified
in the IMPI-MA data; in case of the BERRY validation data, two samples are misclassified (one
“active TB” and one “LTBI” phenotype). Finally, in the case of the BERRY training set, three
samples (one each of “healthy”, “LTBI” and “active TB”) are misclassified.
7.4 Comparisons
The main objective for the Berry et al analysis was to derive a predictive signature, whereas the main
objective for the analysis in this chapter is to assess, given independent input data, how robustly
does the method employed in the Berry et al analysis produce a characteristic signature, and how
do signatures produced overlap with the original 393 signature? We can regard this approach as
repeating the training set analysis three times, and comparing the results.
Firstly, how does the implementation of the Berry et al analysis method in R compare to the
original results? Figure 7.7 shows a two-way Venn diagram demonstrating the overlap. One would
expect perfect overlap if the method is indeed identical. We see that all probes from the 393
signature are reproduced by the R implementation of the method. An additional eleven probes are
also called significant; this may be due to rounding errors due to machine precision settings used
on two different systems; this difference may be caused by inclusion of probes at either of the
non-specific filters or at the time of DE analysis using Kruskal Wallis ANOVA. In any event, the
R implementation of the gene selection procedure reproducibly recreates the 393 probe list with a
few additional probes.
The second question we now address is how do the probes selected from the IMPI-MA data
overlap with the original 393 signature. Figure 7.8 shows this overlap. Interpretation of this extent
of overlap requires some context before we proceed. In the Gedankenexperiment (“thought experi-
ment”) that follows, we consider two sets A and B of 30,000 unique elements, and ask the question:
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(a) IMPI-MA
(b) BERRY validation
(c) BERRY training
Figure 7.5: Heatmaps of differentially expressed probes. Each heatmap shows the expression
values of the selected probes. Values are row-scaled, and range from low (blue) to
intermediate (yellow) to high (red). Samples are clustered using Spearman rank cor-
relation, and probes are clustered using Pearson correlation. Colours: green: healthy,
blue: LTBI, orange: PTB, red: TB-PC. Plot titles reflect the number of included probes.
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Figure 7.6: Multidimensional scaling analysis of differentially expressed probes.
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393 11
393
TRAIN
Figure 7.7: Method validation. Overlap of “393” signature with DE probes from“BERRY training
set (“TRAIN”) as found using R. Each set is labelled on the circle boundary, and the
venn counts are centred within each circle. Please note that the oval sizes are not scaled
to the number of probes for the purpose of better legibility.
how probable is an overlap of size n of two subsets of A and B, each of size k? Using Mathematica,
I created two sets A and B, each consisting of 30,000 elements, randomly subset each by 400 ele-
ments, and calculated the overlap (strictly the size of the intersection of the two subsets Ak ∩ Bk).
This was repeated 20,000 times, and the resulting data charted as a histogram (Figure 7.9). I then
fit three types of distribution to the data (a normal distribution, a kernel mixture distribution and
a Pareto distribution (Figure 7.9)). Using this distribution, I then produced a probability plot for
different sizes n; this shows that any n>15 is very unlikely, with a probability of 0.000655873. An
overlap size exceeding 100 is extremely unlikely to occur by chance (probability=2.59115 * 10−176
). I conclude that most probes in the overlapping region are present because of biological reasons.
The non-overlapping probes may be false positives and false negatives, respectively, depending
which dataset is used as reference.
The two datasets were generated using different versions of the array technology, consisted of
different sample sizes, were drawn from different populations and were analysed using different
values for false discovery rate. Despite this, a statistically highly significant overlap of differentially
expressed probes gives me confidence that overall, the IMPI-MA data is comparable to the Berry
et al data.
Finally, we show the overlap of the 393 probe set with the BERRY training set results using R,
the BERRY validation set and the IMPI-MA data in Figure 7.10.
Despite the fact that this degree of overlap between three datasets is extremely unlikely to occur
by chance, we find that 61 probes are present as differentially expressed probes in the BERRY
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291 292102
393 SA
Figure 7.8: Data similarity. Overlap of 393 probe set and the DE probes selected from the IMPI-
MA data using the same analytic method from a dataset that differs in many respects
from the BERRY training set.
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(a) Overlap size histogram. Histogram of overlap
sizes after 20,000 sampling runs, overlaid by the
PDF of three distributions (Colours: green, nor-
mal distribution; orange, kernel mixture distribu-
tion; blue, Pareto distribution)
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Figure 7.9: Probability of probe overlap.
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Figure 7.10: Overlap of all three datasets with the 393 probe list
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training set, validation set and IMPI-MA subset. I infer that these probes are particularly interesting
from a biological point of view. Do these probes allow for clear separation of active TB and not
active TB? To investigate this, I show in Figure 7.11 three heatmaps, each consisting of the 61
probes present in all result sets, and demonstrate that many samples are still correctly classified as
active or not active TB. Of note is that assignment to either the active or not active TB cluster is
now more frequently done incorrectly. In the original analysis, the samples of IMPI-MA, BERRY
validation and BERRY training sets are misclassified in one, two, and three instances, respectively,
while using the 61 set of overlapping probes results in two, five and eight samples misclassified.
However, active and not-active TB samples still cluster together in each of the two main clusters.
While the 61 probe subset does not appear to improve the classification of the input data, further
investigation of the actual probes that constitute the set will be required to determine their biological
significance. For instance, the probes may capture a conserved feature of the immune response to
M. tuberculosis detectable in blood that is independent of site or severity of disease.
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Figure 7.11: Heatmaps of 61 overlapping probes applied to three datasets. Each heatmap shows
the expression values of the selected probes. Values are row-scaled, and range from
low (blue) to intermediate (yellow) to high (red). Samples are clustered using Spear-
man rank correlation, and probes are clustered using Pearson correlation. Colours:
green: healthy, blue: LTBI, orange: PTB, red: TB-PC. Plot titles reflect the number of
included probes.
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8 An analytic framework for heterogenous
microarray data
Chapter summary
In this chapter I develop the idea of the data in relation to a multi-dimensional hypercube further,
and show how this was used to develop an analytic framework for the IMPI-MA data. Finally,
the code structure for this analytic framework is described, and an overview of the output of the
analysis is given.
8.1 The sample hypercube revisited: what kinds of questions
relating to the three main hypotheses can we ask, and
how can we answer these questions?
Having verified that the data are sound (Chapter 6) and comparable to previously published data
(Chapter 7), we now turn our attention to the addressing the three main hypotheses stated earlier.
8.1.1 Questions
Given the three hypotheses, the questions we aim to ask are related to the detection of differential
transcript abundance for three main contrasts: TB status, HIV status and compartment. Each of
these questions may be posed in different contexts, e.g. differential gene expression (DE) in active
TB vs. not active TB in HIV-1 infected and HIV-1 uninfected individuals, respectively. The results
of DE experiments may then be compared between these contexts, allowing for assessment of
the effect of HIV-1 infection on the transcriptional response to tuberculosis. Table 8.1 lists the
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questions and contexts developed for the analysis of the IMPI-MA data, as well as various metadata
variables that will be required to subset the main dataset, set up the contrasts and specify annotation
variables, if different from the contrast variable. Figure 8.1 shows the questions (1-7) mapped to
3D phenotype space, represented as the hypercube graph discussed earlier.
Table 8.1: Questions. Seven questions addressed in IMPI-MA analysis, listing metadata relevant
to the implementation in R
Question 1: Tuberculosis 2: TB site 3: LTBI 4: HD phenotype
Contrast variable class3 class class ECP
Contrast 1 ActiveTB PTB Healthy Eff TB-PC
Contrast 2 notActive TB TB-PC LTBI EC TB-PC
Colour variable class class class ECP
Data
B.Neg.AN B.Pos.PTB_TBPC B.Pos.HL B.C.Pos.EffEC
B.Pos.AN B.Neg.PTB_TBPC B.Neg.HL PF.C.Pos.EffEC
Question 5: HIV (not active TB) 6: HIV (active TB) 7: Compartment
Contrast variable HIV.Status HIV.Status Compartment
Contrast 1 Positive Positive Blood
Contrast 2 Negative Negative Fluid
Colour variable HIV.Status HIV.Status Compartment
Data
B.N.PosNeg B.A.PosNeg C.BPF (matched)
B.L.PosNeg PF.A.PosNeg C.Neg.matchedBPF
B.H.PosNeg B.PTB.PosNeg C.Pos.matchedBPF
B.TBPC.PosNg C.Pos.EFF.matchedBPF
C.Pos.EC.matchedBPF
Datasets are subsets of all IMPI-MA data, named in triads or tetrads using . as separator. Each triad (tetrad) spe-
cifies SET.SUBSET.(SUBSET).CONTRAST. Abbreviations for datasets: B=blood, PF=pericardial fluid, Neg=HIV-
1 uninfected, Pos=HIV-1 infected, A=active TB, N=not active TB, L=LTBI, H=healthy, PTB=pulmonary tubercu-
losis, TBPC=tuberculous pericarditis, C=tuberculous pericarditis (cardiac), Eff=effusive pericarditis, EC=effusive-
constrictive pericarditis. Contrast variable refers to the name of the variable in the clinical phenotype dataset used to
define the contrast of interest. Colour variable refers to the name of the variable in the clinical phenotype dataset used to
define the factor used for identifying subsets in graphics by colour.
8.1.2 Analyses
Each dataset listed in Table 8.1 was analysed by the three complementary approaches described in
Methods 3.8.
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Figure 8.1: Sample hypercube. Questions listed in Table 8.1 mapped to edges of the six-
dimensional phenotype space rendered in three dimensions. Yellow labels indicate the
question number; labelled edges represent the contrasts examined; greyed-out edges
and vertices represent contrasts and sample classes not available or inappropriate for
analysis. Cubes: A Main cube (Tuberculosis, HIV-1 infection, Compartment) B Not active
tuberculosis C Active tuberculosis D Tuberculous pericarditis Abbreviations: B blood;
F pericardial fluid; A active tuberculosis; N not active tuberculosis; + HIV-1 infected; -
HIV-1 uninfected; m matched samples exist
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8.2 Code description
8.2.1 IMPI-MA: Data manager
The code for this analysis is reproduced in full in Appendix Section A.11. Using Table 8.1 as
reference, the script is based on a similar script described earlier (A.7), but extracts all data subsets
based on the vertices of the extended hypercube and the selected contrasts and contexts. This data
is saved to RData files for later access.
8.2.2 IMPI-MA: Analysis
The code for this analysis is reproduced in full in Appendix Section A.12. Structurally, the code
implements a for-loop, wherein each of the seven questions is addressed. Within each question,
one or several datasets are each subjected to the same analytic workflow of differential expression,
deconvolution and cell-specific differential expression, and weighted gene co-expression network
analysis. Multiple mechanisms for dealing with code exceptions have been implemented. These
deal with missing or incomplete data and insufficient sample size. In addition, memory manage-
ment has been optimised, allowing the code to run with a remarkably small memory footprint. A
single run of this script takes approximately three and a half hours to complete on a 2010 intel dual
core i7 machine with 8GB of non-ECC RAM running Mac OSX 10.8.4.
An important feature of this code is that the output is written to disk using versioned folders, and
the naming of individual output files is based on the question, analysis type, dataset and contrast
and output type. This fully automated process generates output files where the file name contains
a significant amount of metadata allowing for interpretation of the output without reference to
external material.
Outer for-loop
The outer for-loop iterates over a list containing seven “questions”. Each question in turn is a list,
containing all metadata required to perform the analyses and correctly label all output. The overall
code structure is shown in Figure 8.2.
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for (question in questions) (n=7)
for (dataset in datalist) (n=1-4)
preprocess
DE
DC / csDE
output
WGCNA
output
output
Clean up
Clean up & finish
Figure 8.2: Overall code structure for IMPI-MA main script
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Generation of clinical characteristics tables An important consideration for microarray ana-
lysis of clinical samples is the description of the clinical characteristics of the patients included in
the particular analysis. This is required in order to identify potential confounding effects, and to
provide confidence that the two groups identified by the contrast variable are similar, and differ only
in the value of the contrast variable. This essentially means that the two groups to be contrasted
have a Hamming distance of one. In addition, where an analysis of the same contrast is performed
in more than one dataset (i.e. context), it is also useful to show how the different datasets vary
according to clinical parameters.
Given the complexity of this task, the following phenotypic variables were chosen for the clinical
characteristics tables: age, sex and CD4 count. Each clinical table compares these variables within
datasets (across contrasts) and between datasets (across contexts).
The comparisons for each variable are computed and stored in temporary variables. The results
of the various computations are then combined into a single table and exported to raw LATEX.
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Differential gene expression
The DE section of the script performs the following actions:
1. Show raw data (boxplots, MDS, PCA)
2. Preprocess the data: variance stabilising transform followed by quantile normalisation
3. Show pre-processed data
4. Apply filter to remove poor-quality probes
5. Show filtered probes
6. Perform differential expression analysis
7. Show DE results
8. Export the probe lists
Deconvolution and cell-specific differential expression
The deconvolution section of the script performs the following actions:
1. Perform deconvolution based on method in [100]
2. Show proportion matrix as stacked barplot
3. Show boxplots of cell-type proportions by condition
4. Calculate statistics to identify cell-types that differ in proportion by condition (includes multiple testing correc-
tion)
5. Perform cell-type specific differential expression analysis using csSAM [135] and the proportion matrices calcu-
lated in 1.
6. Generate top tables for each cell type and export
Weighted gene co-expression network analysis
The weighted gene co-expression network analysis performs the following actions:
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1. Setup and linking of clinical trait data to expression data
2. Block-wise network construction and module detection
3. Relate modules to external information and identify important genes
4. Output module gene lists and perform gene-ontology analysis
5. Visualise networks of module eigengenes in relation to clinical traits
6. Export module networks in Cytoscape format
7. Plot module heatmaps and eigengene expression
8. Plot boxplots of eigengene expression values by condition (contrast)
9. Calculate statistics to identify modules that differ in expression by condition (includes multiple testing correction)
8.3 Computational output
8.3.1 Output tree
All output is saved in a single directory named using the date and start time of the run in R that
produced the output. Two folders are made within the output folder; one contains all images, and
the other all text files.
8.3.2 Images
Images can be output in multiple raster or vector formats; in order to conserve disk space all images
were output as pdf for the run that produced the output for Chapters 9 to 12. This may be changed
by modifying parameters in the setup script. A single run outputs 2,182 images (at the time of
writing). All image files are labeled automatically with four numbers and a text string in the format
“question#”, “analysis#”, “dataset#”, “figure#” followed by text that specifies the question, ana-
lysis, dataset and type of output. This allows anyone to understand a particular output file simply
by inspecting the filename. In addition, most plots contain some annotation on the image (usually
the image title) that allows the viewer to understand what (s)he is looking at.
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8.3.3 Session Output log
All output usually written to stdout, i.e. the R console under usual configurations of R, is captured
in a text file entitled sessionOutput.txt. This text file captures all warning or error messages created
while running the code, as well as the output of print statements and any output normally sent to
stdout. This file serves two main purposes: (1) Debugging the script by catching informative error
messages and (2) capturing all output not written to file.
The file produced in a single run of the main analysis script is 84 pages long when printed. Table
10.2 and other similar tables were produced based on output in this file. For such a comprehensive
analysis, this type of output serves as a useful reference point when evaluating the overall results
of an analysis run.
8.3.4 Spreadsheets
314 spreadsheet-like objects were produced during the course of the analysis. These objects are
comma-delimited text files and can easily viewed in any spreadsheet programme. The following
analytic steps produce these objects:
1. Differential expression analysis
2. Cell-type specific differential expression analysis (one sheet for each cell type)
3. Gene Ontology enrichment analysis, as produced during WGCNA analysis
4. Results of statistical calculations (e.g. evaluating statistical significance of of differential
module regulation or differences in cell-type proportions between sample classes)
5. Results of gene significance and module membership calculations
8.3.5 Plain text files
1373 plain text files were produced in the course of the analysis. They are simpler in structure than
the csv files, and contain the following classes of data:
1. Entrez IDs for all genes used in the WGCNA analysis
2. Entrez IDs for all genes in modules identified in the WGCNA analysis
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3. Nodes and edges for all modules in weighted gene correlation networks for all analyses.
These files can be imported into Cytoscape (a network visualisation and analysis tool) for
further processing.
8.3.6 LATEX tables
Tabular data for display purposes was formatted in the script as LATEX tables, and written to tex
files. These files could then be incorporated directly in documents like this thesis. Table 10.1 and
other similar tables were produced in this way. A single run of the script at the time of writing
produces 27 ready to use LATEX documents.
8.4 Results as Data: a new resource for generating and
analysing HIV-TB related hypotheses
I have shown that the output of a complex analytic pipeline may yield very comprehensive output
that requires further systematic evaluation in order to understand fully. In this way, one output
described in this thesis is a large dataset consisting of multiple output files that as a whole addresses
a range of questions. In this way, the results of running the analytic pipeline produces new classes
of data that are amenable to further in-depth analysis.
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IMPI-MA: Results in depth
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9 Question 1: Tuberculosis
Chapter summary
Matthew Berry et al have previously published a transcriptomic signature for tuberculosis in HIV
uninfected individuals [82], and others have since confirmed many properties of the signature that
was found [86, 85]. Here I show the results of an analysis that refines and extends the work of
these authors. I present the results analysis for the dataset of Question 1: Blood, HIV negative
with the contrast activeTB vs not active TB as an example of the depth of the analytic framework
and the associated output. As mentioned in Chapter 8, the entire analysis output is extremely
comprehensive, and will not be reproduced in full for the purposes of this thesis. This chapter is
divided into three parts, presenting results for differential expression analysis, deconvolution and
cell-specific differential expression analysis, and weighted gene co-expression network analysis.
Pathway analysis will be presented in the next Chapter.
9.1 Differential gene expression
In this section I present the results of differential expression analysis using quantile normalised
data and a linear models approach. The contrast used was active TB vs. not active TB. Active TB
includes PTB and TB-PC, while not active TB includes healthy and LTBI classes.
9.1.1 Data quality
Boxplots of the non-normalised data show that no sample differs significantly from all others (Fig-
ure 9.1) and the quantile normalised data distributions for each sample are identical. PCA analysis
of the non-normalised as well as normalised data demonstrate no significant batch effects; there is
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large overlap of the four groups displayed.
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Figure 9.1: Data QC: not normalised (left) and normalised (right).
9.1.2 DE probes
Following normalisation and filtering of probes based on probe quality, differential expression ana-
lysis was performed using the R package limma, with false discovery rate set to 0.05. 369 probes
were selected as differentially expressed. Table 9.1 lists the top 30 differentially expressed probes,
ordered by the variable logFC (log2-fold change). A positive value indicates overexpression in
active tuberculosis, and a negative value underexpression in active tuberculosis.
The results of the differential expression analysis can be visualised using a volcano plot (Figure
9.2), which, for each probe, plots the log2-fold change value against the log-odds for differential
expression (B). We conclude from the plot that the majority of probes are unlikely to be differ-
entially expressed, and have low logFC values. The significant probes are labeled by identifier in
blue.
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9.1 Differential gene expression
Table 9.1: Top 30 probes as selected by limma
ProbeID TargetID logFC CI.025 CI.975 AveExpr t P.Value adj.P.Val B
4150270 ANKRD22 1.77 1.23 2.31 8.78 6.41 0.00 0.00 4.98
6060468 S100A8 1.75 1.26 2.23 12.69 7.01 0.00 0.00 6.18
130181 ANKRD22 1.56 1.06 2.07 8.21 6.12 0.00 0.01 4.39
6620209 FCGR1B 1.32 0.98 1.65 7.95 7.75 0.00 0.00 7.58
520360 MS4A6A 1.05 0.72 1.38 10.06 6.27 0.00 0.00 4.69
580706 CCR2 1.02 0.72 1.33 8.86 6.56 0.00 0.00 5.30
840168 CYBB 0.99 0.73 1.26 9.24 7.36 0.00 0.00 6.85
6040711 CCR2 0.98 0.68 1.27 8.72 6.50 0.00 0.00 5.17
450491 CASP1 0.89 0.62 1.15 9.36 6.51 0.00 0.00 5.20
6560156 DUSP3 0.88 0.59 1.16 9.98 6.03 0.00 0.01 4.20
7050382 CASP1 0.86 0.60 1.13 9.44 6.32 0.00 0.00 4.82
20452 TYMP 0.85 0.58 1.12 8.54 6.24 0.00 0.00 4.64
5570039 LOC728744 0.75 0.57 0.92 7.34 8.28 0.00 0.00 8.52
1770152 MS4A6A 0.74 0.51 0.97 10.12 6.38 0.00 0.00 4.93
830035 ATG3 0.72 0.49 0.94 9.37 6.26 0.00 0.00 4.68
240053 GCH1 0.63 0.44 0.83 7.64 6.39 0.00 0.00 4.95
4040022 CD86 0.58 0.40 0.76 7.98 6.40 0.00 0.00 4.97
2360719 IRAK3 0.54 0.37 0.72 7.84 6.09 0.00 0.01 4.33
7200753 TLR7 0.51 0.35 0.66 7.59 6.53 0.00 0.00 5.24
870408 IL15 0.48 0.32 0.63 7.35 6.04 0.00 0.01 4.22
670202 SESTD1 0.47 0.32 0.62 7.71 5.99 0.00 0.01 4.13
1660615 CCR2 0.20 0.14 0.25 6.88 7.02 0.00 0.00 6.20
7050328 SEMA4C -0.16 -0.22 -0.11 6.97 -6.03 0.00 0.01 4.20
5700189 TCTN1 -0.27 -0.36 -0.18 7.22 -6.03 0.00 0.01 4.21
580411 LAX1 -0.46 -0.59 -0.32 7.94 -6.72 0.00 0.00 5.61
5260021 HS.135282 -0.46 -0.61 -0.32 7.47 -6.46 0.00 0.00 5.08
7550008 RNF216 -0.55 -0.70 -0.39 8.10 -6.99 0.00 0.00 6.15
3940484 MEF2D -0.58 -0.75 -0.42 7.98 -6.87 0.00 0.00 5.92
130609 FCGBP -0.83 -1.08 -0.58 7.82 -6.44 0.00 0.00 5.05
4010397 PLEKHG3 -0.95 -1.26 -0.64 9.10 -6.06 0.00 0.01 4.26
Key to variables: ProbeID: Illumina probe identifier, TargetID: Gene name, logFC: log2-fold
change, CI: lower and upper bounds of 95% confidence interval for logFC variable, AveExpr:
average expression value for all arrays, t: t-statistic, P.Value: raw P-value for linear model coef-
ficient, adj.P.Val: Benjamini-Hochberg corrected P value for linear model coefficient, B: log-odds
for differential expression.
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Figure 9.2: Volcano plot of differentially expressed probes. The significant probes are labeled by
identifier in blue.
A more informative plot shows the expression values for differentially expressed probes as a
heatmap, with hierarchical clustering of both samples and probes. Heatmaps of the input data
subset by significant or top 500 probes are shown in Figure 9.3. In both cases, clustering of samples
is near-perfect, with one sample (not active TB) assigned incorrectly to the active TB cluster. It is
further interesting to note that PTB and TB-PC are not separated into distinct subgroups, whereas
healthy and LTBI samples are grouped into separate clusters to some extent. We will return to this
in Section 10.3.
Finally, Figure 9.5 shows the overlap of selected probes from the same dataset using the method
used in Chapter 7 (“Baylor”) and the method used throughout the remainder of this thesis (“Limma”).
34% of probes overlap. This shows that the pipeline used for gene selection can have a major im-
pact on the results. Keeping in mind that the normalisation method used by the Baylor method is
less stringent, and that a higher FDR rate was used for the Baylor analysis, this should not be too
surprising.
Based on the differential expression analysis of this dataset, we conclude that an informative sig-
nature for active tuberculosis, including non-pulmonary tuberculosis, has been identified in blood.
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(a) Heatmap of all significant probes
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(b) Heatmap of top 500 probes
Figure 9.3: Heatmaps of significant and top 500 probes Each heatmap shows the expression val-
ues of the selected (a) or top 500 (b) probes. Values are row-scaled, and range from
low (blue) to intermediate (yellow) to high (red). Samples are clustered using Spear-
man rank correlation, and probes are clustered using Pearson correlation. Colours of
samples: green: healthy, blue: LTBI, orange: PTB, red: TB-PC. Plot titles reflect the
number of included probes.
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Figure 9.4: PCA of differentially expressed probes. Principal component analysis shows that the
selected probes clearly separate active tuberculosis from not active tuberculosis
235 260134
Baylor limma
Figure 9.5: Overlap of differentially expressed probes for two different methods.
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9.2 Array deconvolution and cell-specific differential gene expression
Further work is required to fully characterise the biological meaning of this signature.
9.2 Array deconvolution and cell-specific differential gene
expression
In this section we examine cellular composition of the samples, and the effect that cellular compos-
ition may have on differential gene expression.
9.2.1 Deconvolution results
The results of the deconvolution analysis are shown in Figure 9.6. The algorithm, based on the
least-squares algorithm described by Abbas et al [100], and implemented in the CellMix package
[134], returns a matrix of proportions of cell types in each sample. Some important caveats ap-
ply: Firstly, the matrix of proportions only includes cell types for which expression profiles were
provided. Therefore, even if other cell-types are present in the sample, these will not contribute
to the proportions matrix. The original paper by Abbas described expression profiles for 18 cell
types, and only 12 are reported in the output. This is probably due to the fact that not all probes
in the Abbas dataset (Affymetrix data) are directly mappable to the Illumina data. Indeed, of 359
features defining 17 cell-types in the CellMix package, 212 are mapped to target IDs, and after
removal of duplicate probes, only 143 features are used for the final deconvolution analysis. It is
unclear whether an improved probe mapping will substantially alter the results. Future work will
re-examine this issue, and also compare these results to other deconvolution methods.
The proportions for each cell-type were then summarised for each group, and the results plot-
ted as pairwise box-and-whisker plots (Figure 9.7). These plots are more informative than the
stacked barcharts, as they allow for easy identification of large systematic differences between
sample groups. The median proportions for each cell-type were statistically compared between the
two disease phenotypes, and the results are presented in Table 9.2.
An interesting and unexpected finding is the highly significant difference in the proportion of
natural killer cells (NK cells) that are activated. NK cells are bone-marrow derived mononucleated
cells that originate from lymphocyte progenitor cells. In contrast to lymphocytes, NK cells have
invariant receptors, and respond to a broad range of intracellular pathogens. In order to respond
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Figure 9.6: Barplots of detected and PBMC types. The stacked barcharts show the proportion
of cell-types in each sample (top panel, neutrophils included, bottom panel neutrophils
excluded, representing the PBMC population). Each bar is normalised to 1 (100%).
Samples are ordered according to disease phenotype (not active TB followed by active
TB). The legend lists the cell types identified. Abbreviations: neutro: neutrophils, DC
act: activated dendritic cells, DC: non-activated dendritic cells, mono: monocytes, NK
act: activated natural killer cells, NK: non-activated natural killer cells, B aIGM: BCR-
ligated B cells, B: resting B cells, Tc act: activated CD8 T cell, Tc: resting CD8 T cell,
Th act: activated CD4 T cell, Th: resting CD4 T cell
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9.2 Array deconvolution and cell-specific differential gene expression
to such pathogens, they require activation by interferons and cytokines derived from macrophages
and dendritic cells (e.g. interferon-α , interferon-β (type I interferons), and interleukin-12 (IL-
12). Once bound to cells with intracellular pathogens they release cytotoxic granules (containing
granzymes and perforin) which kill the infected cell.
In previous studies, NK cells were shown to be activated at the site of disease in a mouse model
of tuberculosis, but this did not have an effect on pulmonary bacterial burden [156], questioning the
role NK cells might play in protection against active tuberculosis and controlling the disease. An in
vitro study showed that, in the presence of glutathione and IL-2/ IL-12 stimulation, NK cells inhibit
growth of Mycobacterium tuberculosis in monocytes; this growth inhibition itself was inhibited
when FasL and CD40L, important mediators of NK cell cytotoxicity, were inhibited by antibodies
[157]. This leaves open the question whether NK cells are protective in active tuberculosis in
humans. In a recent study performed on human tuberculosis site-of-disease samples (lung resection
samples) the authors demonstrated that NK cells infiltrated pulmonary granulomatous lesions. In
addition, NK cells from healthy volunteers could be stimulated to release IFNγ and TNFα by M.
tuberculosis H37Rv or M. bovis BCG in the presence of IL-2 [158]. The authors also demonstrated
variation in responses to TB antigens that correlated with variation in the KIR locus.
Given the increased proportion of activated NK cells in active tuberculosis suggested by the
deconvolution results in light of the studies cited above, the functional consequences of this phe-
nomenon require further exploration.
Table 9.2: Significance of differences in cell proportions in active TB vs not active TB. Signi-
ficant differences are highlighted in yellow.
names P-value Bonferroni Benjamini Hochberg
Th 0.2543 1.0000 0.3987
Th act 0.0728 0.8735 0.1747
Tc 0.2990 1.0000 0.3987
Tc act 0.0044 0.0531 0.0266
B 0.0358 0.4299 0.1075
B aIgM 0.6990 1.0000 0.6990
NK 0.0112 0.1338 0.0446
NK act 0.0004 0.0052 0.0052
mono 0.4176 1.0000 0.5011
DC 0.0943 1.0000 0.1886
DC act 0.2817 1.0000 0.3987
neutro 0.6744 1.0000 0.6990
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Figure 9.7: Boxplots of detected and PBMC types. The top panel shows box-and-whisker plots
for cell proportions by disease phenotype for all 12 detected cell types, and the bottom
panel for the PBMC subset. Tc act, NK act and NK are statistically significant after
multiple testing correction.
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9.2 Array deconvolution and cell-specific differential gene expression
9.2.2 Cell-type specific differential expression
Analysis of cell-type specific differential expression was limited to the top 500 differentially ex-
pressed genes combined with the probes in the Abbas data that uniquely identifies each cell type.
By doing so, sensitivity for detecting subtle changes in gene expression in specific cell types was
reduced, but the likelihood of detecting any cell-type specific differential expression was increased,
as we focus on probes known to be differentially expressed, and remove the majority of probes
most likely to contribute to false positive signals caused by excessive noise. So, in the first instance
the cell-type specific differential expression output is principally useful to identify cell-types, or
groups of cell-types, that are of prime interest for the contrast under investigation.
In several instances, members of the list of identified cell-types were combined into functional
classes. This was done where the number of samples in either arm of the contrast was smaller
then the number of cell-types. By using a proportion matrix containing fewer classes, even small
data subsets were amenable to analysis, assuming that the broader classes used were biologically
relevant. Given this caveat, much of the output of cell-type specific differential expression analysis
should be regarded as hypothesis-generating at best, and not necessarily a reflection of biological
reality.
Figure 9.8 demonstrates some results characteristic for many questions and data subsets. Differ-
ential expression of the analysed probes appears to be restricted to mainly NK cells, CD4 T cells
and neutrophils, while other lymphocytes, monocytes and dendritic cells do not show evidence in
favour of a cell-type specific signal. Given that these latter cell types often become active with
regard to tuberculosis at the site of disease, this is not surprising. Deconvolution analysis above
showed an increased proportion of activated NK cells, so it is reasonable to hypothesise that the
differentially regulated probes for this cell subset are involved in NK cell activation and cytotox-
icity. CD4 cells are central to the immune response to tuberculosis. Detection of a differential
expression signal in CD4 T cells but not in other lymphocytes may indicate differential recircula-
tion dynamics following exposure to antigen at the site of disease. Figure 9.9 shows the overlap
of the top 100 differentially expressed probes for three cell types. 36-46% of probes are unique
to these cell-types, highlighting the possibility that this method may be useful for defining specific
biological roles in different cell types in tuberculosis using transcriptomic profiles. I will return to
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Figure 9.8: False discovery rate plots after cell-specific DE
NK cell activation in tuberculosis in the next Chapter.
9.3 Weighted gene co-expression network analysis (WGCNA)
Modular analysis using weighted gene co-expression network analysis was performed next. Using
a soft-thresholding power of 5 and an R2 cutoff of 0.8, sixteen modules were identified. Of the
8000 probes considered for this analysis, 7440 were assigned to one of the modules. The modules1
vary widely in the number of probes they contain, ranging from 3217 to 24. Figure 9.10 shows
the sample dendrogram resulting from hierarchical clustering of the 8000 probes, and below this a
heatmap of phenotypic traits.
In Figure 9.11 we clearly see that the contrast variable (class3) is strongly correlated with all
modules2. This is expected, given that the 8000 probes used for module detection were selected
1Modules are arbitrarily named by the software using colour names as labels. As such, the module names are mean-
ingless.
2The variable class3 encodes “activeTB” and “notActiveTB”, while the variable class encodes “healthy”, “LTBI”,
“PTB” and “TB-PC”. The former is used for the contrast in the differential expression anlysis while the latter is
used mainly for applying the correct colour to the classes in various figures. Correlations are opposite for these two
variables due to the way the categorical variables are converted to numeric values used in the correlation calculations.
178
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
9.3 Weighted gene co-expression network analysis (WGCNA)
34
3640
46
128
18
Neut NK
CD4
Figure 9.9: Cell-type specific differential expression. Venn diagram showing overlap of top 100
DE probes after cell-type specific differential expression analysis for three cell types.
Abbreviations: Neut: neutrophils; NK: natural killer cells; CD4: CD4 T cells.
based on their probability of differential expression. Of interest is the fact that some additional
variables also show significant correlation with most modules. These variables (like fever, weight
loss, night sweats, pulse rate) are expected to correlate with presence and/ or severity of clinical
tuberculosis disease. Interestingly, this relationship is not seen with CD4 count, but this may be
due to incomplete data as CD4 counts were not measured in many HIV-1 uninfected individuals.
Next, we highlight some features of interesting modules. Associations of individual genes with
our trait of interest (clinical tuberculosis) are quantified by the measure “Gene Significance” (GS)
(the absolute value of the correlation between the gene and the trait). In addition, a quantitative
measure of module membership (MM) is defined as the correlation of the module eigengene and
the gene expression profile. For significant modules, the GS and MM measures are correlated;
examples for this are shown in Figure 9.12. Highly connected network hub genes tend to have high
GS and MM values.
Another way to visualise the modules is to plot the values of the module eigengenes underneath
a heatmap of expression data for the particular module, as in Figure 9.13. The barplots suggest that,
for these three modules at least, the expression of the module genes is associated with the contrast
variable (active TB or not active TB). Boxplots summarise the module eigengene expression data
further, and Table 9.3 summarises these comparisons for all detected modules.
Modules can also be visualised in a network context. Figure 9.14 shows this by the example
of the Red and Lightgreen modules. In both cases, results of differential expression analysis have
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Figure 9.10: WGCNA: Traits and modules. In Subfigure a, categorical variables in the phenotype
data were converted to numerical variables, and the matrix rescaled to the interval 0 to
1 for each variable. Missing data is shown in grey. Subfigure b shows the data used as
basis for selecting the soft-thresholding power used in module detection, and the mean
connectivity associated with various soft-thresholding powers. Subfigure c shows the
results of module detection by clustering and dynamic branch cutting.
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9.3 Weighted gene co-expression network analysis (WGCNA)
Table 9.3: Significance of modules for contrast “active TB vs no TB”. Results for comparing ex-
pression values of module eigengenes by Kruskal Wallis test. Uncorrected, Bonferroni-
corrected and Benjamini-Hochberg-corrected P-values/ Q-values are shown. The Mid-
nightblue module is not significant and has been highlighted in yellow. All module
names are simply arbitrary colour labels.
Module name P-value Bonferroni Q-value
1 green 0.0090 0.1971 0.0104
2 turquoise 0.0003 0.0066 0.0007
3 black 5.8765 ·10−05 0.0013 0.0004
4 lightyellow 0.0034 0.0756 0.0047
5 cyan 9.2786 ·10−05 0.0020 0.0004
6 red 9.2786 ·10−05 0.0020 0.0004
7 blue 9.2786 ·10−05 0.0020 0.0004
8 midnightblue 0.0591 1.0000 0.0591
9 darkred 0.0112 0.2454 0.0123
10 tan 0.0006 0.0132 0.0010
11 pink 0.0006 0.0132 0.0010
12 brown 0.0011 0.0248 0.0018
13 purple 0.0001 0.0031 0.0005
14 magenta 0.0003 0.0066 0.0007
15 yellow 0.0090 0.1971 0.0104
16 greenyellow 0.0026 0.0582 0.0039
17 grey60 0.0056 0.1242 0.0073
18 lightcyan 0.0169 0.3718 0.0177
19 lightgreen 0.0006 0.0132 0.0010
20 salmon 0.0003 0.0066 0.0007
21 royalblue 0.0004 0.0095 0.0009
22 grey 9.2786 ·10−05 0.0020 0.0004
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Figure 9.11: Module/ trait relationships. This heatmap shows the Pearson correlation coefficients
(R) and their P-values for a number of phenotypic variables as correlated with the
detected modules. Colours: green = positive correlation; red = negative correlation.
been mapped onto the nodes.
The results of WGCNA-analysis demonstrate that modules significant in tuberculosis can be
identified. These modules await further characterisation at a more detailed level by identifying the
genes central to the modules’ functioning, as well as any pathways or groups of pathways associated
with the modules.
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Figure 9.12: Top 3 GS/MM plots This figure demonstrates correlation of the measures Gene Sig-
nificance vs. Module Membership (GS/MM). The results for three modules are shown.
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Figure 9.13: Three significant modules. Results for three modules are demonstrated in more de-
tail. Bar plots of eigengene expression combined with a heatmap of the probes making
up the module are shown on the left. The right panel shows a box and whisker chart
of a summary of all eigengenes (one per sample) in each of the two contrast classes.
Test statistics for the median difference are shown in Table 9.3. The sample names are
coloured by TB class (green = healthy, blue = LTBI, orange = PTB, red = TB-PC).
Note that for these three modules their respective eigengenes are downregulated in not
active TB and upregulated in active TB
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9.3 Weighted gene co-expression network analysis (WGCNA)
(a) Red module, complete network (b) Red module, zoomed in and only showing genes that
were differentially expressed
(c) Lightgreen module, complete network (d) Lightgreen module, zoomed in view. Differentially ex-
pressed genes are highlighted. These genes appear to
be hubs of the network.
Figure 9.14: Weighted gene co-expression networks. Networks of gene co-expression were gen-
erated in Cytoscape. Nodes reported as differentially expressed in earlier analysis are
coloured on a green (downregulated in active TB) to red (upregulated in active TB)
colour scale. Network edges are weighted by the strength of association between any
of their nodes.
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Part IV
IMPI-MA: Results in breadth
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10 Contrasts involving tuberculosis
In this and the following two chapters I present a broad impression of results for all questions that
form part of the analysis. The results are mainly presented in tabular form and summary images.
The emphasis here is on comparison of results (rendered in broad brushstrokes as opposed to the
level of detail used in the preceding chapter); in particular, the results for two datasets in each
question will be juxtaposed, in order to highlight similarities and differences.
This Chapter deals with questions relating to active and latent tuberculosis, effects of pulmonary
vs. extrapulmonary tuberculosis and differences between haemodynamic phenotypes of TB-PC.
General comment: Due to heterogeneity of the IMPI-MA data, many analyses lack adequate
statistical power. Some data subsets lend themselves to splitting into “training” and “test” sets, as
sufficient numbers of samples are available. Future work will address this by splitting IMPI-MA
data subsets into training and test sets or applying the signatures to other extant microarray datasets
(Berry et al, Maertzdorf et al). The current work does not provide for validation of signatures, and
for this reason should be considered as an exploration of the “space” of signatures in HIV-TB.
10.1 Question 1: Tuberculosis
In this Section I show the results for the contrast “active TB vs. not-active TB”, in order to address
questions regarding the biology of active tuberculosis disease. Related to this question are differ-
ences in biology that are due to the site of active disease (lung vs. pericardium), biological features
of LTBI, and differences in cellular and transcriptional responses in two different haemodynamic
presentations of TB-PC. These three additional questions will be addressed in the following sec-
tions.
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10.1.1 Included patients and samples
I examined the contrast active vs not active TB in blood in two contexts: HIV-1 uninfected and HIV-
1 co-infected individuals. Table 10.1 show the baseline demographic and clinical characteristics of
the study participants on whose samples the microarray analysis is based. This table has been
structured to facilitate comparisons between the two sample sets as well as for the contrast variable
within each sample set1. Three variables were examined: age, sex and CD4 count.
In comparisons across the two study groups, HIV-1/M. tuberculosis co-infected individuals were
younger than their HIV-1 uninfected counterparts, but this difference failed to reach statistical sig-
nificance. HIV-1 infected individuals were predominantly female and HIV-1/M. tuberculosis co-
infected individuals had lower CD4 counts than their HIV-1 uninfected counterparts. Comparing
these three variables within each study group, the HIV-1 uninfected group was well matched for
age and sex (CD4 count could not be assessed), but the HIV-1 infected group was only matched
for age, as all cases of not active TB were female, and the active TB group had significantly lower
median CD4 counts. The sex bias in the HIV-1 infected not active TB group is explained by pat-
terns of health-seeking behaviour in asymptomatic HIV-1 infected persons; in South Africa men
infrequently attend wellness clinics if asymptomatic, therefore females are much more readily re-
cruited into this category. Future studies should employ stratified sampling in order to avoid this
type of bias. In summary, when examining the contrast activeTB vs not active TB we should be
aware of possible bias introduced by different CD4 counts and male to female ratios in the data in
the HIV-1 infected group, and when comparing the results of the two analyses, we should consider
the possibility of sex and CD4 count contributing to any differences in results.
10.1.2 Overall results
In Table 10.2 I show the comparison of the main results of the analytic pipeline. A much higher
number of probes (5404 vs 369) were differentially expressed in the HIV-1 infected group at a
false discovery rate cutoff of 0.05. This is likely due to several factors. Firstly, the second analysis
had greater statistical power to detect differences, as 3.3 times the number of study participants in
the HIV-1 uninfected group were available. Secondly, as noted above, the HIV-1 infected study
1While the table is hard to read, it summarises a lot of data, and allows the comparison of variables within and between
datasets. Comparisons between datasets are read horizontally, and comparisons within datasets are read vertically
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10.1 Question 1: Tuberculosis
Table 10.1: Clinical characteristics: active TB vs not active TB. Two-way comparison of demo-
graphic variables and CD4 count between and with groups of study participants. P-
values less than 0.05 are regarded as significant.
Blood
HIVneg
activeTB-
notActiveTB
Blood
HIVpos
activeTB-
notActiveTB
Pval Test
Age Median LQ UQ Median LQ UQ Pval Test
age_All 33.85 26.55 51.48 32.98 27.2 38.18 0.422 Kruskal-
Wallis
rank
age_ activ-
eTB
40.67 33.69 52.86 33.3 29.6 38.6 0.065 Kruskal-
Wallis
rank
age_ not-
ActiveTB
29.9 22.98 34.2 29.5 25.75 37.3 0.584 Kruskal-
Wallis
rank
age_P
value
0.086 0.084
age_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Sex ratio F/M Female Male ratio F/M Female Male Pval test
sex_All 0.467 7 15 2.650 53 20 0.001 2-sample
test for eq
sex_ activ-
eTB
0.714 5 7 1.300 26 20 0.553 2-sample
test for eq
sex_ not-
ActiveTB
0.250 2 8 Inf 27 0 0.000 2-sample
test for eq
sex_P value 0.531 0.000
sex_Test 2-sample
test for eq
2-sample
test for eq
CD4 Median LQ UQ Median LQ UQ Pval Test
CD4_All 566 404.5 653 260 117 361.5 0.007 Kruskal-
Wallis
rank
CD4_ act-
iveTB
566 404.5 653 167 86 291.5 0.001 Kruskal-
Wallis
rank
CD4_ not-
ActiveTB
333 307.5 467 NA NA
CD4_P
value
NA 0.000
CD4_Test NA Kruskal-
Wallis
rank
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participants grouped by contrast variable were unmatched for sex and CD4 count, and finally, it is
plausible that HIV-1 co-infection introduces additional variability to gene expression. Following
deconvolution analysis, proportions for 3 of 12 cell types were significantly different in HIV-1 un-
infected individuals, whereas 8 of 14 cell types differed in proportion in HIV-1 infected individuals.
For the WGCNA analysis the same soft thresholding power was selected; a similar number of mod-
ules was detected in both cases, with at least 93% of probes assigned to modules. The following
subsection examines some results in more detail.
Table 10.2: Overall results: active TB vs not active TB. Output of the analysis script, showing
the numbers of included samples, and statistics for differential expression, deconvolu-
tion and gene co-expression network analysis. P-values less than 0.05 are regarded as
significant.
Question 1: Tuberculosis
Contrast: Active TB vs. not Active TB
Dataset 1 2
Context Blood, HIV neg Blood, HIV pos
N: Active TB 12 46
N: not Active TB 10 27
Analysis 1: Differential expression
N significant probes (unadjusted) 4121 8847
N significant probes (BH adjusted) 369 5405
N probes used (heatmaps, csDE) 369 2000
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 3 of 12 8 of 14
N of N PBMC significant for contrast (BH) 2 of 11 5 of 13
Cell-specific DE successful yes yes
Number of cell types 7 7
N cell types that reach FDR < 0.4 2 3
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.8 0.8
Soft threshold power 5 5
Number of modules 21 16
Probes assigned to modules (N, %) 7937 (99) 7440 (93)
GO: Entrez IDs submitted 4382 4730
GO: Entrez IDs mapped 2920 3182
N (%) modules cor GS/MM sig 17 (81) 12 (75)
N (%) modules sig for contrast (BH) 20 (95) 16 (100)
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10.1 Question 1: Tuberculosis
10.1.3 Results for context: HIV (datasets: Blood, HIV negative and Blood,
HIV positive)
How well do these differentially expressed probes classify the input data? Figure 10.1 shows heat-
maps of the significantly differentially expressed probes for the HIV-1 uninfected group, and the
top 2000 differentially expressed probes for the HIV-1 infected group. In the first case the input
data is classified well (one “healthy” sample is misclassified), and in the second case, two distinct
clusters are seen: one cluster only contains active TB cases, and the second six active TB cases
in addition to all the not-active TB cases. The reason for this misclassification may lie in the fact
that either an insufficient number of probes were selected, or that the signal due to HIV-1 infection
interferes with the active TB signal.
False discovery rate (FDR) plots for the two analyses (Figure 10.2) offer an additional perspective
on the results. While the signal for cell-specific differential expression is seen in CD4 T cells, NK
cells and to a lesser extent neutrophils in HIV-1 uninfected individuals (see also Chapter 9), we
find stronger signals in CD8 T cells, neutrophils, monocytes and dendritic cells in HIV-1 infected
individuals, while the signal for differential expression in NK cells is much less convincing. This
may be due to effects of HIV-1 on gene expression in these cell subsets in the context of a TH1-
predominant inflammatory background. It is well described that Mycobacterium tuberculosis and
HIV-1 interact significantly (See Chapter 1). Both monocytes and dendritic cells may become
infected with HIV-1 [159], and it is possible that the differential expression in these cell types is
due to effects of HIV-1 which are only seen in the context of active tuberculosis. A possible effect
of HIV-1 on monocytes and dendritic cells is the induction of apoptosis [160], and detection of
induction of pro-apototic factors in these cell subsets would provide additional evidence for this.
Module detection was similar in both groups as see in Figure 10.3. The functional characteristics
of the identified modules are still to be determined.
Finally I looked at the overlap of differentially expressed probes in the two contexts. 237 probes
were found to overlap between the 369 probes found in HIV-1 uninfected individuals and the top
2000 probes in HIV-1 infected individuals, accounting for 64% of the probes in the first set. The
non-overlapping probes may represent noise or HIV-1 specific effects, while the overlapping probes
represent effects driven by active tuberculosis regardless of HIV-1 infection.
193
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
10 Contrasts involving tuberculosis
21
26
7 
co
nt
ro
l
21
25
8 
co
nt
ro
l
21
29
6 
co
nt
ro
l
20
97
0 
co
nt
ro
l
21
23
3 
co
nt
ro
l
21
07
5 
co
nt
ro
l
20
96
7 
co
nt
ro
l
20
02
1 
co
nt
ro
l
20
55
8 
co
nt
ro
l
21
28
5 
co
nt
ro
l
20
86
5 
co
nt
ro
l
20
93
2 
co
nt
ro
l
PC
A0
07
 b
lo
od
PC
A0
34
 b
lo
od
PC
70
 b
lo
od
PC
A0
37
 b
lo
od
PC
A0
40
 b
lo
od
PC
12
4 
bl
oo
d
20
45
0 
co
nt
ro
l
20
92
0 
co
nt
ro
l
PC
55
 b
lo
od
PC
79
 b
lo
od
369 probes 
(a) Heatmap of differentially expressed probes, HIV-1 uninfected
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(b) Heatmap of differentially expressed probes, HIV-1 infected
Figure 10.1: Results for contrast TB status in contexts HIV negative and HIV positive. The
heatmaps show good separation of samples regardless of HIV status. The HIV neg-
ative group was discussed in Chapter 9. In comparison, the HIV positive group had
14.6 times the number of differentially regulated probes; only the top 2000 probes are
shown here. Values are row-scaled, and range from low (blue) to intermediate (yel-
low) to high (red). Samples are clustered using Spearman rank correlation, and probes
are clustered using Pearson correlation. Sample colours: green: healthy, blue: LTBI,
orange: PTB, red: TB-PC. Plot titles reflect the number of included probes.
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(a) False discovery rate plot HIV-1 uninfected
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(b) False discovery rate plot HIV-1 infected
Figure 10.2: Cell-type specific differential expression. False discovery rate plots for the two ana-
lyses. For each plot the x-axis shows the number of differentially expressed probes
called, given the false discovery rate shown on the y-axis.
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Figure 10.3: Module clustering. The plots show the dendrograms resulting form hierarchical clus-
tering of the 8000 probes used in the analysis. Colours indicate the modules to which
probes were assigned; these colours correspond to the module names.
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Figure 10.4: Overlap of differentially expressed probes.
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10.2 Question 2: PTB and extrapulmonary TB
In this Section I examine the contrast “PTB vs TB-PC”. This looks for differences in transcriptional
response detectable in blood based on the site of MTB infection. The underlying hypothesis for
this contrast is that the site of disease elicits an additional signal in the transcriptomic data over and
above that of TB itself.
10.2.1 Included patients and samples
Table 10.3 summarises the variables age, sex and CD4 count across two groups of study subjects
(HIV-1 uninfected and -infected) as well as within each of the two groups across the contrast vari-
able PTB vs TB-PC. HIV-1 infected individuals presenting with TB-PC were younger than their
HIV-1 uninfected counterparts, and HIV-1 infected individuals presenting with PTB were all fe-
male while the female to male ratio in the HIV-1 uninfected group was 0.33. As expected, median
CD4 counts in HIV-1 infected individuals presenting with TB-PC were significantly lower than in
HIV-1 uninfected cases. The HIV-1 infected group was matched for age, but not sex or CD4 count
while HIV-1 uninfected group was matched for age and sex (matching for CD4 count could not be
assessed due to missing data). The finding that HIV-1 infected individuals presenting with TB-PC,
a form of extrapulmonary TB, had lower CD4 counts than those presenting with pulmonary disease
is in line with expectation. In summary, differences in CD4 count and sex should be considered as
potential biasing factors in this analysis.
10.2.2 Overall results
Table 10.4 lists the overall statistics of running the analytic pipeline on the two datasets. It should
be noted that the sample sizes in the HIV-1 uninfected group are very small, and as such, any results
should be regarded as hypothesis generating at best. Another potentially important biasing factor
is the fact that the RNA from the two groups was collected at different times in different study
contexts, and was extracted at different time points. Of all analyses, this one is probably most
susceptible to technical bias.
The number of differentially expressed probes found in the two datasets after multiple testing
correction was 38 (HIV-1 infected) and 0 (HIV-1 uninfected), respectively. In order to explore
197
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
10 Contrasts involving tuberculosis
Table 10.3: Clinical characteristics: PTB vs TB-PC. Two-way comparison of demographic vari-
ables and CD4 count between and with groups of study participants. P-values less than
0.05 are regarded as significant.
Blood
HIVpos
PTB-TBPC
Blood
HIVneg
PTB-TBPC
Pval Test
Age Median LQ UQ Median LQ UQ Pval Test
age_All 33.3 29.6 38.6 40.67 33.69 52.86 0.065 Kruskal-
Wallis
rank
age_
CON_PTB
34.25 28.12 42.27 33.85 31.78 38.6 0.888 Kruskal-
Wallis
rank
age_ TBPC 33.13 29.7 38.32 46.6 35.3 54.01 0.036 Kruskal-
Wallis
rank
age_P
value
0.749 0.308
age_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Sex ratio F/M Female Male ratio F/M Female Male Pval test
sex_All 1.300 26 20 0.714 5 7 0.553 2-sample
test for eq
sex_
CON_PTB
Inf 10 0 0.333 1 3 0.018 2-sample
test for eq
sex_ TBPC 0.800 16 20 1.000 4 4 1.000 2-sample
test for eq
sex_P value 0.006 0.836
sex_Test 2-sample
test for eq
2-sample
test for eq
CD4 Median LQ UQ Median LQ UQ Pval Test
CD4_All 167 86 291.5 566 404.5 653 0.001 Kruskal-
Wallis
rank
CD4_
CON_PTB
322 267.5 454.5 NA NA
CD4_
TBPC
110 78 237.2 566 404.5 653 0.000 Kruskal-
Wallis
rank
CD4_P
value
0.000 NA
CD4_Test Kruskal-
Wallis
rank
NA
198
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
10.2 Question 2: PTB and extrapulmonary TB
classification of the input data and probe overlap, I selected the top 300 differentially expressed
probes (using as ranking measure the log-odds of differential expression), bearing in mind that
many of these probes are potentially (but not definitely) false positives. The sample size in the
HIV-1 uninfected group was too small for meaningful cell-specific differential expression; this will
not be reported here. Finally, a high number of modules was identified in the HIV-1 uninfected
group (67), with all but two probes assigned to modules. In contrast, only 62.1% of probes were
assigned to modules in the HIV-1 infected group.
Table 10.4: Overall results: PTB vs TB-PC. Output of the analysis script, showing the numbers
of included samples, and statistics for differential expression, deconvolution and gene
co-expression network analysis. P-values less than 0.05 are regarded as significant.
Question 2: TB Site
Contrast: PTB vs. TB-PC
Dataset 1 2
Context Blood, HIV pos Blood, HIV neg
N: PTB 10 4
N: TB-PC 36 8
Analysis 1: Differential expression
N significant probes (unadjusted) 3593 2260
N significant probes (BH adjusted) 38 0
N probes used (heatmaps, csDE) 300 300
Analysis 2: Deconvolution
Deconvolution succe sful yes yes
N of N significant for contrast (BH) 3 of 13 0 of 12
N of N PBMC significant for contrast (BH) 2 of 12 0 of 11
Cell-specific DE successful yes no
Number of cell types 7 NA
N cell types that reach FDR < 0.4 1 NA
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.8 0.8
Soft threshold power 7 9
Number of modules 18 67
Probes assigned to modules (N, %) 4971 (62.1) 7998 (99.99)
GO: Entrez IDs submitted 4406 4048
GO: Entrez IDs mapped 2925 2662
N (%) modules cor GS/MM sig 11 (61) 44 (66)
N (%) modules sig for contrast (BH) 18 (100) 37 (55)
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10.2.3 Results for context HIV: (datasets: Blood, HIV negative and Blood,
HIV positive)
The heatmaps in Figure 10.5 show that in both cases, the top 300 selected probes do quite well
in classifying the input data. There are no misclassifications in the HIV-1 uninfected group, and
two cases of PTB are misclassified as TB-PC in the HIV-1 infected group. Given the higher risk
for extrapulmonary tuberculosis in HIV-1 co-infection, concurrent pulmonary and extrapulmonary
tuberculosis in these cases can not be excluded as an explanation for this. In any event, any dif-
ference in transcriptional profiles that are due to the site of TB disease is likely to be small, with a
much more subtle signal than active TB vs. not active TB.
Cell-type specific differential expression analysis offers additional clues about the significance
of any detectable differential expression between sites of tuberculosis disease (Figure 10.6). Due
to small sample numbers, no estimate could be made in the HIV-1 uninfected group, but in HIV-1
infected individuals the cell-type specific signal is strongest in CD8 T cells. Importantly, given
that the TB-PC cases had lower CD4 counts than the PTB cases, the signal may in fact be due to a
significant effect of HIV, rather than a signal due to tuberculosis disease. With this interpretation,
extrapulmonary tuberculosis would serve as a marker of more advanced HIV disease. More likely,
the signal is of mixed origin, with differential severity of HIV-1 infection, M. tuberculosis organism
burden and location-specific changes.
Figure10.7 highlights differences in module detection in the two datasets. A much large number
of modules is found in HIV-1 uninfected individuals.
Figure 10.8 is informative regarding the biological significance of the two signatures; of the top
300 differentially expressed probes, only 14 probes overlap. While it is likely that the selected
probes are biologically informative, the added effect of HIV-1 infection in the context of extrapul-
monary tuberculosis probably leads to the lack of overlap.
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(b) Heatmap of differentially expressed probes, HIV-1 infected
Figure 10.5: Results for contrast TB site in contexts HIV negative and HIV positive. The heat-
maps show good separation of samples based on site of TB infection. Few or no
probes for significantly differentially expressed after Benjamini Hochberg correction,
but despite this the top 300 differentially expressed probes (based on ranking by log-
odds of differential expression) show good separation of the samples. The question of
whether we are seeing a batch effect (the samples were collected in different studies)
or a true biological effect remains currently an open one. Values are row-scaled, and
range from low (blue) to intermediate (yellow) to high (red). Samples are clustered
using Spearman rank correlation, and probes are clustered using Pearson correlation.
Sample colours: orange: PTB, red: TB-PC. Plot titles reflect the number of included
probes. 201
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Figure 10.6: Cell-type specific differential expression. Only the result for HIV-1 infected indi-
viduals is shown, as the HIV-1 uninfected group was too limited in sample numbers
for meaningful analysis.
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Figure 10.7: Module clustering.
202
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
10.2 Question 2: PTB and extrapulmonary TB
286 286
14HIV pos HIV neg
(a) Overlap of top 300 differentially expressed probes
473 47327
HIV pos HIV neg
(b) Overlap of top 500 differentially expressed probes
Figure 10.8: Overlap of differentially expressed probes.
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10.3 Question 3: Latent TB
This subsection addresses the question of whether LTBI leaves a detectable signal in the blood
transcriptome relative to no prior TB sensitisation.
10.3.1 Included patients and samples
Table 10.5 summarises the variables age, sex and CD4 count across two groups of study sub-
jects (HIV-1 uninfected and -infected) as well as within each of the two groups across two groups
defined by the contrast variable LTBI vs healthy. The two groups, as well as the two comparator
groups within each group were matched for age. Both comparator groups within each set were also
matched for sex, but the two sets differed significantly w.r.t. this variable; no male patients were
included in the HIV-1 infected group, whereas both men and women were included in the HIV
negative group. Finally, assessment for matching for CD4 count was only possible in the HIV-1
infected group (where the healthy and LTBI groups were matched for CD4 count), as CD4 count
data was unavailable for the HIV-1 uninfected individuals. In summary, some bias due to sex may
be expected when comparing the results of the two analyses.
10.3.2 Overall results
Table 10.6 lists the results of the analysis for the two datasets of interest. Once again, few to
no probes (0 and 1, respectively) were significantly differentially expressed after multiple testing
correction. Deconvolution and cell-specific differential expression was successful for both datasets,
as was module detection.
10.3.3 Results for context HIV: (datasets: Blood, HIV negative and Blood,
HIV positive)
With selection of the top 300 differentially expressed probes, both HIV-1 uninfected and uninfected
input data sets are separated perfectly into two clusters, suggesting that the probes are biologically
meaningful.
Cell-type specific differential expression in HIV-1 uninfected individuals only exhibited a very
weak signal in natural killer cells and neutrophils, while in HIV-1 infected individuals a very strong
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Table 10.5: Clinical characteristics: Healthy vs LTBI. Two-way comparison of demographic
variables and CD4 count between and with groups of study participants. P-values less
than 0.05 are regarded as significant.
Blood
HIVpos
Healthy-
LTBI
Blood
HIVneg
Healthy-
LTBI
Pval Test
Age Median LQ UQ Median LQ UQ Pval Test
age_All 29.5 25.75 37.3 29.9 22.98 34.2 0.584 Kruskal-
Wallis
rank
age_
CON_LTBI
29.5 25.5 35.3 29.1 22.7 34.7 0.693 Kruskal-
Wallis
rank
age_
CON_healthy
29.5 26.08 39.47 30.7 23.8 32.7 0.711 Kruskal-
Wallis
rank
age_P
value
0.544 0.917
age_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Sex ratio F/M Female Male ratio F/M Female Male Pval test
sex_All Inf 27 0 0.250 2 8 0.000 2-sample
test for eq
sex_
CON_LTBI
Inf 13 0 0.250 1 4 0.002 2-sample
test for eq
sex_
CON_healthy
Inf 14 0 0.250 1 4 0.002 2-sample
test for eq
sex_P value NaN 1.000
sex_Test 2-sample
test for eq
2-sample
test for eq
CD4 Median LQ UQ Median LQ UQ Pval Test
CD4_All 333 307.5 467 NA NA
CD4_
CON_LTBI
333 316 416 NA NA
CD4_
CON_healthy
372 273 542.5 NA NA
CD4_P
value
0.846 NA
CD4_Test Kruskal-
Wallis
rank
NA
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Table 10.6: Overall results: Healthy vs LTBI. Output of the analysis script, showing the numbers
of included samples, and statistics for differential expression, deconvolution and gene
co-expression network analysis. P-values less than 0.05 are regarded as significant.
Question 3: Latent TB infection
Contrast: LTBI vs. Healthy
Dataset 1 2
Context Blood, HIV pos Blood, HIV neg
N: LTBI 13 5
N: Healthy 14 5
Analysis 1: Differential expression
N significant probes (unadjusted) 1329 2111
N significant probes (BH adjusted) 0 1
N probes used (heatmaps, csDE) 300 300
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 0 of 12 0 of 13
N of N PBMC significant for contrast (BH) 0 of 11 0 of 12
Cell-specific DE successful yes yes
Number of cell types 7 4
N cell types that reach FDR < 0.4 2 0
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.8 0.8
Soft threshold power 3 10
Number of modules 21 32
Probes assigned to modules (N, %) 7182 (89.8) 6783 (84.8)
GO: Entrez IDs submitted 3900 4201
GO: Entrez IDs mapped 2573 2805
N (%) modules cor GS/MM sig 8 (38) 21 (65)
N (%) modules sig for contrast (BH) 20 (95) 24 (75)
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(b) Heatmap of differentially expressed probes, HIV-1 infected
Figure 10.9: Results for contrast LTBI in contexts HIV negative and HIV positive. Values are
row-scaled, and range from low (blue) to intermediate (yellow) to high (red). Samples
are clustered using Spearman rank correlation, and probes are clustered using Pearson
correlation. Sample colours: green: healthy, blue: LTBI. Plot titles reflect the number
of included probes.
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neutrophil signal combined with weaker signals for CD8 T cells and NK cells are evident.
Almost all probes were assigned to modules in both cases.
Once again, the top 300 differentially expressed probes hardly overlap (3 out of 300), again high-
lighting the possibility that HIV-1 infection in the context of LTBI drives the differential expression
seen.
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Figure 10.10: Cell-type specific differential expression.
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Figure 10.11: Module clustering.
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Figure 10.12: Overlap of differentially expressed probes.
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10.4 Question 4: Haemodynamic phenotypes in TB-PC
The final question relating to tuberculosis deals with haemodynamic phenotypes. Here I examine
the contrast “effusive TB-PC vs. effusive-constrictive TB-PC”. Here I compare the results of this
analysis for two compartments: blood and pericardial fluid, the site of disease. It is anticipated that
the signal for effusive-constrictive disease, if any, is stronger in the pericardial fluid compartment.
10.4.1 Included patients and samples
As the comparison focuses on matched blood and pericardial fluid samples, all comparisons across
the two datasets are not significant, as they consider the same study subjects. In addition, the
samples are matched for age, sex and CD4 count across the contrast variable. See Table 10.7 for
details.
Table 10.7: Clinical characteristics: Effusive vs Effusive-constrictive pericarditis. Two-way
comparison of demographic variables and CD4 count between and with groups of study
participants. P-values less than 0.05 are regarded as significant.
Blood
TBPC
HIVPos
Eff-EC
Fluid
TBPC
HIVPos
Eff-EC
Pval Test
Age Median LQ UQ Median LQ UQ Pval Test
age_All 32.14 27.91 36.72 32.14 27.91 36.72 1.000 Kruskal-
Wallis
rank
age_ EC 33.08 32.92 38.75 33.08 32.92 38.75 1.000 Kruskal-
Wallis
rank
age_ Eff 30.12 27.51 33.7 30.12 27.51 33.7 1.000 Kruskal-
Wallis
rank
age_P
value
0.184 0.184
age_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Sex ratio F/M Female Male ratio F/M Female Male Pval test
sex_All 0.818 9 11 0.818 9 11 1.000 2-sample
test for eq
sex_ EC 0.800 4 5 0.800 4 5 1.000 2-sample
test for eq
sex_ Eff 0.833 5 6 0.833 5 6 1.000 2-sample
test for eq
sex_P value 1.000 1.000
sex_Test 2-sample
test for eq
2-sample
test for eq
CD4 Median LQ UQ Median LQ UQ Pval Test
CD4_All 98.5 62.5 192.2 98.5 62.5 192.2 1.000 Kruskal-
Wallis
rank
CD4_ EC 105 95 223 105 95 223 1.000 Kruskal-
Wallis
rank
CD4_ Eff 86 49 166.5 86 49 166.5 1.000 Kruskal-
Wallis
rank
CD4_P
value
0.171 0.171
CD4_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
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10.4.2 Overall results
No probes were significantly differentially expressed after multiple testing correction, so again the
top 300 differentially expressed probes ranked by log-odds for differential expression were used for
downstream analyses and visualisations. Deconvolution, cell-type specific differential expression
analysis and module detection were performed successfully. Table 10.8 lists the main results of this
analysis.
Table 10.8: Overall results: Effusive vs Effusive-constrictive pericarditis. Output of the ana-
lysis script, showing the numbers of included samples, and statistics for differential
expression, deconvolution and gene co-expression network analysis. P-values less than
0.05 are regarded as significant.
Question 4: Haemodynamic phenotype
Contrast: Effusive-constrictive pericarditis (EC) vs. Effusive pericarditis (Eff)
Dataset 1 2
Context Blood, TB-PC, HIV pos Fluid, TB-PC, HIV pos
N: EC 9 9
N: Eff 11 11
Analysis 1: Differential expression
N significant probes (unadjusted) 1195 1269
N significant probes (BH adjusted) 0 0
N probes used (heatmaps, csDE) 300 300
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 0 of 13 0 of 13
N of N PBMC significant for contrast (BH) 0 of 12 0 of 12
Cell-specific DE successful yes yes
Number of cell types 7 7
N cell types that reach FDR < 0.4 4 0
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 3 14
Soft threshold power 0.8 0.8
Number of modules 34 12
Probes assigned to modules (N, %) 7808 (97.6) 2250 (28.1)
GO: Entrez IDs submitted 3759 3912
GO: Entrez IDs mapped 2452 2574
N (%) modules cor GS/MM sig 18 (53) 3 (25)
N (%) modules sig for contrast (BH) 33 (97) 1 (8)
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10.4.3 Results for context: Compartment (datasets: TB-PC HIVpos Blood,
TB-PC HIVpos Fluid)
The heatmaps shown in Figure 10.13 show that the top 300 differentially expressed probes cluster
their respective input data perfectly.
Cell-type specific differential expression yielded stronger signals in blood (for CD4 T cells, B
cells NK cells, monocytes and dendritic cells) than in pericardial fluid (for neutrophils and CD8 T
cells). This interesting finding warrants further investigation.
Module clustering is shown in Figure 10.15. Of interest is the fact that most probes were not
assigned to any module.
As seen previously, the overlap of differentially expressed probes is very small when comparing
blood and pericardial fluid. Blood appears to be a very poor mirror for events at the site of disease.
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Figure 10.13: Results for contrast Haemodynamic phenotype in contexts Blood and Fluid. Val-
ues are row-scaled, and range from low (blue) to intermediate (yellow) to high (red).
Samples are clustered using Spearman rank correlation, and probes are clustered us-
ing Pearson correlation. Sample colours: yellow: effusive-constrictive phenotype,
blue: effusive phenotype. Plot titles reflect the number of included probes.
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Figure 10.14: Cell-type specific differential expression.
215
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
10 Contrasts involving tuberculosis
0.
6
0.
7
0.
8
0.
9
 20 samples 8000 probes
hclust (*, "average")d
H
ei
gh
t
Module colors
(a) Module clustering Blood
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
 20 samples 8000 probes
hclust (*, "average")d
H
ei
gh
t
Module colors
(b) Module clustering Fluid
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Figure 10.16: Overlap of differentially expressed probes.
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10.5 Pathway analysis
Pathway analysis was performed as described in Section 3.8.8. Tables 10.9, 10.10 and 10.11 list the
pathways found to be significantly differentially regulated in active tuberculosis in HIV-1 uninfec-
ted and -infected groups, respectively. Figures 10.18 and 10.19show heatmaps for the differentially
regulated pathways in tuberculosis cases.
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Table 10.9: Top pathways in TB (HIV-1 uninfected). Positive results refer to upregulation of the
pathway in active tuberculosis, and negative numbers refer to downregulation. Colours:
green = also downregulated in HIV-TB, red = also upregulated in HIV-TB, yellow =
downregulated in HIV-TB. The Mean logFC value indicates the extent to which the
pathway is up- or downregulated by providing the log2-fold change value.
Pathway Mean
logFC
hsa00190 Oxidative phosphorylation 2.356
hsa03050 Proteasome 1.573
hsa04145 Phagosome 1.365
hsa04610 Complement and coagulation cascades 1.256
hsa04260 Cardiac muscle contraction 1.073
hsa04142 Lysosome 0.930
hsa04620 Toll-like receptor signaling pathway 0.894
hsa04130 SNARE interactions in vesicular transport 0.888
hsa04612 Antigen processing and presentation 0.764
hsa03060 Protein export 0.773
hsa04660 T cell receptor signaling pathway -1.418
hsa04630 Jak-STAT signaling pathway -1.148
hsa04310 Wnt signaling pathway -1.133
hsa04070 Phosphatidylinositol signaling system -1.106
hsa04662 B cell receptor signaling pathway -0.937
hsa04144 Endocytosis -0.884
hsa04012 ErbB signaling pathway -0.853
hsa04720 Long-term potentiation -0.827
hsa00562 Inositol phosphate metabolism -0.818
hsa04742 Taste transduction -0.810
hsa00532 Glycosaminoglycan biosynthesis - chondroitin
sulfate
-0.779
hsa04010 MAPK signaling pathway -0.765
hsa04330 Notch signaling pathway -0.766
hsa04960 Aldosterone-regulated sodium reabsorption -0.748
hsa00514 Other types of O-glycan biosynthesis -0.740
hsa00563 Glycosylphosphatidylinositol(GPI)-anchor biosyn-
thesis
-0.726
hsa03040 Spliceosome -0.720
hsa03013 RNA transport -0.712
hsa04910 Insulin signaling pathway -0.706
hsa04520 Adherens junction -0.689
hsa04110 Cell cycle -0.678
hsa00270 Cysteine and methionine metabolism -0.662
hsa04062 Chemokine signaling pathway -0.640
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Table 10.10: Upregulated pathways in TB (HIV-1 infected). Colours: red = also upregulated in
TB without HIV
Pathway Mean
logFC
hsa04130 SNARE interactions in vesicular transport 1.219
hsa04620 Toll-like receptor signaling pathway 1.136
hsa04380 Osteoclast differentiation 1.133
hsa00190 Oxidative phosphorylation 1.096
hsa04610 Complement and coagulation cascades 1.082
hsa00564 Glycerophospholipid metabolism 0.968
hsa04140 Regulation of autophagy 0.923
hsa00760 Nicotinate and nicotinamide metabolism 0.898
hsa04966 Collecting duct acid secretion 0.887
hsa00600 Sphingolipid metabolism 0.711
hsa00770 Pantothenate and CoA biosynthesis 0.715
hsa04740 Olfactory transduction 0.663
hsa04976 Bile secretion 0.623
hsa02010 ABC transporters 0.622
hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.623
hsa04142 Lysosome 0.622
hsa00512 Mucin type O-Glycan biosynthesis 0.604
hsa04920 Adipocytokine signaling pathway 0.570
hsa04145 Phagosome 0.561
hsa03320 PPAR signaling pathway 0.532
hsa00980 Metabolism of xenobiotics by cytochrome P450 0.511
hsa04260 Cardiac muscle contraction 0.509
hsa04614 Renin-angiotensin system 0.484
hsa00982 Drug metabolism - cytochrome P450 0.462
hsa00900 Terpenoid backbone biosynthesis 0.456
hsa03022 Basal transcription factors 0.443
hsa00480 Glutathione metabolism 0.422
hsa04975 Fat digestion and absorption 0.416
hsa04210 Apoptosis 0.409
hsa00531 Glycosaminoglycan degradation 0.370
hsa00590 Arachidonic acid metabolism 0.352
hsa00910 Nitrogen metabolism 0.344
hsa04710 Circadian rhythm - mammal 0.333
hsa04621 NOD-like receptor signaling pathway 0.314
hsa00380 Tryptophan metabolism 0.313
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Table 10.11: Downregulated pathways in TB (HIV-1 infected). Colours: green = also down in
TB without HIV, yellow = upregulated in TB without HIV
Pathway Mean
logFC
hsa03040 Spliceosome -1.779
hsa03013 RNA transport -1.501
hsa04660 T cell receptor signaling pathway -1.384
hsa00970 Aminoacyl-tRNA biosynthesis -1.259
hsa00290 Valine, leucine and isoleucine biosynthesis -1.220
hsa03008 Ribosome biogenesis in eukaryotes -1.154
hsa00270 Cysteine and methionine metabolism -1.084
hsa03030 DNA replication -1.079
hsa04110 Cell cycle -1.029
hsa03018 RNA degradation -1.024
hsa04612 Antigen processing and presentation -0.851
hsa00620 Pyruvate metabolism -0.830
hsa04520 Adherens junction -0.822
hsa00020 Citrate cycle (TCA cycle) -0.793
hsa04662 B cell receptor signaling pathway -0.753
hsa00640 Propanoate metabolism -0.747
hsa00532 Glycosaminoglycan biosynthesis - chondroitin sulfate -0.729
hsa00010 Glycolysis / Gluconeogenesis -0.707
hsa04514 Cell adhesion molecules (CAMs) -0.700
hsa00280 Valine, leucine and isoleucine degradation -0.687
hsa04672 Intestinal immune network for IgA production -0.668
hsa04310 Wnt signaling pathway -0.651
hsa00250 Alanine, aspartate and glutamate metabolism -0.644
hsa03010 Ribosome -0.665
hsa00670 One carbon pool by folate -0.509
hsa00310 Lysine degradation -0.478
hsa04114 Oocyte meiosis -0.476
hsa03015 mRNA surveillance pathway -0.472
hsa03430 Mismatch repair -0.468
hsa04720 Long-term potentiation -0.465
hsa00051 Fructose and mannose metabolism -0.457
hsa04062 Chemokine signaling pathway -0.447
hsa04070 Phosphatidylinositol signaling system -0.435
hsa04540 Gap junction -0.413
hsa00030 Pentose phosphate pathway -0.418
hsa00410 beta-Alanine metabolism -0.406
hsa00350 Tyrosine metabolism -0.392
hsa04530 Tight junction -0.385
hsa04330 Notch signaling pathway -0.372
hsa04510 Focal adhesion -0.365
hsa00360 Phenylalanine metabolism -0.365
hsa04960 Aldosterone-regulated sodium reabsorption -0.359
hsa00040 Pentose and glucuronate interconversions -0.357
hsa04742 Taste transduction -0.350
hsa00920 Sulfur metabolism -0.354
hsa04640 Hematopoietic cell lineage -0.346
hsa04744 Phototransduction -0.335
hsa00630 Glyoxylate and dicarboxylate metabolism -0.336
hsa04650 Natural killer cell mediated cytotoxicity -0.322
hsa03410 Base excision repair -0.312
hsa04350 TGF-beta signaling pathway -0.306
hsa00340 Histidine metabolism -0.303
hsa03450 Non-homologous end-joining -0.300
hsa04722 Neurotrophin signaling pathway -0.275220
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Figure 10.17 demonstrates the overlap in up- and downregulated pathways in active tuberculosis
in HIV-1 infected and uninfected individuals. 7 and 15 pathways are up and downregulated in active
TB, respectively, regardless of HIV status. Note that one pathway (hsa04612 Antigen processing
and presentation) that is upregulated in HIV-1 uninfected individuals is downregulated in HIV-1
co-infection. It is clear that in addition to the pathways up- or downregulated in active tuberculosis
in HIV-1 uninfected individuals, HIV-1 co-infection results in additional differential pathway reg-
ulation in the presence of active tuberculosis. It is unclear whether this association is causal, and if
so, in which direction.
Broadly speaking, upregulated pathways are concerned with meeting increased energy require-
ments in tuberculosis (oxidative phosphorylation), phagocytosis and downstream events like vesi-
cular transport (phagosome, lysosome) and innate immune responses (Toll-like receptor signalling
and complement pathways). In contrast, downregulated pathways may indicate possible mech-
anisms by which Mycobacterium tuberculosis evades internalisation and killing (e.g endocytosis,
chemokine signalling) and subverts the host metabolic response to one more favourable to its sur-
vival (four metabolic pathways are downregulated). Most pathways up- or downregulated in HIV-1
uninfected individuals show the same pattern of regulation in HIV-1 infection (see Tables 10.10
and 10.11). Multiple additional pathways are also up- or downregulated in HIV-1 co-infected indi-
viduals, including additional metabolic pathways related to lipid metabolism, apoptosis and natural
killer cell mediated cytotoxicity. The latter is of interest as HIV-1 has been shown to affect NK cell
activation by Mycobacteria [161].
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Figure 10.17: Overlap of differentially regulated pathways in active tuberculosis stratified by
HIV status.
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hsa04062 Chemokine signaling pathway
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Figure 10.18: Significant pathways in tuberculosis (HIV-1 uninfected). The heatmap shows
mean estimates for pathway expression for all active TB samples (not active TB
samples are not shown). Colours: red = pathway upregulated; green = pathway
downregulated. (Note: Pathway names are cut off by the heatmap rendering al-
gorithm; some manual editing of the source is required to fix this. The relevant tables
provide the full pathway names)
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Figure 10.19: Significant pathways in tuberculosis (HIV-1 infected). The heatmap shows mean
estimates for pathway expression for all active TB samples (not active TB samples are
not shown). Colours: red = pathway upregulated; green = pathway downregulated.
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10.5.1 Pathway visualisation
Figure 10.20 shows details of the Toll-like receptor pathway as an example of a pathway reported
as upregulated in active tuberculosis in both HIV-1 uninfected and -infected individuals. While
overall the pathway is reported as upregulated relative to controls, it appears that the biological
effects of this upregulation may differ, as different individual genes in this pathway are over- or
underexpressed. In Figure 10.21 we can see the effect of tuberculosis on the antigen processing
and presentation pathway. In HIV-1 uninfected individuals, the MHC class I pathway is upregu-
lated, while in HIV-1 infected individuals, the MHC class II pathway appears to be downregulated.
This sheds some light on potential pathogenetic mechanisms in HIV-TB co-infection. Finally, Fig-
ure 10.22 shows the NK cell cytotoxicity pathway in blood for HIV-1 uninfected individuals. The
set of top 100 probes called as differentially expressed in NK cells using cell-type specific dif-
ferential expression analysis was intersected with the top 2000 differentially expressed probes in
the standard differential expression analysis in order to provide logfold change estimates for the
NK cell “specific” probes. Three of these probes are mapped to genes in the NK cell cytotoxicity
pathway; two of these lie downstream of NKp30, NKp46 and FcγRIII receptors, suggesting that
these receptors are involved in activating NK cells in tuberculosis. TNF-related apoptosis inducing
ligand (TRAIL) is also upregulated in NK cells in tuberculosis, suggesting the effector pathway
by which these NK cells may mediate their effect by inducing apoptosis in cells infected with M.
tuberculosis. These results suggest numerous downstream experiments for future work.
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(a) HIV-1 uninfected
(b) HIV-1 infected
Figure 10.20: Toll-like receptor pathway. Canonical pathway hsa04620 from KEGG, rendered
by pathview software. The log-fold change estimates output by limma are overlaid,
normalised to a range -1 to +1. Colours: red = upregulated in active tuberculosis;
green = downregulated in active tuberculosis.
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(a) HIV-1 uninfected
(b) HIV-1 infected
Figure 10.21: Antigen processing and presentation pathway. Canonical pathway hsa04612 from
KEGG, rendered by pathview software. The logfold change estimates output by
limma are overlaid, normalised to a range -1 to +1. Colours: red = upregulated
in active tuberculosis; green = downregulated in active tuberculosis.
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Figure 10.22: NK cell cytotoxicity pathway (HIV-1 uninfected). Canonical pathway hsa04650,
rendered using pathview. Genes associated with differential expression in NK cells
and shown to be differentially expressed globally in blood are highlighted in colour.
Colours: red = upregulated in active tuberculosis; green = downregulated in tubercu-
losis. See text for interpretation.
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status
Chapter overview
This Chapter deals with questions relating to the effect of HIV-1 infection in two contexts: not
active tuberculosis and active tuberculosis.
11.1 Question 5: HIV (not active TB)
The effect of HIV-1 co-infection on tuberculosis is complex, and causal relationships are not always
clear. In order to isolate the effect of HIV-1 infection from the effect of M. tuberculosis disease, I
present an overview of the analysis of two datasets: blood, LTBI and blood, healthy.
11.1.1 Included patients and samples
Table 11.1 shows that the healthy and LTBI subsets of the class not active TB were matched for
age, sex and CD4 count. Both datasets were individually matched for age for the contrast HIV
negative vs HIV positive. In both cases, a higher proportion of female individuals constituted the
HIV-1 infected class.
11.1.2 Overall results
The overall results (Table 11.2) show similar numbers of differentially expressed probes prior to
multiple testing correction, with no or few (6) probes significant after multiple testing. This is
likely due to the small number of included samples, and the results should be treated with reserve.
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Table 11.1: Clinical characteristics: HIV positive vs HIV negative (not active TB). Two-way comparison of
demographic variables and CD4 count between and with groups of study participants. P-values less
than 0.05 are regarded as significant. This table includes data for the combined group (“not active
TB”), LTBI and healthy.
Blood not
activeTB
HIVpos-
HIVneg
Blood
LTBI
HIVpos-
HIVneg
Blood
Healthy
HIVpos-
HIVneg
Pval Test
Age Median LQ UQ Median LQ UQ Median LQ UQ Pval Test
age_All 29.5 25 36.7 29.3 24.22 35.3 29.8 25.5 38.55 0.844 Kruskal-
Wallis
rank
age_ negat-
ive
29.9 22.98 34.2 29.1 22.7 34.7 30.7 23.8 32.7 0.994 Kruskal-
Wallis
rank
age_ posit-
ive
29.5 25.75 37.3 29.5 25.5 35.3 29.5 26.08 39.47 0.829 Kruskal-
Wallis
rank
age_P
value
0.584 0.693 0.711
age_Test Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Kruskal-
Wallis
rank
Sex ratio F/M Female Male ratio F/M Female Male ratio F/M Female Male Pval test
sex_All 3.625 29 8 3.500 14 4 3.750 15 4 1.000 Fisher’s
Exact Test
sex_ negat-
ive
0.250 2 8 0.250 1 4 0.250 1 4 1.000 Fisher’s
Exact Test
sex_ posit-
ive
Inf 27 0 Inf 13 0 Inf 14 0 1.000 Fisher’s
Exact Test
sex_P value 0.000 0.002 0.002
sex_Test 2-sample
test for eq
2-sample
test for eq
2-sample
test for eq
CD4 Median LQ UQ Median LQ UQ Median LQ UQ Pval Test
CD4_All 333 307.5 467 333 316 416 372 273 542.5 0.981 Kruskal-
Wallis
rank
CD4_ neg-
ative
NA NA
CD4_ pos-
itive
333 307.5 467 333 316 416 372 273 542.5 0.981 Kruskal-
Wallis
rank
CD4_P
value
NA NA NA
CD4_Test NA NA NA
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The top 300 differentially expressed probes based on log-likelihood of differential expression were
used for subsequent analysis.
Table 11.2: Overall results: HIV positive vs HIV negative (not active TB). Output of the ana-
lysis script, showing the numbers of included samples, and statistics for differential
expression, deconvolution and gene co-expression network analysis. P-values less than
0.05 are regarded as significant.
Question 5: HIV (no TB)
Contrast: HIV neg vs. HIV pos
Dataset 1 2
Context Blood, LTBI Blood, Healthy
N: HIV neg 5 5
N: HIV pos 13 14
Analysis 1: Differential expression
N significant probes (unadjusted) 2299 3169
N significant probes (BH adjusted) 0 6
N probes used (heatmaps, csDE) 300 300
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 2 of 13 0 of 12
N of N PBMC significant for contrast (BH) 2 of 12 0 of 11
Cell-specific DE successful yes yes
Number of cell types 4 7
N cell types that reach FDR < 0.4 2 1
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.8 0.8
Soft threshold power 6 7
Number of modules 23 15
Probes assigned to modules (N, %) 7968 (99.6) 6380 (79.75)
GO: Entrez IDs submitted 4114 4251
GO: Entrez IDs mapped 2720 2819
N (%) modules cor GS/MM sig 14 (61) 15 (100)
N (%) modules sig for contrast (BH) 23 (100) 15 (100)
11.1.3 Results for context: not Active TB (datasets: Blood Healthy, Blood
LTBI)
Figure 11.1 shows reasonable clustering of the input data from HIV-1 infected and -uninfected
samples for the top 300 differentially expressed probes. This shows that there probably is a specific
signal of HIV-1 infection, but requires larger numbers to detect reliably. Cell-type specific differ-
ential expression was detectable, and shows different results depending on whether prior immune
sensitisation to M. tuberculosis had occurred (LTBI). In both groups, NK cell and neutrophil sig-
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nals are evident, based on the FDR plots shown in Figure 11.2. In addition, “antigen presenting
cells” (comprising monocytes and dendritic cells), show a significant FDR drop in HIV-1 uninfec-
ted samples, while lymphocytes show possible signal in HIV-1 infected individuals. Please note
that due to small sample numbers in this analysis we show cell-type specific responses for groups
of cells. Module detection was similar in both groups as shown by the module detection plots in
Figure 11.3. Surprisingly, very few probes of either the top 300 or top 500 differentially expressed
probes in either set overlap. A number of possible explanations for exist, but remain speculative
given the high probability of false positives in the probes shown.
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(b) Heatmap of differentially expressed probes, LTBI
Figure 11.1: Results for contrast HIV status in contexts Healthy and LTBI. Values are row-
scaled, and range from low (blue) to intermediate (yellow) to high (red). Samples
are clustered using Spearman rank correlation, and probes are clustered using Pearson
correlation. Sample colours: green: HIV negative, red: HIV positive. Plot titles reflect
the number of included probes.
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Figure 11.2: Cell-type specific differential expression.
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Figure 11.4: Overlap of differentially expressed probes.
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11.2 Question 6: HIV (active TB)
11.2.1 Included patients and samples
This subsection addresses HIV-1 and Mycobacterium tuberculosis co-infection. Four datasets were
included in this analysis: “blood, active TB”, “pericardial fluid, active TB-PC”, “blood, PTB”
and “blood, active TB-PC”. Table 11.3 shows the clinical characteristics of the included study
subjects. Between datasets, the variables sex (HIV-positive) and CD4 count (HIV-positive) were
not matched. Within the two datasets for which results are presented in this thesis (“pericardial
fluid, active TB-PC” and “blood, active TB-PC”, the variables age and CD4 count are not matched.
The HIV-1 infected groups were younger and had lower CD4 counts, in keeping with a higher risk
for extrapulmonary TB at a younger age driven by lower CD4 counts.
11.2.2 Overall results
The overall results (Table 11.4) show similar numbers of differentially expressed probes prior to
multiple testing correction, with no probes significant after multiple testing. This is likely due to
the small number of included samples, and the results should be treated with reserve. The top
300 differentially expressed probes based on log-likelihood of differential expression were used for
subsequent analysis.
11.2.3 Results for context: Compartment (datasets: Blood TB-PC, Fluid
TB-PC)
Figure 11.5 shows reasonable clustering of the input data from HIV-1 infected and -uninfected
samples for the top 300 differentially expressed probes in both blood and pericardial fluid. In both
cases, the HIV-1 uninfected individuals are assigned to a subcluster of HIV-1 infected individuals.
This shows that there possibly is a specific signal of HIV-1 infection, but requires larger numbers to
detect reliably, and this signal may be influenced by active tuberculosis. Cell-type specific differ-
ential expression was detectable, and shows different results depending on compartment. In blood,
the strongest signal is found in neutrophils, while in pericardial fluid all four groups of cells show
evidence of cell-specific differential expression (see Figure 11.6). Again, due to small sample num-
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Table 11.4: Overall results: HIV positive vs HIV negative (active TB). Output of the analysis
script, showing the numbers of included samples, and statistics for differential expres-
sion, deconvolution and gene co-expression network analysis. P-values less than 0.05
are regarded as significant.
Question 6: HIV (active TB)
Contrast: HIV neg vs. HIV pos
Dataset 1 2
Context Blood, TB-PC Fluid, TB-PC
N: HIV neg 6 5
N: HIV pos 32 25
Analysis 1: Differential expression
N significant probes (unadjusted) 2098 1778
N significant probes (BH adjusted) 0 0
N probes used (heatmaps, csDE) 300 300
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 0 of 13 1 of 13
N of N PBMC significant for contrast (BH) 0 of 12 1 of 12
Cell-specific DE successful yes yes
Number of cell types 4 4
N cell types that reach FDR < 0.4 0 2
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.8 0.8
Soft threshold power 6 7
Number of modules 20 16
Probes assigned to modules (N, %) 4768 (60) 4425 (55)
GO: Entrez IDs submitted 4100 4014
GO: Entrez IDs mapped 2698 2653
N (%) modules cor GS/MM sig 6 (30) 8 (50)
N (%) modules sig for contrast (BH) 19 (95) 12 (75)
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bers in this analysis we show cell-type specific responses for groups of cells. Module detection was
similar in both groups as shown by the module detection plots in Figure 11.7. A large number of
probes were not assigned to modules. Very few probes of either the top 300 or top 500 differentially
expressed probes in either set overlap. This is not surprising, as the site of disease has been shown
in previous work to cause changes in HIV-1 viral dynamics relative to blood [49].
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(a) Heatmap of differentially expressed probes, blood
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(b) Heatmap of differentially expressed probes, fluid
Figure 11.5: Results for contrast HIV status in contexts TB-PC Blood and TB-PC Fluid. Val-
ues are row-scaled, and range from low (blue) to intermediate (yellow) to high (red).
Samples are clustered using Spearman rank correlation, and probes are clustered us-
ing Pearson correlation. Sample colours: green: HIV negative, red: HIV positive. Plot
titles reflect the number of included probes.
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(b) False discovery rate plot pericardial fluid
Figure 11.6: Cell-type specific differential expression.
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Figure 11.7: Module clustering.
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Figure 11.8: Overlap of differentially expressed probes.
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11.3 Pathway analysis
Pathway analysis was performed as described in Section 3.8.8. Tables 11.5, 11.6, 11.7 and 11.8
list the pathways found to be significantly differentially regulated in HIV-1 infection in two groups:
not active TB and active TB (see Sections 11.1 and 11.2) . Figure 11.9 shows heatmaps for the
differentially regulated pathways in HIV-1 infection.
Table 11.5: Upregulated pathways in HIV (not active TB). Colours: red = also upregulated in
HIV-1 infection in the active TB group, yellow = downregulated in HIV-1 infection in
the active TB group
Pathway Mean
logFC
hsa03050 Proteasome 1.490
hsa04612 Antigen processing and presentation 1.305
hsa00190 Oxidative phosphorylation 1.212
hsa04672 Intestinal immune network for IgA production 0.868
hsa04623 Cytosolic DNA-sensing pathway 0.853
hsa03040 Spliceosome 0.790
hsa04622 RIG-I-like receptor signaling pathway 0.777
hsa03030 DNA replication 0.756
hsa04145 Phagosome 0.743
hsa04514 Cell adhesion molecules (CAMs) 0.727
hsa00970 Aminoacyl-tRNA biosynthesis 0.677
hsa00010 Glycolysis / Gluconeogenesis 0.662
hsa00240 Pyrimidine metabolism 0.633
hsa04110 Cell cycle 0.623
hsa03008 Ribosome biogenesis in eukaryotes 0.624
hsa00020 Citrate cycle (TCA cycle) 0.602
hsa04260 Cardiac muscle contraction 0.543
hsa03060 Protein export 0.538
hsa00051 Fructose and mannose metabolism 0.489
hsa00100 Steroid biosynthesis 0.485
hsa00480 Glutathione metabolism 0.456
hsa00290 Valine, leucine and isoleucine biosynthesis 0.462
hsa00360 Phenylalanine metabolism 0.434
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Table 11.6: Downregulated pathways in HIV (not active TB). Colours: green = also downregu-
lated in HIV-1 infection in the active TB group, yellow = upregulated in HIV-1 infection
in the active TB group
Pathway Mean
logFC
hsa04012 ErbB signaling pathway -0.824
hsa04910 Insulin signaling pathway -0.751
hsa04150 mTOR signaling pathway -0.749
hsa04144 Endocytosis -0.729
hsa04010 MAPK signaling pathway -0.693
hsa04360 Axon guidance -0.681
hsa04960 Aldosterone-regulated sodium reabsorption -0.680
hsa00590 Arachidonic acid metabolism -0.669
hsa03010 Ribosome -0.694
hsa04630 Jak-STAT signaling pathway -0.617
hsa04320 Dorso-ventral axis formation -0.610
hsa04310 Wnt signaling pathway -0.600
hsa04720 Long-term potentiation -0.583
hsa04916 Melanogenesis -0.557
hsa04722 Neurotrophin signaling pathway -0.555
hsa04510 Focal adhesion -0.538
hsa04666 Fc gamma R-mediated phagocytosis -0.535
hsa04664 Fc epsilon RI signaling pathway -0.506
hsa04070 Phosphatidylinositol signaling system -0.505
hsa04710 Circadian rhythm - mammal -0.507
hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series -0.507
hsa04350 TGF-beta signaling pathway -0.500
hsa04340 Hedgehog signaling pathway -0.500
hsa04210 Apoptosis -0.500
hsa04912 GnRH signaling pathway -0.463
hsa04810 Regulation of actin cytoskeleton -0.454
hsa04730 Long-term depression -0.445
hsa04920 Adipocytokine signaling pathway -0.443
hsa04370 VEGF signaling pathway -0.430
hsa00562 Inositol phosphate metabolism -0.430
hsa04740 Olfactory transduction -0.422
hsa04330 Notch signaling pathway -0.409
hsa04966 Collecting duct acid secretion -0.409
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Table 11.7: Upregulated pathways in HIV (active TB). Colours: red = also upregulated in HIV-1
infection in the not active TB group, yellow = downregulated in HIV-1 infection in the
not active TB group
Pathway Mean
logFC
hsa04740 Olfactory transduction 0.769
hsa04623 Cytosolic DNA-sensing pathway 0.742
hsa04622 RIG-I-like receptor signaling pathway 0.714
hsa00240 Pyrimidine metabolism 0.623
hsa02010 ABC transporters 0.569
hsa00564 Glycerophospholipid metabolism 0.539
hsa04920 Adipocytokine signaling pathway 0.485
hsa00760 Nicotinate and nicotinamide metabolism 0.488
hsa04620 Toll-like receptor signaling pathway 0.458
hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.439
hsa04975 Fat digestion and absorption 0.433
hsa04976 Bile secretion 0.396
hsa04380 Osteoclast differentiation 0.382
hsa04140 Regulation of autophagy 0.377
hsa00982 Drug metabolism - cytochrome P450 0.359
Table 11.8: Downregulated pathways in HIV (active TB). Colours: green = also downregulated
in HIV-1 infection in the not active TB group, yellow = upregulated in HIV-1 infection
in the not active TB group
Pathway Mean
logFC
hsa03013 RNA transport -0.735
hsa00640 Propanoate metabolism -0.581
hsa04810 Regulation of actin cytoskeleton -0.560
hsa04510 Focal adhesion -0.546
hsa00270 Cysteine and methionine metabolism -0.531
hsa00970 Aminoacyl-tRNA biosynthesis -0.532
hsa00290 Valine, leucine and isoleucine biosynthesis -0.522
hsa00010 Glycolysis / Gluconeogenesis -0.473
hsa00280 Valine, leucine and isoleucine degradation -0.471
hsa03040 Spliceosome -0.455
hsa00620 Pyruvate metabolism -0.438
hsa04520 Adherens junction -0.425
hsa04612 Antigen processing and presentation -0.421
hsa00020 Citrate cycle (TCA cycle) -0.408
hsa03060 Protein export -0.394
hsa04670 Leukocyte transendothelial migration -0.362
hsa04530 Tight junction -0.354
hsa00410 beta-Alanine metabolism -0.352
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Figure 11.9: Significant pathways in HIV. The heatmaps show mean estimates for pathway ex-
pression for all HIV-1 infected samples (HIV-1 uninfected samples are not shown).
Colours: red = pathway upregulated; green = pathway downregulated.
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11.3 Pathway analysis
Figure 11.10 shows the extent to which pathways up- or downregulated by HIV-1 infection are
shared by individuals with and without active tuberculosis. This provides additional information
about possible disease mechanisms in HIV-TB. In contrast to the shared pathways affected by active
tuberculosis, pathways affected by HIV show very little overlap in the two groups (not active TB
and active TB). This suggests that active tuberculosis is an important co-regulator of HIV-1-related
pathogenesis. In fact, more pathways are up- or downregulated in opposite directions depending on
TB status than in the same direction. This is discussed further below.
9
0
9
3
0
0
0
2
13
7
0 0
3
28
0
upHIVnoTB downHIVnoTB
upHIVaTB downHIVaTB
Figure 11.10: Overlap of differentially regulated pathways in active tuberculosis stratified by
HIV status.
11.3.1 Pathway visualisation
The antigen processing and presentation pathway which is strongly upregulated by HIV-1 in the
absence of active tuberculosis is downregulated in HIV-TB co-infection. Figure 11.11 shows the
extent of this differential regulation at gene level. This should be compared to Figure 10.21 which
demonstrates the converse situation, i.e. the effect of active tuberculosis on the same pathway, with
and without HIV-1 co-infection.
Another interesting pathway concerns innate defences against viral infections mediated by the
RIG-1-like pathway (hsa04622). This pathway is an important sensor for cytoplasmic viral RNA,
essential for generating a downstream signal that results in type I interferon secretion. RIG-1
is induced by type 1 interferon signalling as well as double-stranded viral RNA. While purified
HIV-1 RNA indeed produces a RIG-1 dependent interferon response, actual HIV-1 infection does
not result in increased interferon production in vitro. This was shown to be due to inhibition of
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the RIG-1 sensor (a DExD/H box RNA helicase) by HIV-1 protease by reducing phosphorylation
of IFN regulatory factor 3 (IRF-3) phosphorylation [162]. The proximal pathway appears to be
upregulated during HIV-1 infection in both active TB and not active TB contexts (see Figure 11.12),
but IRF-3, however, is not upregulated. A possible interpretation of the pathway result is that failure
of upregulating IRF-3 may impair the type I interferon response, which would relate to a previously
published result, in which a similar picture of downregulation of IRF-3 activity, but not IRF-7 was
reported in vitro. [163].
In summary, pathway analysis with mapping of differentially expressed genes onto differentially
regulated pathways provides substantial insight into the complex relationships between HIV-1 and
M. tuberculosis infections.
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(a) Not active TB
(b) Active TB
Figure 11.11: Antigen processing and presentation pathway. Canonical pathway hsa04612 from
KEGG, rendered by pathview software. The logfold change estimates output by
limma are overlaid, normalised to a range -1 to +1. Colours: red = upregulated
in HIV-1 infection; green = downregulated in HIV-1 infection.
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(a) Not active TB
(b) Active TB
Figure 11.12: RIG-I-like receptor signaling pathway. Canonical pathway hsa04622 from KEGG,
rendered by pathview software. The logfold change estimates output by limma are
overlaid, normalised to a range -1 to +1. Colours: red = upregulated in HIV-1 infec-
tion; green = downregulated in HIV-1 infection.
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Chapter overview
In this Chapter I discuss the results of transcriptomic analysis at the site of active tuberculosis in
individuals with tuberculous pericarditis.
12.1 Question 7: Blood and pericardial fluid in TB-PC
While blood transcriptomic responses are informative regarding the nature of the immune response
to tuberculosis with and without HIV-1 co-infection, the site of disease is of considerable interest
in studies of tuberculosis pathogenesis, as it is at the site of infection that the disease develops
and progresses. Given our understanding of transcriptional responses detectable in blood, it is
instructive to assess transcriptional responses in pericardial fluid relative to those in blood.
12.1.1 Included patients and samples
Five datasets were included in this analysis: all matched blood/pericardial fluid samples, and
matched blood pericardial fluid samples for HIV-1 uninfected, HIV-1 infected, Effusive phenotype
and effusive-constrictive phenotype subgroups1. All five sets/ subsets were matched for age and
sex; the HIV-1 infected subsets had significantly lower CD4 counts. Results for two contexts will
be reported here (TB-PC HIV negative, TB-PC HIV positive). As only matched blood and pericar-
dial fluid samples were included, there is no bias due to mismatched demographic or phenotypic
variables, setting this analysis apart from all others.
1The much smaller sample sizes in the haemodynamic phenotype subsets (EFF blood - fluid and EC blood - fluid) are
due to the limited number of study subjects included in this study who had right heart studies at baseline.
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12.1 Question 7: Blood and pericardial fluid in TB-PC
12.1.2 Overall results
Table 12.2 lists the overall results of the three analyses for two datasets. Of all analyses, the contrast
“blood vs. pericardial fluid” yielded the highest number of significantly differentially expressed
probes. This is likely due to the markedly different cellular composition of pericardial fluid com-
pared to blood (see below). For this reason, cell-type specific differential expression is of great in-
terest here. However, as I will show in the pathway analysis section, global transcriptional changes
at the site of disease regardless of cellular origin are still informative about biological processes
at the site of disease, which demonstrate a very strong signal indicative of major reprogramming
of host metabolism, which is likely to benefit M. tuberculosis. Given the significant differences in
cellular composition, the modules identified using weighted gene co-expression network analysis
possibly represent cell-types. This requires further analysis.
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Table 12.2: Overall results blood vs pericardial fluid. Output of the analysis script, showing the
numbers of included samples, and statistics for differential expression, deconvolution
and gene co-expression network analysis. P-values less than 0.05 are regarded as sig-
nificant.
Question 7: Compartment
Contrast: Blood vs. Pericardial Fluid
Dataset 1 2
Context TB-PC HIV neg TB-PC HIV pos
N: Blood 10 41
N: Fluid 10 41
Analysis 1: Differential expression
N significant probes (unadjusted) 7895 12688
N significant probes (BH adjusted) 4211 10434
N probes used (heatmaps, csDE) 2000 2000
Analysis 2: Deconvolution
Deconvolution successful yes yes
N of N significant for contrast (BH) 5 of 15 8 of 15
N of N PBMC significant for contrast (BH) 5 of 14 9 of 14
Cell-specific DE successful yes yes
Number of cell types 7 7
N cell types that reach FDR < 0.4 1 3
Analysis 3: WGCNA
R2 cutoff for scale-free approximation 0.75 0.8
Soft thr shold power 8 7
Number of modules 7 13
Probes assigned to modules (N, %) 8000 (100) 7987 (99.84)
GO: Entrez IDs submitted 4665 4875
GO: Entrez IDs mapped 3131 3275
N (%) modules cor GS/MM sig 6 12
N (%) modules sig for contrast (BH) 7 (100) 13 (100)
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12.1 Question 7: Blood and pericardial fluid in TB-PC
12.1.3 Results for context: HIV status (datasets: TB-PC HIV neg, TB-PC
HIV pos)
The top 2000 differentially expressed probes in both HIV-1 uninfected and -infected individuals
separate the input data into two distinct clusters (blood and pericardial fluid) (Figure 12.1). Of
interest is the large overlap between HIV-1 infected and -uninfected individuals when considering
the top 2000 differentially expressed probes; in contrast, there is very little overlap between the top
500 differentially expressed probes. Figure 12.2 shows the barplots for proportions of detected cell
types. The most striking difference is the low proportion of neutrophils in pericardial fluid. This is
in keeping with the most common presentation of tuberculous pericardial effusions as predomin-
antly lymphocytic (see [139] for data in a South African population). As the neutrophils skew the
proportions of all other cells (mainly PBMC), barplots of PBMC proportions (normalised to 1.0)
are also shown.
Cell-specific differential expression differed between the two groups studied. In HIV-1 uninfec-
ted individuals, the strongest signal was detected in B cells, follow d by CD8 T cells, with weaker
signals in NK cells and dendritic cells. In contrast, HIV-1 infected individuals exhibited strong
signals for cell-type specific differential expression in CD4 T cells, B cells, dendritic cells, and to a
lesser extent also in NK cells and monocytes.
Virtually all probes examined were assigned to modules. These require further analysis to char-
acterise and relate to functional classes like cell types and pathways.
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Figure 12.1: Results for contrast Compartment in contexts TB-PC HIV neg and TB-PC HIV
pos. Values are row-scaled, and range from low (blue) to intermediate (yellow) to
high (red). Samples are clustered using Spearman rank correlation, and probes are
clustered using Pearson correlation. Sample colours: red: blood, yellow: pericardial
fluid. Plot titles reflect the number of included probes.
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(a) HIV-1 uninfected: Barplot, all cell types
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(b) HIV-1 infected: Barplot, all cell types
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(c) HIV-1 uninfected: Boxplot, all cell types
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(d) HIV-1 infected: Boxplot, all cell types
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(e) HIV-1 uninfected: Boxplot, PBMC
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Figure 12.2: Barplots and boxplots of matched blood and pericardial fluid samples. Stacked
bar charts for cell proportions for the analysed samples are shown in subfigures a and
b. Note the striking visual difference between blood and pericardial fluid. Box-and-
whisker charts are shown for all detected cell-types, and for PBMC only in subfigures
c, d and e,f, respectively. Each bar is normalised to 1 (100%). Samples are ordered
according to disease phenotype (not active TB followed by active TB). The legend
lists the cell types identified. Abbreviations: neutro: neutrophils, DC act: activated
dendritic cells, DC: non-activated dendritic cells, mono: monocytes, NK act: activated
natural killer cells, NK: non-activated natural killer cells, B aIGM: BCR-ligated B
cells, B: resting B cells, Tc act: activated CD8 T cell, Tc: resting CD8 T cell, Th act:
activated CD4 T cell, Th: resting CD4 T cell.
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(a) False discovery rate plot HIV-1 uninfected
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Figure 12.3: Cell-type specific differential expression.
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Figure 12.5: Overlap of differentially expressed probes.
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12.2 Pathway analysis
Given the massive differences in differential expression at probe level, pathway analysis is a useful
method to reduce the data to more intuitive biological differences. Tables 12.3, 12.4, 12.5 and 12.6
list the pathways up- and downregulated in pericardial fluid (relative to blood) with and without
HIV-1 co-infection. Pathway heatmaps are not shown,
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Table 12.3: Pathways significantly upregulated in pericardial fluid (HIV-1 uninfected). Col-
ours: red = also upregulated in pericardial fluid in the HIV-1 infected group
Pathway Mean
logFC
hsa00970 Aminoacyl-tRNA biosynthesis 2.808
hsa03008 Ribosome biogenesis in eukaryotes 2.587
hsa00010 Glycolysis / Gluconeogenesis 2.136
hsa03040 Spliceosome 2.054
hsa03030 DNA replication 2.106
hsa04142 Lysosome 2.068
hsa03050 Proteasome 1.966
hsa03013 RNA transport 1.896
hsa00020 Citrate cycle (TCA cycle) 1.932
hsa04612 Antigen processing and presentation 1.769
hsa00190 Oxidative phosphorylation 1.724
hsa00290 Valine, leucine and isoleucine biosynthesis 1.657
hsa04672 Intestinal immune network for IgA production 1.495
hsa00310 Lysine degradation 1.488
hsa00280 Valine, leucine and isoleucine degradation 1.364
hsa00640 Propanoate metabolism 1.365
hsa00270 Cysteine and methionine metabolism 1.355
hsa03018 RNA degradation 1.325
hsa00670 One carbon pool by folate 1.296
hsa03060 Protein export 1.308
hsa04141 Protein processing in endoplasmic reticulum 1.188
hsa00051 Fructose and mannose metabolism 1.201
hsa00510 N-Glycan biosynthesis 1.086
hsa00052 Galactose metabolism 1.038
hsa00520 Amino sugar and nucleotide sugar metabolism 0.921
hsa00511 Other glycan degradation 0.932
hsa03410 Base excision r pair 0.878
hsa03010 Ribosome 0.889
hsa03020 RNA polymerase 0.820
hsa03430 Mismatch repair 0.814
hsa00620 Pyruvate metabolism 0.773
hsa00630 Glyoxylate and dicarboxylate metabolism 0.752
hsa00410 beta-Alanine metabolism 0.739
hsa00350 Tyrosine metabolism 0.732
hsa04260 Cardiac muscle contraction 0.730
hsa04146 Peroxisome 0.692
hsa00450 Selenocompound metabolism 0.675
hsa00100 Steroid biosynthesis 0.650
hsa00250 Alanine, aspartate and glutamate metabolism 0.638
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Table 12.4: Pathways significantly downregulated in pericardial fluid (HIV-1 uninfected). Col-
ours: green = also downregulated in pericardial fluid in the HIV-1 infected group
Pathway Mean
logFC
hsa04650 Natural killer cell mediated cytotoxicity -2.537
hsa04670 Leukocyte transendothelial migration -2.120
hsa04810 Regulation of actin cytoskeleton -1.855
hsa04210 Apoptosis -1.784
hsa04666 Fc gamma R-mediated phagocytosis -1.607
hsa00564 Glycerophospholipid metabolism -1.566
hsa04144 Endocytosis -1.475
hsa04380 Osteoclast differentiation -1.481
hsa04920 Adipocytokine signaling pathway -1.338
hsa00910 Nitrogen metabolism -1.343
hsa04740 Olfactory transduction -1.312
hsa04966 Collecting duct acid secretion -1.299
hsa00760 Nicotinate and nicotinamide metabolism -1.202
hsa04010 MAPK signaling pathway -1.135
hsa04270 Vascular smooth muscle contraction -1.121
hsa04140 Regulation of autophagy -1.118
hsa04664 Fc epsilon RI signaling pathway -1.105
hsa04720 Long-term potentiation -1.097
hsa04640 Hematopoietic cell lineage -1.039
hsa00770 Pantothenate and CoA biosynthesis -1.007
hsa04062 Chemokine signaling pathway -0.953
hsa04360 Axon guidance -0.933
hsa04070 Phosphatidylinositol signaling system -0.904
hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series -0.891
hsa04350 TGF-beta signaling pathway -0.872
hsa04630 Jak-STAT signaling pathway -0.838
hsa00562 Inos tol phosphate metabolism -0.837
hsa04730 Long-term depression -0.824
hsa04614 Renin-angiotensin system -0.817
hsa04530 Tight junction -0.804
hsa04510 Focal adhesion -0.786
hsa04520 Adherens junction -0.774
hsa04310 Wnt signaling pathway -0.714
hsa04662 B cell receptor signaling pathway -0.687
hsa04370 VEGF signaling pathway -0.657
hsa04115 p53 signaling pathway -0.649
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Table 12.5: Pathways significantly upregulated in pericardial fluid (HIV-1 infected). Colours:
red = also upregulated in pericardial fluid in the HIV-1 uninfected group
Pathway Mean logFC
hsa04142 Lysosome 3.400
hsa00970 Aminoacyl-tRNA biosynthesis 2.944
hsa04612 Antigen processing and presentation 2.564
hsa03050 Proteasome 2.532
hsa00010 Glycolysis / Gluconeogenesis 2.300
hsa00190 Oxidative phosphorylation 2.236
hsa03008 Ribosome biogenesis in eukaryotes 2.147
hsa00020 Citrate cycle (TCA cycle) 2.112
hsa04672 Intestinal immune network for IgA production 2.056
hsa03040 Spliceosome 1.704
hsa03030 DNA replication 1.728
hsa03013 RNA transport 1.666
hsa00290 Valine, leucine and isoleucine biosynthesis 1.770
hsa00310 Lysine degradation 1.620
hsa00280 Valine, leucine and isoleucine degradation 1.588
hsa00640 Propanoate metabolism 1.499
hsa00511 Other glycan degradation 1.514
hsa03060 Protein export 1.402
hsa00051 Fructose and mannose metabolism 1.364
hsa00670 One carbon pool by folate 1.333
hsa00520 Amino sugar and nucleotide sugar metabolism 1.273
hsa00270 Cysteine and methionine metabolism 1.225
hsa04141 Protein processing in endoplasmic reticulum 1.143
hsa00052 Galactose metabolism 1.151
hsa00510 N-Glycan biosynthesis 0.983
hsa00410 beta-Alanine metabolism 0.990
hsa00630 Glyoxylate and dicarboxylate metabolism 0.988
hsa04145 Phagosome 0.938
hsa00531 Glycosaminoglycan degradation 0.946
hsa00620 Pyruvate metabolism 0.906
hsa04146 Peroxisome 0.858
hsa04260 Cardiac muscle contraction 0.857
hsa00350 Tyrosine metabolism 0.853
hsa03018 RNA degradation 0.816
hsa03410 Base excision repair 0.810
hsa00480 Glutathione metabolism 0.762
hsa00360 Phenylalanine metabolism 0.751
hsa00071 Fatty acid metabolism 0.694
hsa00250 Alanine, aspartate and glutamate metabolism 0.694
hsa03430 Mismatch repair 0.685
hsa00450 Selenocompound metabolism 0.623
hsa00600 Sphingolipid metabolism 0.602
hsa04610 Complement and coagulation cascades 0.587
hsa00380 Tryptophan metabolism 0.575
hsa00040 Pentose and glucuronate interconversions 0.564
hsa00120 Primary bile acid biosynthesis 0.555
hsa03020 RNA polymerase 0.523
hsa00330 Arginine and proline metabolism 0.509
hsa03320 PPAR signaling pathway 0.508
hsa04621 NOD-like receptor signaling pathway 0.504
hsa00604 Glycosphingolipid biosynthesis - ganglio series 0.503
hsa00603 Glycosphingolipid biosynthesis - globo series 0.486
hsa04973 Carbohydrate digestion and absorption 0.476
hsa00030 Pentose phosphate pathway 0.473
hsa00340 Histidine metabolism 0.448
hsa03440 Homologous recombination 0.437
hsa00650 Butanoate metabolism 0.425
hsa03420 Nucleotide excision repair 0.423
hsa00534 Glycosaminoglycan biosynthesis - heparan sulfate 0.359
hsa04514 Cell adhesion molecules (CAMs) 0.334
hsa04977 Vitamin digestion and absorption 0.281
263
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
12 Contrasts involving the compartment
Table 12.6: Pathways significantly downregulated in pericardial fluid (HIV-1 infected). Col-
ours: green = also downregulated in pericardial fluid in the HIV-1 infected group
Pathway Mean logFC
hsa04650 Natural killer cell mediated cytotoxicity -2.279
hsa04740 Olfactory transduction -1.930
hsa04210 Apoptosis -1.810
hsa04670 Leukocyte transendothelial migration -1.778
hsa00564 Glycerophospholipid metabolism -1.619
hsa04010 MAPK signaling pathway -1.582
hsa04920 Adipocytokine signaling pathway -1.503
hsa04810 Regulation of actin cytoskeleton -1.477
hsa00910 Nitrogen metabolism -1.415
hsa04144 Endocytosis -1.330
hsa04140 Regulation of autophagy -1.328
hsa04720 Long-term potentiation -1.299
hsa04350 TGF-beta signaling pathway -1.246
hsa04666 Fc gamma R-mediated phagocytosis -1.226
hsa04380 Osteoclast differentiation -1.228
hsa04270 Vascular smooth muscle contraction -1.199
hsa04070 Phosphatidylinositol signaling system -1.197
hsa00760 Nicotinate and nicotinamide metabolism -1.163
hsa04360 Axon guidance -1.076
hsa04664 Fc epsilon RI signaling pathway -1.042
hsa00562 Inositol phosphate metabolism -1.020
hsa04310 Wnt signaling pathway -1.001
hsa04966 Collecting duct acid secretion -1.003
hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series -0.997
hsa04730 Long-term depression -0.965
hsa04630 Jak-STAT signaling pathway -0.938
hsa00770 Pantothenate and CoA biosynthesis -0.912
hsa04370 VEGF signaling pathway -0.894
hsa04120 Ubiquitin mediated proteolysis -0.860
hsa04520 Adherens junction -0.811
hsa04012 ErbB signaling pathway -0.809
hsa04115 p53 signaling pathway -0.805
hsa04662 B cell receptor signaling pathway -0.768
hsa04976 Bile secretion -0.723
hsa04062 Chemokine signaling pathway -0.699
hsa00563 Glycosylphosphatidylinositol(GPI)-anchor biosynthesis -0.660
hsa00140 Steroid hormone biosynthesis -0.643
hsa04530 Tight junction -0.630
hsa04640 Hematopoietic cell lineage -0.627
hsa00512 Mucin type O-Glycan biosynthesis -0.596
hsa00590 Arachidonic acid metabolism -0.570
hsa00430 Taurine and hypotaurine metabolism -0.557
hsa02010 ABC transporters -0.544
hsa04510 Focal adhesion -0.537
hsa04742 Taste transduction -0.522
hsa04540 Gap junction -0.518
hsa04971 Gastric acid secretion -0.515
hsa04910 Insulin signaling pathway -0.515
hsa00260 Glycine, serine and threonine metabolism -0.508
hsa04614 Renin-angiotensin system -0.507
hsa04330 Notch signaling pathway -0.470
hsa04660 T cell receptor signaling pathway -0.467
hsa04975 Fat digestion and absorption -0.437
hsa04912 GnRH signaling pathway -0.432
hsa04150 mTOR signaling pathway -0.426
hsa04340 Hedgehog signaling pathway -0.412
hsa00533 Glycosaminoglycan biosynthesis - keratan sulfate -0.415
hsa03022 Basal transcription factors -0.408
hsa04970 Salivary secretion -0.399
hsa00860 Porphyrin and chlorophyll metabolism -0.380
hsa04964 Proximal tubule bicarbonate reclamation -0.377
hsa04710 Circadian rhythm - mammal -0.342
hsa00790 Folate biosynthesis -0.346
hsa04620 Toll-like receptor signaling pathway -0.331
hsa04320 Dorso-ventral axis formation -0.300
hsa00591 Linoleic acid metabolism -0.292
hsa04622 RIG-I-like receptor signaling pathway -0.276
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The most striking finding in pathways differentially regulated at the site of disease is the emphasis
on multiple metabolic pathways. There is concerted upregulation of pathways important in cent-
ral carbon metabolism (e.g. glyoxylate and dicarboxylate metabolism, citrate cycle, propanoate
metabolism), pathways critical to growth in M. tuberculosis. Previous in vitro findings suggest
alignment of MTB metabolism with its current environment [164] as well as large-scale manipula-
tion of host metabolism by trehalose dimycolate, a mycobacterial cell wall lipid [165]. The latter
results in dysregulated host lipid metabolism, a finding associated with caseation of granulomas.
In addition to large-scale metabolic rearrangements, there is upregulation of transcriptional and
translational machinery, indicating site-specific protein synthesis, possibly in direct response to the
infection. Upregulated DNA duplication pathways suggest cell proliferation at the site of disease.
Glycan biosynthesis is also upregulated. As glycans form an important part of mycobacterial cell
walls, one can speculate whether this host pathway is actively utilised by MTB to meet its require-
ments.
Upregulation of the proteasome pathway is probably in part related to upregulated MHC class I
activity, as the proteasome plays a critical role in the function of the adaptive immune system by
producing peptides to display on MHC class I molecules [166].
Downregulated pathways are also of significant interest. Natural killer cell cytotoxicity is strongly
downregulated, perhaps indicating a defensive strategy by the mycobacterium. Other pathways
which intuitively should be upregulated in a protective response are leukocyte transendothelial mi-
gration, Fc- gamma receptor mediated phagocytosis, regulation of autophagy (both ATG-1 and
ATG-8 are downregulated), again hinting at the possibility that the immune response at the site of
disease is inappropriately downregulated.
Finally, the overlap of upregulated and downregulated pathways in HIV-1 uninfected and -
infected individuals is near complete with additional pathways dysregulated in HIV-1 infected indi-
viduals (Figure 12.6). Surprisingly, there are no pathways that are regulated in opposite directions
depending on HIV status.
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Figure 12.6: Overlap of differentially regulated pathways stratified by HIV status
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12.2.1 Pathway visualisation
Figure 12.7 shows the KEGG pathway Antigen processing and presentation. This pathway is uni-
versally upregulated in pericardial fluid in individuals with tuberculous pericarditis, but its effects
may be different depending on HIV-1 infection status. Regardless of HIV status the pathway Nat-
ural killer cell-mediated cytotoxicity is strongly downregulated, raising questions about mechan-
isms involved in this counterintuitive phenomenon. One question that is suggested by the data is
whether downregulation of NK cell cytotoxicty is required for the pathogenesis of tuberculosis.
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(a) HIV-1 uninfected
(b) HIV-1 infected
Figure 12.7: Antigen processing and presentation pathway. Canonical pathway hsa04612 from
KEGG, rendered by pathview software. The logfold change estimates output by limma
are overlaid, normalised to a range -1 to +1. Colours: red = upregulated in pericardial
fluid; green = downregulated in pericardial fluid.
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(a) HIV-1 uninfected
(b) HIV-1 infected
Figure 12.8: Natural killer cell mediated cytotoxicity. Canonical pathway hsa04650 from KEGG,
rendered by pathview software. The logfold change estimates output by limma are
overlaid, normalised to a range -1 to +1. Colours: red = upregulated in pericardial
fluid; green = downregulated in pericardial fluid.
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Overall conclusions
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13 Conclusions and future work
13.1 Summary of novel results
Below I summarise the novel aspects of this work:
1. Creation of a unique and comprehensive microarray dataset (with detailed phenotype inform-
ation) enabling investigation of multiple aspects of HIV-TB in blood and the site of disease.
To my knowledge similar datasets do not exist.
2. Development of a comprehensive analysis pipeline using only open-source software, en-
abling research reproducibility once the dataset and analysis pipeline are jointly published.
In addition to standard differential expression analysis, this pipeline also extracts information
regarding cell proportions, modular organisation of co-expressed genes and pathway enrich-
ment, resulting in a comprehensive overview of biological phenomena in the system under
study.
3. Application of the analytic pipeline to multiple data subsets which are placed in clear rela-
tion to each other using the hypercube analogy that describes sample embedding in pheno-
type space. This maximises the information that can be extracted from the complex signals
embedded in the data.
4. New insights into the biology of HIV-TB were attained using the above methods, in partic-
ular the strong suggestion that NK cells may play an important role in tuberculosis and the
transcriptional response a the site of disease resulting in major metabolic rearrangements that
may support mycobacterial growth.
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13.2 An approach to heterogeneous microarray data
Biology is complicated. Acknowledging this complexity in experimental designs opens the door
to potentially deep insights, at the price of significantly increased analytic difficulty. Given the
potential for interactions between biological processes that define “phenotype classes” like act-
ive tuberculosis or HIV-1 infection, it is important to investigate these processes individually and
jointly.
With linear increases in phenotypic complexity of study samples there is a concurrent exponential
increase in signal complexity, as shown using the hypercube analogy. To make analysis feasible,
the data needs to be understood in relation to the phenotype classes in potentially high-dimensional
parameter spaces.
It is tempting to draw conclusions regarding disease pathogenesis from lists of over- and under-
expressed transcripts. Care must be taken not to over-interpret results, however. Gene expression is
a very complex process, and attempts at measuring this in heterogeneous tissues (blood, pericardial
fluid) sampled from a heterogeneous study population will result in data in which multiple signals
are embedded in a background influenced by stochastic processes. Therefore, while differential
gene expression undoubtedly provides us with the ability to classify samples it also provides us
with information directly related to the biol gical process. Retrieving this “biology signal” from
the background remains challenging, but I hope that methods that aim to isolate multiple signals
from heterogeneous datasets will allow us understand the biology better.
For the study under discussion, transcriptomes of whole blood and pericardial fluid were estab-
lished. Each tissue type has a characteristic cellular composition which strongly influences the
overall transcript abundance. Differences in transcript abundance between conditions of interest
are typically found in studies of this nature. Indeed, differences in transcript abundance may be
identified even when comparing groups created randomly, and the challenge becomes identifying
biologically relevant differences. This strongly argues for use of a combination of analytic methods
that aim to understand the meaning of the tissue (blood and pericardial fluid) transcriptomes.
Transcriptomes vary over time. In this study, a single timepoint was used to generate tran-
scriptomic data. In terms of the two disease groups (pulmonary and pericardial tuberculosis), the
timepoint was determined by the study subject presenting to medical care, and undergoing dia-
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gnostic workup for tuberculosis. This has the consequence that the disease group may contain
significant heterogeneity due to individuals presenting in different stages of the disease (e.g. pul-
monary TB with a single disease focus vs. pulmonary tuberculosis with concomitant disseminated
disease), potentially confounding the results. Therefore, a “snapshot” transcriptome may yield dif-
ferences between tuberculosis cases that are simply due to different disease stages, to some extent
limiting the generalisability of the results.
13.3 Choice of methods
I chose three methods of analysis: differential expression analysis using linear models, decon-
volution and cell-type specific differential expression, and weighted gene co-expression network
analysis. Results were put into biological context using pathway analysis. The three methods com-
plement each other, as different features of the the biological problem are explored. Together, these
methods provide results that may serve as input data for further analyses.
13.4 Results
Expectedly, the largest differences in gene expression can be found when comparing the site of
disease to blood. This is mainly due to different proportions of cell types in the two compartments,
but cell-type specific differential expression strongly suggests that within multiple cell types bio-
logically relevant differences can be identified. Furthermore, the site of disease exhibits markedly
different metabolic activity when compared to blood. It remains to be determined which of these
metabolic alterations is caused by Mycobacterium tuberculosis to facilitate its survival by creat-
ing an environment optimised for its own growth, which are of a defensive nature, and which are
unrelated to the presence of the bacterium. Finally, several pathways thought to play a protective
role in the response to M. tuberculosis are downregulated at the site of disease, possibly indicating
additional defence mechanisms of the pathogen.
The effect of HIV-1 infection on transcriptional profiles is a lot more subtle than the effect of
compartment. For instance, few or no probes were significantly differentially expressed in indi-
viduals with or without concurrent active tuberculosis. This is puzzling, and may be a result of
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small numbers of HIV-1 uninfected samples in the various analyses investigating this contrast.
Despite this, the top 300 and top 500 differentially regulated probes do successfully cluster the
input data, and cell-type specific differential gene expression is detectable. Pathway analysis re-
capitulates some key results (e.g. differential regulation in the RIG-1-like pathway), and also show
that the differential regulation of pathways in HIV-1 infection is strongly influenced by concurrent
active tuberculosis.
The transcriptional response to active tuberculosis is to a large extent conserved regardless of
HIV-1 infection status. This response consists of upregulation of pathways central to energy meta-
bolism, phagocytosis and downstream events and innate immune responses (like Toll-like receptor
signalling). In HIV-1 co-infection, a number of additional pathways are up- or downregulated,
indicating that active tuberculosis and HIV-1 interact on many levels.
In each of the analyses, modules were detected using weighted gene co-expression network
analysis. These modules have not been characterised on a functional level (see Future Work, below),
but is is interesting to note that module size varies widely. What do these modules represent? While
the answer to this is not yet known, I speculate that study of the modules may reveal pathway
groups, expressed in concert, given that some modules contain thousands of genes. In some cases,
the modules may represent an even higher level of organisation, namely cell types.
The strategy employed in this analysis has afforded us a view of different aspects contributing to
HIV-TB pathobiology. In all three main contrasts, a common dual theme emerges: disease (be it
HIV-1 infection or tuberculosis) is associated with striking alterations in immune system function at
many levels as well as significant changes in host metabolism. While this has been known for a long
time, the results presented here in this thesis give a detailed look at the idea that host metabolism
and immune response are part of a higher-order phenomenon: that of pathogens utilising humans
as an ecologic niche by evading immune responses and modifying host metabolism to serve their
respective needs. This opens up new avenues of investigation, in which immune responses and host
metabolic response are assessed as one functional unit. The pathogens’ reliance on host metabolic
pathways may well turn out to be their Achilles heel, and therefore I argue that host metabolic
responses should be studied with the potential of developing new therapeutic strategies.
As a final word on this, as a clinician I would like to state that these results should not come
as a big surprise. On a whole system level (i.e. patient physiology) we are deeply familiar with
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the metabolic consequences of HIV-1 infection (the entity “wasting disease” is AIDS defining,
after all) as well as tuberculosis (or “consumption”, a term no longer in widespread use). Maybe
the focus of future investigations should shift to include mechanisms of wholesale manipulation
of energy metabolism by both pathogens, in addition to defining mechanisms leading to immune
system evasion and immunopathology. This addresses the following speculative scenario: what if
the contribution that HIV-1 infection makes to the increased risk for developing active TB is not
immune dysfunction alone (although this doubtlessly plays a crucial role) but also re-engineering
of host metabolism to better suit M. tuberculosis growth and survival.
13.5 Future work
13.5.1 Informatics
This thesis presents only a few results for a subset of all contrasts examined. The remaining results,
constituting a dataset in their own right require ongoing analysis and interpretation. Specifically,
the modules identified may point to ways how various pathways are connected and co-expressed. I
have shown that some of the results, obtained in a deep sweep of transcriptional activity in active
TB and HIV-1 infection replicate previously published findings. I intend to match all results of this
analysis with the extant TB literature. The potential outcome for each result is threefold:
1. Agreement with published results serving as validation of prior knowledge
2. Disagreement with published results serving as potential alternative hypothesis which may
require experimental assessment
3. Novel finding, indicating the need for validation experiments
I plan to prepare a catalogue of targeted experiments based on the above analysis which may aid
our understanding of HIV-1 infection, tuberculosis and co-infection.
In addition to the present dataset, the opportunity to re-analyse existing datasets using the pipeline
presented here will be utilised, as several groups have published data that is freely accessible.
Ongoing efforts will be made to optimise the analytic pipeline. Pathway analysis, currently
implemented in separate code, will be integrated into the pipeline, and the entire pipeline will be
upgraded to function under the latest release of R and bioconductor.
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13.5.2 Validation
All results of this analysis are at the RNA level. Validation experiments are required to assess these
results in the context of protein-level and cellular level findings. To start this process, targeted
experiments will be designed to utilise stored serum, cell-free pericardial fluid and frozen, unstim-
ulated PBMC and pericardial fluid cells. Validation will include, but not be limited to assessment of
cell proportions by flow cytometry, and comparing these to the results obtained by deconvolution,
as well as determination of key proteins (cytokines, chemokines, enzymes) in the various contexts.
An additional class of validation experiments may be performed at the metabolite level, in order to
define the metabolic niche utilised by M. tuberculosis.
13.5.3 New projects
Not all potential contrasts could be examined; Figure 8.1 illustrates this graphically. This frame-
work can be used to design a new study comparing blood and site of disease samples even in LTBI,
PTB and possibly other forms of tuberculosis, in contexts with or without HIV-1 co-infection. This
may be achieved by careful study design and stratified sampling to ensure that all vertices in high-
dimensional phenotype space are as evenly populated as possible.
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A Code
A.1 Code for functions used throughout
A.1.1 Modified heatmap (heatmap_ad.R)
Changes made to original “heatmap.plus” command from heatmap.plus package:
Added options noan (number of annotations) and rowlab (row labels) to increase the width (lhei)
of column annotation rows for the Colv matrix by the factor noan. This is useful because a large
number of column annotations (e.g. based on phenodata) normally make the Colv matrix unread-
able as it has a fixed width. The rowlab option switches the labelling of the column annotations on
and off as desired. Credit for noan parametrisation of lhei is this post:
http://tolstoy.newcastle.edu.au/R/e9/help/10/02/6307.html.
1 #changelog?
2
3 heatmap_ad<-function (x, Rowv = NULL , Colv = if (symm) "Rowv" else NULL ,
4 distfun = dist , hclustfun = hclust , reorderfun = function(d,
5 w) reorder(d, w), add.expr , symm = FALSE , revC = identical(Colv ,
6 "Rowv"), scale = c("row", "column", "none"), na.rm = TRUE ,
7 margins = c(5, 5), ColSideColors , RowSideColors , cexRow = 0.2 +
8 1/log10(nr), cexCol = 0.2 + 1/log10(nc), labRow = NULL ,
9 labCol = NULL , main = NULL , xlab = NULL , ylab = NULL , keep.dendro =
FALSE , noan=NULL ,rowlab=TRUE ,
10 verbose = getOption("verbose"), ...)
11 {
12 scale <- if (symm && missing(scale))
13 "none"
14 else match.arg(scale)
15 if (length(di <- dim(x)) != 2 || !is.numeric(x))
16 stop("’x’ must be a numeric matrix")
17 nr <- di[1]
18 nc <- di[2]
19 if (nr <= 1 || nc <= 1)
20 stop("’x’ must have at least 2 rows and 2 columns")
21 if (!is.numeric(margins) || length(margins) != 2)
22 stop("’margins ’ must be a numeric vector of length 2")
23 doRdend <- !identical(Rowv , NA)
24 doCdend <- !identical(Colv , NA)
25 if (is.null(Rowv))
26 Rowv <- rowMeans(x, na.rm = na.rm)
27 if (is.null(Colv))
28 Colv <- colMeans(x, na.rm = na.rm)
29 if (doRdend) {
30 if (inherits(Rowv , "dendrogram"))
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31 ddr <- Rowv
32 else {
33 hcr <- hclustfun(distfun(x))
34 ddr <- as.dendrogram(hcr)
35 if (!is.logical(Rowv) || Rowv)
36 ddr <- reorderfun(ddr , Rowv)
37 }
38 if (nr != length(rowInd <- order.dendrogram(ddr)))
39 stop("row dendrogram ordering gave index of wrong length")
40 }
41 else rowInd <- 1:nr
42 if (doCdend) {
43 if (inherits(Colv , "dendrogram"))
44 ddc <- Colv
45 else if (identical(Colv , "Rowv")) {
46 if (nr != nc)
47 stop("Colv = \"Rowv\" but nrow(x) != ncol(x)")
48 ddc <- ddr
49 }
50 else {
51 hcc <- hclustfun(distfun(if (symm)
52 x
53 else t(x)))
54 ddc <- as.dendrogram(hcc)
55 if (!is.logical(Colv) || Colv)
56 ddc <- reorderfun(ddc , Colv)
57 }
58 if (nc != length(colInd <- order.dendrogram(ddc)))
59 stop("column dendrogram ordering gave index of wrong length")
60 }
61 else colInd <- 1:nc
62 x <- x[rowInd , colInd]
63 labRow <- if(rowlab ==TRUE)
64 if (is.null(labRow))
65 if (is.null(rownames(x)))
66 (1:nr)[rowInd]
67
68 else rownames(x)
69 else labRow[rowInd]
70 else NULL
71 labCol <- if (is.null(labCol))
72 if (is.null(colnames(x)))
73 (1:nc)[colInd]
74 else colnames(x)
75 else labCol[colInd]
76 if (scale == "row") {
77 x <- sweep(x, 1, rowMeans(x, na.rm = na.rm))
78 sx <- apply(x, 1, sd, na.rm = na.rm)
79 x <- sweep(x, 1, sx , "/")
80 }
81 else if (scale == "column") {
82 x <- sweep(x, 2, colMeans(x, na.rm = na.rm))
83 sx <- apply(x, 2, sd, na.rm = na.rm)
84 x <- sweep(x, 2, sx , "/")
85 }
86
87 lmat <- rbind(c(NA, 3), 2:1)
88 lwid <- c(if (doRdend) 1 else 0.05, 4)
89 lhei <- c((if (doCdend) 1 else 0.05) + if (!is.null(main)) 0.2 else 0,4)
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90 #lhei <- c((if (doCdend) 1 else 0.05) + if (!is.null(main)) 0.8 else
0,4)
91 if (!missing(ColSideColors)) {
92 if (!is.matrix(ColSideColors))
93 stop("’ColSideColors ’ must be a matrix")
94 if (!is.character(ColSideColors) || dim(ColSideColors)[1] !=
95 nc)
96 stop("’ColSideColors ’ dim()[2] must be of length ncol(x)")
97 lmat <- rbind(lmat[1, ] + 1, c(NA, 1), lmat[2, ] + 1)
98 #lmat <- rbind(lmat[1, ] + 1, c(NA , 1), lmat[3, ] + 1)
99 #lhei <- c(lhei[1], 0.2, lhei [2])
100 lhei <- c(lhei[1], 0.1*noan , lhei [2])
101 }
102 if (!missing(RowSideColors)) {
103 if (!is.matrix(RowSideColors))
104 stop("’RowSideColors ’ must be a matrix")
105 if (!is.character(RowSideColors) || dim(RowSideColors)[1] !=
106 nr)
107 stop("’RowSideColors ’ must be a character vector of length nrow(
x)")
108 lmat <- cbind(lmat[, 1] + 1, c(rep(NA, nrow(lmat) - 1),
109 1), lmat[, 2] + 1)
110 #lwid <- c(lwid[1], 0.2, lwid [2])
111 lwid <- c(lwid[1], 0.2, lwid [2])
112 }
113 lmat[is.na(lmat)] <- 0
114 if (verbose) {
115 cat("layout: widths = ", lwid , ", heights = ", lhei ,
116 "; lmat=\n")
117 print(lmat)
118 }
119 op <- par(no.readonly = TRUE)
120 on.exit(par(op))
121 layout(lmat , widths = lwid , heights = lhei , respect = FALSE)
122
123 #1 draw row side col
124 if (!missing(RowSideColors)) {
125 par(mar = c(margins [1], 0, 0, 0.5))
126 rsc = RowSideColors[rowInd , ]
127 rsc.colors = matrix ()
128 rsc.names = names(table(rsc))
129 rsc.i = 1
130 for (rsc.name in rsc.names) {
131 rsc.colors[rsc.i] = rsc.name
132 rsc[rsc == rsc.name] = rsc.i
133 rsc.i = rsc.i + 1
134 }
135 rsc = matrix(as.numeric(rsc), nrow = dim(rsc)[1])
136 image(t(rsc), col = as.vector(rsc.colors), axes = FALSE)
137 if (length(colnames(RowSideColors)) > 0) {
138 axis(1, 0:( dim(rsc)[2] - 1)/(dim(rsc)[2] - 1), colnames(
RowSideColors),
139 las = 2, tick = FALSE)
140 }
141 }
142 #2 draw col side col
143 if (!missing(ColSideColors)) {
144 par(mar = c(0.5, 0, 0, margins [2]))
145 csc = ColSideColors[colInd , ]
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146 csc.colors = matrix ()
147 csc.names = names(table(csc))
148 csc.i = 1
149 for (csc.name in csc.names) {
150 csc.colors[csc.i] = csc.name
151 csc[csc == csc.name] = csc.i
152 csc.i = csc.i + 1
153 }
154 csc = matrix(as.numeric(csc), nrow = dim(csc)[1])
155 image(csc , col = as.vector(csc.colors), axes = FALSE)
156 if (length(colnames(ColSideColors)) > 0) {
157 axis(2, 0:( dim(csc)[2] - 1)/(dim(csc)[2] - 1), colnames(
ColSideColors),
158 las = 2, tick = FALSE)
159 }
160 }
161
162 #3 draw heatmap
163 par(mar = c(margins [1], 0, 0, margins [2]))
164 if (!symm || scale != "none") {
165 x <- t(x)
166 }
167 if (revC) {
168 iy <- nr:1
169 ddr <- rev(ddr)
170 x <- x[, iy]
171 }
172 else iy <- 1:nr
173
174 image (1:nc , 1:nr, x, xlim = 0.5 + c(0, nc), ylim = 0.5 +
175 c(0, nr), axes = FALSE , xlab = "", ylab = "", ...)
176 axis(1, 1:nc , labels = labCol , las = 2, line = -0.5, tick = 0,
177 cex.axis = cexCol)
178 if (!is.null(xlab))
179 mtext(xlab , side = 1, line = margins [1] - 1.25)
180 axis(4, iy , labels = labRow , las = 2, line = -0.5, tick = 0,
181 cex.axis = cexRow)
182 if (!is.null(ylab))
183 mtext(ylab , side = 4, line = margins [2] - 1.25)
184 if (!missing(add.expr))
185 eval(substitute(add.expr))
186 #4 draw row dendro
187 par(mar = c(margins [1], 0, 0, 0))
188 if (doRdend)
189 plot(ddr , horiz = TRUE , axes = FALSE , yaxs = "i", leaflab = "none")
190 else frame()
191
192 #5 draw col dendro
193 par(mar = c(0, 0, if (!is.null(main)) 2 else 0, margins [2]))#was1
194 if (doCdend)
195 plot(ddc , axes = FALSE , xaxs = "i", leaflab = "none")
196 else if (!is.null(main))
197 frame()
198 #6 title
199 if (!is.null(main))
200 title(main , cex.main = 1.3 * op[["cex.main"]])
201 invisible(list(rowInd = rowInd , colInd = colInd , Rowv = if (keep.dendro
&&
202 doRdend) ddr , Colv = if (keep.dendro && doCdend) ddc))
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203
204
205 }
Listing A.1: heatmapad.R
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A.1.2 Comprehensive heatmap (1) (superHeatmap.R)
Convenient wrapper function for drawing heatmaps in the style used in the Berry et al paper [82].
This function adds options for correlation clustering and coloured dendrograms to the function
parameters, and then draws the heatmap using heatmap_ad.R.
Correlation code is based on this tutorial on the ULB BIGRe lab site, and the coloured dendro-
gram solution is based on this post.
1 superHeatmap <-function(x,y=selected.probes ,phenomatrix=phenomatrix ,scale=
scale ,addTit=NULL){
2
3 #cluster
4 genes.cor <- cor(t(exprs(x)[y,]), use="pairwise.complete.obs",method="
pearson")
5 genes.cor.dist <- as.dist(1-genes.cor)
6 genes.tree <- hclust(genes.cor.dist ,method=’average ’)
7 samples.cor.spearman <- cor(exprs(x)[y,],use="pairwise.complete.obs",method=
"spearman")
8 samples.cor.spearman.dist <- as.dist(1-samples.cor.spearman)
9 samples.tree <- hclust(samples.cor.spearman.dist ,method=’average ’)
10 #dendrogram colors
11
12 #coloured dendrogram
13 smpCol <- as.dendrogram(samples.tree)
14 local({
15 colLab <<- function(n) {
16 if(is.leaf(n)) {
17 a <- attributes(n)
18 i <<- i+1
19 # attr(n, "nodePar ") <-
20 # c(a$nodePar , list(lab.col = mycols[i], lab.font= i%%3),
pch=NULL)
21 attr(n, "edgePar") <-
22 c(a$edgePar , list(col = mycols[i]),lwd=3)
23 }
24 n
25 }
26 mycols <- as.vector(phenomatrix [,1])[order.dendrogram(smpCol)]
27 i <- 0
28 })
29 dL <- dendrapply(smpCol , colLab)
30
31 max.level <- max(abs(range(exprs(x)[y,])))
32
33 br <- c(seq(from=0,to=1,by=1/127),
34 seq(from=1, to=5,by=4/126),
35 max.level
36 )
37
38 #heatmap
39 heatmap_ad(as.matrix(exprs(x)[y,]),
40 scale=scale , ## AVOID RESCALING THE VALUES OF ALL COLUMNS
41 col=palette.BYR(),
42 breaks=br,
43 Rowv=as.dendrogram(genes.tree),
44 Colv=dL,
45 main=paste(nrow(exprs(x)[y,]),"probes",addTit),
46 ColSideColors=phenomatrix ,
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47 margins=c(9,5),
48 #RowSideColors=rsc ,
49 noan=2,labRow="",verbose=TRUE
50 )
51 }
Listing A.2: superHeatmap.R
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A.1.3 Comprehensive heatmap (2) (superHeatmap.R)
Improves on superHeatmap.R by automating the selection of colour levels in the blue-yellow-red
colour ramp.
1 superHeatmap2 <-function(x,y=selected.probes ,phenomatrix=phenomatrix ,scale=
scale ,addTit=NULL ,low=low ,high=high){
2
3 #cluster
4 genes.cor <- cor(t(exprs(x)[y,]), use="pairwise.complete.obs",method="
pearson")
5 genes.cor.dist <- as.dist(1-genes.cor)
6 genes.tree <- hclust(genes.cor.dist ,method=’average ’)
7 samples.cor.spearman <- cor(exprs(x)[y,],use="pairwise.complete.obs",method=
"spearman")
8 samples.cor.spearman.dist <- as.dist(1-samples.cor.spearman)
9 samples.tree <- hclust(samples.cor.spearman.dist ,method=’average ’)
10 #dendrogram colors
11
12 #coloured dendrogram
13 smpCol <- as.dendrogram(samples.tree)
14 local({
15 colLab <<- function(n) {
16 if(is.leaf(n)) {
17 a <- attributes(n)
18 i <<- i+1
19 # attr(n, "nodePar ") <-
20 # c(a$nodePar , list(lab.col = mycols[i], lab.font= i%%3),
pch=NULL)
21 attr(n, "edgePar") <-
22 c(a$edgePar , list(col = mycols[i]),lwd=3)
23 }
24 n
25 }
26 mycols <- as.vector(phenomatrix [,1])[order.dendrogram(smpCol)]
27 i <- 0
28 })
29 dL <- dendrapply(smpCol , colLab)
30
31 max.level <- max(abs(range(exprs(x)[y,])))
32 min.level <- min(abs(range(exprs(x)[y,])))
33 low <-1.05*min.level
34 high <-0.6*max.level
35
36 br <- c(seq(from=min.level ,to=low ,length.out =30),
37 seq(from=low , to=high ,length.out =105),
38 seq(from=high ,to=max.level ,length.out =120),
39 max.level
40 )
41
42 #heatmap
43 heatmap_ad(as.matrix(exprs(x)[y,]),
44 scale=scale , ## AVOID RESCALING THE VALUES OF ALL COLUMNS
45 col=palette.BYR(),
46 #breaks=br ,
47 Rowv=as.dendrogram(genes.tree),
48 Colv=dL,
49 main=paste(nrow(exprs(x)[y,]),"probes",addTit),
50 ColSideColors=phenomatrix ,
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51 margins=c(9,5),
52 #RowSideColors=rsc ,
53 noan=2,labRow="",verbose=TRUE
54 )
55 }
Listing A.3: superHeatmap2.R
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A.1.4 Modified Sample Relations plot (MDS) (plotSampleRelationsAD.R)
Modifies the function plotSampleRelation from the lumi package to plot points using specified plot
character plotchar instead of the sample names; this makes the plot more readable. A background
colour can also be specified.
1 plotSampleRelationsAD <-function (x, subset = NULL , cv.Th = 0.1, standardize
= TRUE ,
2 method = c("cluster", "mds"), dimension = c(1, 2), color = NULL ,
backgr = NULL ,plotchar =24,
3 main = NULL , ...)
4 {
5 if (is(x, "ExpressionSet")) {
6 dataMatrix <- exprs(x)
7 }
8 else if (is.matrix(x)) {
9 dataMatrix <- x
10 }
11 else {
12 stop("The class of \"x\" should be matrix or LumiBatch!")
13 }
14 if (standardize)
15 dataMatrix <- scale(dataMatrix)
16 if (is.null(subset)) {
17 probeList <- rownames(dataMatrix)
18 if (is.null(probeList))
19 probeList <- 1:nrow(dataMatrix)
20 if (cv.Th > 0) {
21 cv.gene <- apply(dataMatrix , 1, function(x) sd(x)/mean(x))
22 subset <- probeList[abs(cv.gene) > cv.Th]
23 if (is.null(main))
24 main <- paste("Sample relations based on", length(subset),
25 "genes with sd/mean >", cv.Th)
26 }
27 else {
28 subset <- probeList
29 if (is.null(main))
30 main <- paste("Sample relations based on", length(subset),
31 "genes")
32 }
33 }
34 else {
35 if (length(subset) == 1 && is.numeric(subset)) {
36 subset <- sample (1: nrow(dataMatrix), min(subset ,
37 nrow(dataMatrix)))
38 }
39 if (is.null(main))
40 main <- paste("Sample relations based on", length(subset),
41 "selected genes")
42 }
43 dd <- dist(t(dataMatrix[subset , ]))
44 method <- match.arg(method)
45 if (method == "cluster") {
46 hc = hclust(dd , "ave")
47 plot(hc, xlab = "Sample", main = main , ...)
48 attr(hc, "geneNum") <- length(subset)
49 attr(hc, "threshold") <- cv.Th
50 return(invisible(hc))
51 }
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52 else {
53 mds.result <- cmdscale(dd, k = max(dimension), eig = TRUE)
54 ppoints <- mds.result$points
55 eig <- mds.result$eig
56 percent <- round(eig/sum(eig) * 100, 1)
57 if (is.null(color)) {
58 color <- 1
59 }
60 else {
61 if (!is.numeric(color)) {
62 allColor <- colors ()
63 if (!all(is.element(color , allColor))) {
64 color <- as.numeric(factor(color , levels = unique(color)))
65 }
66 }
67 }
68 plot(ppoints[, dimension [1]], ppoints[, dimension [2]],
69 type = "n", xlab = paste("Principal Component ",
70 dimension [1], " (", percent[dimension [1]],
"%)",
71 sep = ""), ylab = paste("Principal
Component ",
72 dimension [2], " ("
, percent[dimension [2]], "%)",
73 sep = ""), main =
main , ...)
74 points(ppoints[, dimension [1]], ppoints[, dimension [2]],
75 col = color ,bg=backgr , cex = 1,pch=plotchar)
76 attr(ppoints , "geneNum") <- length(subset)
77 attr(ppoints , "threshold") <- cv.Th
78 return(invisible(ppoints))
79 }
80 }
Listing A.4: plotSampleRelationsAD.R
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A.1.5 Modified 3D Sample Relations plot
Modifies the function plotSampleRelationsAD.R to plot points in 3D space using the first three
principal components. The plot3d command in this function requires the rgl library, which is loaded
in the setup script.
1 plotSampleRelations3D_AD<-function (x, subset = NULL , cv.Th = 0.1,
standardize = TRUE ,
2 method = c("cluster", "mds"), dimension = c
(1, 2,3), color = NULL , backgr = NULL ,plotchar =24, spheresize =2,
3 main = NULL , ...)
4 {
5 if (is(x, "ExpressionSet")) {
6 dataMatrix <- exprs(x)
7 }
8 else if (is.matrix(x)) {
9 dataMatrix <- x
10 }
11 else {
12 stop("The class of \"x\" should be matrix or LumiBatch!")
13 }
14 if (standardize)
15 dataMatrix <- scale(dataMatrix)
16 if (is.null(subset)) {
17 probeList <- rownames(dataMatrix)
18 if (is.null(probeList))
19 probeList <- 1:nrow(dataMatrix)
20 if (cv.Th > 0) {
21 cv.gene <- apply(dataMatrix , 1, function(x) sd(x)/mean(x))
22 subset <- probeList[abs(cv.gene) > cv.Th]
23 if (is.null(main))
24 main <- paste("Sample relations based on", length(subset),
25 "genes with sd/mean >", cv.Th)
26 }
27 else {
28 subset <- probeList
29 if (is.null(main))
30 main <- paste("Sample relations based on", length(subset),
31 "genes")
32 }
33 }
34 else {
35 if (length(subset) == 1 && is.numeric(subset)) {
36 subset <- sample (1: nrow(dataMatrix), min(subset ,
37 nrow(dataMatrix)))
38 }
39 if (is.null(main))
40 main <- paste("Sample relations based on", length(subset),
41 "selected genes")
42 }
43 dd <- dist(t(dataMatrix[subset , ]))
44 method <- match.arg(method)
45 if (method == "cluster") {
46 hc = hclust(dd , "ave")
47 plot(hc, xlab = "Sample", main = main , ...)
48 attr(hc, "geneNum") <- length(subset)
49 attr(hc, "threshold") <- cv.Th
50 return(invisible(hc))
51 }
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52 else {
53 mds.result <- cmdscale(dd, k = max(dimension), eig = TRUE)
54 ppoints <- mds.result$points
55 eig <- mds.result$eig
56 percent <- round(eig/sum(eig) * 100, 1)
57 if (is.null(color)) {
58 color <- 1
59 }
60 else {
61 if (!is.numeric(color)) {
62 allColor <- colors ()
63 if (!all(is.element(color , allColor))) {
64 color <- as.numeric(factor(color , levels = unique(color)))
65 }
66 }
67 }
68 plot3d(ppoints[, dimension [1]], ppoints[, dimension [2]], ppoints[,
dimension [3]],
69 type = "s", size=spheresize ,
70 xlab = paste("Principal Component ",dimension [1], " (", percent[
dimension [1]], "%)",sep = ""),
71 ylab = paste("Principal Component ",dimension [2], " (", percent[
dimension [2]], "%)",sep = ""),
72 zlab = paste("Principal Component ",dimension [3], " (", percent[
dimension [3]], "%)",sep = ""),
73 main = main ,col=color)
74 #points(ppoints[, dimension [1]], ppoints[, dimension [2]], ppoints[,
dimension [3]],col = color ,bg=backgr , cex = 1,pch=plotchar)
75
76 }
77 }
Listing A.5: plotSampleRelations3DAD.R
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A.2 System setup
1 #metadata ####
2 #IMPI_MA microarray analysis pipeline
3 #Universal System Setup
4 #Armin Deffur
5 #File created 18 -02 -2013
6 #Version 1.0
7
8 #1. System Setup ####
9
10 #initialise session
11 rm(list=ls())
12 graphics.off()
13
14 #Local folder configuration ####
15
16 #Projects root (scripts and output)
17 dir.root <- ’/Users/armindeffur/Documents/002_Science_universal/Active_
Research/IMPI -Microarray/Projects ’
18
19 #Functions
20
21 #R-scripts root
22 dir.R.files <- file.path(dir.root , "01_scripts/06_IMPI -MA/Analysis/03_
Functions")
23 print(paste("R scripts source", dir.R.files))
24 ## R utilities folder
25 dir.util <- file.path(dir.R.files , ’util’)
26
27 #Pipelines
28
29 #Data root
30 dir.data_root <-’/Users/armindeffur/Documents/002_Science_universal/Active_
Research/IMPI -Microarray/Data’
31
32 #Load utilities ####
33 source(file.path(dir.util , ’util.R’))
34 source(file.path(dir.util , ’util_chip_analysis.R’))
35 source(file.path(dir.R.files ,"plotSampleRelationsAD.R"))
36 source(file.path(dir.R.files ,"plotSampleRelations3D_AD.R"))
37 source(file.path(dir.R.files ,"heatmap_ad.R"))
38 source(file.path(dir.R.files ,"heatmap_ad2.R"))
39
40 #Global parameters ####
41 verbosity <- 1
42 #export.formats.plots <- c("eps","pdf", "png","jpg")
43 #export.formats.plots <- c("pdf", "png","jpg")
44 export.formats.plots <- c("pdf")
45 export.formats.obj <- c("table")
46 #height =16# use for printing?
47 height =8#use for presentation graphics
48 par(mfrow=c(1,1),mar=c(5, 4, 4, 2) + 0.1,xaxt="s")
49 parbackup <-par(mfrow=c(1,1),mar=c(5, 4, 4, 2) + 0.1,xaxt="s",cex.main =1)
50 plotnumber <-1
51
52 ## Specify if drawings should be done in colors or not.
53 in.colors <- T
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54
55 #load all libraries
56 library(lumi)
57 library(annotate)
58 library(lumiHumanAll.db)
59 library(lumiHumanIDMapping)
60 library(rgl)
61 library(limma)
62 library(xtable)
63 library(gplots)
64 library(VennDiagram)
65 library(tools)
66 library(vegan)
67 library(CellMix)
68 library(csSAM)
69 library(RColorBrewer)
70 library(pwr)
71 library(ClassDiscovery)
72 library(WGCNA)
73 library(RColorBrewer)
74 library(beadarray)
75 library(illuminaHumanv3.db)
76 library(illuminaHumanv4.db)
Listing A.6: SystemSetup.R
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A.3 Data manager (general)
1 #metadata ####
2 #IMPI_MA microarray analysis pipeline
3 #Universal Data Manager
4 #Armin Deffur
5 #File created 18 -02 -2013
6 #Version 1.0
7
8 #System_setup.R####
9
10 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/06_IMPI -MA/Analysis/00_System/System
_setup.R")
11
12 #Local Setup ####
13
14 ## Individual data folders (specific for each part)
15 dir.gx <- file.path(dir.data_root , ’09_IMPI_MA_DATA/04_GX_format ’)
16 print(paste("GX12 -format data repository", dir.gx))
17 dir.gs <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/05_
GenomeStudio_reports ’)
18 print(paste("GenomeStudio report data repository", dir.gs))
19 dir.bgx <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/06_Illumina
Manifest files/HT12v4 ’)
20 print(paste("Illumina manifest file repository", dir.gx))
21 dir.jpg <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/07_
imageData/JPG’)
22 print(paste("Raw image data (.jpg) repository", dir.jpg))
23 dir.tif <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/07_
imageData/TIFF’)
24 print(paste("Raw image data (.tif) repository", dir.tif))
25 dir.pheno <- file.path(dir.data_root , ’09_IMPI_MA_DATA/08_PhenoData ’)
26 print(paste("Phenodata data repository", dir.pheno))
27
28 #Output folders
29 dir.home <-dir.root
30 dir.main <- file.path(dir.root , ’02_output/06_IMPI -MA’,’AllData ’)
31
32 #Current date string used for versioning output
33 ds<-Sys.time()
34
35 #versioned output
36 dir.output.version <-file.path(dir.main ,paste("version_",ds))
37
38 ## Define folder for storing results NB do this for each analysis
39 dir.results <- file.path(dir.output.version , "results")
40 print(paste("Results will be saved to", dir.results))
41
42 ## Define folder for saving figures
43 dir.figures <- file.path(dir.output.version , "figures")
44 print(paste("Figures will be saved to", dir.figures))
45
46 ## Define folder for saving RData files
47 dir.rdata <- file.path(dir.data_root ,’09_IMPI_MA_DATA/05_RData’)
48 print(paste("Data will be saved to", dir.rdata))
49
50 for (dir in c(dir.main , dir.figures , dir.results)) {
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51 if (!file.exists(dir)) {
52 dir.create(dir , recursive=T,showWarnings=T)
53 }
54 }
55
56 figure <-1
57
58 #WD####
59 setwd(dir.main)
60
61 #Data for Differential Expression
62
63 #Data for Deconvolution
64
65 #Data for WGCNA
66
67 #Import expression and phenotype data using lumi ####
68
69 fileName <-file.path(dir.gx,"Armin_Hu_17_8_12_No uRNA_bkg sub_NO Norm__Sample
_Probe_Profile.txt")
70 fileNameAnno <-file.path(dir.gs,"Armin_Hu_17_8_12_No uRNA_bkg sub_NO Norm_
FinalReport.txt")
71 bgxfile <-file.path(dir.bgx ,"HumanHT -12_V4_0_R1_15002873_B.bgx")
72
73 #PHENODATA ORIGINAL
74 #the phenodata below assigns TB status according to Pericardial culture.
This misclassifies TB-PC suspects who were culture positive elsewhere as
"probable" TB (wrong)
75 #phenodataPath <-file.path(dir.pheno ," phenoGS_edited_csv_colour_25_9_2012. csv
")
76
77 #PHENODATA EDIT 1
78 #the phenodata (class3 variable) below defines active TB as ANY positive
site. This means that some probable TBPC cases are defnite TB cases.
This is relevant as the !blood! signature will be determined by any (??)
TB site. This needs to be tested where fluid is negative but another
site positive. It is unclear if this applies to TBM , though. (issues of
blood -brain -barrier , etc.)
79 #Important: when changing this , factors of diagnostic class may change ,
depending which "probable" case is made "definite ".
80 #phenodataPath <-file.path(dir.pheno ," phenoGS_edited_csv_colour_28_10_2012.
csv")
81
82 #PHENODATA EDIT 2
83 #With this in mind , the phenodata source file has been updated to change
sample 20868 control back to probableActiveTB , as the only positive
culture was CSF. It seems unwise to include only one case of TBM , while
there are many TB -PC and PTB.
84 #the phenodata file was edited: sample PCA141 blood and fluid assignments to
chips have been exchanged , as earlier mds plots strongly suggested this
. All results may change that depend on the correct assignment.
85
86 #IMPI -MA data
87 phenodataPath <-file.path(dir.pheno ,"phenoGS_edited_csv_colour_17_01_2013. csv
")
88 sampleInfoDF <-read.csv(phenodataPath , header = TRUE , colClasses = "character
", comment.char = "",check.names = FALSE)
89 allArrays <-lumiR.batch(fileName ,lib.mapping=’lumiHumanIDMapping ’,
sampleInfoFile=sampleInfoDF ,verbose=TRUE)
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90 colnames(exprs(allArrays))<-allArrays$sample_name
91
92 #Berry data
93 berry.sampleInfoDF.train <-read.csv("/Users/armindeffur/Documents/002_Science
_universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_train.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
94 berry.train <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal
/Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_TrainingSet.txt",lib.mapping=’lumiHumanIDMapping ’,sampleInfoFile
=berry.sampleInfoDF.train ,verbose=TRUE)
95
96 berry.sampleInfoDF.test <-read.csv("/Users/armindeffur/Documents/002_Science_
universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_test.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
97 berry.test <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal/
Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_TestSet.txt",lib.mapping=’lumiHumanIDMapping ’,sampleInfoFile=
berry.sampleInfoDF.test ,verbose=TRUE)
98
99 berry.sampleInfoDF.val <-read.csv("/Users/armindeffur/Documents/002_Science_
universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_val.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
100 berry.val <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal/
Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_ValidationSet.txt",lib.mapping=’lumiHumanIDMapping ’,
sampleInfoFile=berry.sampleInfoDF.val ,verbose=TRUE)
101
102 #subset allArrays by compartment
103 fluidArrays <-allArrays[,allArrays$Compartment =="fluid"]
104 bloodArrays <-allArrays[,allArrays$Compartment =="blood"]
105
106 #Data subsetting ####
107
108 #make subsets
109
110 #CSC scheme: compartment , subset , contrast
111
112 save(berry.train ,file=file.path(dir.rdata ,’berry_train.RData’))
113 save(berry.test ,file=file.path(dir.rdata ,’berry_test.RData’))
114 save(berry.val ,file=file.path(dir.rdata ,’berry_val.RData’))
115
116 save(allArrays ,file=file.path(dir.rdata ,’IMPI_MA.RData’))
117
118 hivNegBloodArrays <-bloodArrays[,bloodArrays$HIV.Status =="negative"] #tb
119 B.N.AX<-hivNegBloodArrays[,hivNegBloodArrays$class3 =="activeTB"|
hivNegBloodArrays$class3 =="notActiveTB"]#training
120 B.N.aX<-hivNegBloodArrays[,hivNegBloodArrays$class3 =="probableActiveTB"|
hivNegBloodArrays$class3 =="notActiveTB"]#validation
121 save(B.N.AX,file=file.path(dir.rdata ,’blood_hivNeg_aTB_noTB.RData ’))
122 save(B.N.aX,file=file.path(dir.rdata ,’blood_hivNeg_probTB_noTB.RData ’))
123
124 hivPosBloodArrays <-bloodArrays[,bloodArrays$HIV.Status =="positive"]
125 B.P.AX<-hivPosBloodArrays[,hivPosBloodArrays$class3 =="activeTB"|
hivPosBloodArrays$class3 =="notActiveTB"]
126 B.P.aX<-hivPosBloodArrays[,hivPosBloodArrays$class3 =="probableActiveTB"|
hivPosBloodArrays$class3 =="notActiveTB"]
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127 save(B.P.AX ,file=file.path(dir.rdata ,’blood_hivPos_aTB_noTB.RData ’))
128 save(B.P.aX ,file=file.path(dir.rdata ,’blood_hivPos_probTB_noTB.RData ’))
129
130 ##
131 B.aTB.PN<-bloodArrays[,bloodArrays$class3 =="activeTB"] #tb
132 save(B.aTB.PN ,file=file.path(dir.rdata ,’blood_aTB_HIVposNeg.RData ’))
133 B.noTB.PN<-bloodArrays[,bloodArrays$class3 =="notActiveTB"] #tb
134 save(B.noTB.PN ,file=file.path(dir.rdata ,’blood_noTB_HIVposNeg.RData ’))
135 ##
136
137 B.C<-bloodArrays[,bloodArrays$type=="PC"] #hiv ,hd
138 PF.C<-fluidArrays[,fluidArrays$type=="PC"] #hiv , hd
139 save(B.C,file=file.path(dir.rdata ,’blood_TBPC.RData’))
140 save(PF.C,file=file.path(dir.rdata ,’fluid_TBPC.RData’))
141
142 C.BPF <-allArrays[,allArrays$matching =="m"] #comp
143 C.N.BPF <-C.BPF[,C.BPF$HIV.Status =="negative"]
144 C.P.BPF <-C.BPF[,C.BPF$HIV.Status =="positive"]
145 save(C.BPF ,file=file.path(dir.rdata ,’TBPC_matchedBloodFluid.RData ’))
146 save(C.N.BPF ,file=file.path(dir.rdata ,’TBPC_hivNeg_matchedBloodFluid.RData’)
)
147 save(C.P.BPF ,file=file.path(dir.rdata ,’TBPC_hivPos_matchedBloodFluid.RData’)
)
148
149 datasets <-list(
150 "Berry traininig set"=berry.train ,
151 "Berry test set"=berry.test ,
152 "Berry validation set"=berry.val ,
153 "IMPI_MA"=allArrays ,
154 "Blood , HIV neg , active or not active TB"=B.N.AX,
155 "Blood , HIV neg , probable or not active TB"=B.N.aX ,
156 "Blood , HIV pos , active or not active TB"=B.P.AX,
157 "Blood , HIV pos , probable or not active TB"=B.P.aX ,
158 "Blood , all TBPC"=B.C,
159 "Pericardial Fluid , all TBPC"=PF.C,
160 "Matched blood and pericardial fluid"=C.BPF ,
161 "Matched blood and pericardial fluid , HIV neg"=C.N.BPF ,
162 "Matched blood and pericardial fluid , HIV pos"=C.P.BPF)
163
164 #Berry signatures
165 #file=file.path(dir.gx ," Nature_paper_transcripts ","P22_42_04Mar09_Training_
393_GX11.txt")
166 #np393 <-read.table(file ,header=TRUE ,sep="\t")
167 #char393 <-as.character(np393 [,1])
168
169 #berry.sig <-char393
170 #save(berry.sig ,file=file.path(dir.rdata ,’berry.sig.RData ’))
171
172 #need to get 86 transcript list; downloaded as xls
173
174 #import
175 file86=file.path(dir.gx,"Nature_paper_transcripts","nature09247 -s4.csv")
176 np86 <-read.csv(file86 ,header=TRUE ,sep=",")
177 berry .86 <-np86
178 save(berry.86,file=file.path(dir.rdata ,’berry .86. RData’))
179
180 #import manual berry393
181
182 #not done , need to fix format ...
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183 file393=file.path(dir.gx,"Nature_paper_transcripts","nature09247 -s2.csv")
184 np393 <-read.csv(file393 ,header=TRUE ,sep=",")
185 berry .393 <-np393
186 save(berry .393, file=file.path(dir.rdata ,’berry .393. RData’))
187
188
189 #convert illumina ID to nuID
190 #as character
191 #save as .RData
Listing A.7: Data-manager.R
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A.4 RT-PCR
1
2 #setup ####
3 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/03_RT-PCR/11_RTPCR_paper/RTPCR_
System_setup.R")
4
5 par("xpd"=FALSE)
6 ## Individual data folders (specific for each part)
7 dir.rtpcrdata <- file.path(dir.data_root ,’02_IMPI_immunology data/Assays/RT -
PCR’)
8
9 dir.phenodata <- file.path("/Users/armindeffur/Documents/002_Science_
universal/Active_Research/IMPI -Microarray/Projects/02_output/02_
Phenotype exploration/")
10
11 #Output folders
12 dir.home <-dir.root
13 dir.main <- file.path(dir.root , ’02_output/03_RT-PCR/11_RTPCR_paper ’)
14
15 #Current date string used for versioning output
16 ds<-Sys.time()
17
18 #versioned output
19 dir.output.version <-file.path(dir.main ,paste("ver_",ds))
20
21 ## Define folder for storing results NB do this for each analysis
22 dir.results <- file.path(dir.output.version , "results")
23 ## Define folder for saving figures
24 dir.figures <- file.path(dir.output.version , "figures")
25 for (dir in c(dir.main , dir.figures , dir.results)) {
26 if (!file.exists(dir)) {
27 dir.create(dir , recursive=T,showWarnings=T)
28 }
29 }
30
31 sink(type="output",file=file.path(dir.results ,"session_output.txt"))
32 sessionInfo ()
33 print(paste("Begin time:",ds))
34 print(paste("Results will be saved to", dir.results))
35 print(paste("Figures will be saved to", dir.figures))
36
37
38 height =6
39 #additional functions ####
40 redgreen <-function(n){c(hsv(h=2/6,v=seq(1,0,length=n/2)),hsv(h=0/6,v=seq
(0,1,length=n/2)))}
41 #redgreen <-colorRampPalette(c(" green"," lightgreen ","white","yellow","orange
","red","purple ")) ## (n)
42 #redgreen <-colorRampPalette(c(" lightblue ","gray","white","yellow","red","
purple ")) ## (n)
43 #redgreen <-colorRampPalette(c(" lightgreen "," lightgray","white","red")) ## (n
)
44 redgreen <-colorRampPalette(c("purple","blue","lightblue","lightgreen","
cornsilk","wheat1","red")) ## (n)
45 bluered <-colorRampPalette(c("blue","lightblue","white","pink","red")) ## (n)
46
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47 interleave <- function(v1 ,v2)
48 {
49 ord1 <- 2*(1: length(v1)) -1
50 ord2 <- 2*(1: length(v2))
51 c(v1 ,v2)[order(c(ord1 ,ord2))]
52 }
53 #Data ####
54 #delta CT values
55 data2 <-read.xls(file.path(dir.rtpcrdata ,"rtDat2.XLS"))
56 #ELISA and luminex
57 data2.prot <-read.xls(file.path(dir.rtpcrdata ,"elDat.XLS"))
58 #Phenotype information
59 #make sure to use the latest! The below can vary as the output from the
phenotype explorer in Mathematica changes!
60 phenodata <-read.xls(file.path(dir.phenodata ,"SET1_RT -PCRsumdata +
class20130409.xls"))
61 #Combine two datasets
62 data3 <-merge(phenodata ,data2 ,by.x="ID_KERRYN",by.y="ID")
63 data3.prot <-merge(phenodata ,data2.prot ,by.x="ID_KERRYN",by.y="PersonID")
64 #About the patients: Table 1 calculations ####
65
66 #this stuff needs to be moved into a df
67 pts2 <-phenodata
68 #variables
69 hiv <-pts2$HIV
70 table(hiv)
71
72 tbs <-pts2$TB.class
73 tbs2 <-ftable(tbs ,hiv)
74 tbs2
75 tbs.p<-chisq.test(tbs2)$p.value
76
77 sex <-pts2$SEX
78 table(sex)
79 sex2 <-ftable(sex ,hiv)
80 sex2
81 sex.p<-chisq.test(sex2)$p.value
82
83 fluid <-pts2$Fluid
84 table(fluid)
85 fluid2 <-ftable(fluid ,hiv)
86 fluid2
87 fluid2.p<-chisq.test(fluid2)$p.value
88
89 onart=pts2$ARVS
90 table(onart)
91 onart2 <-ftable(onart ,hiv)
92 onart2
93 onart2.p<-chisq.test(onart2)
94
95 onster=pts2$STEROIDS
96 table(onster)
97 onster2 <-ftable(onster ,hiv)
98 onster2
99 onster.p<-chisq.test(onster2)
100
101 m<-tapply(pts2$AGE_CALC ,hiv ,median ,na.rm=T)
102 i<-tapply(pts2$AGE_CALC ,hiv ,summary)
103 n<-tapply(pts2$AGE_CALC ,hiv ,length)
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104 summary(pts2$AGE_CALC)
105 #boxplot(pts2$AGE_CALC)
106 cbind(median=m,summary=as.character(i),n=n)
107 wilcox.test(pts2$AGE_CALC~hiv)
108
109 m<-tapply(pts2$CD4 ,hiv ,median ,na.rm=T)
110 i<-tapply(pts2$CD4 ,hiv ,summary)
111 n<-tapply(pts2$CD4 ,hiv ,length)
112 summary(pts2$CD4)
113 cbind(median=m,summary=as.character(i),n=n)
114 wilcox.test(pts2$CD4~hiv)
115
116 m<-tapply(pts2$ADA ,hiv ,median ,na.rm=T)
117 i<-tapply(pts2$ADA ,hiv ,summary)
118 n<-tapply(pts2$ADA ,hiv ,length)
119 summary(pts2$ADA)
120 cbind(median=m,summary=as.character(i),n=n)
121 wilcox.test(pts2$ADA~hiv)
122
123 m<-tapply(pts2$IFN.gamma ,hiv ,median ,na.rm=T)
124 i<-tapply(pts2$IFN.gamma ,hiv ,summary)
125 n<-tapply(pts2$IFN.gamma ,hiv ,length)
126 summary(pts2$IFN.gamma)
127 cbind(median=m,summary=as.character(i),n=n)
128 wilcox.test(pts2$IFN.gamma~hiv)
129
130 #Select compartment ####
131
132 #Blood only
133 data3blood <-data3[data3$compart =="Blood" ,]
134 #Fluid only
135 data3fluid <-data3[data3$compart =="Fluid" ,]
136 #the phenotype categories ####
137 compart <-as.factor(data3$compart);levels(compart)<-c("red","yellow")
138 sex <-as.factor(data3$SEX);levels(sex)<-c("white","blue","pink")
139 h<-as.factor(data3$HIV);levels(h)<-c("green","orange","white")
140 lowcd <-as.factor(data3$CD4 .200);levels(lowcd)<-c("white","black","gray")
141 cd4 <-as.factor(data3$CD4);levels(cd4)<-sequential_hcl(28, h=100,c = 100,
power = 1.2)
142 hd<-as.factor(data3$ECP);levels(hd)<-brewer.pal(3,"Set1")
143 tbs <-as.factor(data3$TB.PC);levels(tbs)<-brewer.pal(3,"Set2")
144 tbc <-as.factor(data3$PCF.TB.culture);levels(tbc)<-brewer.pal(4,"Set3")
145 fluid <-as.factor(data3$Fluid);levels(fluid)<-c("white","white","red","pink",
"yellow")
146 #phenomatrix definitions
147 #phenomatrix <-matrix(cbind(as.character(tbc),as.character(tbs),as.character(
hd),as.character(h),as.character(lowcd),as.character(cd4),as.character(
sex),as.character(compart),as.character(fluid)),ncol =9)
148 #colnames(phenomatrix)<-c("TBC","TBS","HD","HIV","lowCD4","CD4","SEX","COMP
","Fluid ")
149 phenomatrix <-matrix(cbind(as.character(h),as.character(compart)),ncol =2)
150 colnames(phenomatrix)<-c("HIV","COMP")
151
152 #for blood
153 compart.blood <-as.factor(data3blood$compart);levels(compart.blood)<-c("red",
"yellow")
154 sex.blood <-as.factor(data3blood$SEX);levels(sex.blood)<-c("white","blue","
pink")
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155 h.blood <-as.factor(data3blood$HIV);levels(h.blood)<-c("green","orange","
white")
156 lowcd.blood <-as.factor(data3blood$CD4 <200);levels(lowcd.blood)<-c("white","
black")
157 cd4.blood <-as.factor(data3blood$CD4);levels(cd4.blood)<-sequential_hcl(28, h
=100,c = 100, power = 1.2)
158 hd.blood <-as.factor(data3blood$ECP);levels(hd.blood)<-brewer.pal(3,"Set1")
159 tbs.blood <-as.factor(data3blood$TB.PC);levels(tbs.blood)<-brewer.pal(3,"Set2
")
160 tbc.blood <-as.factor(data3blood$PCF.TB.culture);levels(tbc.blood)<-brewer.
pal(4,"Set3")
161 fluid.blood <-as.factor(data3blood$Fluid);levels(fluid.blood)<-c("white","
white","red","pink","yellow")
162 phenomatrix.blood <-matrix(cbind(as.character(h.blood),as.character(lowcd.
blood)),ncol =2)
163 colnames(phenomatrix.blood)<-c("HIV","low CD4")
164
165 #for fluid
166 compart.fluid <-as.factor(data3fluid$compart);levels(compart.fluid)<-c("red",
"yellow")
167 sex.fluid <-as.factor(data3fluid$SEX);levels(sex.fluid)<-c("white","blue","
pink")
168 h.fluid <-as.factor(data3fluid$HIV);levels(h.fluid)<-c("green","orange","
white")
169 lowcd.fluid <-as.factor(data3fluid$CD4 <200);levels(lowcd.fluid)<-c("white","
black")
170 cd4.fluid <-as.factor(data3fluid$CD4);levels(cd4.fluid)<-sequential_hcl(28, h
=100,c = 100, power = 1.2)
171 hd.fluid <-as.factor(data3fluid$ECP);levels(hd.fluid)<-brewer.pal(3,"Set1")
172 tbs.fluid <-as.factor(data3fluid$TB.PC);levels(tbs.fluid)<-brewer.pal(3,"Set2
")
173 tbc.fluid <-as.factor(data3fluid$PCF.TB.culture);levels(tbc.fluid)<-brewer.
pal(4,"Set3")
174 fluid.fluid <-as.factor(data3fluid$Fluid);levels(fluid.fluid)<-c("white","
white","red","pink","yellow")
175 phenomatrix.fluid <-matrix(cbind(as.character(h.fluid),as.character(lowcd.
fluid)),ncol =2)
176 colnames(phenomatrix.fluid)<-c("HIV","low CD4")
177 #Unfiltered data ####
178 #datamat <-as.matrix(data3 [,-40:-1])
179 #rownames(datamat)<-data3$ID2
180 #transform RT-PCR data to LFC
181 #datamat=log10 (2^- datamat)
182 #Normalization methods ####
183 #datamat <-t(normalizeQuantileRank.matrix(t(datamat),robust=TRUE))
184 #datamat <-t(normalizeQuantile(t(datamat)))
185 #datamat <-t(normalizeBetweenArrays(t(datamat)))
186 #datamat <-t(normalizeMedianValues(t(datamat)))
187 #datamat <-t(normalizeAverage.matrix(t(datamat)))
188
189 # #Start here: separate quantile normalization of blood and fluid , then
combining to one matrix which is median scaled , then transformed to
expression levels ####
190 bloodmat <-as.matrix(data3blood [,-40:-1])
191 rownames(bloodmat)<-data3blood$ID2
192 # bloodmatN <-t(normalizeQuantileRank.matrix(t(bloodmat),robust=TRUE))
193 # #bloodmatN <-t(normalizeBetweenArrays(t(bloodmat),method =" quantile "))
194 # #bloodmatN=log10(2^- bloodmatN)
195 #
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196 fluidmat <-as.matrix(data3fluid [,-40:-1])
197 rownames(fluidmat)<-data3fluid$ID2
198 # fluidmatN <-t(normalizeQuantileRank.matrix(t(fluidmat),robust=TRUE))
199 # #fluidmatN <-t(normalizeBetweenArrays(t(fluidmat),method =" quantile "))
200 # #fluidmatN=log10 (2^- fluidmatN)
201 #
202 # datamat <-rbind(bloodmatN ,fluidmatN)
203 # datamat <-t(normalizeMedianValues(t(datamat)))
204
205 #not normalized at all (argument for this approach is that all values are
normalized to beta Actin already , which is universally constant):
206 datamat <-rbind(bloodmat ,fluidmat)
207
208 #transformation
209 datamat=log10 (2^- datamat)
210
211 ref.min <-min(datamat)
212 ref.max <-max(datamat)
213
214 #phenomatrix ####
215 phenomatrix=cbind(c(rep("red" ,27),rep("yellow" ,27)),c(rep("red" ,27),rep("
yellow" ,27)))
216 calphenomatrix=rbind(c("blue","blue"),c("blue","blue"),phenomatrix)
217 #gene categories
218 cv=c(rep("red" ,8),rep("green" ,2),rep("yellow" ,3),rep("blue" ,3),rep("white"
,5),rep("purple" ,3),rep("pink" ,7),rep("gray" ,11))
219 genecol=matrix(c(cv ,cv),ncol =2)
220 rownames(genecol)<-colnames(datamat)
221
222 ##Unfiltered raw data: Boxplots ####
223
224 figure <-1
225 setwd(dir.figures)
226
227 par(parbackup)
228 boxplot(datamat~factor(c(rep("blood",nrow(data3)/2),rep("fluid",nrow(data3)/
2))),col=c("red","yellow"),main="Overall expression values for blood and
pericardial fluid")
229 export.plot(file.prefix=paste("fig",figure ,".","boxplot overall expression
blood and fluid"),export.formats=export.formats.plots ,height=height*1.5,
width =(1 + sqrt (5))/2*height*1.5)
230 figure <-figure +1
231
232 m.blood <-median(datamat [1:27 ,])
233 m.fluid <-median(datamat [28:54 ,])
234 blood.fluid.overall.comparison <-wilcox.test(datamat~factor(c(rep("blood",
nrow(data3)/2),rep("fluid",nrow(data3)/2))))
235
236 boxplot(t(datamat),las=2,col=c(rep("red",nrow(data3)/2),rep("yellow",nrow(
data3)/2)),main="Boxplot of expression values by sample")
237 export.plot(file.prefix=paste("fig",figure ,".","boxplot overall expression
blood and fluid"),export.formats=export.formats.plots ,height=height*1.5,
width =(1 + sqrt (5))/2*height*1.5)
238 figure <-figure +1
239
240 npar <-par(mar=c(6,3,3,19),xpd=TRUE)
241
242 boxplot(datamat ,las=2,col=cv,main="Expression in blood and fluid")
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243 legend (45,-5,c("TH1","TH2","TH17","Immunoregulation","Neutrophil","Growth
factors","Fibrosis","MMPs"),fill=c("red","green","yellow","blue","white"
,"purple","pink","gray"),cex =.8)
244 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
245 figure <-figure +1
246
247 boxplot(datamat [1:27,],las=2,col=cv ,main="Expression in blood")
248 legend (45,-5,c("TH1","TH2","TH17","Immunoregulation","Neutrophil","Growth
factors","Fibrosis","MMPs"),fill=c("red","green","yellow","blue","white"
,"purple","pink","gray"),cex =.8)
249 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
250 figure <-figure +1
251
252 boxplot(datamat [28:54,], las=2,col=cv ,main="Expression in fluid")
253 legend (45,-5,c("TH1","TH2","TH17","Immunoregulation","Neutrophil","Growth
factors","Fibrosis","MMPs"),fill=c("red","green","yellow","blue","white"
,"purple","pink","gray"),cex =.8)
254 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
255 figure <-figure +1
256
257 ord <-interleave(seq(1,42),seq (43 ,84))
258 newdat <-cbind(datamat [1:27,], datamat [28:54 ,])
259 boxplot(newdat[,ord],col=c("red","yellow"),las=2,main="Expression levels of
all genes")
260 legend (89,-5,c("blood","fluid"),fill=c("red","yellow"),cex =.8)
261 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
262 figure <-figure +1
263
264 npar <-par(mar=c(5,3,3,3),xpd=TRUE ,mfrow=c(2,2))
265
266 boxplot(newdat[,ord ][,1:16], col=c("red","yellow"),ylab="expression",las=2,
main="TH1")
267 boxplot(newdat[,ord ][ ,17:20] , col=c("red","yellow"),ylab="expression",las=2,
main="TH2")
268 boxplot(newdat[,ord ][ ,21:26] , col=c("red","yellow"),ylab="expression",las=2,
main="TH17")
269 boxplot(newdat[,ord ][ ,27:32] , col=c("red","yellow"),ylab="expression",las=2,
main="Immunoregulation")
270 #legend (" bottomleft",c(" blood","fluid "),fill=c("red","yellow "),cex=.8, horiz=
T)
271 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
272 figure <-figure +1
273
274 boxplot(newdat[,ord ][ ,33:42] , col=c("red","yellow"),ylab="expression",las=2,
main="Neutrophil")
275 boxplot(newdat[,ord ][ ,43:48] , col=c("red","yellow"),ylab="expression",las=2,
main="Growth factors")
276 boxplot(newdat[,ord ][ ,49:62] , col=c("red","yellow"),ylab="expression",las=2,
main="Fibrosis")
277 boxplot(newdat[,ord ][ ,63:84] , col=c("red","yellow"),ylab="expression",las=2,
main="MMPs")
278 #legend (15.5,-10,c("blood","fluid "),fill=c("red","yellow "))par(parbackup)
279 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*1.5, width =(1 + sqrt (5))/2*height*1.5)
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280
281 figure <-figure +1
282 par(parbackup)
283
284
285 npar <-par(mar=c(5.5,3,3,3),xpd=TRUE ,mfrow=c(4,2))
286
287 boxplot(newdat[,ord][,1:16], col=c("red","yellow"),ylab="expression",las=2,
main="TH1")
288 boxplot(newdat[,ord ][ ,17:20] , col=c("red","yellow"),ylab="expression",las=2,
main="TH2")
289 boxplot(newdat[,ord ][ ,21:26] , col=c("red","yellow"),ylab="expression",las=2,
main="TH17")
290 boxplot(newdat[,ord ][ ,27:32] , col=c("red","yellow"),ylab="expression",las=2,
main="Immunoregulation")
291 #legend (" bottomleft",c(" blood","fluid "),fill=c("red","yellow "),cex=.8, horiz=
T)
292
293 boxplot(newdat[,ord ][ ,33:42] , col=c("red","yellow"),ylab="expression",las=2,
main="Neutrophil")
294 boxplot(newdat[,ord ][ ,43:48] , col=c("red","yellow"),ylab="expression",las=2,
main="Growth factors")
295 boxplot(newdat[,ord ][ ,49:62] , col=c("red","yellow"),ylab="expression",las=2,
main="Fibrosis")
296 boxplot(newdat[,ord ][ ,63:84] , col=c("red","yellow"),ylab="expression",las=2,
main="MMPs")
297 #legend (15.5,-10,c("blood","fluid "),fill=c("red","yellow "))par(parbackup)
298 export.plot(file.prefix=paste("fig",figure ,".","boxplot"),export.formats=
export.formats.plots ,height=height*3,width =(1 + sqrt (5))/2*height*1.5)
299
300 figure <-figure +1
301 par(parbackup)
302
303 genes <-colnames(datamat)
304 pvals.gene.by.compartment <-vector ()
305 for (i in 1:42){
306 pvals.gene.by.compartment[i]<-wilcox.test(datamat [1:27,i],datamat [28:54 ,i
])$p.value
307 }
308 bonf <-p.adjust(pvals.gene.by.compartment ,method="bonferroni")
309 bh<-p.adjust(pvals.gene.by.compartment ,method="BH")
310
311 simple.comp.results <-data.frame(genes ,pvals.gene.by.compartment ,bonf ,bh)
312 write.csv(simple.comp.results ,file.path(dir.results ,"genes_by_compartment.
csv"))
313
314 # FIGURE 1 A: Clustered raw data heatmaps (microarray style) ####
315 #heatmap.plus(t(datamat),scale="none",ColSideColors=phenomatrix ,
RowSideColors=genecol ,col=redgreen (30),cexCol =1.2, cexRow=1,margins=c
(10 ,30))
316 par(parbackup)
317 heatmap.plus(t(datamat),scale="none",ColSideColors=phenomatrix ,col=redgreen
(30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
318 #HC using euclidean distance , complete linkage
319 s=round(seq(from=min(datamat),to=max(datamat),by=1) ,1)
320 colvec=redgreen(length(s))
321 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
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323
324 #experimental: calibrated heatmap
325 nr<-nrow(t(datamat))
326 hi<-rep(ref.max ,nr)
327 lo<-rep(ref.min ,nr)
328 caldata <-cbind(hi ,lo ,t(datamat))
329 heatmap.plus(caldata ,scale="none",ColSideColors=calphenomatrix ,col=redgreen
(30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
330 s=round(seq(from=min(datamat),to=max(datamat),by=1) ,1)
331 colvec=redgreen(length(s))
332 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
333 export.plot(file.prefix=paste("fig",figure ,".","all_genes_heatmap"),export.
formats=export.formats.plots ,height=height*1.5,width =(1 + sqrt (5))/2*
height*1.5)
334 figure <-figure +1
335
336 par(parbackup)
337 # FIGURE 1 B and C: Correlation matrices ####
338 #GENES
339 #the gene expression levels are both positively and negatively correlated
340 #cormat <-cor(datamat ,method =" pearson ")
341 #heatmap_2(cormat ,col=redgreen (300) ,scale="none",legend=2,legfrac=8,trim
=.01)
342
343 cormatB <-cor(bloodmat ,method="pearson")
344 #heatmap_2(cormatB ,col=bluered (34),scale ="none",legend=2,legfrac =8)
345 heatmap .2( cormatB ,col=bluered (34),symkey=F,symbreaks=T,trace="none",density.
info="none")
346 export.plot(file.prefix=paste("fig",figure ,".","cormat_B"),export.formats=
export.formats.plots ,height=height*1.5, width=height*1.5)
347 figure <-figure +1
348
349 cormatF <-cor(fluidmat ,method="pearson")
350 #heatmap_2(cormatF ,col=bluered (34),scale ="none",legend=2,legfrac =8)
351 heatmap .2( cormatF ,col=bluered (34),symkey=F,symbreaks=T,trace="none",density.
info="none")
352 export.plot(file.prefix=paste("fig",figure ,".","cormat_F"),export.formats=
export.formats.plots ,height=height*1.5, width=height*1.5)
353 figure <-figure +1
354
355 library(plotrix)
356 cormatB2 <-rescale(cormatB ,c(-1,1))
357
358 #Data filtering step ####
359
360 #non -specific filtering: all
361 ct=38
362 f1<-kOverA(floor (.95*nrow(datamat)),log(2^-ct ,10))
363 flist <-filterfun(f1)
364 ans <-genefilter(t(datamat),flist)
365 datamat.filter <-t(t(datamat)[ans ,])
366
367 f2<-kOverA(floor (.95*nrow(datamat [1:27 ,])),log(2^-ct ,10))
368 flist.blood <-filterfun(f2)
369 ans.blood <-genefilter(t(datamat [1:27 ,]),flist.blood)
370 bloodmat.filter <-t(t(datamat [1:27 ,])[ans.blood ,])
371
372 f3<-kOverA(floor (.95*nrow(datamat [28:54 ,])),log(2^-ct ,10))
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373 flist.fluid <-filterfun(f3)
374 ans.fluid <-genefilter(t(datamat [28:54 ,]),flist.fluid)
375 fluidmat.filter <-t(t(datamat [28:54 ,])[ans.fluid ,])
376 #FIGURE S1A Clustered raw data heatmaps (microarray style) ## Filtered raw
data ####
377 par(parbackup)
378 #heatmap.plus(t(datamat),scale="none",ColSideColors=phenomatrix ,
RowSideColors=genecol ,col=redgreen (30),cexCol =1.2, cexRow=1,margins=c
(10 ,30))
379 heatmap.plus(t(datamat.filter),scale="none",ColSideColors=phenomatrix ,col=
redgreen (30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
380 #HC using euclidean distance , complete linkage
381 s=round(seq(from=min(datamat.filter),to=max(datamat.filter),by=1) ,1)
382 colvec=redgreen(length(s))
383 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
384
385
386 nr.filter <-nrow(t(datamat.filter))
387 hi.filter <-rep(ref.max ,nr.filter)
388 lo.filter <-rep(ref.min ,nr.filter)
389 caldata.filter <-cbind(hi.filter ,lo.filter ,t(datamat.filter))
390 heatmap.plus(caldata.filter ,scale="none",ColSideColors=calphenomatrix ,col=
redgreen (30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
391 s=round(seq(from=min(datamat),to=max(datamat),by=1) ,1)
392 colvec=redgreen(length(s))
393 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
394 export.plot(file.prefix=paste("fig",figure ,".","filtered_genes_heatmap"),
export.formats=export.formats.plots ,height=height*1.5, width =(1 + sqrt (5)
)/2*height*1.5)
395 figure <-figure +1
396
397 #FIGURE S1 B and C: Correlation matrices ## Filtered raw data ####
398 #GENES
399 #the gene expression levels are both positively and negatively correlated
400
401 cormatB.filter <-cor(bloodmat.filter ,method="pearson")
402 heatmap_2( cormatB.filter ,col=bluered (34),scale="none",legend=2,legfrac =8)
403 export.plot(file.prefix=paste("fig",figure ,".","filtered_genes_
correlationMatrix_blood"),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
404 figure <-figure +1
405
406 cormatF.filter <-cor(fluidmat.filter ,method="pearson")
407 heatmap_2( cormatF.filter ,col=bluered (34),scale="none",legend=2,legfrac=8,
trim =.01)
408 export.plot(file.prefix=paste("fig",figure ,".","filtered_genes_
correlationMatrix_fluid"),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
409 figure <-figure +1
410
411 #Moderated test statistics for blood versus fluid ####
412
413 #Design and contrast matrices for all samples and subsets
414 comp <-as.factor(c(rep("Blood" ,27),rep("Fluid" ,27)))
415 design=model.matrix(~ -1+factor(comp))
416 colnames(design)<-levels(comp)
417 design
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418 contrast <-makeContrasts(Fluid -Blood ,levels=design)
419 contrast
420
421 #Linear model: blood vs fluid
422 fit <-lmFit(t(datamat.filter),design)
423 fit2 <-contrasts.fit(fit ,contrast)
424 fit2 <-eBayes(fit2)
425
426 par(parbackup)
427 gr<-decideTests(fit2 ,adjust.method="none")
428 vennDiagram(gr)
429 vc<-vennCounts(gr)
430
431 gr2 <-decideTests(fit2 ,adjust.method="fdr")
432 vc2 <-vennCounts(gr2)
433 vennDiagram(gr2)
434 #Results ####
435 #DE
436 result1 <-topTable(fit2 ,number=vc2[,2][2], adjust.method="BH",coef=1,sort.by="
P",resort.by="logFC")
437 result1
438 #FIGURE 4: Volcano plot ####
439 par(parbackup)
440 volcanoplot(fit2 ,coef=1,highlight=vc2[,2][2],cex=1,pch=20,col="red")
441 abline(v=0,col="blue",lty="dashed")
442 export.plot(file.prefix=paste("fig",figure ,".","selected_genes_volcanoPlot")
,export.formats=export.formats.plots ,height=height*1.5, width =(1 + sqrt
(5))/2*height*1.5)
443 figure <-figure +1
444 #Table 2 and full result tables ####
445
446 resultFullTable <-xtable(result1 ,digits=c(NA,NA ,2,3,-3,-3,2))
447 write.csv(resultFullTable ,file.path(dir.results ,"SelectedGeneTopTableFull.
csv"))
448
449 #Table 2
450 result1table <-xtable(result1[,c(1,2,4,5)],digits=c(NA,NA ,2,-3,-3))
451 write.csv(result1table ,file.path(dir.results ,"SelectedGeneTopTable.csv"))
452 #print(result1table ,floating=FALSE ,include.rownames=FALSE)
453
454 #FIGURE 2A: Clustered result data heatmap (microarray style) results ####
455 par(parbackup)
456 heatmap.plus(t(datamat.filter)[result1$ID ,],scale="none",ColSideColors=
phenomatrix ,col=redgreen (30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
457 #HC using euclidean distance , complete linkage
458 s=round(seq(from=min(datamat.filter[,result1$ID]),to=max(datamat.filter[,
result1$ID]),by=1) ,1)
459 colvec=redgreen(length(s))
460 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
461
462 nr.select <-nrow(t(datamat.filter)[result1$ID ,])
463 hi.select <-rep(ref.max ,nr.select)
464 lo.select <-rep(ref.min ,nr.select)
465 caldata.select <-cbind(hi.select ,lo.select ,t(datamat.filter)[result1$ID ,])
466 heatmap.plus(caldata.select ,scale="none",ColSideColors=calphenomatrix ,col=
redgreen (30),cexCol =1.2, cexRow=1,margins=c(10 ,24))
467 s=round(seq(from=min(datamat),to=max(datamat),by=1) ,1)
468 colvec=redgreen(length(s))
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469 legend("right",as.character(s), fill=colvec , ncol = 1, cex = .8,y.intersp
=.8, title="LFC")
470 export.plot(file.prefix=paste("fig",figure ,".","selected_genes_heatmap"),
export.formats=export.formats.plots ,height=height*1.5, width =(1 + sqrt (5)
)/2*height*1.5)
471 figure <-figure +1
472
473 #FIGURE 2 B and C: Correlation matrices for selected genes ####
474
475 cormatB.select <-cor(bloodmat.filter[,result1$ID],method="pearson")
476 heatmap_2( cormatB.select ,col=bluered (34),scale="none",legend=2,legfrac=8,
trim =.01)
477 export.plot(file.prefix=paste("fig",figure ,".","selected_genes_
correlationMatrix_blood"),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
478 figure <-figure +1
479
480 cormatF.select <-cor(fluidmat.filter[,result1$ID],method="pearson")
481 heatmap_2( cormatF.select ,col=bluered (34),scale="none",legend=2,legfrac=8,
trim =.01)
482 export.plot(file.prefix=paste("fig",figure ,".","selected_genes_
correlationMatrix_fluid"),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
483 figure <-figure +1
484
485 #FIGURE 3 PCA (oompa package)####
486 par(parbackup)
487 par(mfrow=c(1,3),mar=c(10,10,6,6))
488 par(xaxt="s")
489
490 #all genes
491 l=rownames(datamat)
492 trueClasses <- as.factor(comp)
493 spca <- SamplePCA(t(datamat), trueClasses)
494 plot(spca , col = c("red", "blue"),main="All genes",cex=2,cex.axis=2,cex.main
=3,cex.lab =2.5)
495 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
496 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
497 # mark the group centers
498 x1 <- predict(spca , matrix(apply(t(datamat[grep("b",rownames(datamat)) ,]),
1, mean), ncol =1))
499 points(x1[1], x1[2], col=’red’, cex=6,pch=9)
500 x2 <- predict(spca , matrix(apply(t(datamat[grep("f",rownames(datamat)) ,]),
1, mean), ncol =1))
501 points(x2[1], x2[2], col=’blue’, cex=6,pch=9)
502
503 #filtered genes
504 l=rownames(datamat.filter)
505 trueClasses1 <- as.factor(comp)
506 spca1 <- SamplePCA(t(datamat.filter), trueClasses1)
507 plot(spca1 , col = c("red", "blue"),main="Filtered genes",cex=2,cex.axis=2,
cex.main=3,cex.lab =2.5)
508 mtext(sprintf("%.2f",spca1@variances [1]/sum(spca1@variances)),side=1,line=3,
adj=1,cex =1.5)
509 mtext(sprintf("%.2f",spca1@variances [2]/sum(spca1@variances)),side=2,line=3,
adj=1,cex =1.5)
510 # mark the group centers
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511 x1 <- predict(spca1 , matrix(apply(t(datamat.filter[grep("b",rownames(datamat
)) ,]), 1, mean), ncol =1))
512 points(x1[1], x1[2], col=’red’, cex=6,pch=9)
513 x2 <- predict(spca1 , matrix(apply(t(datamat.filter[grep("f",rownames(datamat
)) ,]), 1, mean), ncol =1))
514 points(x2[1], x2[2], col=’blue’, cex=6,pch=9)
515
516 #selected genes
517 trueClasses2 <- as.factor(comp)
518 spca2 <- SamplePCA(t(datamat.filter)[result1$ID ,], trueClasses2)
519 plot(spca2 , col = c("red", "blue"),main="Selected genes",cex=2,cex.axis=2,
cex.main=3,cex.lab =2.5)
520 mtext(sprintf("%.2f",spca2@variances [1]/sum(spca2@variances)),side=1,line=3,
adj=1,cex =1.5)
521 mtext(sprintf("%.2f",spca2@variances [2]/sum(spca2@variances)),side=2,line=3,
adj=1,cex =1.5)
522 # mark the group centers
523 x1 <- predict(spca2 , matrix(apply(t(datamat.filter[grep("b",rownames(datamat
)) ,])[result1$ID ,], 1, mean), ncol =1))
524 points(x1[1], x1[2], col=’red’, cex=6,pch=9)
525 x2 <- predict(spca2 , matrix(apply(t(datamat.filter[grep("f",rownames(datamat
)) ,])[result1$ID ,], 1, mean), ncol =1))
526 points(x2[1], x2[2], col=’blue’, cex=6,pch=9)
527
528
529 sprintf("%.10f" ,0.25)
530
531 export.plot(file.prefix=paste("fig",figure ,".","PCA of 3 data subsets"),
export.formats=export.formats.plots ,height=height*1.5, width=2*(1 + sqrt
(5))/2*height*1.5)
532 figure <-figure +1
533
534 par(parbackup)
535 #screeplot(spca)
536 #screeplot(spca1)
537 #screeplot(spca1 ,type=" lines")
538 #screeplot(spca2)
539
540 #TABLE S1: Phenodata
541
542 phenodataTS2 <-phenodata[,c(2,4,5,12,13,15,14,26,27,28,35,36,37,38)]
543 write.csv(phenodataTS2 ,file.path(dir.results ,"TABLES2.csv"))
544 #pdat <-xtable(phenodataTS2)
545 #print(pdat)
546
547
548 #Protein
549
550 subjects <-rownames(datamat)
551 #Blood only
552 data3blood.prot <-data3.prot[data3.prot$compart =="blood" ,]
553 #Fluid only
554 data3fluid.prot <-data3.prot[data3.prot$compart =="fluid" ,]
555
556 bloodmat.p<-matrix(as.numeric(as.matrix(data3blood.prot [,-40:-1])),nrow =25)
557 rownames(bloodmat.p)<-data3blood.prot$SampleID
558 fluidmat.p<-matrix(as.numeric(as.matrix(data3fluid.prot [,-40:-1])),nrow =25)
559 rownames(fluidmat.p)<-data3fluid.prot$SampleID
560
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561 datamat.p<-as.matrix(rbind(bloodmat.p,fluidmat.p))
562 colnames(datamat.p)<-c("IL1B","IL6","IL18","TNF","IFNG","CXCL10","IL13","
IL17","IL22","IL23A","TGFB1","IL10","IL8","IL12P70","GAL3","ACSDKP","
TIMP1","TIMP2","MMP2TIMP1","MMP9TIMP2","MMP1","MMP2","MMP3","MP7","MMP8"
,"MMP9")
563
564 datamat.p.sel <-datamat.p[,is.element(colnames(datamat.p),result1$ID)]
565 ord.p<-interleave(seq(1,9),seq (10 ,18))
566 newdat.p<-cbind(datamat.p.sel[1:25,], datamat.p.sel [26:50 ,])
567 par(parbackup)
568 boxplot(newdat.p[,ord.p],col=c("red","yellow"),las=2,main="Levels of 9
proteins")
569 legend("topright",c("blood","fluid"),fill=c("red","yellow"),cex =.8)
570
571 datamat.p.notsel <-datamat.p[,!is.element(colnames(datamat.p),result1$ID)]
572 ord.p.notsel <-interleave(seq (1 ,17),seq (18 ,34))
573 newdat.p.notsel <-cbind(datamat.p.notsel [1:25,], datamat.p.notsel [26:50 ,])
574 par(parbackup)
575 boxplot(newdat.p.notsel[,ord.p.notsel],col=c("red","yellow"),las=2,main="
Levels of other proteins")
576 legend("topright",c("blood","fluid"),fill=c("red","yellow"),cex =.8)
577
578 #plot both on one page (log10 scale)
579 par(mfrow=c(2,1))
580 boxplot(log10(newdat.p[,ord.p]+1),col=c("red","yellow"),las=2,main="Levels
of 9 proteins (where mRNA was DE)")
581 legend("topleft",c("bl","fl"),fill=c("red","yellow"),cex =.7)
582 boxplot(log10(newdat.p.notsel[,ord.p.notsel ]+1),col=c("red","yellow"),las=2,
main="Levels of other proteins (where mRNA was not DE)")
583 legend("topleft",c("bl","fl"),fill=c("red","yellow"),cex =.7)
584 par(parbackup)
585 export.plot(file.prefix=paste("fig",figure ,".","boxplots of proteins by
compartment"),export.formats=export.formats.plots ,height=height*1.5,
width =(1 + sqrt (5))/2*height*1.5)
586 figure <-figure +1
587
588 proteins <-colnames(datamat.p)
589 pvals.protein.by.compartment <-vector ()
590 for (i in 1:26){
591 try(pvals.protein.by.compartment[i]<-wilcox.test(datamat.p[1:25,i],datamat
.p[26:50 ,i])$p.value)
592 }
593 bonf.prot <-p.adjust(pvals.protein.by.compartment ,method="bonferroni")
594 bh.prot <-p.adjust(pvals.protein.by.compartment ,method="BH")
595 simple.comp.results.prot <-data.frame(proteins ,pvals.protein.by.compartment ,
bonf.prot ,bh.prot)
596 write.csv(simple.comp.results.prot ,file.path(dir.results ,"proteins_by_
compartment.csv"))
597
598 proteins.sel <-colnames(datamat.p.sel)
599 pvals.protein.by.compartment.sel <-vector ()
600 for (i in 1:ncol(datamat.p.sel)){
601 try(pvals.protein.by.compartment.sel[i]<-wilcox.test(datamat.p.sel [1:25,i
],datamat.p.sel [26:50 ,i])$p.value)
602 }
603 bonf.prot.sel <-p.adjust(pvals.protein.by.compartment.sel ,method="bonferroni"
)
604 bh.prot.sel <-p.adjust(pvals.protein.by.compartment.sel ,method="BH")
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605 simple.comp.results.prot.sel <-data.frame(proteins.sel ,pvals.protein.by.
compartment.sel ,bonf.prot.sel ,bh.prot.sel)
606 write.csv(simple.comp.results.prot.sel ,file.path(dir.results ,"selected_
proteins_by_compartment.csv"))
607
608 proteins.notsel <-colnames(datamat.p.notsel)
609 pvals.protein.by.compartment.notsel <-vector ()
610 for (i in 1:ncol(datamat.p.notsel)){
611 try(pvals.protein.by.compartment.notsel[i]<-wilcox.test(datamat.p.notsel
[1:25,i],datamat.p.notsel [26:50 ,i])$p.value)
612 }
613 bonf.prot.notsel <-p.adjust(pvals.protein.by.compartment.notsel ,method="
bonferroni")
614 bh.prot.notsel <-p.adjust(pvals.protein.by.compartment.notsel ,method="BH")
615 simple.comp.results.prot.notsel <-data.frame(proteins.notsel ,pvals.protein.by
.compartment.notsel ,bonf.prot.notsel ,bh.prot.notsel)
616 write.csv(simple.comp.results.prot.notsel ,file.path(dir.results ,"non_
selected_proteins_by_compartment.csv"))
617
618 #median ratios of proteins
619 apply(datamat.p.sel[26:50,],2,median ,na.rm=T)/apply(datamat.p.sel[1:25,],2,
median ,na.rm=T)
620
621 #THE END OF TABLES AND FIGURES FOR THE PAPER ####
622 #NOTHING BELOW IS SHOWN IN PAPER BUT LACK OF HIV EFFECT NEEDS TO BE
MENTIONED!
623
624 #Moderated test statistics for blood ONLY ####
625
626 #Contrast for blood
627 #HIV status
628 comp <-as.factor(data3blood$HIV)
629 levels(comp)<-c("Neg","Pos")
630 design=model.matrix(~ -1+factor(comp))
631 colnames(design)<-levels(comp)
632 design
633 contrast <-makeContrasts(Pos -Neg ,levels=design)
634 contrast
635
636 #Linear model: blood
637 fit <-lmFit(t(bloodmat.filter),design)
638 fit2 <-contrasts.fit(fit ,contrast)
639 fit2 <-eBayes(fit2)
640
641 gr<-decideTests(fit2 ,adjust.method="none")
642 vennDiagram(gr)
643 vc<-vennCounts(gr)
644 gr2 <-decideTests(fit2 ,adjust.method="fdr")
645 vc2 <-vennCounts(gr2)
646 vennDiagram(gr2)
647
648 #this shows that 2 genes are DE after BH correction
649
650 #Results
651 #DE without correction
652 result1 <-topTable(fit2 ,number=vc[,2][2], adjust="fdr",coef=1,sort.by="P")
653 result1
654
655 #Clustered result data heatmap (microarray style) blood only ####
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656 heatmap.plus(t(bloodmat.filter)[result1$ID ,],scale="none",ColSideColors=
phenomatrix.blood ,col=redgreen (24))
657
658 #Moderated test statistics for fluid ONLY ####
659
660 #Contrasts and linear models for fluid
661
662 #HIV status
663 comp <-as.factor(data3fluid$HIV)
664 levels(comp)<-c("Neg","Pos")
665 design=model.matrix(~ -1+factor(comp))
666 colnames(design)<-levels(comp)
667 design
668 contrast <-makeContrasts(Pos -Neg ,levels=design)
669 contrast
670
671 fit <-lmFit(t(fluidmat.filter),design)
672 fit2 <-contrasts.fit(fit ,contrast)
673 fit2 <-eBayes(fit2)
674
675 gr<-decideTests(fit2 ,adjust.method="none")
676 vennDiagram(gr)
677 vc<-vennCounts(gr)
678 gr2 <-decideTests(fit2 ,adjust.method="fdr")
679 vc2 <-vennCounts(gr2)
680 vennDiagram(gr2)
681
682 #Low CD4
683 comp <-as.factor(data3fluid$CD4 <200)
684 levels(comp)<-c("high","low")
685 design=model.matrix(~ -1+factor(comp))
686 colnames(design)<-levels(comp)
687 design
688 contrast <-makeContrasts(high -low ,levels=design)
689 contrast
690
691 fit <-lmFit(t(fluidmat.filter),design)
692 fit2 <-contrasts.fit(fit ,contrast)
693 fit2 <-eBayes(fit2)
694
695 gr<-decideTests(fit2 ,adjust.method="none")
696 vennDiagram(gr)
697 vc<-vennCounts(gr)
698 gr2 <-decideTests(fit2 ,adjust.method="fdr")
699 vc2 <-vennCounts(gr2)
700 vennDiagram(gr2)
701
702 #Results: Nothing is DE by HIV status or low CD4. The genes are not HIV
genes ...
Listing A.8: RT-PCR code
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A.5 Relation of IMPI-MA data to BERRY dataset
1 ##TO DO
2 #1. table 1
3 #2. export probe lists (not annotated)
4 #3. annotate probe lists and export
5
6 #setup ####
7 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/06_IMPI -MA/Analysis/00_System/System
_setup.R")
8 source(file.path(dir.R.files ,"superHeatmap.R"))
9 par("xpd"=FALSE)
10 ## Individual data folders (specific for each part)
11 dir.rdata <- file.path(dir.data_root ,’09_IMPI_MA_DATA/05_RData’)
12
13 #Output folders
14 dir.home <-dir.root
15 dir.main <- file.path(dir.root , ’02_output/06_IMPI -MA/DifferentialExpression
’,’DE_Baylor ’)
16
17 #Current date string used for versioning output
18 ds<-Sys.time()
19
20 #versioned output
21 dir.output.version <-file.path(dir.main ,paste("version_",ds))
22
23 ## Define folder for storing results NB do this for each analysis
24 dir.results <- file.path(dir.output.version , "results")
25 ## Define folder for saving figures
26 dir.figures <- file.path(dir.output.version , "figures")
27 for (dir in c(dir.main , dir.figures , dir.results)) {
28 if (!file.exists(dir)) {
29 dir.create(dir , recursive=T,showWarnings=T)
30 }
31 }
32
33
34 #sink(type=" output",file=file.path(dir.results ," session_output.txt"))
35 sessionInfo ()
36 print(paste("Begin time:",ds))
37 print(paste("Results will be saved to", dir.results))
38
39
40 print(paste("Figures will be saved to", dir.figures))
41
42
43
44 #load data ####
45 load(file.path(dir.rdata ,’berry_train.RData ’))
46 load(file.path(dir.rdata ,’berry_val.RData’))
47 load(file.path(dir.rdata ,’blood_hivNeg_aTB_noTB.RData’))
48
49
50 #Average Normalization
51 #This replicates the data output by GenomeStudio , starting with raw , non -
normalized summary data
52
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53 datalist <-list("SA blood IMPI hiv neg"=B.N.AX ,"SA blood VAL hiv neg"=berry.
val ,"Berry Training Set"=berry.train)
54 #scaling normalization (as in SOFT data)
55 for (i in 1: length(datalist)){
56 datalist [[i]]<-ssn(datalist [[i]],scaling=TRUE ,bgMethod=’none’,fgMethod=’mean
’)
57 }
58
59 ########################################.
60
61 #Make Table 1####
62 ########################################.
63
64 #Table 1: Compare groups across the 3 sets ####
65
66 ##### ALL
67 agedata <-list(as.numeric(pData(berry.train)$age),
68 as.numeric(pData(berry.val)$age),
69 as.numeric(pData(B.N.AX)$AGE_CALC))
70
71 lapply(agedata ,length)
72
73 lapply(agedata ,summary)
74 kruskal.test(agedata)
75
76 sexdata <-matrix(
77 rbind(
78 table(pData(berry.train)$sex),
79 table(pData(berry.val)$sex),
80 table(pData(B.N.AX)$SEX)
81 ),ncol =2)
82 rownames(sexdata)<-c("Berry.train","Berry.val","B.N.AX");colnames(sexdata)<-
c("Female","Male")
83 prop.test(sexdata)
84
85 table(pData(berry.train)$CrudeEthnicity)
86 table(pData(berry.val)$CrudeEthnicity)
87 table(pData(B.N.AX)$ETHNICITY)
88
89 ethnicity <-matrix(
90 rbind(
91 c(11,17,7,6,0,0,1),
92 c(51,0,0,0,0,0,0),
93 c(21,0,0,0,0,1,0)
94 ),ncol =7)
95 rownames(ethnicity)<-c("Berry.train","Berry.val","B.N.AX");colnames(
ethnicity)<-c("Black","White","Asian other","South Asian","Coloured","
Indian","Other")
96 fisher.test(ethnicity ,simulate.p.value=TRUE)
97
98 table(pData(berry.train)$threeclass)
99 table(pData(berry.val)$threeclass)
100 table(pData(B.N.AX)$class)
101
102 twoclass <-matrix(
103 rbind(
104 c(13 ,29),
105 c(20 ,31),
106 c(12 ,10)
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107 ),ncol =2)
108 colnames(twoclass)<-c("Active TB","Not active TB")
109 rownames(twoclass)<-c("Berry.train","Berry.val","B.N.AX")
110 prop.test(twoclass)
111
112 fourclass <-matrix(
113 rbind(
114 c(12,17 ,13 ,0),
115 c(0,31,20,0),
116 c(5,5,4,8)
117 ),ncol =4)
118 colnames(fourclass)<-c("Healthy","LTBI","PTB","TB -PC")
119 rownames(fourclass)<-c("Berry.train","Berry.val","B.N.AX")
120 fisher.test(fourclass ,simulate.p.value=TRUE)
121
122 ##### healthy
123 agedata.h<-list(as.numeric(pData(berry.train)[pData(berry.train)$threeclass
=="Control",]$age),
124 #as.numeric(pData(berry.val)[pData(berry.val)$threeclass =="
Control",]$age),
125 as.numeric(pData(B.N.AX)[pData(B.N.AX)$class =="CON_healthy" ,]$
AGE_CALC))
126
127 lapply(agedata.h,length)
128
129 lapply(agedata.h,summary)
130 kruskal.test(agedata.h)
131
132 tstdata.h<-list(as.numeric(pData(berry.train)[pData(berry.train)$threeclass
=="Control",]$TST),
133 #as.numeric(pData(berry.val)[pData(berry.val)$threeclass =="
Control",]$age),
134 as.numeric(pData(B.N.AX)[pData(B.N.AX)$class =="CON_healthy"
,]$TST))
135
136 lapply(tstdata.h,length)
137
138 lapply(tstdata.h,summary)
139 kruskal.test(tstdata.h)
140
141 sexdata.h<-matrix(
142 rbind(
143 table(pData(berry.train)[pData(berry.train)$threeclass =="Control" ,]$sex)
,
144 #table(pData(berry.val)$sex),
145 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_healthy" ,]$SEX)
146 ),ncol =2)
147 rownames(sexdata.h)<-c("Berry.train","B.N.AX");colnames(sexdata.h)<-c("
Female","Male")
148 prop.test(sexdata.h)
149
150 table(pData(berry.train)[pData(berry.train)$threeclass =="Control" ,]$
CrudeEthnicity)
151 #table(pData(berry.val)$CrudeEthnicity)
152 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_healthy" ,]$ETHNICITY)
153
154 ethnicity.h<-matrix(
155 rbind(
156 c(0,12,0,0,0,0,0),
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157 #c(51,0,0,0,0,0,0),
158 c(5,0,0,0,0,0,0)
159 ),ncol =7)
160 rownames(ethnicity.h)<-c("Berry.train","B.N.AX");colnames(ethnicity.h)<-c("
Black","White","Asian other","South Asian","Coloured","Indian","Other")
161 fisher.test(ethnicity.h,simulate.p.value=TRUE)
162
163
164 ##### LTBI
165 agedata.l<-list(as.numeric(pData(berry.train)[pData(berry.train)$threeclass
=="Latent" ,]$age),
166 as.numeric(pData(berry.val)[pData(berry.val)$threeclass =="
Latent" ,]$age),
167 as.numeric(pData(B.N.AX)[pData(B.N.AX)$class =="CON_LTBI" ,]$
AGE_CALC))
168
169 lapply(agedata.l,length)
170
171 lapply(agedata.l,summary)
172 kruskal.test(agedata.l)
173
174 tstdata.l<-list(as.numeric(pData(berry.train)[pData(berry.train)$threeclass
=="Latent" ,]$TST),
175 as.numeric(pData(berry.val)[pData(berry.val)$threeclass =="
Latent" ,]$TST),
176 as.numeric(pData(B.N.AX)[pData(B.N.AX)$class =="CON_LTBI" ,]$
TST))
177
178 lapply(tstdata.l,length)
179
180 lapply(tstdata.l,summary)
181 kruskal.test(tstdata.l)
182
183 sexdata.l<-matrix(
184 rbind(
185 table(pData(berry.train)[pData(berry.train)$threeclass =="Latent" ,]$sex),
186 table(pData(berry.val)[pData(berry.val)$threeclass =="Latent" ,]$sex),
187 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_LTBI" ,]$SEX)
188 ),ncol =2)
189 rownames(sexdata.l)<-c("Berry.train","Berry.val","B.N.AX");colnames(sexdata.
l)<-c("Female","Male")
190 prop.test(sexdata.l)
191
192 table(pData(berry.train)[pData(berry.train)$threeclass =="Latent" ,]$
CrudeEthnicity)
193 table(pData(berry.val)[pData(berry.val)$threeclass =="Latent" ,]$
CrudeEthnicity)
194 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_LTBI" ,]$ETHNICITY)
195
196 ethnicity.l<-matrix(
197 rbind(
198 c(7,2,5,3,0,0,0),
199 c(31,0,0,0,0,0,0),
200 c(5,0,0,0,0,0,0)
201 ),ncol =7)
202 rownames(ethnicity.l)<-c("Berry.train","Berry.val","B.N.AX");colnames(
ethnicity.l)<-c("Black","White","Asian other","South Asian","Coloured","
Indian","Other")
203 fisher.test(ethnicity.l,simulate.p.value=TRUE)
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204
205 #####TB
206 agedata.t<-list(as.numeric(pData(berry.train)[pData(berry.train)$threeclass
=="PTB" ,]$age),
207 as.numeric(pData(berry.val)[pData(berry.val)$threeclass =="
PTB",]$age),
208 as.numeric(pData(B.N.AX)[pData(B.N.AX)$class3 =="activeTB" ,]$
AGE_CALC))
209
210 lapply(agedata.t,length)
211
212 lapply(agedata.t,summary)
213 kruskal.test(agedata.t)
214
215 sexdata.t<-matrix(
216 rbind(
217 table(pData(berry.train)[pData(berry.train)$threeclass =="PTB" ,]$sex),
218 table(pData(berry.val)[pData(berry.val)$threeclass =="PTB" ,]$sex),
219 table(pData(B.N.AX)[pData(B.N.AX)$class3 =="activeTB" ,]$SEX)
220 ),ncol =2)
221 rownames(sexdata.t)<-c("Berry.train","Berry.val","B.N.AX");colnames(sexdata.
t)<-c("Female","Male")
222 prop.test(sexdata.t)
223
224 table(pData(berry.train)[pData(berry.train)$threeclass =="PTB" ,]$
CrudeEthnicity)
225 table(pData(berry.val)[pData(berry.val)$threeclass =="PTB" ,]$CrudeEthnicity)
226 table(pData(B.N.AX)[pData(B.N.AX)$class3 =="activeTB" ,]$ETHNICITY)
227
228 ethnicity.t<-matrix(
229 rbind(
230 c(4,3,2,3,0,0,1),
231 c(20,0,0,0,0,0,0),
232 c(11,0,0,0,0,1,0)
233 ),ncol =7)
234 rownames(ethnicity.t)<-c("Berry.train","Berry.val","B.N.AX");colnames(
ethnicity.t)<-c("Black","White","Asian other","South Asian","Coloured","
Indian","Other")
235 fisher.test(ethnicity.l,simulate.p.value=TRUE)
236
237 classdata.t<-matrix(
238 rbind(
239 table(factor(pData(berry.train)[pData(berry.train)$threeclass =="PTB" ,]$
threeclass ,levels=c("PTB","TB -PC"))),
240 table(factor(pData(berry.val)[pData(berry.val)$threeclass =="PTB" ,]$
threeclass ,levels=c("PTB","TB -PC"))),
241 table(pData(B.N.AX)[pData(B.N.AX)$class3 =="activeTB" ,]$class)
242 ),ncol =2)
243 rownames(classdata.t)<-c("Berry.train","Berry.val","B.N.AX");colnames(
classdata.t)<-c("PTB","TB -PC")
244 prop.test(classdata.t)
245
246 tech <-matrix(
247 rbind(
248 table(factor(rep("Tempus" ,42),levels=c("Tempus","paxGene"))),
249 table(factor(rep("Tempus" ,51),levels=c("Tempus","paxGene"))),
250 table(factor(rep("paxGene" ,22),levels=c("Tempus","paxGene")))
251 ),ncol =2)
336
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
A.5 Relation of IMPI-MA data to BERRY dataset
252 rownames(tech)<-c("Berry.train","Berry.val","B.N.AX");colnames(tech)<-c("
Tempus","paxGene")
253 prop.test(tech)
254
255 #Table 1: Compare groups within each set ####
256
257 #age
258 #train
259 age.train <-list(agedata.h[[1]], agedata.l[[1]], agedata.t[[1]])
260 lapply(age.train ,length)
261 lapply(age.train ,summary)
262 kruskal.test(age.train)
263
264 #val
265 age.val <-list(agedata.l[[2]], agedata.t[[2]])
266 lapply(age.val ,length)
267 lapply(age.val ,summary)
268 kruskal.test(age.val)
269
270 #bnax
271 age.bnax <-list(agedata.h[[2]], agedata.l[[3]], agedata.t[[3]])
272 lapply(age.bnax ,length)
273 lapply(age.bnax ,summary)
274 kruskal.test(age.bnax)
275
276 #sex
277 #train
278 sexdata.train <-matrix(
279 rbind(
280 table(pData(berry.train)[pData(berry.train)$threeclass =="Control" ,]$sex)
,
281 table(pData(berry.train)[pData(berry.train)$threeclass =="Latent" ,]$sex),
282 table(pData(berry.train)[pData(berry.train)$threeclass =="PTB" ,]$sex)
283 ),ncol =2)
284 rownames(sexdata.train)<-c("Healthy","Latent","PTB");colnames(sexdata.train)
<-c("Female","Male")
285 prop.test(sexdata.train)
286
287
288 #val
289 sexdata.val <-matrix(
290 rbind(
291 table(pData(berry.val)[pData(berry.val)$threeclass =="Latent" ,]$sex),
292 table(pData(berry.val)[pData(berry.val)$threeclass =="PTB" ,]$sex)
293 )
294 ,ncol =2)
295 rownames(sexdata.val)<-c("Latent","PTB");colnames(sexdata.val)<-c("Female","
Male")
296 prop.test(sexdata.val)
297
298 #bnax
299 sexdata.bnax <-matrix(
300 rbind(
301 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_healthy" ,]$SEX),
302 table(pData(B.N.AX)[pData(B.N.AX)$class =="CON_LTBI" ,]$SEX),
303 table(pData(B.N.AX)[pData(B.N.AX)$class3 =="activeTB" ,]$SEX)
304 ),ncol =2)
305 rownames(sexdata.bnax)<-c("Healthy","Latent","TB");colnames(sexdata.bnax)<-c
("Female","Male")
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306 prop.test(sexdata.bnax)
307
308 #ethnicity
309
310 ethnicity.train <-matrix(
311 rbind(
312 c(0,12,0,0,0,0,0),
313 c(7,2,5,3,0,0,0),
314 c(4,3,2,3,0,0,1)
315 ),ncol =7)
316 rownames(ethnicity.train)<-c("Healthy","Latent","TB");colnames(ethnicity.
train)<-c("Black","White","Asian other","South Asian","Coloured","Indian
","Other")
317 fisher.test(ethnicity.train ,simulate.p.value=TRUE)
318
319 ethnicity.val <-matrix(
320 rbind(
321 #c(0,12,0,0,0,0,0),
322 c(31,0,0,0,0,0,0),
323 c(20,0,0,0,0,0,0)
324 ),ncol =7)
325 rownames(ethnicity.val)<-c("Latent","TB");colnames(ethnicity.val)<-c("Black"
,"White","Asian other","South Asian","Coloured","Indian","Other")
326 #prop.test(ethnicity.val)#fails
327
328 ethnicity.bnax <-matrix(
329 rbind(
330 c(5,0,0,0,0,0,0),
331 c(5,0,0,0,0,0,0),
332 c(11,0,0,0,0,1,0)
333 ),ncol =7)
334 rownames(ethnicity.bnax)<-c("Healthy","Latent","TB");colnames(ethnicity.bnax
)<-c("Black","White","Asian other","South Asian","Coloured","Indian","
Other")
335 fisher.test(ethnicity.bnax ,simulate.p.value=FALSE)
336
337 tabledata <-read.csv("/Users/armindeffur/Documents/002_Science_universal/
Active_Research/IMPI -Microarray/Documents/PhD/10_Thesis/Thesis_all/
Tables/DE_1_table1.csv",sep=",")
338
339 #show data ####
340
341 #boxplots and stripcharts
342 figure <-1
343 setwd(dir.figures)
344 #Need to figure out how to do this automatically. this fails if the order of
samples in the input data is changed
345 tbstat=list(as.factor(B.N.AX$class2),as.factor(berry.val$confirmed_diagnosis
),as.factor(berry.train$confirmed_diagnosis))
346 levels(tbstat [[1]]) <-c("green","deepskyblue","orange","red","red")
347 levels(tbstat [[2]]) <-c("deepskyblue","orange")
348 levels(tbstat [[3]]) <-c("green","green","deepskyblue","orange")
349 colnames(exprs(datalist [[1]]))<-B.N.AX$sample_name
350 colnames(exprs(datalist [[2]]))<-berry.val$sample_name
351 colnames(exprs(datalist [[3]]))<-berry.train$sample_name
352 # the order of this depends completely on the order in the csv file - it
should not impact on the actual analysis. Just need to make sure that
the class assignments for DE are correct
353 plotnum <-1
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354 for (i in 1: length(datalist)){
355 boxplot(datalist [[i]],main=names(datalist)[i],col=as.character(tbstat [[i]]))
356 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],’
boxplot ’),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height);plotnum <-plotnum +1
357 }
358
359 figure <-figure +1
360
361 #Outlier plot
362 plotnum <-1
363 for (i in 1: length(datalist)){
364 plot(datalist [[i]],what="outlier",main=names(datalist)[i])
365 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],
’outlier_plot’),export.formats=export.formats.plots ,height=height ,width
=(1 + sqrt (5))/2*height);plotnum <-plotnum +1
366 }
367 figure <-figure +1
368
369 #MDS all genes
370 plotnum <-1
371 for (i in 1: length(datalist)){
372 plotSampleRelationsAD(datalist [[i]],method="mds",color=as.character(tbstat [[
i]]),plotchar =16)
373 legend("bottomleft",
374 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("Healthy
","Latent","PTB"))[[i]],
375 pch=16,
376 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
377 cex =.8
378 )
379 export.plot(file.prefix=paste(’fig’,figure ,".",plotnum ,’mds_all’,names(
datalist [[i]])),export.formats=export.formats.plots ,height=height*0.7,
width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
380 }
381 figure <-figure +1
382
383 #PCA all genes
384 plotnum <-1
385 for (i in 1: length(datalist)){
386 l=colnames(exprs(datalist [[i]]))
387 trueClasses <-list(as.factor(B.N.AX$class2),as.factor(berry.val$confirmed_
diagnosis),as.factor(berry.train$confirmed_diagnosis))
388 spca <- SamplePCA(exprs(datalist [[i]]), trueClasses [[i]])
389 plot(spca , col=list(c("deepskyblue","orange","green","red","red"),c("
deepskyblue","orange"),c("green","green","deepskyblue","orange"))[[i]],
main="All genes")#,cex=2,cex.axis=2,cex.main=3,cex.lab=2.5,pch =16)
390 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
391 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
392 legend("bottomleft",
393 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("Healthy
","Latent","PTB"))[[i]],
394 pch=16,
395 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
396 cex =.8
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397 )
398 # mark the group centers
399 #x1 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("b",rownames(
exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
400 #points(x1[1], x1[2], col=’red ’, cex=6,pch =9)
401 #x2 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("f",rownames(
exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
402 #points(x2[1], x2[2], col=’blue ’, cex=6,pch =9)
403
404 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,’pca_all’,names(
datalist [[i]])),export.formats=export.formats.plots ,height=height*0.7,
width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
405 }
406 figure <-figure +1
407 ##
408
409 ########################################.
410 #Baylor method
411 ########################################.
412
413 #preprocess ####
414 #threshold then median scale raw data
415 for (i in 1: length(datalist)){
416 lower.thresh <- 10
417 data.raw <- exprs(datalist [[i]])
418 data.raw.thresh <-data.raw
419 data.raw.thresh[data.raw <lower.thresh]<-lower.thresh
420 genemedians <- apply(data.raw.thresh , 1, median)
421 data.ms <- data.raw.thresh / genemedians
422 exprs(datalist [[i]]) <-data.ms
423 }
424
425 #boxplots of median scaled data
426 plotnum <-1
427 for (i in 1: length(datalist)){
428 boxplot(datalist [[i]],main=names(datalist)[i],col=as.character(tbstat [[i
]]))
429 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],
’boxplot.ms’),export.formats=export.formats.plots ,height=height ,width =(1
+ sqrt (5))/2*height);plotnum <-plotnum +1
430 }
431 figure <-figure +1
432
433 #profile plots of median scaled data (not implemented)
434 #plotnum <-1
435 #for (i in 1: length(datalist)){
436 #par(mar=c(10,7,2,1))
437 #matplot(log2(t(exprs(datalist [[i]]))),type="l",ylim=c(-7,7),ylab="
Expression (log2)",xaxt=’n’,main=paste(names(datalist)[i],’profile plot
all probes ’));
438 #abline(a=1,b=0,col=" yellow ");
439 #abline(a=-1,b=0,col=" yellow ");
440 #abline(a=-0,b=0,col=" yellow ");
441 #axis(1,at=1: dim(exprs(datalist [[i]]))[[2]] ,lab=colnames(exprs(datalist [[i
]])),las =2)
442 #par(parbackup)
443 #export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnum ,names(datalist)[i],’
profile_plot all probes ’),export.formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
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444 #}
445 #figure <-figure +1
446
447 #filter ####
448
449 #detection filter
450 detection.threshold <- 0.01
451 samples.threshold.fraction <- 0.1
452 present.probes <-list()
453 plotnum <-1
454 for (i in 1: length(datalist)){
455 data.detection <-detection(datalist [[i]])
456 samples.threshold <- samples.threshold.fraction * ncol(data.detection)
457 is.present <- data.detection < detection.threshold
458 # is.present is Boolean matrix with present/absent status for individual
gene and chip
459 present.samples.per.probe <- apply(is.present , 1, sum)
460 # present.samples.per.probe is vector with number of chips that have present
call for
461 # each probe
462 present.probes [[i]] <- present.samples.per.probe > samples.threshold
463 # present.probes is Boolean vector with present/absent status for each probe
taken over all
464 # chips
465 print(paste(sum(present.probes [[i]]), "probes present in at least 10% of the
samples"))
466
467 sample.breaks <- seq(-0.5, ncol(exprs(datalist [[i]]))+0.5, by=1)
468 h <- hist(present.samples.per.probe , breaks=sample.breaks ,
469 main=paste(’Number of samples with "present" call per probe\n’,
names(datalist)[[i]]),
470 xlab="Number of samples with present call", ylab="Number of probes
",
471 col="#BBFFBB",labels=TRUE)
472 abline(v=floor(samples.threshold)+0.5, col=’#880000 ’, lwd =2)
473 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],’
present_call_histogram ’),expor .formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
474
475 }
476
477 figure <-figure +1
478
479 #fold -change filter
480 samples.threshold.fraction <- 0.1
481 fold.threshold <-2
482 updown.probes <-list()
483 updata <-list()
484 downdata <-list()
485 selected.probes <-list()
486 plotnum <-1
487 for (i in 1: length(datalist)){
488
489 samples.threshold <- samples.threshold.fraction * ncol(exprs(datalist [[i]]))
;
490 is.up <- exprs(datalist [[i]]) > fold.threshold;
491
492 print(paste(sum(is.up), "up -regulated probes in",names(datalist)[[i]]));
493 up.samples.per.probe <- apply(is.up , 1, sum);
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494
495 up.probes <- up.samples.per.probe > samples.threshold;
496
497 print(paste(sum(up.probes), "probes upregulated in at least 10% of the
samples in",names(datalist)[[i]]));
498 updata [[i]]<-apply(is.up ,2,sum);
499
500 is.down <- exprs(datalist [[i]]) < 1/fold.threshold;
501 print(paste(sum(is.down), "down -regulated probes in",names(datalist)[[i]]));
502 down.samples.per.probe <- apply(is.down , 1, sum);
503 down.probes <- down.samples.per.probe > samples.threshold;
504 print(paste(sum(down.probes), "probes downregulated in at least 10% of the
samples in",names(datalist)[[i]]));
505 downdata [[i]]<-apply(is.down ,2,sum);
506
507 is.changed <- is.up | is.down;
508 print(paste(sum(is.changed), "changed probes in",names(datalist)[[i]]));
509 changed.samples.per.probe <- apply(is.changed , 1, sum);
510 changed.probes <- changed.samples.per.probe > samples.threshold;
511 print(paste(sum(changed.probes), "probes changed in at least 10% of the
samples in",names(datalist)[[i]]));
512 vardata <-apply(is.changed ,2,sum);
513 updown.probes [[i]] <- up.probes | down.probes;
514 print(paste(sum(updown.probes [[i]]), "probes upregulated or downregulated in
at least 10% of the samples in",names(datalist)[[i]]));
515
516 #final selection of probes passing both filters
517 selected.probes [[i]]<-present.probes [[i]]&updown.probes [[i]]
518
519 print(paste(sum(selected.probes [[i]]), "probes pass both filters in",names(
datalist)[[i]]));
520
521 par(mar=c(7,5,1,1))
522 barplot(updata [[i]],las=2,col=as.character(tbstat [[i]]),ylab="Number of
probes with FC > 2",cex.lab=.8,ylim=c(0 ,9000),main=names(datalist)[[i]])
523 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],’
probes with FC > 2’),export.formats=export.formats.plots ,height=height ,
width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
524 barplot(downdata [[i]],las=2,col=as.character(tbstat [[i]]),ylab="Number of
probes with FC < .5",cex.lab=.8,ylim=c(0 ,9000),main=names(datalist)[[i]])
525 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],’
probes with FC < .5’),export.formats=export.formats.plots ,height=height ,
width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
526 par(parbackup)
527
528 }
529 figure <-figure +1
530
531 #visualise selected probes ####
532
533 #plotnum <-1
534 #for (i in 1: length(datalist)){
535 #par(mar=c(10,7,2,1))
536 #matplot(log2(t(exprs(datalist [[i]])[selected.probes [[i]],])),type="l",ylim=
c(-8,8),ylab="Fold Change (log2)",xaxt=’n’,main=paste(names(datalist)[i
],’profile plot selected probes ’));
537 #abline(a=1,b=0,col=" yellow ");
538 #abline(a=-1,b=0,col=" yellow ");
539 #abline(a=-0,b=0,col=" yellow ");
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540 #axis(1,at=1: dim(exprs(datalist [[i]]))[[2]] ,lab=colnames(exprs(datalist [[i
]])),las =2)
541 #par(parbackup)
542
543 #export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnum ,names(datalist)[i],’
profile plot selected probes ’),export.formats=export.formats.plots ,
height=height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
544 #}
545
546 #figure <-figure +1
547
548 #heatmaps
549 plotnum <-1
550 for (i in 1: length(datalist)){
551 phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat [[i
]])),ncol =2)
552 superHeatmap(x=datalist [[i]],y=selected.probes [[i]], phenomatrix=phenomatrix ,
scale="none")
553 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],’
heatmap selected probes ’),export.formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
554 }
555 figure <-figure +1
556
557 #Data PCA and MDS: selected probes
558 plotnum <-1
559 for (i in 1: length(datalist)){
560 plotSampleRelationsAD(datalist [[i]][ selected.prob s [[i]],],method="mds",
color=as.character(tbstat [[i]]),plotchar =16)
561 legend("bottomleft",
562 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("
Healthy","Latent","PTB"))[[i]],
563 pch=16,
564 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
565 cex =.8
566 )
567 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,’mds_selected ’,names(
datalist [[i]])),export.formats=export.formats.plots ,height=height*0.7,
width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
568 }
569 figure <-figure +1
570
571 #selected probes
572 plotnum <-1
573 for (i in 1: length(datalist)){
574 l=colnames(exprs(datalist [[i]][ selected.probes [[i]],]))
575 trueClasses <-list(as.factor(B.N.AX$class2),as.factor(berry.val$confirmed_
diagnosis),as.factor(berry.train$confirmed_diagnosis))
576 spca <- SamplePCA(exprs(datalist [[i]][ selected.probes [[i]],]), trueClasses
[[i]])
577 plot(spca , col=list(c("deepskyblue","orange","green","red","red"),c("
deepskyblue","orange"),c("green","green","deepskyblue","orange"))[[i]],
main=paste(sum(selected.probes [[i]]),"selected probes",sep=" "))#,cex=2,
cex.axis=2,cex.main=3,cex.lab=2.5,pch =16)
578 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
579 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
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580 legend("bottomleft",
581 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("
Healthy","Latent","PTB"))[[i]],
582 pch=16,
583 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
584 cex =.8
585 )
586 # mark the group centers
587 #x1 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("b",rownames
(exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
588 #points(x1[1], x1[2], col=’red ’, cex=6,pch =9)
589 #x2 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("f",rownames
(exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
590 #points(x2[1], x2[2], col=’blue ’, cex=6,pch =9)
591 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,’pca_selected ’,
names(datalist [[i]])),export.formats=export.formats.plots ,height=height*
0.7,width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
592 }
593 figure <-figure +1
594
595 #statistics ####
596
597 #classes
598
599 tbstat.class=list(as.factor(B.N.AX$class2),as.factor(berry.val$confirmed_
diagnosis),as.factor(berry.train$confirmed_diagnosis))
600
601 ##this needs to be sorted out!
602 #this depends on the order of samples in the RData file
603 #consider automating this instead of manually defining
604 levels(tbstat.class [[1]]) <-c("no TB","no TB","active TB","active TB","active
TB")#force 2 condition KW
605 levels(tbstat.class [[2]]) <-c("no TB","active TB")
606 levels(tbstat.class [[3]]) <-c("no TB","no TB","latent TB","active TB")#3
condition KW as per Nature paper
607 #levels(tbstat.class [[3]]) <-c("no TB","no TB","no TB","active TB")#2
condition KW as per Nature paper
608
609 data.fil=list()
610 for (i in 1: length(datalist)){
611
612 data.fil[[i]]<-datalist [[i]][ selected.probes [[i]],]
613 par(mar=c(7,5,1,1))
614 boxplot(data.fil[[i]],las=2,col=as.character(tbstat [[i]]),main=paste(names(
datalist)[[i]],’Boxplot of selected probes ’))
615 par(parbackup)
616 export.plot(file.prefix=paste(’fig’,figure ,’.’,i,names(datalist)[[i]],’
boxplot selected probes ’),export.formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height)
617 }
618 figure <-figure +1
619
620
621 #KW for loop
622 data.fil.probe.names <-list()
623 data.fil.probenumber <-list()
624 for (i in 1: length(datalist)){
625 data.fil.probe.names [[i]]<-rownames(exprs(data.fil[[i]]))
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626 data.fil.probenumber [[i]]<-nrow(data.fil[[i]])
627 }
628
629
630 #Let ’s first set alpha:
631 #kruskal.wallis.alpha <- 0.01 nil significant here ... and limma also set to
0.05, so it ’s only fair
632 kruskal.wallis.alpha <- 0.01
633
634 kruskal.wallis.table <-list(data.frame (),data.frame (),data.frame ())
635
636 ## Run the KW test on gene
637 for (i in 1: length(datalist)){
638 ksdat <-as.matrix(exprs(data.fil[[i]]))
639 g=tbstat.class [[i]]
640 for(j in 1:data.fil.probenumber [[i]]){
641 x <- as.vector(ksdat[j,])
642 ks.test <- kruskal.test(x, g)
643 ## Store the result in the data frame
644 kruskal.wallis.table [[i]] <- rbind(kruskal.wallis.table [[i]],data.
frame(id=data.fil.probe.names [[i]][j],p.value=ks.test$p.value))
645 }
646 }
647
648 nb.tests <-list()
649 for (i in 1: length(datalist)){
650 nb.tests [[i]] <- data.fil.probenumber [[i]]
651 kruskal.wallis.table [[i]]$E.value <- kruskal.wallis.table [[i]]$p.value * nb.
tests[[i]]
652 kruskal.wallis.table [[i]]$FWER <- pbinom(q=0, p=kruskal.wallis.table [[i]]$p.
value ,size=nb.tests[[i]], lower.tail=FALSE)
653 kruskal.wallis.table [[i]] <- kruskal.wallis.table [[i]][ order(kruskal.wallis.
table[[i]]$p.value ,decreasing=FALSE), ]
654 kruskal.wallis.table [[i]]$q.value.factor <- nb.tests[[i]] / 1:nb.tests[[i]]
655 kruskal.wallis.table [[i]]$q.value <- kruskal.wallis.table [[i]]$p.value *
kruskal.wallis.table [[i]]$q.value.factor
656 }
657
658 head(kruskal.wallis.table [[1]])
659 head(kruskal.wallis.table [[2]])
660 head(kruskal.wallis.table [[3]])
661
662
663 for (i in 1: length(datalist)){
664
665 plot(kruskal.wallis.table [[i]]$p.value ,
666 kruskal.wallis.table [[i]]$E.value ,
667 main=paste(’Multitesting corrections: ’,names(datalist)[i]),
668 xlab=’Nominal p-value ’,
669 ylab=’Multitesting -corrected statistics ’,
670 log=’xy’,
671 col=’blue’,
672 panel.first=grid(col=’#BBBBBB ’,lty=’solid’))
673 lines(kruskal.wallis.table [[i]]$p.value ,
674 kruskal.wallis.table [[i]]$FWER ,
675 pch=20,col=’darkgreen ’, type=’p’
676 )
677 lines(kruskal.wallis.table [[i]]$p.value ,
678 kruskal.wallis.table [[i]]$q.value ,
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679 pch=’+’,col=’darkred ’, type=’p’
680 )
681 abline(h=kruskal.wallis.alpha , col=’red’, lwd=2)
682 legend(’topleft ’, legend=c(’E-value’, ’p-value ’, ’q-value ’), col=c(’blue’, ’
darkgreen ’,
683 ’darkred ’
), lwd=2,bg=’white ’,bty=’o’)
684 }
685
686 #results ####
687 #calculation of effect size for original nature paper
688 effect.size <-pwr.t2n.test(n1=13,n2=29,d=NULL ,sig.level =0.01, power =0.9,
alternative="two.sided")$d
689
690 #calculation of significance level , using effect size calculated above with
90% power for t-test #note this does not work when doing stats using
Kruskal Wallis ANOVA for 3 conditions ...
691
692 #sig <-list(
693 # pwr.t2n.test(n1=12,n2=10,d=effect.size ,sig.level=NULL ,power =0.9,
alternative ="two.sided ")$sig.level ,
694 # pwr.t2n.test(n1=20,n2=31,d=effect.size ,sig.level=NULL ,power =0.9,
alternative ="two.sided ")$sig.level ,
695 # pwr.t2n.test(n1=13,n2=29,d=effect.size ,sig.level=NULL ,power =0.9,
alternative ="two.sided ")$sig.level
696 #)
697
698 #alt sig - empiric
699 sig <-list (0.08 ,0.0001 ,0.01)
700
701 diff.genes <-list()
702 for (i in 1: length(datalist)){
703 last.significant.element <- max(which(kruskal.wallis.table [[i]]$q.value <=
sig[[i]]))
704 selected <- 1:last.significant.element
705 diff.genes.factor <- kruskal.wallis.table [[i]]$id[selected]
706 diff.genes [[i]] <- as.vector(diff.genes.factor)
707 }
708
709 intersect12 <-intersect(diff.genes [[1]], diff.genes [[2]])
710 intersect13 <-intersect(diff.genes [[1]], diff.genes [[3]])
711 intersect23 <-intersect(diff.genes [[2]], diff.genes [[3]])
712
713 #this can be compared to limma , also at 0.05 given sample size
714
715 #heatmaps ####
716 plotnum <-1
717 for (i in 1: length(datalist)){
718 phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat [[i
]])),ncol =2)
719 superHeatmap(x=datalist [[i]],y=diff.genes[[i]], phenomatrix=phenomatrix ,
scale="none",addTit=paste("diff. exp.",names(datalist)[i]))
720 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],
’heatmap DE probes ’),export.formats=export.formats.plots ,height=height ,
width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
721 }
722 figure <-figure +1
723
724 #Two -way overlap heatmaps not run ####
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725 # plotnum <-1
726 # for (i in 1: length(datalist)){
727 # phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat
[[i]])),ncol =2)
728 # superHeatmap(x=datalist [[i]],y=intersect12 ,phenomatrix=phenomatrix ,scale
="none",addTit=paste(" overlap IMPI VAL",names(datalist)[i]))
729 # export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnum ,names(datalist)[i
],’heatmap DE probes: overlap IMPI VAL ’),export.formats=export.formats.
plots ,height=height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
730 # }
731 # figure <-figure +1
732 #
733 # plotnum <-1
734 # for (i in 1: length(datalist)){
735 # phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat
[[i]])),ncol =2)
736 # superHeatmap(x=datalist [[i]],y=intersect13 ,phenomatrix=phenomatrix ,scale
="none",addTit=paste(" overlap IMPI TRAIN",names(datalist)[i]))
737 # export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnum ,names(datalist)[i
],’heatmap DE probes: overlap IMPI TRAIN ’),export.formats=export.formats
.plots ,height=height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
738 # }
739 # figure <-figure +1
740 #
741 #
742 # #the below gives an interesting error using intersect23: intersect23 [25]
does not exist in datalist [[1]]; it’s a nuID not found on newer chips
743 # #fix:
744 # intersect23b <-intersect(row.names(exprs(datalist [[1]])),intersect23)
745 #
746 # plotnum <-1
747 # for (i in 1: length(datalist)){
748 # phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat
[[i]])),ncol =2)
749 # superHeatmap(x=datalist [[i]],y=intersect23b ,phenomatrix=phenomatrix ,
scale="none",addTit=paste(" overlap VAL TRAIN",names(datalist)[i]))
750 # export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnum ,names(datalist)[i
],’heatmap DE probes: overlap VAL TRAIN ’),export.formats=export.formats.
plots ,height=height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
751 # }
752 # figure <-figure +1
753
754 #Data PCA and MDS ####
755
756 plotnum <-1
757 for (i in 1: length(datalist)){
758 plotSampleRelationsAD(datalist [[i]][ diff.genes [[i]],],method="mds",color=
as.character(tbstat [[i]]),plotchar =16)
759 legend("bottomleft",
760 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("
Healthy","Latent","PTB"))[[i]],
761 pch=16,
762 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
763 cex =.8
764 )
765 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,’mds_selected ’,names(
datalist [[i]])),export.formats=export.formats.plots ,height=height*0.7,
width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
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766 }
767 figure <-figure +1
768
769 #selected genes
770 plotnum <-1
771 for (i in 1: length(datalist)){
772 l=colnames(exprs(datalist [[i]][ diff.genes[[i]],]))
773 trueClasses <-list(as.factor(B.N.AX$class2),as.factor(berry.val$confirmed_
diagnosis),as.factor(berry.train$confirmed_diagnosis))
774 spca <- SamplePCA(exprs(datalist [[i]][ diff.genes[[i]],]), trueClasses [[i
]])
775 plot(spca , col=list(c("deepskyblue","orange","green","red","red"),c("
deepskyblue","orange"),c("green","green","deepskyblue","orange"))[[i]],
main=paste(length(diff.genes [[i]]),"selected probes",sep=" "))#,cex=2,
cex.axis=2,cex.main=3,cex.lab=2.5,pch =16)
776 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
777 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
778 legend("bottomleft",
779 list(c("Healthy","Latent","PTB","TB -PC"),c("Latent","PTB"),c("
Healthy","Latent","PTB"))[[i]],
780 pch=16,
781 col=list(c("green","deepskyblue","orange","red"),c("deepskyblue","
orange"),c("green","deepskyblue","orange"))[[i]],
782 cex =.8
783 )
784 # mark the group centers
785 #x1 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("b",rownames
(exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
786 #points(x1[1], x1[2], col=’red ’, cex=6,pch =9)
787 #x2 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[grep("f",rownames
(exprs(datalist [[i]]))) ,]), 1, mean), ncol =1))
788 #points(x2[1], x2[2], col=’blue ’, cex=6,pch =9)
789 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,’pca_selected ’,
names(datalist [[i]])),export.formats=export.formats.plots ,height=height*
0.7,width =(1 + sqrt (5))/2*height*0.7);plotnum <-plotnum +1
790 }
791 figure <-figure +1
792 ##
793
794 #Export the probe lists ####
795 #######################################.
796
797 dict.bnax <-nuID2IlluminaID(as.character(diff.genes [[1]]) ,species="Human")
798 dict.val <-nuID2IlluminaID(as.character(diff.genes [[2]]) ,species="Human")
799 dict.train <-nuID2IlluminaID(as.character(diff.genes [[3]]) ,species="Human")
800
801 dict.bnax.entrez <-nuID2EntrezID(as.character(diff.genes [[1]]) ,filterTh =
NULL ,lib.mapping=’lumiHumanIDMapping ’, returnAllInfo = TRUE)
802 dict.val.entrez <-nuID2EntrezID(as.character(diff.genes [[2]]) ,filterTh = NULL
,lib.mapping=’lumiHumanIDMapping ’, returnAllInfo = TRUE)
803 dict.train.entrez <-nuID2EntrezID(as.character(diff.genes [[3]]) ,filterTh =
NULL ,lib.mapping=’lumiHumanIDMapping ’, returnAllInfo = TRUE)
804
805 dict2.bnax <-merge(dict.bnax ,kruskal.wallis.table [[1]],by.x="nuID",by.y="id")
806 dict2.val <-merge(dict.val ,kruskal.wallis.table [[2]],by.x="nuID",by.y="id")
807 dict2.train <-merge(dict.train ,kruskal.wallis.table [[3]],by.x="nuID",by.y="id
")
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808
809 dict3.bnax <-merge(dict2.bnax ,dict.bnax.entrez ,by.x="nuID",by.y=0)
810 dict3.val <-merge(dict2.val ,dict.val.entrez ,by.x="nuID",by.y=0)
811 dict3.train <-merge(dict2.train ,dict.train.entrez ,by.x="nuID",by.y=0)
812
813 write.csv(dict3.bnax ,file=file.path(dir.results ,"DE_Baylor_BNAX.csv"))
814 write.csv(dict3.val ,file=file.path(dir.results ,"DE_Baylor_val.csv"))
815 write.csv(dict3.train ,file=file.path(dir.results ,"DE_Baylor_train.csv"))
816
817 ########################################
818 #overlap computations for 393
819 ########################################
820
821 #import probe lists
822
823 #load Berry 393 and 86 probe data ####
824
825 load(file.path(dir.rdata ,’berry.sig.RData’))
826 load(file.path(dir.rdata ,’berry .86. RData’))
827 load(file.path(dir.rdata ,’berry .393. RData’))
828
829 #annotate probe lists
830 dict <-probeID2nuID(berry.sig ,species="Human")
831 dict .86 <-IlluminaID2nuID(as.character(berry .86[ ,1]),species="Human")
832 dict .393 <-IlluminaID2nuID(as.character(berry .393[ ,1]),species="Human")
833
834 #intersectOfOverlapWith393 <-intersect(intersect13 ,dict [,7])
835
836 #intersectBerryWith393 <-intersect(diff.genes [[2]], dict [,7])
837
838 #intersectSAWith393 <-intersect(diff.genes [[1]] , dict [,7])
839
840 ##Venn 4-way at probe level ####
841 x.1<-diff.genes [[1]]
842 x.2<-diff.genes [[2]]
843 x.3<-diff.genes [[3]]
844 x.4<-as.character(dict [,7])
845 x.5<-as.character(dict .86[ ,7])
846
847 venndatax.hivNeg <-list(x.1,x.2,x.3,x.4)
848 sixtyone <-intersect(intersect(intersect(x.1,x.2),x.3),x.4)
849 so.a<-nuID2IlluminaID(as.character(sixtyone),species="Human")
850 so.b<-nuID2EntrezID(as.character(sixtyone),filterTh = NULL ,lib.mapping=’
lumiHumanIDMapping ’, returnAllInfo = TRUE)
851 so.c<-merge(so.a,so.b,by.x="nuID",by.y=0)
852
853 write.csv(so.c,file=file.path(dir.results ,"TripleOverlap61probes.csv"))
854
855 temp.venn <-venn.diagram(
856 x = venndatax.hivNeg ,
857 category=c("SA","VAL","TRAIN","393"),
858 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
859 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.
tiff",sep ="")),
860 filename = NULL ,
861 #filename = "/Users/armindeffur/Desktop/file.tiff",
862 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
863 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
864 inverted = TRUE ,
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865 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
866 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
867 # main.cex = 2, sub.cex = 1,
868 fill=c("blue","green","red","gray"),
869 alpha=c(.4 ,.4 ,.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
870 )
871
872 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
873 grid.draw(temp.venn)
874 dev.off()
875 figure <-figure +1
876
877 ##Venn 5-way at probe level ####
878 x.1<-diff.genes [[1]]
879 x.2<-diff.genes [[2]]
880 x.3<-diff.genes [[3]]
881 x.4<-as.character(dict [,7])
882 x.5<-as.character(dict .86[ ,7])
883
884 venndatax.hivNeg <-list(x.1,x.2,x.3,x.4,x.5)
885
886 temp.venn <-venn.diagram(
887 x = venndatax.hivNeg ,
888 category=c("SA","VAL","TRAIN","393","86"),
889 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
890 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.
tiff",sep ="")),
891 filename = NULL ,
892 #filename = "/Users/armindeffur/Desktop/file.tiff",
893 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
894 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
895 inverted = TRUE ,
896 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
897 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
898 # main.cex = 2, sub.cex = 1,
899 fill=c("blue","green","red","gray","orange"),
900 alpha=c(.4 ,.4 ,.4 ,.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
901 )
902
903 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
904 grid.draw(temp.venn)
905 dev.off()
906 figure <-figure +1
907
908 ##Venn 4-way at gene level ####
909 gx.1<-unique(as.character(nuID2IlluminaID(x.1)[,2]))
910 gx.2<-unique(as.character(nuID2IlluminaID(x.2)[,2]))
911 gx.3<-unique(as.character(nuID2IlluminaID(x.3)[,2]))
912 gx.4<-unique(as.character(nuID2IlluminaID(x.4)[,2]))
913
914 venndatax.hivNeg.genes <-list(gx.1,gx.2,gx.3,gx.4)
915
916 temp.venn.2<-venn.diagram(
917 x = venndatax.hivNeg.genes ,
918 category=c("SA","VAL","TRAIN","393"),
919 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
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920 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
921 filename = NULL ,
922 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
923 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
924 inverted = TRUE ,
925 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
926 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
927 # main.cex = 2, sub.cex = 1,
928 fill=c("blue","green","red","gray"),
929 alpha=c(.4 ,.4 ,.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
930 )
931 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
932 grid.draw(temp.venn .2)
933 dev.off()
934 figure <-figure +1
935
936 ##Venn 4-way at probe level for top 500 probes ####
937
938 xEQ.1<-as.character(kruskal.wallis.table [[1]][1:500 ,1])
939 xEQ.2<-as.character(kruskal.wallis.table [[2]][1:500 ,1])
940 xEQ.3<-as.character(kruskal.wallis.table [[3]][1:500 ,1])
941 x.4<-as.character(dict [,7]);
942 venndatax.hivNeg .500 <-list(xEQ.1,xEQ.2,xEQ.3,x.4)
943 temp.venn.3<-venn.diagram(
944 x = venndatax.hivNeg .500,
945 category=c("SA","VAL","TRAIN","393"),
946 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
947 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_top_500.
tiff",sep ="")),
948 filename = NULL ,
949 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
950 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
951 inverted = TRUE ,
952 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
953 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
954 # main.cex = 2, sub.cex = 1,
955 fill=c("blue","green","red","gray"),
956 alpha=c(.4 ,.4 ,.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
957 )
958 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
959 grid.draw(temp.venn .3)
960 dev.off()
961 figure <-figure +1
962
963 ##Venn 4-way at gene level for top 500 probes ####
964
965 g500x.1<-unique(as.character(nuID2IlluminaID(xEQ .1)[,2]))
966 g500x.2<-unique(as.character(nuID2IlluminaID(xEQ .2)[,2]))
967 g500x.3<-unique(as.character(nuID2IlluminaID(xEQ .3)[,2]))
968 g500x.4<-unique(as.character(nuID2IlluminaID(x.4)[,2]))
969
970 venndatax.hivNeg.genes .500 <-list(g500x.1,g500x.2,g500x.3,g500x .4)
971
972 temp.venn.4<-venn.diagram(
973 x = venndatax.hivNeg.genes .500,
974 category=c("SA","VAL","TRAIN","393"),
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975 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
976 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
977 filename = NULL ,
978 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
979 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
980 inverted = TRUE ,
981 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
982 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
983 # main.cex = 2, sub.cex = 1,
984 fill=c("blue","green","red","gray"),
985 alpha=c(.4 ,.4 ,.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
986 )
987 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
988 grid.draw(temp.venn .4)
989 dev.off()
990 figure <-figure +1
991
992 ##Heatmaps: full intersect at probe and gene level ####
993
994 in.common.probe <-intersect(x.1, intersect(x.2, intersect(x.3,x.4)))
995 in.common <-intersect(gx.1, intersect(gx.2, intersect(gx.3,gx.4)))
996
997 plotnum <-1
998 for (i in 1: length(datalist)){
999 phenomatrix <-matrix(cbind(as.character(tbstat [[i]]),as.character(tbstat [[i
]])),ncol =2)
1000 superHeatmap(x=datalist [[i]],y=in.common.probe ,phenomatrix=phenomatrix ,
scale="none",addTit=paste("overlap",names(datalist)[i]))
1001 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnum ,names(datalist)[i],
’heatmap in common probes ’),export.formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height);plotnum <-plotnum +1
1002 }
1003 figure <-figure +1
1004
1005 ##Venn: 393 and AOG_R_method_ rain probe (validation of implementation of
Baylor method in R)#####
1006 venndatax.val.meth <-list(x.3,x.4)
1007 temp.venn.5<-venn.diagram(
1008 x = venndatax.val.meth ,
1009 category=c("TRAIN","393"),
1010 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
1011 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
1012 filename = NULL ,
1013 scaled = F, ext.text = TRUE , ext.line.lwd = 2,
1014 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
1015 inverted = TRUE ,
1016 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
1017 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
1018 # main.cex = 2, sub.cex = 1,
1019 fill=c("blue","green"),
1020 alpha=c(.4 ,.4),height =3000 , width =(1 + sqrt (5))/2*3000
1021 )
1022 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_2set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
1023 grid.draw(temp.venn .5)
1024 dev.off()
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1025 figure <-figure +1
1026
1027 ##Venn: 393 and AOG_R_method_train gene (validation of implementation of
Baylor method in R) #####
1028 venndatax.val.meth.g<-list(gx.3,gx.4)
1029 temp.venn.6<-venn.diagram(
1030 x = venndatax.val.meth.g,
1031 category=c("TRAIN","393"),
1032 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
1033 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
1034 filename = NULL ,
1035 scaled = F, ext.text = TRUE , ext.line.lwd = 2,
1036 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
1037 inverted = TRUE ,
1038 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
1039 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
1040 # main.cex = 2, sub.cex = 1,
1041 fill=c("blue","green"),
1042 alpha=c(.4 ,.4),height =3000 , width =(1 + sqrt (5))/2*3000
1043 )
1044 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_2set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
1045 grid.draw(temp.venn .6)
1046 dev.off()
1047 figure <-figure +1
1048
1049 ##Venn: SA and 393 probe ####
1050
1051 venndatax.val.SA<-list(x.1,x.4)
1052 temp.venn.7<-venn.diagram(
1053 x = venndatax.val.SA ,
1054 category=c("SA","393"),
1055 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
1056 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
1057 filename = NULL ,
1058 scaled = F, ext.text = TRUE , ext.line.lwd = 2,
1059 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
1060 inverted = TRUE ,
1061 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
1062 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
1063 # main.cex = 2, sub.cex = 1,
1064 fill=c("blue","green"),
1065 alpha=c(.4 ,.4),height =3000 , width =(1 + sqrt (5))/2*3000
1066 )
1067 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_2set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
1068 grid.draw(temp.venn .7)
1069 dev.off()
1070 figure <-figure +1
1071
1072 ##Venn: SA and 393 gene ####
1073
1074 venndatax.val.SA.g<-list(gx.1,gx.4)
1075 temp.venn.8<-venn.diagram(
1076 x = venndatax.val.SA.g,
1077 category=c("SA","393"),
1078 #filename = file.path(dir.figures ,"fig71_Venn_3set_lh_al_ah.tiff"),
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1079 #filename = file.path(dir.figures ,paste("fig",figure ,"_Venn_4set_gene.tiff
",sep ="")),
1080 filename = NULL ,
1081 scaled = T, ext.text = TRUE , ext.line.lwd = 2,
1082 ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
1083 inverted = TRUE ,
1084 cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
1085 #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
1086 # main.cex = 2, sub.cex = 1,
1087 fill=c("blue","green"),
1088 alpha=c(.4 ,.4),height =3000 , width =(1 + sqrt (5))/2*3000
1089 )
1090 pdf(file=file.path(dir.figures ,paste("fig",figure ,"_Venn_2set_probe.pdf",sep
="")),height=7,width =(1 + sqrt (5))/2*7)
1091 grid.draw(temp.venn .8)
1092 dev.off()
1093 figure <-figure +1
Listing A.9: RelationIMPI-MA to TB-AOG
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1 #setup ####
2 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/06_IMPI -MA/Analysis/00_System/System
_setup.R")
3 source(file.path(dir.R.files ,"superHeatmap.R"))
4 par("xpd"=FALSE)
5 export.formats.plots <- c("pdf","png")
6 #phenodata directory
7 dir.pheno <- file.path(dir.data_root , ’09_IMPI_MA_DATA/08_PhenoData ’)
8 print(paste("Phenodata data repository", dir.pheno))
9
10 ## Individual data folders (specific for each part)
11 dir.rdata <- file.path(dir.data_root ,’09_IMPI_MA_DATA/05_RData’)
12
13 #Output folders
14 dir.home <-dir.root
15 dir.main <- file.path(dir.root , ’02_output/06_IMPI -MA/AllData ’,’QC_and_
Unsupervised ’)
16
17 #Current date string used for versioning output
18 ds<-date()
19
20 #versioned output
21 dir.output.version <-file.path(dir.main ,paste("version_",ds))
22
23 ## Define folder for storing results NB do this for each analysis
24 dir.results <- file.path(dir.output.version , "results")
25 ## Define folder for saving figures
26 dir.figures <- file.path(dir.output.version , "figures")
27 for (dir in c(dir.main , dir.figures , dir.results)) {
28 if (!file.exists(dir)) {
29 dir.create(dir , recursive=T,showWarnings=T)
30 }
31 }
32
33 sink(type="output",file=file.path(dir.results ,"session_output.txt"))
34 sessionInfo ()
35 print(paste("Begin time:",ds))
36
37 print(paste("Results will be saved to", dir.results))
38 print(paste("Figures will be saved to", dir.figures))
39
40
41 figure <-1
42
43 #data
44 load(file.path(dir.rdata ,’IMPI_MA.RData’))
45 load(file.path(dir.rdata ,’berry_train.RData ’))
46 load(file.path(dir.rdata ,’berry_test.RData ’))
47 load(file.path(dir.rdata ,’berry_val.RData’))
48
49 #subset allArrays by compartment
50 fluidArrays <-allArrays[,allArrays$Compartment =="fluid"]
51 bloodArrays <-allArrays[,allArrays$Compartment =="blood"]
52
53 #treemap ####
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54
55 datacats <-read.csv(file.path(dir.pheno ,"phenodf_simple.csv"))
56
57 tmPlot(datacats ,index=c("class2","Compartment","matching","HIV.Status"),
vSize="N",vColor="N",type="value",pal="Set3")
58 tmPlot(datacats ,index=c("class2","Compartment","HIV.Status"),vSize="N",
vColor="N",type="value",pal="Set3")
59
60 #QC and plots ####
61
62 #QC summary
63 allarraysum <-summary(allArrays ,"QC")
64 allArrays
65
66 berry.trainsum <-summary(berry.train ,"QC")
67 berry.train
68
69 berry.testsum <-summary(berry.test ,"QC")
70 berry.train
71
72 berry.valsum <-summary(berry.val ,"QC")
73 berry.val
74
75 par(mfrow=c(1,1),mar=c(5, 4, 4, 2) + 0.1)
76 setwd(dir.figures)
77
78 array.list <-list("All IMPI Arrays"=allArrays ,"IMPI blood Arrays"=bloodArrays
,"IMPI fluid Arrays"=fluidArrays ,"Berry train"=berry.train ,"Berry test"=
berry.test ,"Berry SA validation"=berry.val)
79
80 # #PDF plots
81 # plotnumber <-1
82 # for (i in 1: length(array.list)) {
83 # density(array.list[[i]],addLegend=FALSE ,main=paste (" Density plot",names(
array.list)[i]))
84 # export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnumber ,names(array.
list[i])),export.formats=export.formats.plots ,height=height/2,width =(1 +
sqrt (5))/2*height/2)
85 # plotnumber <-plotnumber +1
86 # }
87 # figure <-figure +1
88 #
89 # #CDF plots
90 # plotnumber <-1
91 # for (i in 1: length(array.list)) {
92 # plotCDF(array.list[[i]],addLegend=FALSE ,main=paste ("CDF plot",names(
array.list)[i]))
93 # export.plot(file.prefix=paste(’fig ’,figure ,’.’,plotnumber ,names(array.
list[i])),export.formats=export.formats.plots ,height=height/2,width =(1 +
sqrt (5))/2*height/2)
94 # plotnumber <-plotnumber +1
95 # }
96 # figure <-figure +1
97
98
99 #thesis versions:
100 #PDF plots
101 plotnumber <-1
102 for (i in 1: length(array.list)) {
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103 density(array.list[[i]],addLegend=FALSE ,main=NULL)
104 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnumber ,names(array.list
[i])),export.formats=export.formats.plots ,height=height/1.5,width =(1 +
sqrt (5))/2*height/1.5)
105 plotnumber <-plotnumber +1
106 }
107 figure <-figure +1
108
109 #CDF plots
110 plotnumber <-1
111 for (i in 1: length(array.list)) {
112 plotCDF(array.list[[i]],addLegend=FALSE ,main=NULL)
113 export.plot(file.prefix=paste(’fig’,figure ,’.’,plotnumber ,names(array.list
[i])),export.formats=export.formats.plots ,height=height/1.5,width =(1 +
sqrt (5))/2*height/1.5)
114 plotnumber <-plotnumber +1
115 }
116 figure <-figure +1
117
118 #example of a pairplot of 5 samples
119 pairs(allArrays [,1:5], smoothScatter=TRUE ,main="Smooth scatter , arrays 1 to 5
")
120 export.plot(file.prefix=paste(’fig’,figure ,’smooth_scatter ’),export.formats=
export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
121 figure <-figure +1
122
123 #examples of MA plot of 5 samples
124 MAplot(allArrays [,1:5], smoothScatter=TRUE ,main="MA plot , arrays 1 to 5")
125 export.plot(file.prefix=paste(’fig’,figure ,’MA_1_to_5’),export.formats=
export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
126 figure <-figure +1
127
128 #colour factors for labeling plots by compartment
129 comlist <-as.factor(allArrays$Compartment)
130 levels(comlist)<-c("gray","yellow")
131 comlist2 <-comlist
132 levels(comlist2)<-c("red","tan1")
133 comlist3 <-as.factor(allArrays$class2)
134 levels(comlist3)<-c("deepskyblue","orange","orange","green","red","red","red
")
135 pchlist <-comlist
136 levels(pchlist)<-c(21 ,24)
137 pchlist2 <-as.numeric(as.vector(pchlist))
138
139 levels(pchlist)<-c(16 ,1)
140 pchlist3 <-as.numeric(as.vector(pchlist))
141
142 #boxplots of all IMPI data
143 boxplot(allArrays ,col=as.character(comlist),subset=NULL ,main="Boxplot of all
samples",boxwex =.8,cex =2)
144 export.plot(file.prefix=paste(’fig’,figure ,’boxplot_all_IMPI’),export.
formats=export.formats.plots ,height=height*1.0,width =(1 + sqrt (5))/2*
height*1.0)
145 figure <-figure +1
146
147 #Sample relations of all IMPI_MA data ####
148
149 labs <-allArrays$sample_name
150 plotSampleRelation(allArrays ,method="mds",color=as.character(comlist))
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151 export.plot(file.prefix=paste(’fig’,figure ,’mds_all_IMPI’),export.formats=
export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
152 figure <-figure +1
153
154 plotSampleRelation(allArrays ,method="cluster",labels=labs)
155 export.plot(file.prefix=paste(’fig’,figure ,’sample_hc’),export.formats=
export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
156 figure <-figure +1
157
158 plotSampleRelationsAD(allArrays ,method="mds",color=as.character(comlist),
backgr=as.character(comlist2))
159 export.plot(file.prefix=paste(’fig’,figure ,’mds_all_IMPI_v2’),export.formats
=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
160 figure <-figure +1
161
162 plotSampleRelationsAD(allArrays ,subset=NULL ,method="mds")
163
164 plotSampleRelationsAD(allArrays ,method="mds",color=as.character(comlist3),
plotchar=pchlist3)
165 legend("bottomright",
166 c("fluid","blood TBPC","blood PTB","blood LTBI","blood healthy"),
167 pch=c(1,16 ,16 ,16 ,16),
168 col=c("red","red","orange","deepskyblue","green"),
169 cex =.8
170 )
171 export.plot(file.prefix=paste(’fig’,figure ,’mds_all_IMPI_v3’),export.formats
=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
172
173 #3d PCA and scatterplot to check how blood and fluid separate in 3
dimensions
174 plotSampleRelations3D_AD(allArrays ,method="mds",color=as.character(comlist),
backgr=as.character(comlist2))
175 rgl.snapshot( file.path(dir.figures ,paste(’fig’,figure ,’mds_all_IMPI_3D’)),
fmt="png", top=TRUE )
176
177 figure <-figure +1
178
179 #Sample relations of blood data
180
181 #colour factors for labeling plots by category
182 comlist.blood.diag <-as.factor(bloodArrays$class2)
183 levels(comlist.blood.diag)<-c("deepskyblue","orange","orange","green","red",
"red","red")
184
185 comlist.blood.HIV <-as.factor(bloodArrays$HIV.Status)
186 levels(comlist.blood.HIV)<-c("green","red")
187 pchlist <-comlist.blood.HIV
188 levels(pchlist)<-c(21 ,24)
189 pchlist2 <-as.numeric(as.vector(pchlist))
190 levels(pchlist)<-c(0,7)
191 pchlist3 <-as.numeric(as.vector(pchlist))
192
193 plotSampleRelationsAD(bloodArrays ,method="mds",color=as.character(comlist.
blood.diag),plotchar=pchlist3)
194 legend("topright",
195 c("Healthy+","LTBI+","PTB+","TBPC+","Healthy -","LTBI -","PTB -","TBPC -"
),
196 pch=c(7,7,7,7,0,0,0,0),
197 col=c("green","deepskyblue","orange","red"),
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198 ncol=2,
199 cex =.8
200 )
201 export.plot(file.prefix=paste(’fig’,figure ,’mds_blood_dx_hiv’),export.
formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
202 figure <-figure +1
203
204
205 comlist.blood.sex <-as.factor(bloodArrays$SEX)
206 levels(comlist.blood.sex)<-c("red","deepskyblue")
207 comlist.blood.ster <-as.factor(bloodArrays$STEROIDS)
208 levels(comlist.blood.ster)<-c("grey","green","red")
209 pchlist <-comlist.blood.ster
210 levels(pchlist)<-c(0,6,17)
211 pchlist2 <-as.numeric(as.vector(pchlist))
212
213 plotSampleRelationsAD(bloodArrays ,method="mds",color=as.character(comlist.
blood.sex),plotchar=pchlist2)
214 legend("topright",
215 c("F?S","F-S","F+S","M?S","M-S","M+S"),
216 pch=c(0,6,17,0,6,17),
217 col=c("red","red","red","deepskyblue","deepskyblue","deepskyblue"),
218 ncol=2,
219 cex =.8
220 )
221
222 export.plot(file.prefix=paste(’fig’,figure ,’mds_blood_sex_ster’),export.
formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
223 figure <-figure +1
224
225 #XP
226 comlist.blood.set <-bloodArrays$sample_name
227 pca <-grep("PCA",comlist.blood.set)
228 pc<-grep("PC[0-9]",comlist.blood.set)
229 eu<-grep("control",comlist.blood.set)
230
231 comlist.blood.set[eu]<-"blue"
232 comlist.blood.set[pca]<-"red"
233 comlist.blood.set[pc]<-"green"
234
235 plotSampleRelationsAD(bloodArrays ,method="mds",color=as.character(comlist.
blood.set),plotchar =15)
236 legend("topright",
237 c("EU","SET2","SET1"),
238 pch=c(15 ,15 ,15),
239 col=c("blue","red","green"),
240 ncol=2,
241 cex =.8
242 )
243 export.plot(file.prefix=paste(’fig’,figure ,’mds_blood_SETs’),export.formats=
export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
244 figure <-figure +1
245 #XP
246
247
248 #Sample relations of fluid data
249
250 #colour factors for labeling plots by category
251 comlist.fluid.diag <-as.factor(fluidArrays$class2)
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252 levels(comlist.fluid.diag)<-c("red","purple")
253
254 comlist.fluid.HIV <-as.factor(fluidArrays$HIV.Status)
255 levels(comlist.fluid.HIV)<-c("green","red")
256 pchlist <-comlist.fluid.HIV
257 levels(pchlist)<-c(21 ,24)
258 pchlist2 <-as.numeric(as.vector(pchlist))
259 levels(pchlist)<-c(0,7)
260 pchlist3 <-as.numeric(as.vector(pchlist))
261
262 plotSampleRelationsAD(fluidArrays ,method="mds",color=as.character(comlist.
fluid.diag),plotchar=pchlist3)
263 legend("bottomleft",
264 c("def+","prob+","def -","prob -"),
265 pch=c(7,7,0,0),
266 col=c("red","purple","red","purple"),
267 cex =.8
268 )
269 export.plot(file.prefix=paste(’fig’,figure ,’mds_fluid_TBdx_hiv’),export.
formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height)
270 figure <-figure +1
Listing A.10: Overview of all data
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1 #metadata ####
2 #IMPI_MA microarray analysis pipeline: question -based version
3 #Universal Data Manager
4 #Armin Deffur
5 #File created 10 -06 -2013
6 #Version 1.0
7
8 #System_setup.R####
9
10 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/06_IMPI -MA/Analysis/00_System/System
_setup.R")
11
12 #Local Setup ####
13
14 ## Individual data folders (specific for each part)
15 dir.gx <- file.path(dir.data_root , ’09_IMPI_MA_DATA/04_GX_format ’)
16 print(paste("GX12 -format data repository", dir.gx))
17 dir.gs <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/05_
GenomeStudio_reports ’)
18 print(paste("GenomeStudio report data repository", dir.gs))
19 dir.bgx <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/06_Illumina
Manifest files/HT12v4 ’)
20 print(paste("Illumina manifest file repository", dir.gx))
21 dir.jpg <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/07_
imageData/JPG’)
22 print(paste("Raw image data (.jpg) repository", dir.jpg))
23 dir.tif <- file.path(dir.data_root , ’09_IMPI_MA_DATA_unversioned/07_
imageData/TIFF’)
24 print(paste("Raw image data (.tif) repository", dir.tif))
25 dir.pheno <- file.path(dir.data_root , ’09_IMPI_MA_DATA/08_PhenoData ’)
26 print(paste("Phenodata data repository", dir.pheno))
27
28 #Output folders
29 dir.home <-dir.root
30 dir.main <- file.path(dir.root , ’02_output/06_IMPI -MA’,’AllData ’)
31
32 #Current date string used for versioning output
33 ds<-Sys.time()
34
35 #versioned output
36 dir.output.version <-file.path(dir.main ,paste("version_",ds))
37
38 ## Define folder for storing results NB do this for each analysis
39 dir.results <- file.path(dir.output.version , "results")
40 print(paste("Results will be saved to", dir.results))
41
42 ## Define folder for saving figures
43 dir.figures <- file.path(dir.output.version , "figures")
44 print(paste("Figures will be saved to", dir.figures))
45
46 ## Define folder for saving RData files
47 dir.rdata <- file.path(dir.data_root ,’09_IMPI_MA_DATA/06_RData_Q’)
48 print(paste("Data will be saved to", dir.rdata))
49
50 for (dir in c(dir.main , dir.figures , dir.results)) {
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51 if (!file.exists(dir)) {
52 dir.create(dir , recursive=T,showWarnings=T)
53 }
54 }
55
56 figure <-1
57
58 #WD####
59 setwd(dir.main)
60
61 #Data for Differential Expression
62
63 #Data for Deconvolution
64
65 #Data for WGCNA
66
67 #Import expression and phenotype data using lumi ####
68
69 fileName <-file.path(dir.gx ,"Armin_Hu_17_8_12_No uRNA_bkg sub_NO Norm__Sample
_Probe_Profile.txt")
70 fileNameAnno <-file.path(dir.gs,"Armin_Hu_17_8_12_No uRNA_bkg sub_NO Norm_
FinalReport.txt")
71 bgxfile <-file.path(dir.bgx ,"HumanHT -12_V4_0_R1_15002873_B.bgx")
72
73 #PHENODATA ORIGINAL
74 #the phenodata below assigns TB status according to Pericardial culture.
This misclassifies TB-PC suspects who were culture positive elsewhere as
"probable" TB (wrong)
75 #phenodataPath <-file.path(dir.pheno ," phenoGS_edited_csv_colour_25_9_2012. csv
")
76
77 #PHENODATA EDIT 1
78 #the phenodata (class3 variable) below defines active TB as ANY positive
site. This means that some probable TBPC cases are defnite TB cases.
This is relevant as the !blood! signature will be determined by any (??)
TB site. This needs to be tested where fluid is negative but another
site positive. It is unclear if this applies to TBM , though. (issues of
blood -brain -barrier , etc.)
79 #Important: when changing this , factors of diagnostic class may change ,
depending which "probable" case is made "definite ".
80 #phenodataPath <-file.path(dir.pheno ," phenoGS_edited_csv_colour_28_10_2012.
csv")
81
82 #PHENODATA EDIT 2
83 #With this in mind , the phenodata source file has been updated to change
sample 20868 control back to probableActiveTB , as the only positive
culture was CSF. It seems unwise to include only one case of TBM , while
there are many TB -PC and PTB.
84 #the phenodata file was edited: sample PCA141 blood and fluid assignments to
chips have been exchanged , as earlier mds plots strongly suggested this
. All results may change that depend on the correct assignment.
85
86 #IMPI -MA data
87 phenodataPath <-file.path(dir.pheno ,"phenoGS_edited_csv_colour_17_01_2013. csv
")
88 sampleInfoDF <-read.csv(phenodataPath , header = TRUE , colClasses = "character
", comment.char = "",check.names = FALSE)
89 allArrays <-lumiR.batch(fileName ,lib.mapping=’lumiHumanIDMapping ’,
sampleInfoFile=sampleInfoDF ,verbose=TRUE)
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90 colnames(exprs(allArrays))<-allArrays$sample_name
91
92 #Berry data
93 berry.sampleInfoDF.train <-read.csv("/Users/armindeffur/Documents/002_Science
_universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_train.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
94 berry.train <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal
/Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_TrainingSet.txt",lib.mapping=’lumiHumanIDMapping ’,sampleInfoFile
=berry.sampleInfoDF.train ,verbose=TRUE)
95
96 berry.sampleInfoDF.test <-read.csv("/Users/armindeffur/Documents/002_Science_
universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_test.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
97 berry.test <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal/
Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_TestSet.txt",lib.mapping=’lumiHumanIDMapping ’,sampleInfoFile=
berry.sampleInfoDF.test ,verbose=TRUE)
98
99 berry.sampleInfoDF.val <-read.csv("/Users/armindeffur/Documents/002_Science_
universal/Active_Research/IMPI -Microarray/Data/03_TB_AOG/data/Berry_
pheno/phenoData_val.csv", header = TRUE , colClasses = "character",
comment.char = "",check.names = FALSE)
100 berry.val <-lumiR.batch("/Users/armindeffur/Documents/002_Science_universal/
Active_Research/IMPI -Microarray/Data/03_TB_AOG/New_data/MatthewRequest_
02Feb11_ValidationSet.txt",lib.mapping=’lumiHumanIDMapping ’,
sampleInfoFile=berry.sampleInfoDF.val ,verbose=TRUE)
101
102 #subset allArrays by compartment
103 fluidArrays <-allArrays[,allArrays$Compartment =="fluid"]
104 bloodArrays <-allArrays[,allArrays$Compartment =="blood"]
105
106 #Data subsetting ####
107
108 #CSC scheme: compartment , subset , contrast
109
110 save(berry.train ,file=file.path(dir.rdata ,’berry_train.RData’))
111 save(berry.test ,file=file.path(dir.rdata ,’berry_test.RData’))
112 save(berry.val ,file=file.path(dir.rdata ,’berry_val.RData’))
113
114 save(allArrays ,file=file.path(dir.rdata ,’IMPI_MA.RData’))
115
116 #Question 1: Tuberculosis
117 hivNegBloodArrays <-bloodArrays[,bloodArrays$HIV.Status =="negative"] #tb
118 B.Neg.AN<-hivNegBloodArrays[,hivNegBloodArrays$class3 =="activeTB"|
hivNegBloodArrays$class3 =="notActiveTB"]#training
119 B.Neg.aN<-hivNegBloodArrays[,hivNegBloodArrays$class3 =="probableActiveTB"|
hivNegBloodArrays$class3 =="notActiveTB"]#validation
120 save(B.Neg.AN ,file=file.path(dir.rdata ,’blood_hivNeg_aTB_noTB.RData ’))
121 save(B.Neg.aN ,file=file.path(dir.rdata ,’blood_hivNeg_probTB_noTB.RData ’))
122
123 hivPosBloodArrays <-bloodArrays[,bloodArrays$HIV.Status =="positive"]
124 B.Pos.AN<-hivPosBloodArrays[,hivPosBloodArrays$class3 =="activeTB"|
hivPosBloodArrays$class3 =="notActiveTB"]
125 B.Pos.aN<-hivPosBloodArrays[,hivPosBloodArrays$class3 =="probableActiveTB"|
hivPosBloodArrays$class3 =="notActiveTB"]
126 save(B.Pos.AN ,file=file.path(dir.rdata ,’blood_hivPos_aTB_noTB.RData ’))
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127 save(B.Pos.aN ,file=file.path(dir.rdata ,’blood_hivPos_probTB_noTB.RData ’))
128
129 #Question 2: HIV in active TB
130 B.A.PosNeg <-bloodArrays[,bloodArrays$class3 =="activeTB"] #tb
131 save(B.A.PosNeg ,file=file.path(dir.rdata ,’blood_aTB_HIVPosNeg.RData ’))
132 PF.A.PosNeg <-fluidArrays[,fluidArrays$class3 =="activeTB"]
133 save(PF.A.PosNeg ,file=file.path(dir.rdata ,’fluid_aTB_HIVPosNeg.RData ’))
134 B.PTB.PosNeg <-bloodArrays[,bloodArrays$class2 =="CON_PTB_definite"]
135 save(B.PTB.PosNeg ,file=file.path(dir.rdata ,’blood_defPTB_HIVPosNeg.RData ’))
136 B.TBPC.PosNeg <-bloodArrays[,bloodArrays$class2 =="TBPC_definite"]
137 save(B.TBPC.PosNeg ,file=file.path(dir.rdata ,’blood_defTBPC_HIVPosNeg.RData’)
)
138
139 #Question 3: Compartment
140 C.BPF <-allArrays[,allArrays$matching =="m"]
141 save(C.BPF ,file=file.path(dir.rdata ,’TBPC_matchedBloodFluid.RData ’))
142 C.Neg.matchedBF <-C.BPF[,C.BPF$HIV.Status =="negative"]
143 save(C.Neg.matchedBF ,file=file.path(dir.rdata ,’TBPC_hivNeg_matchedBloodFluid
.RData’))
144 C.Pos.matchedBF <-C.BPF[,C.BPF$HIV.Status =="positive"]
145 save(C.Pos.matchedBF ,file=file.path(dir.rdata ,’TBPC_hivPos_matchedBloodFluid
.RData’))
146 C.Pos.EFF.matchedBF <-C.Pos.matchedBF[,C.Pos.matchedBF$ECP=="Eff"]
147 save(C.Pos.EFF.matchedBF ,file=file.path(dir.rdata ,’TBPC_hivPos_EFF_
matchedBloodFluid.RData ’))
148 C.Pos.EC.matchedBF <-C.Pos.matchedBF[,C.Pos.matchedBF$ECP=="EC"]
149 save(C.Pos.EC.matchedBF ,file=file.path(dir.rdata ,’TBPC_hivPos_EC_
matchedBloodFluid.RData ’))
150
151 #Question 4: LTBI
152 B.Neg.HL<-hivNegBloodArrays[,hivNegBloodArrays$class3 =="notActiveTB"]
153 save(B.Neg.HL ,file=file.path(dir.rdata ,’blood_hivNeg_H_L.RData’))
154 B.Pos.HL<-hivPosBloodArrays[,hivPosBloodArrays$class3 =="notActiveTB"]
155 save(B.Pos.HL ,file=file.path(dir.rdata ,’blood_hivPos_H_L.RData’))
156
157 #Question 5: HIV in not active TB
158 B.N.PosNeg <-bloodArrays[,bloodArrays$class3 =="notActiveTB"]
159 save(B.N.PosNeg ,file=file.path(dir.rdata ,’blood_notActiveTB_PosNeg.RData ’))
160 B.H.PosNeg <-bloodArrays[,bloodArrays$class2 =="CON_healthy"]
161 save(B.H.PosNeg ,file=file.path(dir.rdata ,’blood_healthy_PosNeg.RData ’))
162 B.L.PosNeg <-bloodArrays[,bloodArrays$class2 =="CON_LTBI"]
163 save(B.L.PosNeg ,file=file.path(dir.rdata ,’blood_LTBI_PosNeg.RData ’))
164
165 #Question 6: TB site
166 B.Pos.PTB_TBPC <-hivPosBloodArrays[,hivPosBloodArrays$class3 =="activeTB"]
167 save(B.Pos.PTB_TBPC ,file=file.path(dir.rdata ,’blood_hivPos_PTB_TBPC.RData’))
168 B.Neg.PTB_TBPC <-hivNegBloodArrays[,hivNegBloodArrays$class3 =="activeTB"]
169 save(B.Neg.PTB_TBPC ,file=file.path(dir.rdata ,’blood_hivNeg_PTB_TBPC.RData’))
170
171 #Question 7: Haemodynamic phenotype
172 B.C.Pos.EffEC <-hivPosBloodArrays[,hivPosBloodArrays$ECP=="Eff"|
hivPosBloodArrays$ECP=="EC"]
173 save(B.C.Pos.EffEC ,file=file.path(dir.rdata ,’blood_TBPC_hivPos_EffEC.RData’)
)
174 PF.C.Pos.EffEC <-fluidArrays [,( fluidArrays$ECP=="Eff"|fluidArrays$ECP=="EC")&
fluidArrays$HIV.Status =="positive"]
175 save(PF.C.Pos.EffEC ,file=file.path(dir.rdata ,’fluid_TBPC_hivPos_EffEC.RData’
))
176
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177 #Signatures
178
179 #Berry signatures
180 #file=file.path(dir.gx ," Nature_paper_transcripts ","P22_42_04Mar09_Training_
393_GX11.txt")
181 #np393 <-read.table(file ,header=TRUE ,sep="\t")
182 #char393 <-as.character(np393 [,1])
183
184 #berry.sig <-char393
185 #save(berry.sig ,file=file.path(dir.rdata ,’berry.sig.RData ’))
186
187 #need to get 86 transcript list; downloaded as xls
188
189 #import
190 file86=file.path(dir.gx,"Nature_paper_transcripts","nature09247 -s4.csv")
191 np86 <-read.csv(file86 ,header=TRUE ,sep=",")
192 berry .86 <-np86
193 save(berry.86,file=file.path(dir.rdata ,’berry .86. RData’))
194
195 #import manual berry393
196
197 #not done , need to fix format ...
198 file393=file.path(dir.gx ,"Nature_paper_transcripts","nature09247 -s2.csv")
199 np393 <-read.csv(file393 ,header=TRUE ,sep=",")
200 berry .393 <-np393
201 save(berry .393, file=file.path(dir.rdata ,’berry .393. RData’))
Listing A.11: Data-manager-Q.R
365
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
A Code
A.8 Analysis: IMPI-MA
1 ##TO DO
2 #1. table 1 code
3
4 #setup ####
5 #Current date string used for versioning output
6
7 source("/Users/armindeffur/Documents/002_Science_universal/Active_Research/
IMPI -Microarray/Projects/01_scripts/06_IMPI -MA/Analysis/00_System/System
_setup.R")
8 source(file.path(dir.R.files ,"superHeatmap.R"))
9 source(file.path(dir.R.files ,"superHeatmap2.R"))
10 par("xpd"=FALSE)
11 ## Individual data folders (specific for each part)
12 dir.rdata <- file.path(dir.data_root ,’09_IMPI_MA_DATA/06_RData_Q’)
13
14 #Output folders
15 dir.home <-dir.root
16 dir.main <- file.path(dir.root , ’02_output/06_IMPI -MA/DE_DC_CN’,’DE_AD_TB’)
17 ds<-Sys.time()
18 #versioned output
19 dir.output.version <-file.path(dir.main ,paste("version_",ds))
20
21 ## Define folder for storing results NB do this for each analysis
22 dir.results <- file.path(dir.output.version , "results")
23
24 ## Define folder for saving figures
25 dir.figures <- file.path(dir.output.version , "figures")
26
27 for (dir in c(dir.main , dir.figures , dir.results)) {
28 if (!file.exists(dir)) {
29 dir.create(dir , recursive=T,showWarnings=T)
30 }
31 }
32
33 #sink(type=" output",file=file.path(dir.results ," session_output.txt"))
34 sessionInfo ()
35 print(paste("Begin time:",ds))
36 print(paste("Results will be saved to", dir.results))
37 print(paste("Figures will be saved to", dir.figures))
38
39 #all iterators and their definitions
40 #q.i: loop over questions (n=7)
41 #filename: loop over filenames when loading RDtata files
42 #dataindex: loop over datasets when making datalist , colourmaps
43
44 #Make questions
45 #Questions constructs ####
46
47 questions=list(
48 "Tuberculosis"=list(
49 "datalist_filenames"=list("blood_hivNeg_aTB_noTB.RData","blood_hivPos_
aTB_noTB.RData"),
50 "dataset_variables"=list("B.Neg.AN","B.Pos.AN"),
51 "dataset_names"=list("Blood HIVneg activeTB -notActiveTB","Blood HIVpos
activeTB -notActiveTB"),
52 "contrast_variable"="class3",
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53 "colour_variable"="class",
54 "colourmap"=list("deepskyblue"="CON_LTBI","orange"="CON_PTB","green"="
CON_healthy","red"="TBPC"),
55 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY),
56 "wgcna_pheno"=c(),#column numbers in phenodata specific for the question
; may be empty
57 "wgcna_contrast"=list()
58 ),
59 "TBSite"=list(
60 "datalist_filenames"=list("blood_hivPos_PTB_TBPC.RData","blood_hivNeg_
PTB_TBPC.RData"),
61 "dataset_variables"=list("B.Pos.PTB_TBPC","B.Neg.PTB_TBPC"),
62 "dataset_names"=list("Blood HIVpos PTB -TBPC","Blood HIVneg PTB -TBPC"),
63 "contrast_variable"="class",
64 "colour_variable"="class",
65 "colourmap"=list("orange"="CON_PTB","red"="TBPC"),
66 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY),
67 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
68 ),
69 "LTBI"=list(
70 "datalist_filenames"=list("blood_hivPos_H_L.RData","blood_hivNeg_H_L.
RData"),
71 "dataset_variables"=list("B.Pos.HL","B.Neg.HL"),
72 "dataset_names"=list("Blood HIVpos Healthy -LTBI","Blood HIVneg Healthy -
LTBI"),
73 "contrast_variable"="class",
74 "colour_variable"="class",
75 "colourmap"=list("green"="CON_healthy","deepskyblue"="CON_LTBI"),
76 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY),
77 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
78 ),
79 "hdPhenotype"=list(
80 "datalist_filenames"=list("blood_TBPC_hivPos_EffEC.RData","fluid_TBPC_
hivPos_EffEC.RData"),
81 "dataset_variables"=list("B.C.Pos.EffEC","PF.C.Pos.EffEC"),
82 "dataset_names"=list("Blood TBPC HIVPos Eff -EC","Fluid TBPC HIVPos Eff -
EC"),
83 "contrast_variable"="ECP",
84 "colour_variable"="ECP",
85 "colourmap"=list("blue"="Eff","yellow"="EC"),
86 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY),
87 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
88 ),
89 "hiv_noTB"=list(
90 "datalist_filenames"=list("blood_notActiveTB_PosNeg.RData","blood_LTBI_
PosNeg.RData","blood_healthy_PosNeg.RData"),
91 "dataset_variables"=list("B.N.PosNeg","B.L.PosNeg","B.H.PosNeg"),
92 "dataset_names"=list("Blood not activeTB HIVpos -HIVneg","Blood LTBI
HIVpos -HIVneg","Blood Healthy HIVpos -HIVneg"),
93 "contrast_variable"="HIV.Status",
94 "colour_variable"="HIV.Status",
95 "colourmap"=list("green"="negative","red"="positive"),
96 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY ,
illuminaHumanv4PROBEQUALITY),
97 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
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98 ),
99 "hiv_TB"=list(
100 "datalist_filenames"=list("blood_aTB_HIVPosNeg.RData","fluid_aTB_
HIVPosNeg.RData","blood_defPTB_HIVPosNeg.RData","blood_defTBPC_HIVPosNeg
.RData"),
101 "dataset_variables"=list("B.A.PosNeg","PF.A.PosNeg","B.PTB.PosNeg","B.
TBPC.PosNeg"),
102 "dataset_names"=list("Blood activeTB HIVpos -HIVneg","Fluid activeTB
HIVpos -HIVneg","Blood PTB HIVpos -HIVneg","Blood TB-PC HIVpos -HIVneg"),
103 "contrast_variable"="HIV.Status",
104 "colour_variable"="HIV.Status",
105 "colourmap"=list("green"="negative","red"="positive"),
106 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY ,
illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY),
107 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
108 ),
109 "Compartment"=list(
110 "datalist_filenames"=list("TBPC_matchedBloodFluid.RData","TBPC_hivNeg_
matchedBloodFluid.RData","TBPC_hivPos_matchedBloodFluid.RData","TBPC_
hivPos_EFF_matchedBloodFluid.RData","TBPC_hivPos_EC_matchedBloodFluid.
RData"),
111 "dataset_variables"=list("C.BPF","C.Neg.matchedBF","C.Pos.matchedBF","C.
Pos.EFF.matchedBF","C.Pos.EC.matchedBF"),
112 "dataset_names"=list("TB -PC all blood -fluid","TB-PC HIVneg blood -fluid",
"TB -PC HIVpos blood -fluid","TB-PC HIVpos EFF blood -fluid","TB -PC HIVpos
EC blood -fluid"),
113 "contrast_variable"="Compartment",
114 "colour_variable"="Compartment",
115 "colourmap"=list("red"="blood","yellow"="fluid"),
116 "pqlist"=list(illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY ,
illuminaHumanv4PROBEQUALITY ,illuminaHumanv4PROBEQUALITY ,
illuminaHumanv4PROBEQUALITY),
117 "wgcna_pheno"=c()#column numbers in phenodata specific for the question;
may be empty
118 )
119 )
120
121 #for loops ####
122 #q.i is question iterator; length = 7
123
124 #debug
125 #q.i<-1
126
127 #real
128 for (q.i in 1: length(questions)){
129 #Question (c.q: "current question ")
130 c.q=questions [[q.i]]
131
132 #definitions for the current question ####
133 datalist.filenames=c.q$datalist_filenames
134 dataset.variables=c.q$dataset_variables
135 dataset.names=c.q$dataset_names
136 contrast.variable=c.q$contrast_variable
137 colour.variable=c.q$colour_variable
138 colourmap=c.q$colourmap
139 pqlist=c.q$pqlist
140 extra.traits <-c.q$wgcna_pheno
141
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142 print(paste("Results for Question ",q.i,": ",names(questions)[q.i],sep=""))
143
144 #load data and make datalist ####
145
146 for (filename in datalist.filenames){
147 load(file.path(dir.rdata ,filename))
148 }
149
150 datalist <-list()
151 for (dataindex in 1: length(datalist.filenames)){
152 datalist [[ dataindex ]]<-eval(parse(text=dataset.variables [[ dataindex ]]))
153 names(datalist)[[ dataindex ]] <-dataset.names [[ dataindex ]]
154 }
155
156 #make pqlist ####
157 pqlist <-c.q$pqlist
158
159 print(paste(c("Data to be analysed:",names(datalist))))
160
161 #generate table 1####
162 print("Table 1 data generation")
163 #
164 #Table 1: Compare groups across datasets
165
166 #contrasts
167 contr <-lapply(dataset.variables ,function(any){
168 as.factor(eval(parse(text=paste(any ,"$",contrast.variable ,sep=""))))
169 }
170 )
171 #AGE ####
172 ##### AGE across all
173 ageAA <-lapply(datalist ,function(part){as.numeric(pData(part)$AGE_CALC)})
174 n.age <-lapply(ageAA ,length)
175 sum.age <-lapply(ageAA ,summary)
176 test.age <-try(kruskal.test(ageAA))
177 if(class(test.age)=="try -error"){
178 test.age$p.value=NA
179 test.age$method="NA"}
180
181 ##### AGE across (contrast1)
182 ageAC1 <-lapply(datalist ,function(part){
183 as.numeric(pData(part)
184 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep="")
))
185 == levels(
186 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[1]] ,]
187 $AGE_CALC)
188 }
189 )
190
191 n.age.C1<-lapply(ageAC1 ,length)
192 sum.age.C1<-lapply(ageAC1 ,summary)
193 test.age.C1<-try(kruskal.test(ageAC1))
194
195 if(class(test.age.C1)=="try -error"){
196 test.age.C1$p.value=NA
197 test.age.C1$method="NA"}
198
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199
200 ##### AGE across (contrast1)
201 ageAC2 <-lapply(datalist ,function(part){
202 as.numeric(pData(part)
203 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep="")
))
204 == levels(
205 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[2]] ,]
206 $AGE_CALC)
207 }
208 )
209
210 n.age.C2<-lapply(ageAC2 ,length)
211 sum.age.C2<-lapply(ageAC2 ,summary)
212 test.age.C2<-try(kruskal.test(ageAC2))
213
214 if(class(test.age.C2)=="try -error"){
215 test.age.C2$p.value=NA
216 test.age.C2$method="NA"}
217
218
219
220 ##### AGE down (all sets)
221
222 age.down.data <-list()
223 age.down.n<-list()
224 age.down.sum <-list()
225 age.down.test <-list()
226 for (set in 1: length(datalist)){
227 age.down.data[[set]]<-list(ageAC1 [[set]],ageAC2 [[set]])
228 age.down.n[[set]]<-lapply(age.down.data[[set]],length)
229 age.down.sum[[set]]<-lapply(age.down.data[[set]],summary)
230 age.down.test[[set]]<-try(kruskal.test(age.down.data[[set]]))
231 if(class(age.down.test[[set]])=="try -error"){
232 age.down.test[[set]]$p.value=NA
233 age.down.test[[set]]$method="NA"}
234
235 }
236 #SEX ####
237 #SEX all across
238 sexAA <-lapply(datalist ,function(part){as.factor(pData(part)$SEX)})
239 for(sexindex in 1: length(sexAA)){levels(sexAA [[ sexindex ]]) <-c("Female","Male
")}
240
241 sexAAdata <-t(matrix(as.numeric(unlist(lapply(sexAA ,function(z){rbind(as.
vector(table(z)))}))),ncol=length(sexAA),dimnames=list(c("Female","Male"
),unlist(dataset.names))))
242 sexAA.test <-try(if(length(sexAA)==2){prop.test(sexAAdata)}else{fisher.test(
sexAAdata)})
243 if(class(sexAA.test)=="try -error"){
244 sexAA.test$p.value=NA
245 sexAA.test$method="NA"}
246
247 ##### Sex across (contrast1)
248 sexAC1 <-lapply(datalist ,function(part){
249 as.factor(pData(part)
250 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep="")
))
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251 == levels(
252 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[1]] ,]
253 $SEX)
254 }
255 )
256
257 for(sexindex in 1: length(sexAC1)){levels(sexAC1 [[ sexindex ]]) <-c("Female","
Male")}
258 sexAC1data <-t(matrix(as.numeric(unlist(lapply(sexAC1 ,function(z){rbind(as.
vector(table(z)))}))),ncol=length(sexAC1),dimnames=list(c("Female","Male
"),unlist(dataset.names))))
259 sexAC1.test <-try(if(length(sexAC1)==2){prop.test(sexAC1data)}else{fisher.
test(sexAC1data)})
260
261 if(class(sexAC1.test)=="try -error"){
262 sexAC1.test$p.value=NA
263 sexAC1.test$method="NA"}
264
265
266 ##### Sex across (contrast2)
267 sexAC2 <-lapply(datalist ,function(part){
268 as.factor(pData(part)
269 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep=""))
)
270 == levels(
271 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[2]] ,]
272 $SEX)
273 }
274 )
275
276 for(sexindex in 1: length(sexAC2)){levels(sexAC2 [[ sexindex ]]) <-c("Female","
Male")}
277
278 sexAC2data <-t(matrix(as.numeric(unlist(lapply(sexAC2 ,function(z){rbind(as.
vector(table(z)))}))),ncol=length(sexAC2),dimnames=list(c("Female","Male
"),unlist(dataset.names))))
279 sexAC2.test <-try(if(length(sexAC2)==2){prop.test(sexAC2data)}else{fisher.
test(sexAC2data)})
280
281 if(class(sexAC2.test)=="try -error"){
282 sexAC2.test$p.value=NA
283 sexAC2.test$method="NA"}
284
285 ##### Sex down
286 sex.down.data <-list()
287 sex.down.test <-list()
288 for (set in 1: length(datalist)){
289 sex.down.data[[set]]<-matrix(rbind(sexAC1data[set ,], sexAC2data[set ,]),ncol
=2,dimnames=list(levels(contr [[1]]) ,c("Female","Male")))
290 sex.down.test[[set]]<-try(prop.test(sex.down.data[[set]]))
291 if(class(sex.down.test[[set]])=="try -error"){
292 sex.down.test[[set]]$p.value=NA
293 sex.down.test[[set]]$method="NA"}
294 }
295
296
297 #CD4
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298 #CD4 ####
299 ##### CD4 across all
300 CD4AA <-lapply(datalist ,function(part){as.numeric(pData(part)$CD4)})
301 n.CD4 <-lapply(CD4AA ,length)
302 sum.CD4 <-lapply(CD4AA ,summary)
303 test.CD4 <-try(kruskal.test(CD4AA))
304
305 if(class(test.CD4)=="try -error"){
306 test.CD4$p.value=NA
307 test.CD4$method="NA"}
308
309 ##### CD4 across (contrast1)
310 CD4AC1 <-lapply(datalist ,function(part){
311 as.numeric(pData(part)
312 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep="")
))
313 == levels(
314 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[1]] ,]
315 $CD4)
316 }
317 )
318
319 n.CD4.C1<-lapply(CD4AC1 ,length)
320 sum.CD4.C1<-lapply(CD4AC1 ,summary)
321 test.CD4.C1<-try(kruskal.test(CD4AC1))
322
323 if(class(test.CD4.C1)=="try -error"){
324 test.CD4.C1$p.value=NA
325 test.CD4.C1$method="NA"}
326
327 ##### CD4 across (contrast2)
328 CD4AC2 <-lapply(datalist ,function(part){
329 as.numeric(pData(part)
330 [eval(parse(text=paste("pData(part)$",contrast.variable ,sep="")
))
331 == levels(
332 as.factor(eval(parse(text=paste(dataset.variables ,"$",
contrast.variable ,sep="")))))[[2]] ,]
333 $CD4)
334 }
335 )
336
337 n.CD4.C2<-lapply(CD4AC2 ,length)
338 sum.CD4.C2<-lapply(CD4AC2 ,summary)
339 test.CD4.C2<-try(kruskal.test(CD4AC2))
340
341 if(class(test.CD4.C2)=="try -error"){
342 test.CD4.C2$p.value=NA
343 test.CD4.C2$method="NA"}
344 ##### CD4 down (all sets)
345
346 CD4.down.data <-list()
347 CD4.down.n<-list()
348 CD4.down.sum <-list()
349 CD4.down.test <-list()
350 for (set in 1: length(datalist)){
351 CD4.down.data[[set]]<-list(CD4AC1 [[set]],CD4AC2 [[set]])
352 CD4.down.n[[set]]<-lapply(CD4.down.data[[set]],length)
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353 CD4.down.sum[[set]]<-lapply(CD4.down.data[[set]],summary)
354 CD4.down.test[[set]]<-try(kruskal.test(CD4.down.data[[set]]))
355 if(class(CD4.down.test[[set]])=="try -error"){
356 CD4.down.test[[set]]$p.value=NA
357 CD4.down.test[[set]]$method="NA"}
358 }
359 #print and export table 1 for each question ####
360
361 names.across <-c(unlist(lapply(dataset.variables ,function(x){c(paste(x,"Med")
,paste(x,"LQ"),paste(x,"UQ"))})),"P val","Test")
362 age.line0 <-c(rep(c("Median","LQ","UQ"),length(dataset.names)),"Pval","Test")
363 age.line1 <-c(unlist(lapply(n.age ,function(x){c(x,"","")})),"","")
364 age.line2 <-unlist(list(lapply(sum.age ,function(x){x[c(3,2,5)]}),list(sprintf
("%.3f",test.age$p.value)),list(substr(test.age$method ,1 ,20))))
365 age.line3 <-unlist(list(lapply(sum.age.C1 ,function(x){x[c(3,2,5)]}),list(
sprintf("%.3f",test.age.C1$p.value)),list(substr(test.age.C1$method
,1,20))))
366 age.line4 <-unlist(list(lapply(sum.age.C2 ,function(x){x[c(3,2,5)]}),list(
sprintf("%.3f",test.age.C2$p.value)),list(substr(test.age.C2$method
,1,20))))
367 age.line5 <-unlist(list(unlist(lapply(age.down.test ,function(x){c(sprintf("
%.3f",x$p.value),"","")})),list("","")),recursive=T)
368 age.line6 <-unlist(list(unlist(lapply(age.down.test ,function(x){c(substr(x$
method ,1 ,20),"","")})),list("","")),recursive=T)
369
370 sex.line0 <-c(rep(c("prop F","Female","Male"),length(dataset.names)),"Pval","
test")
371 sex.line1 <-c(as.character(apply(sexAAdata ,1, function(x){
372 c(
373 sprintf("%.3f",x[1]/x[2]),
374 x[1],
375 x[2]
376 )
377 })),sprintf("%.3f",sexAA.test$p.value),
378 substr(sexAA.test$method ,1 ,20))
379 sex.line2 <-c(as.character(apply(sexAC1data ,1, function(x){
380 c(
381 sprintf("%.3f",x[1]/x[2]),
382 x[1],
383 x[2]
384 )
385 })),sprintf("%.3f",sexAC1.test$p.value),
386 substr(sexAC1.test$method ,1 ,20))
387
388 sex.line3 <-c(as.character(apply(sexAC2data ,1, function(x){
389 c(
390 sprintf("%.3f",x[1]/x[2]),
391 x[1],
392 x[2]
393 )
394 })),sprintf("%.3f",sexAC2.test$p.value),
395 substr(sexAC2.test$method ,1 ,20))
396 sex.line4 <-unlist(list(unlist(lapply(sex.down.test ,function(x){c(sprintf("
%.3f",x$p.value),"","")})),list("","")),recursive=T)
397 sex.line5 <-unlist(list(unlist(lapply(sex.down.test ,function(x){c(substr(x$
method ,1 ,20),"","")})),list("","")),recursive=T)
398
399 CD4.line0 <-c(rep(c("Median","LQ","UQ"),length(dataset.names)),"Pval","Test")
400 CD4.line1 <-c(unlist(lapply(n.CD4 ,function(x){c(x,"","")})),"","")
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401 CD4.line2 <-unlist(list(lapply(sum.CD4 ,function(x){x[c(3,2,5)]}),list(sprintf
("%.3f",test.CD4$p.value)),list(substr(test.CD4$method ,1 ,20))))
402 CD4.line3 <-unlist(list(lapply(sum.CD4.C1 ,function(x){x[c(3,2,5)]}),list(
sprintf("%.3f",test.CD4.C1$p.value)),list(substr(test.CD4.C1$method
,1,20))))
403 CD4.line4 <-unlist(list(lapply(sum.CD4.C2 ,function(x){x[c(3,2,5)]}),list(
sprintf("%.3f",test.CD4.C2$p.value)),list(substr(test.CD4.C2$method
,1,20))))
404 CD4.line5 <-unlist(list(unlist(lapply(CD4.down.test ,function(x){c(sprintf("
%.3f",x$p.value),"","")})),list("","")),recursive=T)
405 CD4.line6 <-unlist(list(unlist(lapply(CD4.down.test ,function(x){c(substr(x$
method ,1 ,20),"","")})),list("","")),recursive=T)
406
407
408 dft <-data.frame(rbind(
409 age.line0 ,age.line2 ,age.line3 ,age.line4 ,age.line5 ,age.line6 ,
410 sex.line0 ,sex.line1 ,sex.line2 ,sex.line3 ,sex.line4 ,sex.line5 ,
411 CD4.line0 ,CD4.line2 ,CD4.line3 ,CD4.line4 ,CD4.line5 ,CD4.line6
412 ))
413
414 names.down <-c("Age","age_All",paste("age_",levels(contr [[1]])),"age_P value"
,"age_Test",
415 "Sex","sex_All",paste("sex_",levels(contr [[1]])),"sex_P value"
,"sex_Test",
416 "CD4","CD4_All",paste("CD4_",levels(contr [[1]])),"CD4_P value"
,"CD4_Test"
417 )
418
419 row.names(dft)<-c(names.down)
420
421 names(dft)<-unlist(c(lapply(dataset.names ,function(x){c(x,"","")}),"Pval","
Test"))
422
423 #hardcoded!
424 #xt<-xtable(dft ,align=c("p{1cm}|","p{1cm}|","p{0.8cm}|","p{0.8cm}|","p{1cm
}|","p{0.8cm}|","p{0.8cm}|","p{0.8cm}|","p{1cm}"))
425 xt<-xtable(dft ,align=c("|",rep(c("p{1cm}|"),ncol(dft)),"p{1cm}|"))
426
427 print(xt ,hline.after =-1:nrow(dft),include.colnames=T,size=c("tiny"),file=(
428 file.path(dir.results ,paste("Table 1 for question ",q.i,": ",names(
questions)[[q.i]],".tex",sep=""))
429 ))
430
431
432
433 #temporary q.i closure
434 #}
435
436 #start analysis ####
437
438 #analysis for loop
439 for (i in 1: length(datalist)){
440
441 print(paste("current dataset: ",names(datalist)[[i]]))
442 ##DE analysis ####
443 analysis="DE"
444 an.count <-1
445 print("Analysis 1: Differential expression")
446
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447 #define empty lists required for DE analysis ####
448 tbstat=list()
449
450 datalist.v<-list()
451 datalist.q<-list()
452 data.fil <-list()
453 data.v.fil <-list()
454
455 tbstat.class=list()
456 classcolours=list()
457
458 design <-list()
459 contrast <-list()
460 fit <-list()
461 fit2 <-list()
462 gr<-list()
463 vc<-list()
464 gr2 <-list()
465 vc<-list()
466 vc2 <-list()
467 reslist <-list()
468 reslistTT <-list()
469 reslistTTall <-list()
470 reslistTT30 <-list()
471 reslistTT100 <-list()
472 reslistTT2000 <-list()
473 reslistTT8000 <-list()
474 reslistTT16000 <-list()
475
476 #Make class levels and colours ####
477
478 #tbstat=list(as.factor(B.N.AX$class2),as.factor(B.P.AX$class2))
479 tbstat [[i]]<-as.factor(eval(parse(text=paste(dataset.variables [[i]],"$",
colour.variable ,sep=""))))
480 #levels(tbstat [[i]]) <-colourmap
481 #}
482
483 #for (dataindex in 1: length(datalist)){
484 classcolours [[i]]<-tbstat [[i]]
485 levels(classcolours [[i]]) <-colourmap
486 #}
487
488 #Show raw data ####
489
490 #boxplots and stripcharts
491 figure <-1
492 setwd(dir.figures)
493
494 #fix this by integrating into for loop
495 colnames(exprs(datalist [[i]]))<-eval(parse(text=paste(dataset.variables [[i
]],"$","sample_name",sep="")))
496 #colnames(exprs(datalist [[1]]))<-B.N.AX$sample_name
497 #colnames(exprs(datalist [[2]]))<-B.P.AX$sample_name
498
499
500 # the order of this depends completely on the order in the csv file - it
should not impact on the actual analysis. Just need to make sure that
the class assignments for DE are correct
501
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502 #for (i in 1: length(datalist)){
503 boxplot(datalist [[i]],main=names(datalist)[i],col=as.character(
classcolours [[i]]))
504 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’boxplot ’),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
505 #}
506
507 figure <-figure +1
508
509 #Outlier plot
510 #for (i in 1: length(datalist)){
511 plot(datalist [[i]],what="outlier",main=names(datalist)[i])
512 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’outlier_plot’),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
513 #}
514 figure <-figure +1
515
516 #MDS all probes
517
518 #for (i in 1: length(datalist)){
519 plotSampleRelationsAD(datalist [[i]],method="mds",color=as.character(
classcolours [[i]]),plotchar =16)
520 legend("bottomleft",
521 levels(tbstat [[i]]),
522 pch=16,
523 col=levels(classcolours [[i]]),
524 cex =.8
525 )
526 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"MDS_all"),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
527 #}
528 figure <-figure +1
529
530 #PCA all probes
531 #for (i in 1: length(datalist)){
532 l=colnames(exprs(datalist [[i]]))
533 #trueClasses <-tbstat
534 spca <- SamplePCA(exprs(datalist [[i]]), tbstat [[i]])
535 plot(spca , col=levels(classcolours [[i]]),main=paste(nrow(exprs(datalist [[i
]]))," probes"))#,cex=2,cex.axis=2,cex.main=3,cex.lab=2.5,pch =16)
536 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
537 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
538 legend("bottomleft",
539 levels(tbstat [[i]]),
540 pch=16,
541 col=levels(classcolours [[i]]),
542 cex =.8
543 )
544 # mark the group centers
545
546 for (type in 1: length(levels(tbstat [[i]]))){
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547 x1 <- predict(spca , matrix(apply(t(exprs(datalist [[i]])[,grep(levels(
tbstat [[i]])[[type]],eval(parse(text=paste("datalist [[i]]$",colour.
variable ,sep=""))))]), 2, mean), ncol =1))
548 points(x1[1], x1[2], col=levels(classcolours [[i]])[[type]], cex=6,pch=9)}
549
550
551 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"PCA_all"),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
552 #}
553 figure <-figure +1
554
555 #preprocess ####
556
557 #Variance stabilising transformation
558 #datalist.v<-list()
559 #for (i in 1: length(datalist)){
560 datalist.v[[i]]<-lumiT(datalist [[i]], simpleOutput=FALSE)
561 #}
562 #Quantile normalise
563 #datalist.q<-list()
564 #for (i in 1: length(datalist.v)){
565 datalist.q[[i]]<-lumiN(datalist.v[[i]],method="quantile")
566 #}
567
568 #show preprocessed data ####
569 #boxplots of quantile normalised data
570 #for (i in 1: length(datalist.q)){
571 boxplot(datalist.q[[i]],main=names(datalist.q)[i],col=as.character(
classcolours [[i]]))
572 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’boxplot (q norm
)’),export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5)
)/2*height)
573 #}
574 figure <-figure +1
575
576 #density plots of quantile normalised data
577 #for (i in 1: length(datalist.q)){
578 density(datalist.q[[i]],main=names(datalist)[i],col=as.character(
classcolours [[i]]),addLegend=FALSE)
579 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’density plot
qnorm’),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
580 #}
581 figure <-figure +1
582
583 #MDS all probes (normalised)
584
585 #for (i in 1: length(datalist.q)){
586 plotSampleRelationsAD(datalist.q[[i]],method="mds",color=as.character(
classcolours [[i]]),plotchar =16)
587 legend("bottomleft",
588 levels(tbstat [[i]]),
589 pch=16,
590 col=levels(classcolours [[i]]),
591 cex =.8)
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592 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"MDS_norm"),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
593 #}
594 figure <-figure +1
595
596
597 #PCA all probes (normalised)
598 #for (i in 1: length(datalist.q)){
599 l=colnames(exprs(datalist.q[[i]]))
600 spca <- SamplePCA(exprs(datalist.q[[i]]), tbstat [[i]])
601 plot(spca , col=levels(classcolours [[i]]),main=paste(nrow(exprs(datalist.q
[[i]]))," probes (normalised)"))#,cex=2,cex.axis=2,cex.main=3,cex.lab
=2.5,pch =16)
602 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
603 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
604 legend("bottomleft",
605 levels(tbstat [[i]]),
606 pch=16,
607 col=levels(classcolours [[i]]),
608 cex =.8)
609 # mark the group centers
610 for (type in 1: length(levels(tbstat [[i]]))){
611 x1 <- predict(spca , matrix(apply(t(exprs(datalist.q[[i]])[,grep(levels(
tbstat [[i]])[[type]],eval(parse(text=paste("datalist [[i]]$",colour.
variable ,sep=""))))]), 2, mean), ncol =1))
612 points(x1[1], x1[2], col=levels(classcolours [[i]])[[type]], cex=6,pch=9)}
613
614
615 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"PCA_all"),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
616 #}
617 figure <-figure +1
618
619 #filter ####
620
621 #new filter (requires beadarray; boxplot now uses ggplot2) (libraries
require integration with system setup)
622
623 #filter qnorm data
624 #data.fil <-list()
625 #for (i in 1: length(datalist.q)){
626 x <- pqlist [[i]]
627 mapped_probes <- mappedkeys(x)
628 # Convert to a list
629 xx <- as.list(x[mapped_probes ])
630 ids <- as.character(nuID2IlluminaID(as.character(featureNames(datalist.q[[
i]])),chipVersion=getChipInfo(datalist.q[[i]])$chipVersion [[1]]))
631 is<-intersect(names(unlist(xx)),ids)#remove probes not in database , then
the mget call will not fail
632 qual <- unlist(mget(is, pqlist [[i]]))
633 table(qual)
634 rem <- qual == "No match" | qual == "Bad" | is.na(qual)
635 data.fil[[i]]<- datalist.q[[i]][!rem , ]
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636 data.v.fil[[i]]<- datalist.v[[i]][!rem , ]
637
638 #show filtered probes ####
639
640 #filtered probes (PROBEQUALITY)
641 #for (i in 1: length(data.fil)) {
642 par(mar=c(7,5,1,1))
643 boxplot(data.fil[[i]],las=2,col=as.character(classcolours [[i]]),main=paste
(names(datalist)[[i]],’Boxplot of selected probes ’))
644 par(parbackup)
645 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’boxplot
filtered probes ’),export.formats=export.formats.plots ,height=height ,
width =(1 + sqrt (5))/2*height)
646 #}
647
648 figure <-figure +1
649
650 #MDS selected probes
651
652 #for (i in 1: length(data.fil)){
653 plotSampleRelationsAD(data.fil[[i]],method="mds",color=as.character(
classcolours [[i]]),plotchar =16)
654 legend("bottomleft",
655 levels(tbstat [[i]]),
656 pch=16,
657 col=levels(classcolours [[i]]),
658 cex =.8)
659 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"MDS_filtered"),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
660 #}
661 figure <-figure +1
662
663 #PCA all probes (filtered)
664
665 #for (i in 1: length(data.fil)){
666 l=colnames(exprs(data.fil[[i]]))
667 spca <- SamplePCA(exprs(data.fil[[i]]), tbstat [[i]])
668 plot(spca , col=levels(classcolours [[i]]),main=paste(nrow(exprs(data.fil[[i
]]))," probes (filtered)"))#,cex=2,cex.axis=2,cex.main=3,cex.lab=2.5,pch
=16)
669 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
670 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
671 legend("bottomleft",
672 levels(tbstat [[i]]),
673 pch=16,
674 col=levels(classcolours [[i]]),
675 cex =.8)
676 # mark the group centers
677 for (type in 1: length(levels(tbstat [[i]]))){
678 x1 <- predict(spca , matrix(apply(t(exprs(data.fil[[i]])[,grep(levels(
tbstat [[i]])[[type]],eval(parse(text=paste("datalist [[i]]$",colour.
variable ,sep=""))))]), 2, mean), ncol =1))
679 points(x1[1], x1[2], col=levels(classcolours [[i]])[[type]], cex=6,pch=9)}
680
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681 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],"PCA_filtered"),export
.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height
)
682 #}
683 figure <-figure +1
684
685 #DE statistics ####
686
687 tbstat.class=list()
688 tbstat.class [[i]]<-as.factor(eval(parse(text=paste(dataset.variables [[i]],"$
",contrast.variable ,sep=""))))
689 contrast.levels <-levels(tbstat.class [[i]])
690
691 print(table(tbstat.class [[i]]))
692
693 #for (i in 1: length(data.fil)){
694 design [[i]]= model.matrix(~ -1+factor(tbstat.class [[i]]))
695 colnames(design [[i]]) <-levels(tbstat.class [[i]])
696 design [[i]]
697 #contrast [[i]]<-makeContrasts(activeTB -notActiveTB ,levels=design [[i]])
698 contrast [[i]]<-makeContrasts(
699 paste(contrast.levels [[1]] ,"-",contrast.levels [[2]]) ,
700 levels=design [[i]]
701 )
702 contrast [[i]]
703
704 #This is not ideal: use vanill pvalue of 0.05 and deal with very large or
small results
705 # effect.size <-pwr.t2n.test(n1=13,n2=29,d=NULL ,sig.level =0.01 , power =0.9,
alternative ="two.sided ")$d
706 # pval <-pwr.t2n.test(n1=table(tbstat.class[[i]]) [[1]],n2=table(tbstat.class
[[i]])[[2]] ,d=effect.size ,sig.level=NULL ,power =0.9, alternative ="two.
sided")$sig.level*3
707
708
709 # pwr.t2n.test(n1=5,n2=13,d=effect.size ,sig.level=NULL ,power =0.9, alternative
="two.sided")$sig.level*effect.size
710 # pwr.t2n.test(n1=20,n2=31,d=effect.size ,sig.level=NULL ,power =0.9,
alternative ="two.sided ")$sig.level*effect.size
711
712 #Linear model: tb status
713 fit[[i]]<-lmFit(data.fil[[i]],design [[i]])
714 fit2[[i]]<-contrasts.fit(fit[[i]],contrast [[i]])
715 fit2[[i]]<-eBayes(fit2[[i]])
716 gr[[i]]<-decideTests(fit2[[i]],adjust.method="none",p.value =0.05)
717 vc[[i]]<-vennCounts(gr[[i]])
718 gr2[[i]]<-decideTests(fit2[[i]],adjust.method="fdr",p.value =0.05)
719 vc2[[i]]<-vennCounts(gr2[[i]])
720 #Venn diagrams of DE probes
721 vennDiagram(gr[[i]])
722 vennDiagram(gr2[[i]])
723
724 #print unmodified results
725 print(paste("There are",vc[[i]][[4]] ,"probes significant at P=0.05 (
unadjusted) and",vc2[[i]][[4]] ,"probes significant at P=0.05 (BH
adjusted)"))
726
727 if(sum(mapply(abs ,gr2[[i]])) <300) {
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728 print(paste("with p value = 0.05","there are",sum(mapply(abs ,gr2[[i]])),"
DE probes and top 300 results will be used for the remainder",sep=" "));
729 gr2[[i]]=is.element(rownames(exprs(data.fil[[i]])),as.character(
probeID2nuID(topTable(fit2[[i]],coef=1,number =300, adjust.method="BH",
confint=T,sort.by="B",resort.by="logFC")[[1]]) [,7]))
730 }
731
732 if(sum(mapply(abs ,gr2[[i]])) >2000) {
733 print(paste("with p value = 0.05","there are",sum(mapply(abs ,gr2[[i]])),"
DE probes and top 2000 results will be used for the remainder",sep=" "))
;
734 gr2[[i]]=is.element(rownames(exprs(data.fil[[i]])),as.character(
probeID2nuID(topTable(fit2[[i]],coef=1,number =2000 , adjust.method="BH",
confint=T,sort.by="B",resort.by="logFC")[[1]]) [,7]))}
735
736 vc2[[i]]<-vennCounts(gr2[[i]])
737
738 #Venn diagrams of DE probes
739 vennDiagram(gr[[i]])
740 vennDiagram(gr2[[i]])
741
742 #results
743 reslist [[i]]<-featureNames(data.fil[[i]][ gr2[[i]]!=0,])
744 reslistTTall [[i]]<-topTable(fit2[[i]],coef=1,adjust.method="BH", confint=T
,sort.by="B",resort.by="logFC")
745 reslistTT30 [[i]]<-topTable(fit2[[i]],coef=1,number =30, adjust.method="BH",
confint=T,sort.by="B",resort.by="logFC")
746 reslistTT [[i]]<-topTable(fit2[[i]],coef=1,number =500, adjust.method="BH",
confint=T,sort.by="B",resort.by="logFC")
747 reslistTT100 [[i]]<-topTable(fit2[[i]],coef=1,number =100, adjust.method="BH"
, confint=T,sort.by="B",resort.by="logFC")
748 reslistTT2000 [[i]]<-topTable(fit2[[i]],coef=1,number =2000, adjust.method="
BH", confint=T,sort.by="B",resort.by="logFC")
749 reslistTT8000 [[i]]<-topTable(fit2[[i]],coef=1,number =8000, adjust.method="
BH", confint=T,sort.by="B",resort.by="logFC")
750 reslistTT16000 [[i]]<-topTable(fit2[[i]],coef=1,number =16000 , adjust.method=
"BH", confint=T,sort.by="B",resort.by="logFC")
751
752 #can also restrict by pvalue , lfc , etc.
753 #}
754
755 #volcanoplot
756 #for (i in 1: length(fit2)){
757 volcanoplot(fit2[[i]],coef=1, highlight=vc2[[i]][ ,2][2] , cex=1,pch=20,col="
red")
758 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’volcanoplot DE
probes ’),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
759 #}
760
761 figure <-figure +1
762
763 #show DE probes ####
764
765 #heatmaps
766 #DE probes
767
768 #for (i in 1: length(data.fil)){
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769 phenomatrix <-matrix(cbind(as.character(classcolours [[i]]),as.character(
classcolours [[i]])),ncol =2)
770 superHeatmap2(x=data.fil[[i]],y=gr2[[i]]!=0,phenomatrix=phenomatrix ,scale=
"row")
771 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],’heatmap DE
probes by pval’),export.formats=export.formats.plots ,height=height ,width
=(1 + sqrt (5))/2*height)
772 #}
773 figure <-figure +1
774 #top 500 by B
775
776 #for (i in 1: length(data.fil)){
777 phenomatrix <-matrix(cbind(as.character(classcolours [[i]]),as.character(
classcolours [[i]])),ncol =2)
778
779 subset <-is.element(rownames(exprs(data.fil[[i]])),as.character(
probeID2nuID(reslistTT [[i]][[1]]) [,7]))
780
781 superHeatmap2(x=data.fil[[i]],y=subset ,phenomatrix=phenomatrix ,scale="row"
)
782 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’heatmap diff probes
top 500 by B’),export.formats=export.formats.plots ,height=height ,width
=(1 + sqrt (5))/2*height);par(parbackup)
783 #}
784 figure <-figure +1
785
786 #MDS DE probes
787
788 #for (i in 1: length(data.fil)){
789 plotSampleRelationsAD(data.fil[[i]][ gr2[[i]]!=0,],method="mds",color=as.
character(classcolours [[i]]),plotchar =16)
790 legend("bottomleft",
791 levels(tbstat [[i]]),
792 pch=16,
793 col=levels(classcolours [[i]]),
794 cex =.8)
795 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"MDS_DE"),export
.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height
)
796 #}
797 figure <-figure +1
798
799 #PCA all probes (DE)
800
801 #for (i in 1: length(data.fil)){
802 l=colnames(exprs(data.fil[[i]]))
803 spca <- SamplePCA(exprs(data.fil[[i]][ gr2[[i]]!=0,]), tbstat [[i]])
804 plot(spca , col=levels(classcolours [[i]]),main=paste(nrow(exprs(data.fil[[i
]][ gr2[[i]]!=0,]))," probes"))#,cex=2,cex.axis=2,cex.main=3,cex.lab=2.5,
pch =16)
805 mtext(sprintf("%.2f",spca@variances [1]/sum(spca@variances)),side=1,line=3,
adj=1,cex =1.5)
806 mtext(sprintf("%.2f",spca@variances [2]/sum(spca@variances)),side=2,line=3,
adj=1,cex =1.5)
807 legend("bottomleft",
808 levels(tbstat [[i]]),
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809 pch=16,
810 col=levels(classcolours [[i]]),
811 cex =.8)
812 # mark the group centers
813 for (type in 1: length(levels(tbstat [[i]]))){
814 x1 <- predict(spca , matrix(apply(t(exprs(data.fil[[i]][ gr2[[i]]!=0,])[,
grep(levels(tbstat [[i]])[[type]],eval(parse(text=paste("datalist [[i]]$",
colour.variable ,sep=""))))]), 2, mean), ncol =1))
815 points(x1[1], x1[2], col=levels(classcolours [[i]])[[type]], cex=6,pch=9)}
816
817 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"PCA_DE"),export
.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*height
)
818 #}
819 figure <-figure +1
820
821 #Export the probe lists ####
822
823 dict <-nuID2IlluminaID(as.character(reslist [[i]]),species="Human")
824 dict.entrez <-nuID2EntrezID(as.character(reslist [[i]]),filterTh = NULL ,lib.
mapping=’lumiHumanIDMapping ’, returnAllInfo = TRUE)
825 dict3 <-merge(dict ,dict.entrez ,by.x="nuID",by.y=0)
826
827 reslistTT2000 [[i]]$ProbeID <-sapply(reslistTT2000 [[i]]$ProbeID ,function(x){
sprintf("%010d",as.numeric(x))})
828 full <-merge(dict3 ,reslistTT2000 [[i]],by.x="Array_Address_Id",by.y="ProbeID",
all.x=T)
829
830 write.csv(dict3 ,file=file.path(dir.results ,paste(analysis ,dataset.names [[i
]],".csv")))
831 write.csv(reslistTT [[i]],file=file.path(dir.results ,paste(analysis ,dataset.
names[[i]],"_top500.csv")))
832 write.csv(full ,file=file.path(dir.results ,paste(analysis ,dataset.names [[i]],
"_sigWithFC.csv")))
833 write.csv(reslistTT2000 [[i]],file=file.path(dir.results ,paste(analysis ,
dataset.names [[i]],"_top2000.csv")))
834
835 xtabTop30 <-xtable(reslistTT30 [[i]],align=c(rep(c("|p{1.2cm}"),ncol(
reslistTT30 [[i]])),"|p{1cm}|"))
836
837 print(xtabTop30 ,hline.after=-1: nrow(reslistTT30 [[i]]),include.colnames=T,
include.rownames=F,size=c("tiny"),file=(
838 file.path(dir.results ,paste("Top 30 probes for question ",q.i,": ",names(
questions)[[q.i]],"_",dataset.names [[i]],".tex",sep=""))
839 ))
840
841 #temp closure for DE code
842 #} #opened on line 379
843
844 #Comparison
845
846 # #check overlap HIVneg and HIVpos (i.e. this is a comparison , not a
contrast)####
847 #
848 # #this can be moved to venn script later
849 #
850 # #Venn diagram (this is actually pretty good)
851 # venndatax=list()
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852 # venndatax [[i]]<-reslist [[i]]
853 # venndata500 <-list()
854 # #for (i in 1: length(reslistTT)){
855 # venndata500 [[i]]<-reslistTT [[i]][,2]
856 # #}
857 # venndata100 <-list()
858 # #for (i in 1: length(reslistTT100)){
859 # venndata100 [[i]]<-reslistTT100 [[i]][,2]
860 # #}
861 # temp.venn.7<-venn.diagram(
862 # x = venndatax ,
863 # category=c(" HIVneg","HIVpos "),
864 # #filename = file.path(dir.figures ," fig71_Venn_3set_lh_al_ah.tiff"),
865 # #filename = file.path(dir.figures ,paste ("fig",figure ,"_Venn_4set_gene.
tiff",sep ="")),
866 # filename = NULL ,
867 # scaled = F, ext.text = TRUE , ext.line.lwd = 2,
868 # ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
869 # inverted = TRUE ,
870 # cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
871 # #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
872 # # main.cex = 2, sub.cex = 1,
873 # fill=c("green","red"),
874 # alpha=c(.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
875 # )
876 # pdf(file=file.path(dir.figures ,paste ("fig",figure ,"_Venn_2set_probe.pdf",
sep ="")),height=7,width =(1 + sqrt (5))/2*7)
877 # grid.draw(temp.venn .7)
878 # dev.off()
879 # figure <-figure +1
880 #
881 # temp.venn.8<-venn.diagram(
882 # x = venndata500 ,
883 # category=c(" HIVneg","HIVpos "),
884 # #filename = file.path(dir.figures ," fig71_Venn_3set_lh_al_ah.tiff"),
885 # #filename = file.path(dir.figures ,paste ("fig",figure ,"_Venn_4set_gene.
tiff",sep ="")),
886 # filename = NULL ,
887 # scaled = F, ext.text = TRUE , ext.line.lwd = 2,
888 # ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
889 # inverted = TRUE ,
890 # cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
891 # #main = "Overlap", sub = "MA, VAL , TRAIN ","393",
892 # # main.cex = 2, sub.cex = 1,
893 # fill=c("green","red"),
894 # alpha=c(.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
895 # )
896 # pdf(file=file.path(dir.figures ,paste ("fig",figure ,"_Venn_2set_top500_probe
.pdf",sep ="")),height=7,width =(1 + sqrt (5))/2*7)
897 # grid.draw(temp.venn .8)
898 # dev.off()
899 # figure <-figure +1
900 #
901 # temp.venn.9<-venn.diagram(
902 # x = venndata100 ,
903 # category=c("HIV neg","HIVpos "),
904 # #filename = file.path(dir.figures ," fig71_Venn_3set_lh_al_ah.tiff"),
905 # #filename = file.path(dir.figures ,paste ("fig",figure ,"_Venn_4set_gene.
tiff",sep ="")),
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906 # filename = NULL ,
907 # scaled = F, ext.text = TRUE , ext.line.lwd = 2,
908 # ext.dist = -0.15, ext.length = 0.9, ext.pos = -4,
909 # inverted = TRUE ,
910 # cex = 2.5, cat.cex = 2.5, rotation.degree = 0,
911 # #main = "Overlap", sub = "MA , VAL , TRAIN ","393",
912 # # main.cex = 2, sub.cex = 1,
913 # fill=c("green","red"),
914 # alpha=c(.4 ,.4),height =3000, width =(1 + sqrt (5))/2*3000
915 # )
916 # pdf(file=file.path(dir.figures ,paste ("fig",figure ,"_Venn_2set_top100_probe
.pdf",sep ="")),height=7,width =(1 + sqrt (5))/2*7)
917 # grid.draw(temp.venn .9)
918 # dev.off()
919 # figure <-figure +1
920
921 #deconvolution ####
922 analysis="Deconvolution"
923 an.count <-2
924 print("Analysis 2: Deconvolution and csDE")
925
926 #setup ####
927 #questions:
928 #do I use VST data?
929 #do I use filtered subset for proportions and csDE?
930
931 #for (i in 1: length(datalist.v)){
932 figure <-1
933 #VST already done as well as filtering
934 dtd <-as(datalist.v[[i]],"ExpressionSet")
935 #colnamelist <-contrast.variable
936 meth=list("Abbas"=gedBlood(dtd ,verbose=T))
937 #for (h in 1:1){
938 h<-1
939
940 #deconvolution ####
941 decdat1 <-meth[[h]]
942 colname <-contrast.variable
943 colnames(coef(decdat1))<-eval(parse(text=paste("dtd$",colname ,sep="")))
944 decdat2 <-asCBC(decdat1)
945 decmat <-as.matrix(coef(decdat1))
946 decmat.red <-decmat[apply(decmat ,1,sum) >0,]
947 numbers <-as.vector(table(colnames(decmat.red)))
948 names <-names(table(colnames(decmat.red)))
949 nstring=paste("N=(",names [1]," ",numbers [1],",",names [2]," ",numbers [2],
")",sep="")
950
951
952 #stacked bar plot all types ####
953 par(parbackup)
954 par(mar=c(8 ,4.5 ,4.5 ,8))
955 barplot(coef(decdat1),las=2,col=brewer.pal(12,"Set3"),legend.text=
rownames(coef(decdat1)),main=paste("Proportions of" ,nrow(coef(decdat1))
,"cell types",names(meth)[[h]],names(datalist)[[i]],nstring),beside=F,
ylab="Proportion",
956 args.legend=c(x=ncol(decmat.red)*1.35,y=1,cex =.7),
957 cex.names =.8)
958 par(parbackup)
385
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
A Code
959 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"stacked_barplot
_all",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
960 figure <-figure +1
961
962
963 #stacked barplot detected types ####
964 par(parbackup)
965 par(mar=c(8 ,4.5 ,4.5 ,8))
966 barplot(decmat.red ,las=2,col=brewer.pal(12,"Set3"),legend.text=rownames(
decmat.red),main=paste("Proportions of" ,nrow(decmat.red),"cell types",
names(meth)[[h]],names(datalist)[[i]],nstring),beside=F,ylab="Proportion
",args.legend=c(x=ncol(decmat.red)*1.35,y=1,cex =.7),cex.names =.8)
967 par(parbackup)
968 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"stacked_barplot
_detected",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
969 figure <-figure +1
970
971
972 #stacked barplot CBC ####
973 par(parbackup)
974 par(mar=c(8 ,4.5 ,4.5 ,8))
975 barplot(coef(decdat2),las=2,col=brewer.pal(12,"Set3"),legend.text=
rownames(coef(decdat2)),main=paste("Proportions of CBC cell types",names
(meth)[[h]],names(datalist)[[i]],nstring),b side=F,ylab="Proportion",
args.legend=c(x=ncol(coef(decdat2))*1.35,y=1,cex =.7),cex.names =.8)
976 par(parbackup)
977 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"stacked_barplot
(CBC)",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
978 figure <-figure +1
979
980 #stacked barplot detected types (PBMC only) ####
981 decmat.red.PBMC <-matrix(data=NA,nrow=nrow(decmat.red)-1,ncol=ncol(decmat
.red))
982 rownames(decmat.red.PBMC)<-rownames(decmat.red[-nrow(decmat.red) ,])
983 colnames(decmat.red.PBMC)<-colnames(decmat.red)
984 for (l in 1:ncol(decmat.red)){
985 decmat.red.PBMC[,l]<-decmat.red[-nrow(decmat.red),l]/sum(decmat.red[-
nrow(decmat.red),l])
986 }
987
988 #stacked barplot PBMC ####
989 par(parbackup)
990 par(mar=c(8 ,4.5 ,4.5 ,8))
991 barplot(decmat.red.PBMC ,las=2,col=brewer.pal(12,"Set3"),legend.text=
rownames(decmat.red.PBMC),main=paste("Proportions of" ,nrow(decmat.red.
PBMC),"PBMC cell types",names(meth)[[h]],names(datalist)[[i]],nstring),
beside=F,ylab="Proportion",args.legend=c(x=ncol(decmat.red.PBMC)*1.35,y
=1,cex =.7),cex.names =.8)
992 par(parbackup)
993 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"stacked_barplot
(PBMC)",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
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994 figure <-figure +1
995
996 #boxplot by condition ####
997
998 #convert and calculate
999 clN <-colnames(decmat.red)
1000 dN<-t(decmat.red)
1001 vN<-as.vector(dN)
1002 clvN <-rep(clN ,nrow(decmat.red))
1003 typesN <-rownames(decmat.red)
1004 typevN <-list()
1005 for (j in 1:nrow(decmat.red)){typevN [[j]]= rep(typesN [[j]],ncol(decmat.
red))}
1006 typev2N <-unlist(typevN)
1007 ndN <-data.frame(vN ,clvN ,typev2N)
1008 levs <-levels(as.factor(colnames(decmat.red)))
1009
1010 #plot
1011 par(mar=c(10.5 ,4.5 ,4.5 ,8))
1012 boxplot(vN~clvN*typev2N ,data=ndN ,las=2,col=c("red","green","blue","
yellow")[1: length(levs)],main=paste("Relative abundance of cell types by
",colname ,"in",names(datalist)[[i]],nstring ,names(meth)[[h]]),varwidth=
FALSE)
1013 legend("topleft",legend =(levs),fill=c("red","green","blue","yellow"))
1014 par(parbackup)
1015 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"boxplot_by_
celltype",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
1016 figure <-figure +1
1017
1018 #exp
1019 #par(mar=c(10.5 ,4.5 ,4.5 ,8))
1020 #boxplotBy(decmat.red ,as.factor(colnames(decmat.red)),col=c("blue","
yellow "),main=paste("func:boxplotBy",colnamelist [[i]],"in",names(
datalist)[[i]],nstring ,names(meth)[[h]]),scale=TRUE)
1021 #par(parbackup)
1022 #export.plot(file.prefix=paste("fig",figure ,".",i," boxplot_by_celltype",
names(datalist)[[i]],names(meth)[[h]]),export.formats=export.formats.
plots ,height=height*1.5,width =(1 + sqrt (5))/2*height*1.5)
1023 #exp
1024 #}
1025 #}
1026
1027 #stats for comparisons ####
1028 statlist <-list()
1029 for (k in 1:nrow(decmat.red)) {statlist [[k]]<-wilcox.test(
1030 decmat.red[k,colnames(decmat.red)==levs [1]], decmat.red[k,colnames(
decmat.red)==levs [2]]
1031 )$p.value}
1032 tests <-data.frame("names"=rownames(decmat.red),"pval"=as.vector(unlist(
statlist)),"man_B"=as.vector(unlist(statlist))*nrow(decmat.red),"bonf"=p
.adjust(as.vector(unlist(statlist)),method="bonferroni"),"BH"=p.adjust(
as.vector(unlist(statlist)),method="BH"))
1033 write.csv(tests ,file=file.path(dir.results ,paste("Stats_",q.i,’.’,an.
count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,"_
wilcox.csv",sep="")))
1034
1035
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1036
1037 #boxplot by condition for matched blood/fluid for proportions normalised as
PBMCs (i.e. neutrophils removed)####
1038 #convert
1039
1040 clN <-colnames(decmat.red.PBMC)
1041 dN<-t(decmat.red.PBMC)
1042 vN<-as.vector(dN)
1043 clvN <-rep(clN ,nrow(decmat.red.PBMC))
1044 typesN <-rownames(decmat.red.PBMC)
1045 typevN <-list()
1046 for (j in 1:nrow(decmat.red.PBMC)){typevN [[j]]= rep(typesN [[j]],ncol(
decmat.red.PBMC))}
1047 typev2N <-unlist(typevN)
1048 ndN <-data.frame(vN ,clvN ,typev2N)
1049 levs <-levels(as.factor(colnames(decmat.red.PBMC)))
1050 par(mar=c(10.5 ,4.5 ,4.5 ,8))
1051 boxplot(vN~clvN*typev2N ,data=ndN ,las=2,col=c("red","green","blue","
yellow")[1: length(levs)],main=paste("Relative abundance of PBMC types by
",colname ,"in",names(datalist)[[i]],nstring ,names(meth)[[h]]))
1052 legend("topleft",legend =(levs),fill=c("red","green","blue","yellow"))
1053 par(parbackup)
1054 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"boxplot_by_PBMC
_celltype",names(meth)[[h]]),export.formats=export.formats.plots ,height=
height*1.5,width =(1 + sqrt (5))/2*height*1.5)
1055 figure <-figure +1
1056
1057 #stats for comparisons ####
1058 statlist <-list()
1059 for (k in 1:nrow(decmat.red.PBMC)) {statlist [[k]]<-wilcox.test(
1060 decmat.red.PBMC[k,colnames(decmat.red.PBMC)==levs [1]], decmat.red.PBMC[
k,colnames(decmat.red.PBMC)==levs [2]]
1061 )$p.value}
1062 #tests.PBMC <-data.frame(" names"= rownames(decmat.red.PBMC) ,"pval"=as.
vector(unlist(statlist))*nrow(decmat.red.PBMC))#bonferroni
1063 tests.PBMC <-data.frame("names"=rownames(decmat.red.PBMC),"pval"=as.
vector(unlist(statlist)),"man_B"=as.vector(unlist(statlist))*nrow(decmat
.red),"bonf"=p.adjust(as.vector(unlist(statlist)),method="bonferroni"),"
BH"=p.adjust(as.vector(unlist(statlist)),method="BH"))
1064 write.csv(tests.PBMC ,file=file.path(dir.results ,paste("Stats_PBMC_",q.i,
’.’,an.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname
,"_wilcox.csv",sep="")))
1065
1066 #csde ####
1067
1068 #PC added to B cells
1069 th<-apply(coef(decdat1)[1:2,],2,sum)
1070 tc<-apply(coef(decdat1)[3:4,],2,sum)
1071 b<-apply(coef(decdat1)[5:10,],2,sum)
1072 #pc<-coef(decdat1)[10,]
1073 nk<-apply(coef(decdat1)[11:12,],2, sum)
1074 mo<-apply(coef(decdat1)[13:14,],2, sum)
1075 dc<-apply(coef(decdat1)[15:16,],2, sum)
1076 neut <-coef(decdat1)[17,]
1077
1078 props <-matrix(
1079 rbind(th ,tc ,b,nk,mo,dc,neut
1080 ),nrow =7)
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1081 rownames(props)<-c("th","tc","b","nk","mo","dc","neut")
1082 colnames(props)<-colnames(coef(decdat1))
1083
1084 #Smallprops
1085 l<-apply(coef(decdat1)[1:10,],2,sum)
1086 nk<-apply(coef(decdat1)[11:12,],2, sum)
1087 apc <-apply(coef(decdat1)[13:16,],2, sum)
1088 neut <-coef(decdat1)[17,]
1089
1090 smallprops <-matrix(
1091 rbind(l,nk ,apc ,neut
1092 ),nrow =4)
1093 rownames(smallprops)<-c("lym","nk","apc","neut")
1094 colnames(smallprops)<-colnames(coef(decdat1))
1095
1096 subset <-is.element(rownames(exprs(datalist.v[[i]])),as.character(
probeID2nuID(reslistTT [[i]][[1]]) [,7]))
1097 subset2 <-is.element(rownames(exprs(datalist.v[[i]])),as.character(
targetID2nuID(featureData(Abbas)$SYMBOL ,lib=’lumiHumanIDMapping ’)))
1098 subset3 <-is.element(nuID2targetID(rownames(exprs(datalist.v[[i]]))),
featureData(Abbas)$SYMBOL)
1099 subset4 <-is.element(rownames(exprs(datalist.v[[i]])),as.character(
probeID2nuID(reslistTT2000 [[i]][[1]]) [,7]))
1100 subset5 <-is.element(rownames(exprs(datalist.v[[i]])),as.character(
probeID2nuID(reslistTT8000 [[i]][[1]]) [,7]))
1101
1102 if(min(table(tbstat.class [[i]]))<nrow(props)) {
1103 props <-smallprops
1104 print("smallprops used")} else {print("props used")}
1105
1106 #cs.de<-ged(dtd[subset|subset2 ,],coef(decdat1),data=as.factor(colnames(
coef(decdat1))),verbose=TRUE ,nperm =1000)
1107 #cs.de<-ged(dtd ,props ,data=as.factor(colnames(coef(decdat1))),verbose=
TRUE ,nperm =1000)
1108 # rm(cs.de)
1109 cs.de<-c(1,2,3)
1110 plot(x=1:3,y=1:3, main="csDE has failed!")
1111 try(
1112 cs.de<-ged(
1113 dtd[subset|subset3 ,],
1114 props ,
1115 data=as.factor(colnames(props)),
1116 verbose=TRUE ,nperm =1000))
1117 par(parbackup);
1118 try(csplot(cs.de));
1119 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"csDE_FDR_by_
celltype",names(datalist)[[i]],names(meth)[[h]]),export.formats=export.
formats.plots ,height=height*1.5,width =(1 + sqrt (5))/2*height*1.5);
1120 figure <-figure +1
1121
1122 tt<-"no csDE result"
1123 try(tt<-csTopTable(cs.de ,decreasing=F))
1124 if(tt!="no csDE result"){
1125 names(tt$neut)
1126 dict.th<-nuID2IlluminaID(as.character(names(tt$th)),species="Human")
1127 write.csv(dict.th,file=file.path(dir.results ,paste("csDE_Th_",q.i,’.’,an
.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv
",sep="")))
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1128 dict.tc<-nuID2IlluminaID(as.character(names(tt$tc)),species="Human")
1129 write.csv(dict.tc,file=file.path(dir.results ,paste("csDE_Tc_",q.i,’.’,an
.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv
",sep="")))
1130 dict.b<-nuID2IlluminaID(as.character(names(tt$b)),species="Human")
1131 write.csv(dict.b,file=file.path(dir.results ,paste("csDE_B_",q.i,’.’,an.
count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv"
,sep="")))
1132 dict.nk<-nuID2IlluminaID(as.character(names(tt$nk)),species="Human")
1133 write.csv(dict.nk,file=file.path(dir.results ,paste("csDE_NK_",q.i,’.’,an
.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv
",sep="")))
1134 dict.mo<-nuID2IlluminaID(as.character(names(tt$mo)),species="Human")
1135 write.csv(dict.mo,file=file.path(dir.results ,paste("csDE_MO_",q.i,’.’,an
.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv
",sep="")))
1136 dict.dc<-nuID2IlluminaID(as.character(names(tt$dc)),species="Human")
1137 write.csv(dict.dc,file=file.path(dir.results ,paste("csDE_DC_",q.i,’.’,an
.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".csv
",sep="")))
1138 dict.neut <-nuID2IlluminaID(as.character(names(tt$neut)),species="Human")
1139 write.csv(dict.neut ,file=file.path(dir.results ,paste("csDE_neut_",q.i,’.
’,an.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,"
.csv",sep="")))
1140 dict.lym <-nuID2IlluminaID(as.character(names(tt$lym)),species="Human")
1141 write.csv(dict.lym ,file=file.path(dir.results ,paste("csDE_lym_",q.i,’.’,
an.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".
csv",sep="")))
1142 dict.apc <-nuID2IlluminaID(as.character(names(tt$apc)),species="Human")
1143 write.csv(dict.apc ,file=file.path(dir.results ,paste("csDE_apc_",q.i,’.’,
an.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",colname ,".
csv",sep="")))} else print(tt)
1144
1145 # }methods in deconvolution for loop
1146 #}deconvoloution for loop
1147
1148 #wgcna ####
1149 analysis="wgcna"
1150 an.count <-3
1151 print("Analysis 3: WGCNA")
1152
1153 #setup ####
1154 #for (i in 1: length(datalist)){
1155 #reset figure
1156 figure <-1
1157 #select data for WGCNA: use top 8000 DE genes
1158 subset <-is.element(rownames(exprs(data.fil[[i]])),as.character(probeID2nuID(
reslistTT8000 [[i]][[1]]) [,7]))
1159
1160 usedata <-data.fil[[i]][ subset ,]
1161 datExpr0 = data.frame(t(exprs(usedata)))
1162
1163 # Take a quick look at what is in the data set:
1164 dim(datExpr0);
1165 names(datExpr0)[1:10];#probes
1166 rownames(datExpr0)#samples
1167
1168 #1.b Checking data for excessive missing values and identification of
outlier microarray samples ####
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1169 #check for missing values
1170 gsg=goodSamplesGenes(datExpr0 ,verbose =3);
1171 gsg$allOK
1172 #remove offending samples
1173 if (!gsg$allOK)
1174 {
1175 # Optionally , print the gene and sample names that were removed:
1176 if (sum(!gsg$goodGenes) >0)
1177 printFlush(paste("Removing genes:", paste(names(datExpr0)[!gsg$goodGenes
], collapse = ", ")));
1178 if (sum(!gsg$goodSamples) >0)
1179 printFlush(paste("Removing samples:", paste(rownames(datExpr0)[!gsg$
goodSamples], collapse = ", ")));
1180 # Remove the offending genes and samples from the data:
1181 datExpr0 = datExpr0[gsg$goodSamples , gsg$goodGenes]
1182 }
1183
1184 #cluster samples to look for outliers ####
1185 sampleTree = flashClust(dist(datExpr0), method = "average");
1186 # Plot the sample tree: Open a graphic output window of size 12 by 9 inches
1187 # The user should change the dimensions if the window is too large or too
small.
1188 #sizeGrWindow (12,9)
1189 #pdf(file = "Plots/sampleClustering.pdf", width = 12, height = 9);
1190 par(cex = 0.6);
1191 par(mar = c(0,4,2,0))
1192 plot(sampleTree , main = "Sample clustering to detect outliers", sub="", xlab
="", cex.lab = 1.5,
1193 cex.axis = 1.5, cex.main = 2)
1194 # Plot a line to show the cut
1195 abline(h = 80, col = "red")
1196 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’outlier plot all
samples ’),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
1197 par(parbackup)
1198 figure <-figure +1
1199
1200 # Determine cluster under the line
1201 clust = cutreeStatic(sampleTree , cutHeight = 80, minSize = 10)
1202 table(clust)
1203 # clust 1 contains the samples we want to keep.
1204 keepSamples = (clust ==1)
1205 datExpr = datExpr0[keepSamples , ]
1206 nGenes = ncol(datExpr)
1207 nSamples = nrow(datExpr)
1208
1209 #removing outliers breaks the code further down. For now , don ’t remove
outliers at all
1210 datExpr=datExpr0
1211
1212 #1.c Prepare clinical trait data #####
1213 traitData = pData(usedata);
1214 dim(traitData)
1215 names(traitData)
1216
1217 # remove columns that hold information we do not need.
1218 base.traits <-c(2,7,19,45,47,9,10,11,12,13,14,15,16,17,18,20,22,38)
1219
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1220 allTraits = traitData[, c(base.traits ,extra.traits)]
1221 #allTraits = traitData
1222 #allTraits = allTraits[, c(2, 11:36) ];
1223 dim(allTraits)
1224 names(allTraits)
1225
1226 pcSamples = rownames(datExpr);
1227 traitRows = match(pcSamples , allTraits$sample_name);
1228 datTraits = allTraits[traitRows , -1];
1229 rownames(datTraits)<-traitData$sample_name
1230
1231 datTraits <-data.frame(apply(datTraits ,2, function(x){replace(x, x =="",NA)})
)
1232
1233 datTraits[, c(1,2,3,4,5,13,14,17)] <- lapply(datTraits[, c
(1,2,3,4,5,13,14,17)], as.factor)
1234 datTraits[, c(1,2,3,4,5,13,14,17)] <- lapply(datTraits[, c
(1,2,3,4,5,13,14,17)], as.numeric)
1235
1236 datTraits <-as.matrix(datTraits)
1237 datTraits <-apply(datTraits ,2,as.numeric)
1238
1239 #datTraits <-data.frame(lapply(datTraits ,as.numeric))
1240 rownames(datTraits) = allTraits[traitRows , 1];
1241 collectGarbage ();
1242 datTraits <- datTraits[,colSums(is.na(datTraits))<nrow(datTraits)]#this
removes all columns where all values are NA
1243 uniquelength <- apply(datTraits ,2, function(x) length(unique(x[!is.na(x)])))
1244
1245 datTraits <- subset(datTraits , select=uniquelength >1)#this removes all
columns where all values are the same after removing NAs
1246 datTraits <-data.frame(datTraits)
1247 #expression data and phenotype data are now in analagous data frames
1248
1249 #Visualisation of how the traits relate to the sample dendrogram ####
1250 # Re -cluster samples
1251 sampleTree2 = flashClust(dist(datExpr), method = "average")
1252
1253 # Convert traits to a color representation: white means low , red means high ,
grey means missing entry
1254 traitColors = numbers2colors(as.matrix(datTraits), signed = FALSE);
1255
1256 # Plot the sample dendrogram and the colors underneath.
1257 plotDendroAndColors(sampleTree2 , traitColors ,cex.dendroLabels = 0.5,cex.
colorLabels =.5,cex.lab=.7,cex.axis=.7,
1258 groupLabels = colnames(datTraits),
1259 main = "Sample dendrogram and trait heatmap")
1260 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’samples_trait_combo_
plot’),export.formats=export.formats.plots ,height=height ,width =(1 + sqrt
(5))/2*height)
1261 par(parbackup)
1262 figure <-figure +1
1263
1264 #2.c.1 Choosing the soft -thresholding power: analysis of network topology
####
1265 # Choose a set of soft -thresholding powers
1266 powers = c(c(1:10) , seq(from = 12, to=20, by=2))
1267 # Call the network topology analysis function
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1268 sft = pickSoftThreshold(datExpr , powerVector = powers , RsquaredCut = 0.80,
verbose = 5)
1269 # Plot the results:
1270 #sizeGrWindow (9, 5)
1271 par(mfrow = c(1,2));par(mar=c(4,4,2,2))
1272 cex1 = 0.9;
1273 # Scale -free topology fit index as a function of the soft -thresholding power
1274 plot(sft$fitIndices [,1], -sign(sft$fitIndices [,3])*sft$fitIndices [,2],
1275 xlab="Soft Threshold (power)",ylab="Scale Free Topology Model Fit ,
signed R^2",type="n",
1276 main = paste("Scale independence"));
1277 text(sft$fitIndices [,1], -sign(sft$fitIndices [,3])*sft$fitIndices [,2],
1278 labels=powers ,cex=cex1 ,col="red");
1279 # this line corresponds to using an R^2 cut -off of h
1280 abline(h=0.80 , col="red")
1281 # Mean connectivity as a function of the soft -thresholding power
1282 plot(sft$fitIndices [,1], sft$fitIndices [,5],
1283 xlab="Soft Threshold (power)",ylab="Mean Connectivity", type="n",
1284 main = paste("Mean connectivity"))
1285 text(sft$fitIndices [,1], sft$fitIndices [,5], labels=powers , cex=cex1 ,col="
red")
1286 par(mfrow = c(1,1));
1287
1288 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’scale_independence_
and _mean_connectivity ’),export.formats=export.formats.plots ,height=
height ,width =(1 + sqrt (5))/2*height)
1289 par(parbackup)
1290 figure <-figure +1
1291 print(paste("Soft -thresholding power:",sft$powerEstimate ))
1292
1293 #2.c.2 Block -wise network construction and module detection ####
1294 thispower = sft$powerEstimate
1295 if (is.na(thispower)){
1296 thispower=min(sft$fitIndices[sft$fitIndices$SFT.R.sq >0.75 ,]$Power)
1297 print("No power estimate for R squared of .80, using .75")
1298 print(paste("New soft -thresholding power:",thispower ))}
1299
1300 bwnet = blockwiseModules(datExpr , maxBlockSize = 8000,
1301 power = thispower ,#networkType=’signed ’,TOMType ="
signed",
1302 minModuleSize = 20,
1303 reassignThreshold = 0, mergeCutHeight = 0.25,
1304 numericLabels = TRUE ,
1305 saveTOMs = FALSE ,
1306 saveTOMFileBase = "TBPC_TOM_blockwise_10K",
1307 verbose = 3)
1308 #xxx
1309
1310 # Convert labels to colors for plotting
1311 mergedColors = labels2colors(bwnet$colors)
1312 # Plot the dendrogram and the module colors underneath
1313 plotDendroAndColors(bwnet$dendrograms [[1]], mergedColors[bwnet$blockGenes
[[1]]] ,
1314 "Module colors",
1315 dendroLabels = FALSE , hang = 0.03,
1316 addGuide = TRUE , guideHang = 0.05,
1317 main=paste(names(datalist [[1]]) ,nrow(datExpr),"samples",
ncol(datExpr),"probes")
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1318 )
1319 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’dendrogram_and_module
_colours ’),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
1320 par(parbackup)
1321 figure <-figure +1
1322
1323 #plotColorUnderTree(bwnet$dendrograms [[1]] , mergedColors[bwnet$blockGenes
[[1]]])
1324 #save the tree (module assignment and module eigengene information)
1325 bwmoduleLabels = bwnet$colors
1326 bwmoduleColors = labels2colors(bwnet$colors)
1327 bwMEs = bwnet$MEs;
1328 bwgeneTree = bwnet$dendrograms [[1]];
1329 # Relabel blockwise modules
1330 bwLabels = matchLabels(bwnet$colors , bwmoduleLabels);
1331 # Convert labels to colors for plotting
1332 bwModuleColors = labels2colors(bwLabels)
1333
1334 print("number of genes in each module")
1335 print(table(bwLabels))
1336
1337 #3. Relating modules to external information and identifying important genes
####
1338
1339 #3.a Quantifying module trait associations ####
1340
1341 # Define numbers of genes and samples
1342 nGenes = ncol(datExpr);
1343 nSamples = nrow(datExpr);
1344 # Recalculate MEs with color labels
1345 MEs0 = moduleEigengenes(datExpr , bwmoduleColors)$eigengenes
1346 MEs = orderMEs(MEs0)
1347 moduleTraitCor = cor(MEs , datTraits , use = "p");
1348 moduleTraitPvalue = corPvalueStudent(moduleTraitCor , nSamples);
1349
1350 # Will display correlations and their p-values
1351 textMatrix = paste(signif(moduleTraitCor , 2), "\n(",
1352 signif(moduleTraitPvalue , 1), ")", sep = "");
1353 dim(textMatrix) = dim(moduleTraitCor)
1354
1355 par(mar = c(5,9,2,2));par(mfrow=c(1,1))
1356 # Display the correlation values within a heatmap plot
1357 labeledHeatmap(Matrix = moduleTraitCor ,
1358 xLabels = names(datTraits),
1359 yLabels = names(MEs),
1360 ySymbols = names(MEs),
1361 colorLabels = FALSE ,
1362 colors = greenWhiteRed (50),
1363 textMatrix = textMatrix ,
1364 setStdMargins = FALSE ,
1365 cex.text = 0.5,
1366 zlim = c(-1,1),
1367 main = paste("Module -trait relationships"))
1368 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’module -trait_
relationships ’),export.formats=export.formats.plots ,height=height ,width
=(1 + sqrt (5))/2*height)
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1369 par(parbackup)
1370 figure <-figure +1
1371
1372 # clustered version , with NA columns removed
1373
1374 par(mar = c(2,2,2,5));par(cex.main =.5);
1375 heatmap(moduleTraitCor[,!apply(moduleTraitCor ,2,is.na)[1,]],col=
greenWhiteRed (50),main="Clustered module -trait relationships",mar=c(6,1)
,cexRow =.5, cexCol =.5)
1376 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’clust_module -trait_
relationships ’),export.formats=export.formats.plots ,height=height ,width
=(1 + sqrt (5))/2*height)
1377 par(parbackup)
1378 figure <-figure +1
1379
1380 #3.b Gene relationship to trait and important modules: Gene Significance and
Module Membership ####
1381
1382 #We quantify associations of individual genes with our trait of interest (
which depends on the question/ contrast) by defining Gene Significance
GS
1383 #as (the absolute value of) the correlation between the gene and the trait.
For each module , we also define a
1384 #quantitative measure of module membership MM as the correlation of the
module eigengene and the gene expression
1385 #profile. This allows us to quantify the similarity of all genes on the
array to every module.
1386
1387 #in this context ’class ’ refers to the contrast variable!
1388 class=as.data.frame(eval(parse(text=paste("datTraits$",contrast.variable))))
1389 names(class)=contrast.variable
1390
1391 # names (colors) of the modules
1392 modNames = substring(names(MEs), 3)
1393 geneModuleMembership = as.data.frame(cor(datExpr , MEs , use = "p"));
1394 MMPvalue = as.data.frame(corPvalueStudent(as.matrix(geneModuleMembership),
nSamples));
1395 names(geneModuleMembership) = paste("MM", modNames , sep="");
1396 names(MMPvalue) = paste("p.MM", modNames , sep="");
1397
1398 geneTraitSignificance = as.data.frame(cor(datExpr , class , use = "p"));
1399 GSPvalue = as.data.frame(corPvalueStudent(as.matrix(geneTraitSignificance),
nSamples));
1400 names(geneTraitSignificance) = paste("GS.", names(class), sep="");
1401 names(GSPvalue) = paste("p.GS.", names(class), sep="");
1402
1403 #3.c Intramodular analysis: identifying genes with high GS and MM####
1404
1405 #Using the GS and MM measures , we can identify genes that have a high
significance for class as well as high module membership in interesting
modules. We plot a scatterplot of Gene Significance vs. Module
Membership in all modules:
1406
1407 par(parbackup);
1408 for (mods in modNames){
1409 module = mods
1410 column = match(module , modNames);
1411 moduleGenes = bwmoduleColors == module;
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1412
1413 if(length(abs(geneModuleMembership[moduleGenes , column ])) >19){
1414
1415 verboseScatterplot(abs(geneModuleMembership[moduleGenes , column ]),
1416 abs(geneTraitSignificance[moduleGenes , 1]),
1417 abline=T,abline.color = "red",
1418 xlab = paste("Module Membership in", module , "module"),
1419 ylab = paste("Gene significance for",contrast.variable),
1420 main = paste(mods ," module membership vs. gene
significance\n"),
1421 cex.main = 1.2, cex.lab = 1.2, cex.axis = 1.2, col =
module)
1422 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],’MM_vs_GS_’,module),
export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/2*
height)
1423 par(parbackup)
1424 }
1425
1426 figure <-figure +1}#moved figure out of for loop!
1427
1428 #3.d Summary output of network analysis results ####
1429
1430 #retrieve various annotations to attach to feature and module data
1431 features <-featureNames(usedata)
1432 annotSYM <-as.character(getSYMBOL(features ,"lumiHumanAll.db"))
1433 annotACC <-as.character(lookUp(features ,"lumiHumanAll.db","ACCNUM"))
1434 annotCHR <-as.character(lookUp(features ,"lumiHumanAll.db","CHR"))
1435 annotCHRLOC <-as.character(lookUp(features ,"lumiHumanAll.db","CHRLOC"))
1436 annotENSEMBL <-as.character(lookUp(features ,"lumiHumanAll.db","ENSEMBL"))
1437 annotENTREZID <-as.character(lookUp(features ,"lumiHumanAll.db","ENTREZID"))
1438 annotGO <-as.character(lookUp(features ,"lumiHumanAll.db","GO"))
1439 annotREFSEQ <-as.character(lookUp(features ,"lumiHumanAll.db","REFSEQ"))
1440 annotUNIPROT <-as.character(lookUp(features ,"lumiHumanAll.db","UNIPROT"))
1441
1442 annot <-data.frame(cbind(features ,annotSYM ,annotACC ,annotCHR ,annotCHRLOC ,
annotENSEMBL ,annotENTREZID ,annotGO ,annotREFSEQ ,annotUNIPROT))
1443 ##-- need to do this manually:
1444 dim(annot)
1445 names(annot)
1446 probes = names(datExpr)
1447 probes2annot = match(probes , annot$features)
1448 # The following is the number or probes without annotation:
1449 sum(is.na(probes2annot))
1450 # Should return 0.It doesn ’t. Not a surprise.
1451
1452 # Create the starting data frame
1453 geneInfo0 = data.frame(substanceBXH = probes ,
1454 geneSymbol = annot$annotSYM[probes2annot],
1455 LocusLinkID = annot$annotENTREZID[probes2annot],
1456 moduleColor = bwmoduleColors ,
1457 geneTraitSignificance ,
1458 GSPvalue)
1459 # Order modules by their significance for class
1460 modOrder = order(-abs(cor(MEs , class , use = "p")));
1461 # Add module membership information in the chosen order
1462 for (mod in 1:ncol(geneModuleMembership)){
1463 oldNames = names(geneInfo0)
1464 geneInfo0 = data.frame(geneInfo0 , geneModuleMembership[, modOrder[mod]],
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1465 MMPvalue[, modOrder[mod]]);
1466 names(geneInfo0) = c(oldNames , paste("MM.", modNames[modOrder[mod]], sep="
"),
1467 paste("p.MM.", modNames[modOrder[mod]], sep=""))
1468 }
1469 # Order the genes in the geneInfo variable first by module color , then by
geneTraitSignificance
1470 geneOrder = order(geneInfo0$moduleColor , -abs(eval(parse(text=paste("
geneInfo0$GS.",contrast.variable ,sep="")))));
1471 geneInfo = geneInfo0[geneOrder , ]
1472 write.csv(geneInfo ,file=file.path(dir.results ,paste(’table ’,q.i,’.’,an.count
,’.’,i,’.’,names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],"
geneInfoClass.csv")))
1473
1474 #4 Interfacing network analysis with other data such as functional
annotation and gene ontology ####
1475
1476 #4.a Output gene lists for use with online software and services ####
1477
1478 # Match probes in the data set to the probe IDs in the annotation file
1479 probes = names(datExpr)
1480 probes2annot = match(probes , annot$features)
1481 # Get the corresponding Locus Link IDs
1482 allLLIDs = as.numeric(annot$annotENTREZID[probes2annot ]);
1483 allLLIDs=allLLIDs[!is.na(allLLIDs)]
1484 # $ Choose interesting modules
1485 intModules = unique(bwmoduleColors)
1486
1487 for (module in intModules){
1488 # Select module probes
1489 modGenes = (bwmoduleColors == module)
1490 # Get their entrez ID codes
1491 modLLIDs = allLLIDs[modGenes ];
1492 # Write them into a file
1493 fileName = file.path(dir.results ,paste(’LLID’,q.i,’.’,an.count ,’.’,i,’.’,
names(datalist)[[i]],"_LocusLinkIDs -", module , ".txt",sep=""));
1494 write.table(as.data.frame(modLLIDs), file = fileName ,row.names = FALSE ,
col.names = FALSE)
1495 }
1496
1497 # As background in the enrichment analysis , we will use all probes in the
analysis.
1498 fileName = file.path(dir.results ,paste(’ALL -LLID’,q.i,’.’,an.count ,’.’,i,’.’
,names(datalist)[[i]],"_entrez_ids -all.txt"));
1499 write.table(as.data.frame(allLLIDs), file = fileName ,
1500 row.names = FALSE , col.names = FALSE)
1501
1502 #4.b Enrichment analysis directly within R####
1503 GOenr = GOenrichmentAnalysis(bwmoduleColors , allLLIDs , organism = "human",
nBestP = 20, includeOffspring=FALSE);
1504 tab = GOenr$bestPTerms [[4]]$enrichment
1505 names(tab)
1506 write.table(tab ,file=file.path(dir.results ,paste(’GO’,q.i,’.’,an.count ,’.’,i
,’.’,names(datalist)[[i]],"_GOEnrichmentTable.csv")),sep=",",quote=TRUE ,
row.names=FALSE)
1507
1508 #on -screen
1509 keepCols = c(1, 2, 5, 6, 7, 12, 13);
1510 screenTab = tab[, keepCols ];
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1511 # Round the numeric columns to 2 decimal places:
1512 numCols = c(3, 4);
1513 screenTab[, numCols] = signif(apply(screenTab[, numCols], 2, as.numeric), 2)
1514 # Truncate the the term name to at most 40 characters
1515 screenTab[, 7] = substring(screenTab[, 7], 1, 40)
1516 # Shorten the column names:
1517 colnames(screenTab) = c("module", "size", "p-val", "Bonf", "nInTerm", "ont",
"term name");
1518 rownames(screenTab) = NULL;
1519 # Set the width of R output. The reader should play with this number to
obtain satisfactory output.
1520 options(width =95)
1521 # Finally , display the enrichment table:
1522 screenTab
1523
1524 #5. Network visualization using WGCNA functions ####
1525
1526 #5a. make TOMplot#only run this if lots of memory. don ’t include in RData
####
1527
1528 #problems:
1529 #1. not complete network , but only one block at a time
1530 #2. despite this , it is too big
1531
1532 # Calculate topological overlap anew: this could be done more efficiently by
saving the TOM
1533
1534 #get hold of TOMs inRData files in ~
1535
1536 # calculated during module detection , but let us do it again here. #!No!
1537 #dissTOM = 1-TOMsimilarityFromExpr(datExpr , power = 11);
1538
1539 # do this for eachj block , i.e.TOM?
1540
1541 # ##don ’t do TOM plots at this stage
1542 # load("TBPC_TOM_blockwise_10K-block .1. RData")
1543 # TOM <-as.matrix(TOM)
1544 # dissTOM1=1-TOM
1545 # # Transform dissTOM with a power to make moderately strong connections
more visible in the heatmap
1546 # plotTOM1 = dissTOM1 ^7;
1547 # # Set diagonal to NA for a nicer plot
1548 # #diag(plotTOM1) = NA;
1549 # # Call the plot function
1550 # #sizeGrWindow (9,9)
1551 #
1552 # ##-- can ’t plot whole tom due to memory constraints ...
1553 # plotDendroAndColors(bwnet$dendrograms [[1]], bwModuleColors[bwnet$
blockGenes [[1]]] ,
1554 # "Module colors", main = "Gene dendrogram and module
colors in block 1",
1555 # dendroLabels = FALSE , hang = 0.03,
1556 # addGuide = TRUE , guideHang = 0.05)
1557 # TOMplot(plotTOM1 ,bwnet$dendrograms [[1]] , bwModuleColors[bwnet$blockGenes
[[1]]] , main = "Network heatmap plot , all genes , block1 ")
1558 #
1559 # #Plot only some genes..
1560 #
1561 # nSelect = 1500
398
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
A.8 Analysis: IMPI-MA
1562 # # For reproducibility , we set the random seed
1563 # set.seed (10);
1564 # select = sample(dim(plotTOM1)[[1]] , size = nSelect);
1565 # selectTOM = dissTOM1[select , select ];
1566 # # There is no simple way of restricting a clustering tree to a subset of
genes , so we must re-cluster.
1567 # selectTree = flashClust(as.dist(selectTOM), method = "average ")
1568 # selectColors = bwmoduleColors[select ];
1569 # # Open a graphical window
1570 # #sizeGrWindow (9,9)
1571 # # Taking the dissimilarity to a power , say 10, makes the plot more
informative by effectively changing
1572 # # the color palette; setting the diagonal to NA also improves the clarity
of the plot
1573 # plotDiss = selectTOM ^7;
1574 # diag(plotDiss) = NA;
1575 # TOMplot(plotDiss , selectTree , selectColors , main = "Network heatmap plot ,
selected genes ")
1576 # rm(TOM)
1577
1578 #5.b Visualizing the network of eigengenes ####
1579 # Recalculate module eigengenes
1580 MEs = moduleEigengenes(datExpr , bwmoduleColors)$eigengenes
1581 # Isolate numeric traits from the clinical traits and add the traits to
existing module eigengenes
1582
1583 MEtraits <-list()
1584 for (trait in 1: length(datTraits)){
1585 tmp <-as.data.frame(datTraits [[trait ]])
1586 names(tmp)<-names(datTraits[trait ])
1587 string=paste("ME network for ",names(datTraits[trait]),sep="")
1588 data=orderMEs(cbind(MEs ,tmp))
1589 MEtraits [[ trait ]]= data
1590 names(MEtraits)[[trait ]]= string
1591 }
1592
1593 # Plot the relationships among the eigengenes and the trait
1594 par(cex = 0.9)
1595 for (m in 1: length(MEtraits)){
1596 plotEigengeneNetworks(MEtraits [[m]],names(MEtraits)[[m]], marDendro = c
(0,3,1,5), marHeatmap = c(3,4,1,1), cex.lab = 0.8, xLabelsAngle = 90)
1597 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,names(
questions)[[q.i]],’.’,analysis ,names(datalist)[i],m,names(MEtraits)[[m
]]),export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5)
)/2*height)
1598 par(parbackup)
1599 }
1600 figure <-figure +1
1601
1602 #6 Exporting network data to network visualization software ####
1603
1604 #6.a Exporting to Cytoscape
1605
1606 # Recalculate topological overlap if needed
1607 TOM = TOMsimilarityFromExpr(datExpr , power = thispower);
1608 # Read in the annotation file - #_# not needed
1609 #annot = read.csv(file =file.path(dir.results ," GeneAnnotation.csv"));
1610 # Select modules
1611
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1612 modules = intModules
1613 probesM = features[bwnet$blockGenes [[1]]]
1614 # Select module probes
1615 for (cytmod in modules){
1616 inModule = is.finite(match(bwModuleColors[bwnet$blockGenes [[1]]] , cytmod));
1617 modProbes = probesM[inModule ];
1618 modGenes = annot$annotSYM[match(modProbes , annot$features)];
1619 # Select the corresponding Topological Overlap
1620 modTOM = TOM[inModule , inModule ];
1621 dimnames(modTOM) = list(modProbes , modProbes)
1622 # Export the network into edge and node list files Cytoscape can read
1623 setwd(dir.results)
1624
1625 exportNetworkToCytoscape(modTOM ,
1626 edgeFile = paste(’CS’,q.i,’.’,an.count ,’.’,i,
’.’,names(datalist)[[i]],"CS-edges -", paste(cytmod , collapse="-"), ".txt
", sep=""),
1627 nodeFile = paste(’CS’,q.i,’.’,an.count ,’.’,i,
’.’,names(datalist)[[i]],"CS-nodes -", paste(cytmod , collapse="-"), ".txt
", sep=""),
1628 weighted = TRUE ,
1629 threshold = 0.02,
1630 nodeNames = modProbes ,
1631 altNodeNames = modGenes ,
1632 nodeAttr = bwmoduleColors[bwnet$blockGenes
[[1]]][ inModule ]);
1633 rm(modTOM)
1634 collectGarbage ()
1635 }
1636 setwd(dir.figures)
1637
1638 #7. Plot module heatmap and eigengene expression ####
1639
1640 datME=MEs
1641
1642 # for (module in intModules){ #(see above)
1643 # which.module=module
1644 # ME=datME[, paste("ME",which.module , sep ="")]
1645 # par(mfrow=c(2,1), mar=c(0.3, 5.5, 10, 2))
1646 # #plotDendroAndColors(sampleTree2 , traitColors ,cex.dendroLabels = 0.5,cex
.colorLabels =.5,cex.lab=.7,cex.axis=.7,
1647 # # groupLabels = names(datTraits),saveMar=F)
1648 # plotMat(t(scale(datExpr[,bwmoduleColors ==which.module ][ sampleTree2 $
order ,]) ),nrgcols =30, rlabels=F,clabels=row.names(datExpr)[sampleTree2$
order],rcols=which.module ,ccols=as.character(classcolours [[i]])[
sampleTree2$order],main=which.module , cex.main =1)
1649 # par(mar=c(4, 3.8, 0, 0.7))
1650 # barplot(ME[sampleTree2$order], col=which.module , main="", cex.main=2,
1651 # ylab=" eigengene expression",xlab=" array sample ")
1652 # export.plot(file.prefix=paste(’fig ’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],module ,"dend_
order"),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
1653 # par(parbackup)
1654 # }
1655 # figure <-figure +1
1656
1657 for (module in intModules){ #(see above)
1658 which.module=module
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1659 ME=datME[, paste("ME",which.module , sep="")]
1660 par(mfrow=c(2,1), mar=c(0.3, 5.5, 13, 2))
1661 #plotDendroAndColors(sampleTree2 , traitColors ,cex.dendroLabels = 0.5,cex.
colorLabels =.5,cex.lab=.7,cex.axis=.7,
1662 # groupLabels = names(datTraits),saveMar=F)
1663 plotMat(t(scale(datExpr[,bwmoduleColors == which.module ]) ),nrgcols =30,
rlabels=F,clabels=row.names(datExpr),rcols=which.module ,ccols=as.
character(classcolours [[i]]),main=which.module , cex.main =1)
1664 par(mar=c(4, 3.8, 0, 0.7))
1665 barplot(ME, col=which.module , main="", cex.main=2,
1666 ylab="eigengene expression",xlab="array sample")
1667 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],module ,"orig_
order"),export.formats=export.formats.plots ,height=height ,width =(1 +
sqrt (5))/2*height)
1668 par(parbackup)
1669 }
1670 figure <-figure +1
1671
1672 par(parbackup)
1673
1674 #boxplots and stats for DE modules
1675 par(parbackup)
1676 for (module in intModules){ #(see above)
1677 which.module=module
1678 ME=datME[, paste("ME",which.module , sep="")]
1679 boxplot(list(ME[tbstat.class [[i]]== levels(tbstat.class [[i]]) [[1]]] ,ME[
tbstat.class [[i]]== levels(tbstat.class [[i]]) [[2]]]) ,col=c("blue","red"),
main=module ,names=levels(tbstat.class [[i]]))
1680 export.plot(file.prefix=paste(’fig’,q.i,’.’,an.count ,’.’,i,’.’,figure ,
names(questions)[[q.i]],’.’,analysis ,names(datalist)[i],module ,"boxplot"
),export.formats=export.formats.plots ,height=height ,width =(1 + sqrt (5))/
2*height)
1681 }
1682 figure <-figure +1
1683
1684 #stats for comparisons
1685 statlist.modules <-list()
1686 for (mod in 1: length(intModules)) {
1687 which.module=intModules [[mod]]
1688 ME=datME[, paste("ME",which.module , sep="")]
1689 statlist.modules [[mod]]<-wilcox.test(
1690 ME[tbstat.class [[i]]== levels(tbstat.class [[i]]) [[1]]] ,ME[tbstat.class [[i
]]== levels(tbstat.class [[i]]) [[2]]]
1691 )$p.value}
1692 tests.modules <-data.frame("names"=intModules ,"pval"=as.vector(unlist(
statlist.modules)),"man_B"=as.vector(unlist(statlist.modules))*length(
intModules),"bonf"=p.adjust(as.vector(unlist(statlist.modules)),method="
bonferroni"),"BH"=p.adjust(as.vector(unlist(statlist.modules)),method="
BH"))
1693 write.csv(tests.modules ,file=file.path(dir.results ,paste("Module_stats_",q.i
,’.’,an.count ,’.’,i,"_",names(datalist)[[i]],names(meth)[[h]],"_",
colname ,"_wilcox.csv",sep="")))
1694
1695 #the end ####
1696 #}wgcna for loop
1697
1698 #clean up
1699 rm(TOM)
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1700 collectGarbage ()
1701
1702 }
1703
1704 rm(list=as.character(dataset.variables))
1705 collectGarbage ()
1706 }
1707
1708 print(paste("End time:",Sys.time()))
Listing A.12: SevenQuestions
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